

BIOMARKERS: TARGETS FOR CANCER DIAGNOSIS

TGL 192

ABSTRACT

Biomarkers are substances in bodily fluids which allow for the determination of the presence of a malignancy or the progression of an existing one. We examine some of the recent work in this area and then focus on five specific malignancies.

Terrence McGarty

September 2022

NOTICE

This document represents the personal opinion of the author and is not meant to be in any way the offering of medical advice or otherwise. It represents solely an analysis by the author of certain data which is generally available. The author furthermore makes no representations that the data available in the referenced papers is free from error. The Author also does not represent in any manner or fashion that the documents and information contained herein can be used other than for expressing the opinions of the Author. Any use made and actions resulting directly or otherwise from any of the documents, information, analyses, or data or otherwise is the sole responsibility of the user and The Author expressly takes no liability for any direct or indirect losses, harm, damage or otherwise resulting from the use or reliance upon any of the Author's opinions as herein expressed. There is no representation by The Author, express or otherwise, that the materials contained herein are investment advice, business advice, legal advice, medical advice or in any way should be relied upon by anyone for any purpose. The Author does not provide any financial, investment, medical, legal or similar advice in this document or in its publications on any related Internet sites.

Furthermore, this document contains references to and quotes from papers and documents under the premise of Fair Use in order to present ideas and understandings in context. The Author has attempted to make any and all references to such material separate from those of the author per se and has referenced the source expressly in all cases. These documents are for the dissemination of ideas and have no commercial intent. The Author would appreciate any communications relating to these documents and these should be sent to: tmcgarty@telmarc.com.

Contents

1 INTRODUCTION

Over the past few decades, we have seen the proliferation of biomarkers as a means to determine the presence of a cancer or its progression. Unlike a biopsy, namely an invasive determination of the cellular morphology exhibiting the presence of the malignancy, the biomarkers are inferential. Namely they take a set of markers such as proteins, mRNA, or sequences of portions of a gene to infer a malignancy. Specifically, the inference has both a classic sensitivity and specificity and in turn an area under the curve, AUC, Biomarkers are not dispositive.

NIH defines biomarkers as follows:

A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.[1]

Biomarkers have become a significant factor in diagnosing various cancers. The biomarkers broadly speaking are parts of the cancer cells which have been released into the blood stream or urine and are then detectable by various means. Our focus here is on bladder cancer and biomarkers in the urine. We have previously examined other biomarkers such as exosomes in prostate cancer[2].

Biomarkers, as we examine herein, are to be found in the blood, urine or other bodily fluids such as that in the lung. The above definition is delimited to molecules that are part of cancer cells not cancer cells themselves. Thus, for example, in examining urine we may examine cytology of cells actually in toto in the urine or molecules such as DNA, RNA, miRNA, lncRNA, and even proteins.

The challenges of using biomarkers are several folds. First one must be able to identify a specific marker type, such as a miRNA, to a specific organ and a specific state of that organ. Thus, if we are looking for a breast cancer target we need to be certain that the biomarker in question is from the breast and only the breast and that its presence signifies a malignancy. Second, we need to be able to identify the marker in the body fluid in question. Third we need to have a test with high sensitivity and specificity. Fourth we generally need to have a multiplicity of markers to have more accurate targeting.

The object of this report is to lay out the basic elements of biomarkers and to consider several malignancies in which they can be applied. Our intent is not to be inclusive but to be representative.

We have chosen five cancers to examine and then consider progress in the use of biomarkers. They are shown below:

---

[1] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker

[2] https://www.researchgate.net/publication/325023533_Liquid_Biopsy_and_Cancer

Bladder	• Bladder cancer is a comples set of malignancies starting with the bladder wall. It is akin to epidermal cancers.
Breast	• Breast cancer, a glandular cancer, has a multiplicity of forms and presentations. It is essential to know the type in order to effectively treat.
Prostate	• Prostate cancer is , a glandualr cancer, is somewhat understood especially as regards to its genetic makeup. Therapeutics are still limited and surgical resection is still the domoinant approach.
Melanoma	• Melanoma is a potentially very aggressive and lethal cancer of the skin. Like bladder cancer it is epithelial yet unlike bladder is is much more cell specific.
Thyroid	• Thyroid cancer is a third glandular cancer, mostly being indolent but certain versions are one of the deadliest.

Now the process of establishing a viable set of biomarkers is complex. Typically, a good biomarker is a complex set of genes, proteins, mRNA, DNA and the like. They must be specific to the organ, specific to a malignancy and specific to a state of that malignancy. A classic example is PSA and prostate cancer. It varies greatly from patient to patient depending on age, prostate size, and other factors. Despite there being a single threshold of say 4 for PSA, 4 for a patient of 40 is not the same as a 4 for a patient of 80.

The biomarker development process is quite complex. It can be outlined as we show below:



Identify
- The first step is to identify one or several malignant cell related markers such as mRNA, miRNA, DNA or the like.

Validate
- Demonstrate the relative uniqueness of the markers to just that specific malignancy

Test
- Provide clinical evidence that confirms the markers in a large section of patients

Assess
- Perform detailed clinical assessments to determine the sensitivity and specificity of the putative test

Implement
- Develop a method and procedure to apply the tests in large scale patient environments

It should be clear that each of the above steps is subject to significant challenges that would inhibit progress.

The key challenge is having the lesion emit an exosome or other biomarker which can then be used. Amongst the challenges is that the marker must have a uniqueness since it is possible that benign cells may also be emitting such markers.

Our objective here is to attempt to examine the status of biomarkers and to lay out the challenges in their development.

As Cosby has recently noted:

Liquid biopsy approaches are relatively well developed for cancer therapy monitoring and disease relapse, but they also have incredible potential in the cancer early detection and screening field. There are, however, several challenges to overcome before this potential can be met. Research in this area needs to be cohesive and, as a driver of research, Cancer Research UK is in an ideal position to enable this. …

The development of multi-cancer early detection (MCED) tests has generated a lot of recent attention. And it is clear to see why. A single test for simultaneous detection of multiple cancers is an exciting prospect for early detection and screening and there is evidence to suggest the approach will have utility.

Modelling work suggests that 26% of cancer-related deaths could be avoided using MCED screens to detect cancers in 50–79-year-olds in the United States. However, whilst there are now a small number of multi-cancer tests with real potential in terms of early detection, none are yet proven.

Furthermore, even if tests such as this do show utility in a clinical setting, there are question marks over placing too much emphasis on them. For example, any multi-cancer test will ideally need to identify the tissue of origin following a positive result to avoid costly additional tests to locate the cancer. There will be no 'magic bullet' solution to the early detection problem— and MCED tests would not solve everything. This means CRUK needs to focus on the whole continuum of challenges in early diagnosis—from discovery research, through translation to regulation and implementation in clinical pathways, as articulated in our Roadmap.

Detecting cancer with a non-invasive liquid biopsy approach is an incredibly exciting prospect for cancer diagnostics. But there are many challenges still to overcome. In early-stage cancers, the low and variable number of biomarkers raises the simple problem that different blood samples from the same individual might yield different results.

Low biomarker amounts also dictate that liquid biopsy techniques must be highly sensitive; however, the high sensitivity needed to detect ctDNA—or other biomarkers—can affect the specificity of the test.

There is a concern that benign mutations could well trigger false-positive results [13]. Personalised approaches, such as the INVAR work, which can increase sensitivity, operate by targeted sequencing across a patient-specific list of mutations—and are, as such, not well suited *for early detection or diagnosis of new cancers. Currently, the cost of sequencing would also be prohibitive for utilization as a screening tool.*

New ways of increasing sensitivity need to be developed for the potential of liquid biopsies in screening and early detection to be reached. There are several promising avenues of research on this front—alternate methods of ctDNA analysis including novel epigenetic assay methods, examining fragmentation patterns or combining ctDNA with other molecular marker types such as circulating proteins.

Despite the incredible advances made utilizing ctDNA as a biomarker for liquid biopsies, there is still a lack of pathophysiologic information that needs to be addressed for a robust understanding of how and when it is released from tumours.

We also need more discovery and translational research to help us understand the biological nature of the early lesions detected by liquid biopsy (which may differ from those detected through conventional means)—what is their prognosis and how should we optimally treat or monitor them? Another vital issue is the way in which prospective screening and early diagnostic tests are evaluated. Studies using cancer patients who already have a diagnosis are likely to overestimate sensitivity. This is because those patients are likely to have received a symptomatic diagnosis and are therefore likely to have a more advanced cancer compared to cancers in the average-risk population.

To address this, we need studies that evaluate the effectiveness of any liquid biopsy-based screen or early detection test to be conducted prospectively using the target population— i.e., those who have yet to experience symptoms. This, of course, raises further questions over who would get these tests, how to make that cost-effective and how best to evaluate MCEDs. The usual criterion of impact on cancer-specific mortality for a new screening test would be practically impossible to reach for a test that aims to detect 50 cancer types. For a screening test to be implemented, there must be a demonstrable cancer-specific mortality benefit of using a given test.

For example, fewer people die of lung cancer as a result of introducing a lung cancer test. Based on the very low and varying cancer incidence rates for different cancer types (and their subsequent mortalities) in a screening population, a screening trial for a diagnostic test for one cancer would need to be designed to not only find enough cases of that cancer in the general population but also to allow follow-up on those people over a long enough period of time to see the effect of the test on mortality.

And this is just for a single cancer. If you have a multi-cancer detection test and if you were to demonstrate the gold standard cancer-specific mortality endpoint for all of the cancers that the test detects, you would need enough incident cases of each cancer and enough deaths specifically from each cancer to show a significant difference.

This would necessitate a trial with a massive number of people, beyond reasonable constraints of cost and feasibility. As such, we may need to consider alternate ways to evaluate these MCEDs. TOWARDS THE FUTURE Whilst treatments for cancer have made revolutionary steps forward, early detection research has made comparatively limited progress, presenting a persistent *scientific and clinical challenge. Now, with advances in technology starting to open-up new research paths, a test that could reliably pick up signs of cancer before it takes hold is a clear goal of early detection research.*

Liquid biopsies clearly have huge potential here, and a growing evidence base in the literature shows that the level of interest in the research community is high. Along with other early detection approaches, (and potentially integrated with them) research into liquid biopsies is a key part of our strategy.

Fundamentally, biomarkers are physical manifestations of the presence of some type of malignant process in some specific organ. The typical biomarkers are such things as DNA, mRNA. miRNA, lncRNA, circRNA, specific genes, specific methylation profiles and the like. The problem is quite complex because we must know the one-to-one unique mapping between measurable and organ and the nature of the cancer. In addition, we generally have very few measurable available. Thus, although biomarkers are attractive means to identify malignancies, they face a significant uphill battle.

2 EXOSOMES AND CELLS

Cells shed contents from time to time and that content ends up flowing through the various bodily fluids. We now present a brief overview of exosomes and their structure and dynamics. The exosomes and their related contents can provide information regarding the possible malignant cells which are their origin.

2.1 EXOSOME STRUCTURE

Exosomes are emitted from cells. They may contain various elements of the cells such as proteins or RNA variants. As such having collected an exosome one putatively can extract information regarding the cell that emitted it. As Jia et al have noted:

Exosomes are membrane vesicles of endocytic origin, which shaped from inward budding of membrane of multi-vesicular bodies (MVB) and released from the cell into the extracellular environment with the plasma membrane. Most prokaryotic and eukaryotic cells can release exosomes, including stroma cell, reticulocytes, epithelial cells, and tumor cells, which have been isolated from serum, urine, bile, and breast milk.

According to proteomic analyses, exosomes have been verified to contain a selective enrichment of a discrete set of cellular protein associated with cell surface receptors, cytosolic signaling proteins, metabolic enzymes, antigen presentation, and major histocompatibility complex (MHC), heat shock protein (HPSs, as HSP70, HSP90, HSP60, HSP70), and tetraspanins. Although previously considered as cellular waste products, recent studies have showed that exosomes carry number of functional molecules, provide shelter to the transported molecules and act as intercellular correspondents by shuttling molecules between cells.

*There are a large number of mobile membrane limited vesicles called **extracellular vesicles** (EVs) in the extracellular environment, which can be further subcategorized based on their size, biogenesis and release mechanism, and content into **exosomes**, **microvesicles** (MVs), and **apoptotic** bodies.*

Exosomes and MVs[3] *have a distinct biogenesis, while the most dramatic difference between exosomes and MVs is how they are formed. Exosomes are formed from inward budding of an endosome resulting in a multivesicular body (MVB), with the plasma membrane, which is secreted by succeeding fusion of the MVB. On the other hand, MVs are released directly by budding from the cellular plasma.*

Moreover, most of discussed studies claimed that their studies were based on exosomes. Henceforth, exosomes and microvesicles are collectively referred to as exosomes unless indicated. Several studies have indicated the potential mechanisms by which exosomes are internalized and released. Accumulating evidence has indicated that impose stress on cells, growth factors and increases in intracellular calcium can induce the release of exosomes.

---

[3] Exosomes are 30-100 nm whereas MVs are 100-1000 nm. Exosomes bud near the inside of the cell.

Exosomes also exert a feedback mechanism regulating the release of exosomes from normal mammary, it means that exosomes released from breast cancer cells and normal human mammary epithelial cells are regulated by exosomes derived from their own cells.

Other investigations have revealed that that exosomes are internalized via phagocytosis or lipid raft domains. In breast tumor cells, detachment of cells is an intense stimulation for the secretion of exosomes. Exosomes have also been expected to contributed to cell-cell communication by activating them directly by surface expressed ligands or by conveying signal molecules between cells. To be specific, exosomes interact with target cells via receptors, endocytosis, fusion with plasma membrane, or the release of their cargo. Cancer cell derived exosomes usually carry molecular signs and effectors of the disease, such as mutant oncoproteins, oncogenic transcripts, microRNA, and DNA sequences.

When taken up by recipient non-malignant cells, such exosomes contribute to horizontal cellular transformation and phenotypic reprograming, traverse the tumor microenvironment, and finally result in the cell malignant transformation.

What is more, as the content of exosomes is closely connected to the original cells which the exosomes are derived, exosomes are increasingly considered as novel diagnostic or prognostic biomarkers. Recently, growing number of studies have also revealed the important role of exosomes as both indicators of cancer development and a prospective new treatment approach in breast cancer.

The above focuses on breast cancer but exosomes are broadly released by many if not all cancers. The exosome is shown graphically below:

See Jia et al



The ability to transport miRNA, mRNA and DNA allows for remote assessment of the genetic makeup of the source.



MVs bud directly from the plasma membrane, whereas exosomes are repressed by small vesicles of different sizes that are formed as the ILV by budding into early endosomes and multivesicular body and are released by fusion of multivesicular body fuse with lysosomes. **a.** By endocytosis of membrane segments, the initial endosome arises, containing receptors and transmembrane proteins of the plasma membrane. **b.** Instead of lysosomal degradation, the matured late endosome transforms by inward budding of tiny vesicles into a multivesicular body. Furthermore, the exosomal cargo as proteins and miRNA, is selectively loaded into the vesicles. **c.** MVs bud directly from the plasma membrane, whereas the exosomes are released into the extracellular space by fusion of the multivesicular body with the plasma membrane **d.** Cell-secreted exosomes can travel through biological fluids (e.g. serum, lymph) and be internalized by recipient cells.

2.2 CIRCULATING TUMOR CELLS

In contrast to exosomes, encapsulated cell extracts, circulating tumor cells are full and complete cells[4]. CTCs as they are called, contain a wealth of information but are limited in density. As Eslami-S et al note:

Metastasis formation is the main cause of cancer-related death in patients with solid tumours. ***At the beginning of this process, cancer cells escape from the primary tumour to the blood circulation where they become circulating tumour cells (CTCs).*** *Only a small subgroup of CTCs will survive during the harsh journey in the blood and colonise distant sites. The in-depth analysis of these metastasis-competent CTCs is very challenging because of their extremely low concentration in peripheral blood.*

So far, only few groups managed to expand in vitro and in vivo CTCs to be used as models for large-scale descriptive and functional analyses of CTCs. These models have shown already the high variability and complexity of the metastatic cascade in patients with cancer, and open a new avenue for the development of new diagnostic and therapeutic approaches. …

CTCs are one of the circulating biomarkers of liquid biopsies that reveal information about the biology of the metastatic cascade in patients with cancer. *Their potential is not limited just to be a diagnostic or therapeutic biomarker and it is important to thoroughly study metastasis-*

---

[4] See Wojcik et al regarding urinary cytology.

competent CTCs because this knowledge might help to develop new therapeutic strategies to eradicate specifically these bad CTCs.

The in vitro and in vivo studies using CTCs reviewed in this article could be the "holy grail" to characterise the metastatic process in flagrante. Although only few groups managed to generate CTC lines or developed robust methods to expand CTCs, their discoveries have added significant knowledge on the metastatic cascade the underlying mechanisms of which may be more complex than the situation in experimental models.

In addition, CDX, particularly from patients with very advanced disease who have exhausted all conventional treatment options, might be an interesting alternative non-invasive strategy because obtaining tissue biopsies for testing/developing new treatment strategies may not be feasible in these patients. Indeed, CDX can provide novel insights into the biology of malignant cells in that specific patient (i.e., patient specific model) to provide practical information on the therapeutic response. Nevertheless, CTC analysis alone is not sufficient to understand metastatic progression, particularly due to the crucial contribution of the microenvironment of metastatic organs. For example, the interaction with other blood cells (e.g., neutrophils) can help CTCs to survive their dangerous travel in the blood.

Moreover, after extravasation at a distant site, their survival will depend on the existing environment conditions (e.g., low oxygen levels in bone marrow) [69] and on the presence of immune cells that attack the invaders. Including in future studies both CTCs and circulating host cells will open a whole new dimension for the study of metastasis. Interestingly, when we tried to determine whether there is one key step in the metastatic cascade by using a modified Drake equation, our simulation predicted that the most critical parameter is the survival duration of CTCs. This suggests that therapies targeting CTC survival in the vascular system may significantly reduce the risk of metastasis.

Finally, efforts should now focus on developing a standardised and robust method to expand CTCs from different cancer types. Novel approaches to increase CTC capture rate play an important role, and projects have been started by different consortia, such as the European Liquid Biopsy Academy (ELBA), and the European Liquid Biopsy Society (ELBS, www.elbs.eu). The establishment of CTC lines and the development of CDX represent a great opportunity to decode the metastatic cascade and test cancer drugs that specifically target CTCs.

3 MEASURES

There has been considerable development in methods and techniques to isolate and identify various markers in human cells[5]. As Tamura et al have noted:

Liquid biopsy is a minimally invasive biopsy method that uses molecules in body fluids as biomarkers, and it has attracted attention as a new cancer therapy tool. Liquid biopsy has considerable clinical application potential, such as in early diagnosis, pathological condition monitoring, and tailored treatment development based on cancer biology and the predicted treatment response of individual patients.

Extracellular vesicles (EVs) are lipid membranous vesicles released from almost all cell types, and they represent a novel liquid biopsy resource.

EVs carry complex molecular cargoes, such as proteins, RNAs [e.g., mRNA and noncoding RNAs (microRNA, transfer RNA, circular RNA and long noncoding RNA)], and DNA fragments; these cargoes are delivered to recipient cells and serve as a cell-to-cell communication system. The molecular contents of EVs largely reflect the cell of origin and thus show cell-type specificity. In particular, cancer-derived EVs contain cancer-specific molecules expressed in parental cancer cells.

Therefore, analysis of cancer-derived EVs might indicate the presence and nature of cancer. High-speed analytical technologies, such as mass spectrometry and high-throughput sequencing, have generated large data sets for EV cargoes that can be used to identify many candidate EV-associated biomarkers. Here, we will discuss the challenges and prospects of EV-based liquid biopsy compared to other biological resources (e.g., circulating tumor cells and cell-free DNA) and summarize the novel studies that have identified the remarkable potential of EVs as a cancer biomarker.

From Piao et al:

---

[5] See, https://www.qiagen.com/us/applications/cancer-research/cancer-liquid-biopsy, for a variety of commercially available methods.

Type of Liquid Biopsy Sample	Origin	Detection Methods	Advantages	Disadvantages	Applications in BCa
CTC	Primary tumors; Metastatic sites.	Microfilters; Immunocytochemistry; Immunomagnetic assays; CellSearch System; CytoTrack; Epic CTC Platform; HD-CTC; RT-PCR.	High specificity; Non-invasive analysis; Represent genomic information from the tumor or metastatic sites in real time; Can observe response to therapeutic treatments.	Low sensitivity to monitor tumors, particularly early stage tumors.	Valuable prognosis marker associated with disease-free survival in metastatic BCa; Useful for deciding therapeutic approaches, since it is strongly correlated to tumor stage, histological grade, and metastasis.
ctDNA	Released from viable tumors by activating secretion, apoptosis, or necrosis; Destruction of CTCs.	PCR; Pyrosequencing; RT-PCR; NGS; ddPCR; BEAMing technology; CAPP-Seq.	High sensitivity; Non-invasive analysis; Stability in variable degradation microenvironments; Can be used to detect mutations related to carcinogenesis.	Require a specific method to distinguish tumor origin DNA from healthy origin DNA, since both release ctDNA; Low yield in plasma; Low sensitivity to monitor tumors, particularly early stage tumors.	Genomic alterations such as specific mutations, deletions, and methylation variations detected in ctDNA from BCa urine and plasma are correlated to disease recurrence and progression; Alterations in ctDNAs with differential sensitivity to therapeutic agents could be used as markers of therapy response in metastatic patients.

Type of Liquid Biopsy Sample	Origin	Detection Methods	Advantages	Disadvantages	Applications in BCa
Exosome	Primary tumors; Cells in various body fluids	Real-time PCR; ddPCR; NGS; Microarray; Western blotting; ELISA.	Non-invasive analysis; High stability in variable degradation microenvironments; Better sensitivity and specificity than CTC and ctDNA in various bio-specimens.	Challenging protocols to analyze genomic materials in exosomes	Urinary exosomal miRNAs show potential for BCa detection; Long non-coding RNAs and proteins in urinary exosomes are proposed to be enriched in BCa.

3.1 mRNA

Messenger RNA, mRNA, does find its way into various bodily fluids and it is there that we can address it and ascertain the impact regarding cancer. There are various forms of RNA and each of these has information regarding a potential malignancy.

As Happel et al note :

Extracellular RNA acts as a signalling molecule, traveling though body fluids carrying information from cell to cell.

Types of exRNA include both longer messenger RNA (mRNA) and long non-coding RNA (lncRNA), as well as various types of small non-coding RNAs (ncRNAs).

Non-coding RNAs can generally be broken down into two groups, regulatory ncRNAs and housekeeping ncRNAs…

Regulatory ncRNAs include lncRNA, microRNA (miRNA), piwi-interacting RNA (piRNA), small interfering RNA (siRNA), tRNA-derived fragments and Y RNA.

Regulatory small ncRNAs have emerged as vital players in various biological processes. They are known primarily for their role as regulators of gene expression at the post-transcriptional level; however, they have a wide range of functions. …

Housekeeping ncRNAs include ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), and small nucleolar RNA (snoRNA). Housekeeping ncRNAs are highly abundant and are essential for cellular activities such as the translation of RNA into proteins, and transcriptional splicing.

The term exRNA includes many types of RNA. *Small non-coding exRNAs are often the focus of studies due to their abundance, ease of detection, and regulatory function. MiRNA are of particular interest due to their role in post-transcriptional regulation of gene expression. Changes in miRNA expression are associated with various pathological conditions and dysregulation of miRNA expression is a hallmark of human cancer*

Extracellular RNA is secreted by all cell types and can be found in a variety of biofluids including plasma, serum, breast milk, saliva, cerebrospinal fluid (CSF), bile, semen, and urine.

While many ncRNAs are found in human biofluids, miRNA, piRNA, snoRNA, tRNA-derived RNA fragments (tRF), and Y RNA represent the most prominent types of exRNA found within various human biofluids. Carriers of exRNA include extracellular vesicles (EVs), ribonucleoprotein complexes (RNPs), and lipoprotein complexes (LPPs). ExRNAs are either encased within extracellular vesicles, or, are tightly associated with proteins to avoid degradation by RNAses. ExRNAs, in extracellular vesicles and/or associated with protein complexes, can then be transferred from donor cells to recipient cells, where they can elicit functional responses and regulate a number of biological processes

As Ferandez Lazaro et al note:

Urine is divided into sediments, which allows the macroscopic study of crystalline structures in the form of salts and supernatants, where we find proteins, metabolites, nucleic acids and vesicles of extracellular origin. The prostate-specific antigen (PSA) is found to increase in the urine in patients with prostate cancer, although the clinical routine determines it in blood. Urine DNA comes from glomerular filtration where the fragments are 100 base pairs, although it depends on the patient's condition. The enzymatic activity of DNAse-1 produces a high fragmentation of DNA with high (≥1 kpb) or low (<100 bp) molecular weight. Urine DNA analysis has determined mutations in KRAS in pancreatic and colorectal cancers. In addition, in non-small-cell lung cancer, the epidermal growth factor receptor (EGFR) has detected mutations with sensitivities similar to those obtained in plasma.

However, the detection of mRNA is not possible due to the action of RNases, although it is possible to detect micro RNA found inside urine exosomes.

In the saliva (hypotonic solution), there exist isolated proteins, DNA and RNA, and metabolites and microbiota, that are also present in the blood. Thus, their concentration changes can be used as biomarkers to detect early-stage cancer or to monitor the response to therapeutic management. Salivary diagnostics are non-invasive, easy to use tools for patient specimen collection. Saliva testing potentially allows the patient to gather their own saliva samples, even at home, thus saving healthcare costs, enabling convenient and multiple sampling as well as having a positive impact on patient compliance

The authors continue:

Although less abundant than cfDNA, also there is cell-free circulating (cfRNA) that can be determined in the serum of patients.

This cfRNA can be found: ctRNA, microRNA (miRNA), messenger RNA (mRNA) and non-coding RNAs and for monitoring tumor genetic dynamics *…*

ctRNA in blood is also used to identify mutations in genes of interest, but additionally, provides information about relative expression levels of important genes. In this sense, programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions.

First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1.

Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons.

PD-L1 expression was detected in the plasma ctRNA of all cancer types at varying frequencies but no PD-L1 messenger RNA (mRNA) was detected in cancer-free individuals there was a high degree of concordance between expression of PD-L1 protein in tumor tissues and PD-L1 gene expression in plasma, and both methods were equally predictive of pharmacological response*.*

These findings may provide additional predictive information on the outcome of patients on anti-PD-L1 therapy. In addition, elevated levels of telomerase reverse transcriptase mRNA (hTERT) are often found in different types of tumors such as breast or colon cancer but no hTERT mRNA was detected in cancer-free individuals. However, there are difficulties in using mRNA as a biomarker in LB because mRNA is protected in extracellular vesicles, and is associated with protein complexes. Additionally, the reproducibility and utility of cell-free mRNA as a biomarker are limited due to its instability, low abundance, and intracellular mRNA contamination from specimen processing

3.2 CIRCULAR RNA

As Wen et al noted:

Circular RNA (circRNA) is a novel class of singlestranded RNAs with a closed loop structure. The majority of circRNAs are formed by a back-splicing process in pre-mRNA splicing. Their expression is dynamically regulated and shows spatiotemporal patterns among cell types, tissues and developmental stages. CircRNAs have important biological functions in many physiological processes, and their aberrant expression is implicated in many human diseases.

Due to their high stability, circRNAs are becoming promising biomarkers in many human diseases, such as cardiovascular diseases, autoimmune diseases and human cancers.

In this review, we focus on the translational potential of using human blood circRNAs as liquid biopsy biomarkers for human diseases. We highlight their abundant expression, essential *biological functions and significant correlations to human diseases in various components of peripheral blood, including whole blood, blood cells and extracellular vesicles. In addition, we summarize the current knowledge of blood circRNA biomarkers for disease diagnosis or prognosis.*

Zhang et al note:

Based on their patterns of biogenesis from genomic regions, circular RNAs (circRNAs) can be divided into four categories: exonic circRNAs, circular intronic RNAs, exon-intron circRNAs, and intergenic circRNAs. There are many hypotheses for the mechanism of circRNA formation, among which the lariat-driven circularization and intron-pairing-driven circularization mechanisms are the most widely accepted.

Research into the formation of circRNAs has had a positive catalytic effect on the exploration of their functions; however, many proposed mechanisms require further analysis and verification. Unlike linear RNAs, which are terminated with 5' caps and 3' tails, circRNAs are characterized by covalently closed loop structures that lack 5' to 3' polarity and polyadenylated tails. This intrinsic characteristic has led to a general underestimation of the existence of circular RNAs in previous polyadenylated transcriptome analyses.

However, in recent years, RNA sequencing technologies and bioinformatics approaches have identified a large number of circRNAs in humans, mice, nematodes, zebrafish, fruit flies, protists, and plants. Furthermore, these technologies have enabled characterization of the abundance and diversity of circRNAs, as well as their dynamic expression patterns in various developmental stages and physiological conditions. Many circRNAs are expressed in a tissue-specific manner.

For example, circRmst and circKlhl2 are expressed at high levels in the mouse brain but are not found in the liver or lung, and circ-MBL expression in the Drosophila ovary is much lower than that in the head. The expression levels of some circRNAs also change at different ages or developmental stages. For example, one study found that the levels of multiple circRNAs, including MM9_ circ004501 and MM9_circ013636, were higher in the brains of 22-month-old rats than in those of 1-year-old rats.

To date, circRNAs have been reported to function as competing endogenous RNAs or "miRNA sponges", mediators of RNA/protein interactions, and scaffolds in the assembly of protein complexes.

In addition, circRNAs can be translated into functional proteins, sequester proteins from their native subcellular localization modulate the expression of parental genes, regulate alternative splicing, and modulate the stability of mRNAs.

The ability of circRNAs to function as miRNA sponges has been studied in most detail. The presence of miRNA binding sites or response elements in some circRNAs enables them to regulate the function of miRNAs by acting as competitive endogenous RNAs (ceRNAs) or "miRNA sponges" [26, 40, 46, 47]. Competitive binding of miRNAs to ceRNAs reduces the *expression levels of the free miRNAs and inhibits their ability to affect gene expression at the transcriptional or post-transcriptional level.*

However, the biological significance of the classic role of ceRNAs as miRNA sponges is being increasingly debated, and a recent study demonstrated that most circRNAs do not function in the same way as "real" miRNA sponges. The protein interactions of a number of circRNAs, such as circ-Foxo3 and circ008274, have been studied extensively in disease states, especially tumors. Ectopic expression of circ-Foxo3 inhibits cell cycle progression by binding to the cell cycle proteins cyclin-dependent kinase 2 and cyclin dependent kinase inhibitor 1 (p21).

Moreover, a number of endogenous circRNAs can be translated into proteins, which calls into doubt the notion that they function as non-coding RNAs exclusively.

Other studies have shown that synthesized circRNAs containing multiple FLAGcoding sequences can also be translated into proteins in the absence of a particular element for internal ribosome entry, through a mechanism similar to rolling circle amplification.

CircRNAs can also regulate gene transcription.

For example, circ-EIF3J and circ-PAIP2 can combine with the U1 small nuclear ribonucleoprotein to interact with RNA polymerase II and enhance the expression of their parental genes in HeLa and HEK2393 cells. The enormous number of circRNAs identified to date suggests that they may have complex and diverse functions. In terms of characterizing the mechanisms underlying tumor formation and development, the roles of circRNAs as miRNA sponges have been studied in most detail, followed by their interactions with proteins.

However, the relationships between cancer and the abilities of circRNAs to be translated into proteins, modulate the stability of mRNAs and the splicing of pre-RNAs, and regulate parental gene transcription have not been studied in detail. These potential new roles of circRNAs in tumor development require further investigation.

The authors then continue:

Recently, genome-wide analyses have shown that various circRNAs play a role in a number of pathological processes, including the development of cancer, through transcriptional and posttranscriptional regulatory mechanisms. The identification of differences in gene expression levels between tumor and normal samples is an important component of cancer biology research. Analyses of a variety of tumor cells and corresponding normal cells have revealed abnormal circRNA expression levels in a variety of cancers.

In addition, other studies have shown that circRNAs participate in the initiation and progression of tumors, and can be used as molecular markers of the activation of signal transduction pathways related to cancer development Although a large number of studies have examined the use of proteins and miRNAs as biomarkers of cancer, circRNAs have a number of unique advantages. The main advantages of circRNAs as cancer biomarkers include their ability to be *detected via RT-PCR analyses of minimally invasive blood, urine, or saliva samples [43, 66, 67], as well as their high circulating stability.*

***Indeed, circRNAs are unusually stable RNA molecules, presumably because they lack an open end and are therefore able to avoid conventional RNA degradation pathways**.*

Notably, circRNAs play an important role in regulating the Wnt/β-catenin pathway, an important signaling mechanism involved in tumor progression. It is possible that targeted inhibition of circRNAs could block the Wnt/β-catenin pathway to inhibit tumor growth and development.

3.3 MICRO RNA

As Martins et al note :

Similarly, the levels of several miRNAs are often altered in cancer patients, allowing to determine miRNA signatures with diagnostic and prognostic potential. Tumors and their microenvironment release miRNAs that exist in the bloodstream in ribonucleoprotein complexes or incorporated into EVs. In particular, circulating miRNA profiles seem to be concordant with the ones of tumor tissues.

However, EV-incorporated miRNAs seem to represent only a small fraction of the miRNAs present in circulation and to have distinct diagnostic performance. The DNA in exosomes (exoDNA) can also be a valuable source of information, given that it is less prone to degradation than cfDNA and released from living cells, thus probably reflecting tumor-driving alterations more accurately than ctDNA that is derived from apoptotic and necrotic cells.

Contrarily to exosomes, that are derived from intracellular compartments, tumor-associated microparticles (taMPs) are membrane-derived vesicles that display cell surface markers from their source. As so, the expression of the cancer markers epithelial cell adhesion molecule (EpCAM) and CD147 in taMPs was shown to be specific of cancer patients, which could potentially be used for diagnostic purposes.

From Tamura et al the following Table presents various RNA types their source and usage:

Cancer	*Biological Source*	*RNA types*	*Markers*	*Potential application*
Prostate cancer	Urine	mRNA	PSA, PCA-3, TMPRSS:ERG	Diagnostic/Monitoring
	Urine	miRNA	PCA3, ERG, SPDEF	Diagnosis
	Urine	miRNA	let-7c, miR-21, miR-107, miR-145, miR-196a-5p, miR-204, miR-375, miR-501-3p, miR-574-3p, miR-2909	Diagnosis

Cancer	*Biological Source*	*RNA types*	*Markers*	*Potential application*
	Serum/ Plasma	miRNA	let-71. miR-16, miR-24, miR-26a. miR-26b, miR-30c-Sp. miR-34b. miR-92 b. miR-93. miR-103. miR-107. miR-l30b. nWt-141. miR-l81a-2. miR-19S. mlR-197. miR-200c-3p. miR-2lO-3p. nWt-223. miR-298i. miR-30U. miR-326. miR-328, miR-331-3p. miR-346. mlR-37S. miR-432, miR-S74-3p. m.R-62S, miR-1290. miR-2110	Diagnosis
	Plasma	miRNA	miR-17. miR-20a. miR-23a. miR-130b. miR-198. miR-200b. miR-375, miR-379. miR-S13a, miR-572, miR-S77. miR-S82-3p. mlR-609. miR-619. miR-624. mft-1236, m.R-1290	Prognosis
	Serum	miRNA	miR-1246	Prognosis
	Urine	hcftNA	p2l	Diagnosis
	Plasma	hcftNA	SAP30L- ASl, SChLAPl	Diagnosis
	Plasma/Urine	mRNA	AR-V7	Predict hormone therapy resistance (Abiraterone and/or Enzalutamide)
Bladder Cancer	Urine	miRNA	miR-21. miR-93, miR-200c. miR-940	Diagnosis
	Urine	miRNA	miR-21-So, miR-44S4. mlR-72ft miR-200c-3a miR-29b-3p. miR-200b-3o	Diagnosis
	Urine	miRNA	miR-37S.miR-146a	Diagnosis
	Urine	miRNA	miR-146t>-So, miR-ISS-Sp	Diagnosis
	Urine	hcftNA	HOTA1R. HOX- AS-2. MALATl. SOX2. OCT4	Diagnosis/Prognosis
	Serum	hcftNA	PCAT1, UEC1. SNHG16	Diagnosis/Prognosis
	Serum	hcftNA	UCA1	Diagnosis
	Urine/ Serum	drcftNA	PftVlTS	Diagnosis/Prognosis
Renal cancer	Serum	miRNA	miR-210. miR-1233	Diagnosis
	Urine	miRNA	miR-150 In combination «with miR-34b-So.	Diagnosis
			miR-449a and miR-486-Sp	
	Serum	miRNA	miR-224	Prognosis
	Plasma	miRNA	miR-26a-1-3p, miR- let-7-l. miRN-61S-3p	Prognosis
	Urine	hcftNA	GSTAt, CEBPA, PCBD1	Diagnosis
Breast cancer	Plasma	miRNA	miR-21, miR-1246	Diagnosis
	Plasma	miRNA	miR-105	Diagnosis

Cancer	***Biological Source***	***RNA types***	***Markers***	***Potential application***
	Serum	miRNA	miR-21, miR222, miR-155	Prognosis/Predict chemoresistance (miR-21, miR-1SS: Doxorubicin. Paclitaxel)
	Serum	miRNA	miR-200a. miR-200c. miR-205	Diagnosis
	Blood/Milk/Ductal fluids	miRNA	miR-16, miR-1246, miR-45t miR-205	Diagnosis
	Serum	lncRNA	HOT AIR	Prognosis/Monitoring
	Serum	lncRNA	SNHG14	Predict chemoresistance Trastusumab
	Plasma	mRNA	TrpCS. rndrl. MUCl and flotillin2	Predict chemoresistance (Anthracycline/taxane)
	Serum	mRNA	GSTP1	Predict chemoresistance (Anthracycline/taxane)
Ovarian cancer	Serum	miRNA	miR-21, miR-141. miR-200a, miR-200c. mft-200b. miR-203, miR-20S, miR-214	Diagnosis
	Serum	miRNA	miR-1246	Predict chemoresistance (Paclitaxel)
Pancreatic cancer	Serum/Urine	miRNA	miR-17-So, miR-21	Diagnosis
	Plasma	miRNA	miR-l55	Predict chemoresistance (Gemcitabine)
	Saliva	mRNA	Apftbkft ASP* Daf2, FoxPI. Bco31781. Gng2	Diagnosis
Liver cancer (HCC)	Plasma	tftNA	ValTAC-3, GlyTCC-S, ValAAC-S. GluCTC-S	Diagnosis
	Serum	dteftNA	crcUHRFl	Diagnosis/immunotherapy resistance (antl-PD-1)
	Serum	miRNA	miR-21, miR-l0b	Prognosis
Gastro cancer	Serum	miRNA	HOTTIP	Diagnosis/Prognosis
	Serum	hcftNA	hcUEGC	Diagnosis
	Serum	d reft HA	orcSHKBPI	Diagnosis
Esophageal cancer (ESCC)	Serum	miRNA	miR-21	Diagnosis
Colon cancer	Serum	miRNA	let-7a. miR-1229. miR-1246. miR-ISO. miR-21, miR-223. miR-23a	Diagnosis
	Serum	miRNA	miR-4772-3p	Prognosis

Cancer	*Biological Source*	*RNA types*	*Markers*	*Potential application*
Rectal cancer Others	Plasma	miRNA	miR-30d-Sp, miR-181a-Sp and miR-48fc-Sp	Diagnosis
Lung cancer	Plasma	miRNA	miR-l5la-Sp. miR-30a-3ft miR-200b-Sp, miR-629. miR-100. and miR-l54-3p	Diagnosis
Lung cancer (NSCLC)	Plasma	miRNA	let-7f. miR-20b, miR-30c-3p. miR-223. miR-301	Diagnosis
Lung cancer (LSCC)	Plasma	miRNA	miR-20S. miR-19a, miR-190. miR-30b. miR-20a	Monitoring
Lung cancer (NSCLC)	Serum	miRNA	miRNA-222-3p	Prognosis/Predict chemoresistance (Gemcitabine)
Lung cancer (NSCLC)	Serum	miRNA	miRNA-14fea-Sp	Predict chemoresistance (Cisciatin)
Lung cancer (NSCLC)	Plasma	mRNA	PD-L1	Predict immunotherapy resistance (anti-PD-1)
Melanoma	Plasma	mRNA	PD-L1	Predict immunotherapy resistance anti-PD-1
Glioblastoma	Serum/ Cerebrospinal fluid	miRNA	miR-21	Diagnosis/Prognosis
	Cerebrospinal fluid	miRNA	miR-21	Diagnosis
	Serum	miRNA	RNU6-1. miR-320, miR-574-3p	Diagnosis
	Serum	mRNA	MGMT APNG	Predict chemoresistance (Temozolomide)

We present a brief summary of miRNAs, their generation, and the basic principles related to cancers. The understanding of miRNAs is a continuing process and in reviewing the literature the initial understanding starting in 1993 was limited but it has recently exploded in detail. One of the earliest was the let or lethal miRNA, known as let-7. As Su et al have noted:

MicroRNAs (miRNAs) are a group of small noncoding RNAs capable of regulating specific gene expression. Let-7 miRNA was first discovered in Caenorhabditis elegans and it is highly conserved in human tissues. The human let- 7 family of miRNA contains 12 members of miRNA. Today, these members have become the most studied miRNAs and they have attracted attention of researchers in various fields, such as development, stem cell biology, aging, and metabolism.

Furthermore, there is a large body of evidence linking the loss of let-7 expression and the development of poorly differentiated, aggressive cancers. In addition to the canonical biogenesis pathway, let-7 has been found to be regulated by protein factors, such as RNA binding proteins previously identified as regulators of protein-coding mRNAs. Moreover, the direct interaction between miRNAs has recently been identified as a novel pathway to control let-7 expression. In this review, we discuss the multifaceted roles of let-7 and provide an overview of its regulation at multiple levels.

Su et al provide an excellent summary of how much detail is known about let-7. Specifically, we know how it is initiated and generated and how it controls downstream elements. let-7 provides a useful baseline for examining the 2300 or so miRNAs.

3.3.1 Generation

In the classic review paper by Esquela-Kerscher and Slack, they present an excellent discussion on miRNAs. First, we present the overall construct. miRNAs are produced like all RNA and then pass through the Drosha/Pasha complex and emerge from the nucleus as a double RNA with a loop. Dicer cuts the loop creating single strand short RNAs which are the miRNA.

The generation of miRNAs follow several possible pathways. Yang and Li had outlined some of these previously. The simplest explanation is that of the canonical pathway which we explain below.

1. The canonical pathway starts with the reading of a gene section with a Polymerase II (Pol II) and the production of a pri-miRNA (primary miRNA) molecule. This is a complex nucleotide molecule with loops and a poly A tail.

2. Then the enzyme Drosha, along with co-factor Pasha in the nucleus, cut the tails and the pre-miRNA is formed which is smaller but still with loops about 70 nt long. This sequence has a hairpin segment.

3. Exportin moves the duplex molecule outside the nucleus into the cytoplasm.

4. In the cytoplasm, Dicer cuts the pre-miRNA into two sections, the one without the loop being the mature miRNA.

5. At that point the mature miRNA finds a mature mRNA to which it binds to a complement site and at that point the mRNA is inactivated.

6. Specifically as Esquela-Kerscher and Slack had noted:

The mature miRNA then binds to complementary sites in the mRNA target to negatively regulate gene expression in one of two ways that depend on the degree of complementarity between the miRNA and its target. miRNAs that bind to mRNA targets with imperfect complementarity block target gene expression at the level of protein translation. However, recent evidence indicates that miRNAs might also affect mRNA stability.

Complementary sites for miRNAs using this mechanism are generally found in the 3′ untranslated regions (3’ UTRs) of the target mRNA *genes. miRNAs that bind to their mRNA targets with perfect (or nearly perfect) complementarity induce target-mRNA cleavage (lower right). miRNAs using this mechanism bind to miRNA complementary sites that are generally found in the coding sequence or open reading frame (ORF) of the mRNA target.*



We summarize this process as follows. This is a canonical example which adheres to the original understanding.



DNA Transcribes 300-5000 bases into a pri mi RNA in the nucleus

Drosha protein cuts the pri mi RNA into pre mi RNA of 70 base pairs and it moves outside of the nucleus

Dicer protein cuts the pre mi RNA to an mi RNA of 22 base pairs with 3' and 5' ends

miRNA migrates and attached to RNA with matching base pairs but may form a loop. Thus for example there may be a 12 BP attachment and a 12 BP loop

Resulting mRNA is no longer functional and there is a repression of the translation into a protein

Now we have the more detailed description where we show how miRNA can interfere with RNA translation by either inhibiting it or by slicing the RNA and in turn also inhibiting it. We depict that below. Note the two final operations on the miRNA, cleavage and repression.



An example of the miRNA binding is shown below:



This provides a rudimentary presentation of miRNA generation.

3.3.2 Variances

Yang and Li had presented a discussion of variants on the miRNA description above. In the canonical form above, the generation is Drosha dependent and Dicer dependent. There are other modes of generation as well. One is Drosha independent – Dicer dependent and the other is Drosha independent – Dicer independent.

We summarize the Yang and Li results in the following Table:

	Dicer Dependent	***Dicer Independent***
Drosha Dependent	*Canonical animal miRNAs are generated through cleavages of hairpin precursors by RNase III enzymes. In the nucleus, the single strand-double strand junction of the pri-miRNA hairpin is recognized the catalytic site of the RNase III enzyme Drosha. This cleavage exported to the cytoplasm, where it is cleaved toward the terminal loop end by the RNase III enzyme Dicer. The duplexes are loaded into miRNA-class Argonaute effectors. One of the duplex strands is preferentially retained in Ago to form the functional RNA-induced silencing complex.*	*Pri-mir is processed by Drosha/DGCR8, and the resulting pre-mir-451 is directly incorporated to Ago2. The Slicer activity of Ago2 cleaves the arm of pre-mir, giving rise to ac-pre-mir, which is further resected by an as yet unknown mechanism to generate mature miR.*
Drosha Independent	*Mirtrons are short intronic hairpins that are excised by splicing and linearized by lariat debranching; tailed mirtrons require further resection by nucleases. RNA pol III-transcribed MHV68 tRNA-shRNA fusions are processed into pre-miRNA-like hairpins Endo-shRNAs without lower stems for Drosha/DGCR8 processing may derive from pol III transcription or cleavage by as yet unknown endo- or exonucleases. These noncanonical miRNAs, are incorporated to Ago1–4. Endogenous substrates with extended dsRNA character, including hpRNAs, transposable elements, antisense pseudogenes and natural antisense transcripts are directly cleaved by Dicer to generate siRNAs. These may potentially sort to all of the mammalian Agos, but presumably only those that load Ago2 can fulfill target slicing.*	

There also are extensive considerations regarding the miRNA-mRNA interactions. Cloonan has recently done work on this area. Cloonan has especially raised the issues we presented above regarding just how the miRNA interact with the mRNA. Cloonan notes:

One thing that is becoming clear with the uncovering of these different interaction types is that miRNAs stably interact with hundreds to thousands of mRNAs, and some consideration needs to be given to separating biological noise from functionally-driven signal. Differentiating direct from indirect consequences of miRNA action makes it easier to specifically examine the mechanisms by which miRNAs interact with their mRNA targets, but this requires more scientific rigor if it is to disentangle the functional consequences of those interactions. Issues of miRNA target detection and miRNA mode of action are intertwined with discussion of the major effect and roles of miRNAs in the cell. And, as our understanding of miRNA biology improves, so too will our ability to predict and model target interactions.

Although prediction tools have strongly dictated the way we studied miRNAs in the past, their relevancy will change as our repertoire of experimental tools improve. This will in turn shape our understanding of how, where, and why miRNAs function, ideally converging on a model that incorporates all of the data, not just those that are convenient.

Namely, understanding the issues Cloonan presents one can understand that the simple model of miRNA and mRNA interference is substantially more complex than at first glance.

3.3.3 Cancer Implications

There has been a great amount of research regarding the impact of miRNA on cancer and especially on PCa. miRNAs may downregulate tumor suppressor genes such as PTEN. This has been seen in miRNA 21. Colin and Croce have provided several review articles regarding miRNA and their influence on cancers. They argue that miRNA alterations are heavily involved in the initiation of many cancers. Their focus had been on CLL, chronic lymphocytic leukemia, and its initiating miRNAs, miR 15 and miR 16. Coppola et al (2010) provide a detailed summary of miRNAs and PCa.

3.3.3.1 Functions

The graphic from Coppola et al is shown below where it depicts a collection of miRNAs which impact various parts of the PCa process.



For example, miR34 can cause the activation and recapitulate p53 which in turn induces cell cycle arrest and apoptosis. Loss of the miR-34 can result in the impairment of the p53 control of apoptosis and permit the cells to proliferate. Coppola et al perform a detailed analysis of all of the above related miRNAs and their resultant impact on PCa. miR-21 up-regulation leads to PTEN loss and thus is an oncogene.

Recent work by Poliseno et al has shown that PTEN can be down regulated via miR-106b. It had already been known that PTEN could be down-regulated by miR-22, miR-25 and miR-302.

Their work demonstrated that miR-22 and miR-106b are overexpressed in PCa miR-106b is an intronic miRNA. The work of Poliseno thus has demonstrated a proto-oncogenic miRNA dependent network that regulates PTEN and thus can have a significant role in initiating PCa.

Micro RNAs are regulators of mRNA, the post transcriptional result which is then used to generate via translation the operative protein. Currently there are nearly 1,000 identified miRNAs. They are generally 22 nucleotides long, short segments, and they usually target specific mRNA and silence it. Each one of the miRNAs may act upon many mRNAs.

As He and Hannon state:

Non-coding RNAs participate in a surprisingly diverse collection of regulatory events, ranging from copynumber control in bacteria[1] *to X-chromosome inactivation in mammals*[2]*.MicroRNAs (miRNAs) are a family of 21–25-nucleotide small RNAs that, at least for those few that have characterized targets, negatively regulate gene expression at the post-transcriptional leve.*

Members of the miRNA family were initially discovered as small temporal RNAs (stRNAs) that regulate developmental transitions in Caenorhabditis elegans[6]*. Over the past few years, it has become clear that stRNAs were the prototypes of a large family of small RNAs, miRNAs, that now claim hundreds of members in worms, flies, plants and mammals.*

The functions of miRNAs are not limited to the regulation of developmentally timed events. Instead, they have diverse expression patterns and probably regulate many aspects of development and physiology. Although the mechanisms through which miRNAs regulate their target genes are largely unknown, the finding that at least some miRNAs feed into the RNA INTERFERENCE (RNAi) pathway has provided a starting point in our journey to understand the biological roles of miRNAs.

miRNAs are simple yet complex entities and key players in the epigenetics which control gene expression.

It is clear from the above that miRNAs can positively and negatively impact many elements in the pathways we have considered in HGPIN and PCa. Coppola et al review several of the key ones. For example:

- miR-146: Down regulates the AR.
- miR-34: Can recapitulate p53 resulting in apoptosis and arrest.
- miR-23: can result in c-myc overexpression and cell proliferation.

In a recent paper by Poliseno et al they have identified several others:

- miR-106b: Down-regulates PTEN and triggers PIN in murine models.
- miR-22, miR-25, miR-302: Down-regulating of PTEN.

Similarly, the papers by Petrocca et al and that by Calin and Croce detail many of the miRNAs and their impacts on many cancers. As seen in the above graphic these are but a few in the overall targeting of PCa control genes. As Coppola et al state:

The hypothesis that miRs can be regarded as new broad-spectrum oncogenes or tumor suppressor genes has opened a revolutionary field of research with exciting diagnostic and therapeutic perspectives.

The compelling hint of a widespread miR deregulation in cancer pathogenesis came from the analysis of the genomic distribution of 186 miR. In this study, it was demonstrated that more than half of them mapped in cancer-associated genomic regions, namely in chromosomal sites prone to deletions, amplifications or recombinations. These aberrations can result in miR down- or up-regulation, conferring selective advantages to mutated cells.

Additional mechanisms of miR deregulation include altered expression of miRs as a consequence of excessive or deficient processing; aberrant transcription of the precursors by epigenetic silencing of miR promoters or as a result of the activity of oncogenic transcription factors; and more rarely, point mutations in mature miRs or in target sequences that can interfere with normal target recruitment

The problem that we will have in any modeling of HGPIN and PCa is not only do we have issues regarding the somewhat well-known genes but the impact of the epigenetic factors is unknown, complex, and possibly random.

Furthermore, miRNAs can act in a positive or negative manner depending upon the cell and the activated networks in the cell. From Croce (2009) we have:

Importantly, miRNAs should not be described as oncogenes or tumor suppressor genes, unless the tissue or cell type involved in their action is specified. For example, miR-221 and miR-222 target an oncogene, KIT, and inhibit the growth of erythroblastic leukaemia[30], and therefore function as tumor suppressors in erythroblastic cells. but they also target at least four important tumor suppressors −phosphatase and tensin homologue (PTEN), p27, p57 and tissue inhibitor of metalloproteinases 3 (TIMP3) −and function as oncogenic miRNAs by suppressing these tumor suppressors in various human solid tumours[31] (TABLE 1). Therefore, before describing a miRNA as a tumor suppressor or an oncogene, it is necessary to specify in which cell or tissue, as cellular context is crucial for the function of miRNAs….

Recent work on miR-34 has demonstrated its impact on p53 (Rakhlin et al) and the fact that miR-34 significantly mediates the role of p53 in apoptosis in AR dependent PCa.

As Sevli et al state:

The miRNAs have critical functions in gene expression and their dysregulation may cause tumor formation and progression. Today, it is known that tumors possess widespread deregulated miRNA levels. Over-expression or down-regulation of specific miRNAs in different tumor types make them potential therapeutic targets and diagnostic markers. Up-regulated miRNAs *inhibiting tumor suppressor genes in tumor cells are commonly termed as oncogenic miRNAs or oncomirs. The miRNAs whose down-regulation promotes tumor progression are tumor suppressor miRNAs. One type of mRNA may possibly be targeted by multiple different miRNAs with variable efficiencies. Conversely, a single miRNA may target more than one mRNA. Thus, to be able to observe a tumorigenic phenotype, some significant changes should occur in microRNome content of the cells.*

3.3.3.2 MiRNA and Stem Cells

As we have indicated elsewhere, the concept of the cancer stem cell has received significant attention. There has also been a great deal of work on the area of linking miRNAs and the stem cell model for PCa. In a recent work by Liu et al (2011) the authors demonstrate the nexus between miR-34a and its ability to inhibit PCa stem cells by directly repressing CD44. They observe that cancer stem cells have been observed in many solid cancers by using the fact that CD44 adheres to the cell surface. PCa stem cells with enhance clonogenic and tumor initiating and metastatic capacities are often enriched with CD44+ cell population. The work of Liu et al demonstrated that the administration of miR-34a to PCa cells inhibited PCa metastasis and inhibited PCa regeneration. This is one of the first uses of miRNA as a tumor suppressor.

In a recent paper by Xia (2008) the author states:

The key characteristics of stem cells are that they are capable of self-renewal and differentiation. The mechanisms by which stem cells maintain self-renewal and differentiation are complicated. In the past years, protein-coding genes had been broadly investigated in stem cell self-renewal and differentiation.

Recent studies indicate miRNAs as one of the most abundant classes of post-transcriptional regulators proved to be crucial in a wide range of biological processes, which suggest that miRNAs may also play essential roles in stem cell self-renewal and differentiation. Disruption of Dicer function in murine ESs influences miRNA processing and greatly impairs their ability to differentiate …

Cancer stem cells (CSCs) are the cells within a tumor that possess the capacity to self-renew and to produce the heterogeneous lineages of cancer cells that comprise the tumor. CSCs can thus only be defined experimentally by their ability of self-renewal and tumor propagation.

The implementation of this approach explains the use of alternative terms in the literature, such as "tumor-initiating cells" to describe putative CSCs. …

The identification of growth and differentiation pathways responsible for CSC proliferation and survival will help in the discovery of novel therapeutic targets. Previous studies have shown that many signal pathways may participate in regulating CSC functions, including Wnt/β-catenin, Notch, and Sonic hedgehog homolog (SHH). The canonical Wnt cascade has emerged as a critical regulator of stem cells and activation of Wnt signalling has also been associated with various cancers …

CSC maintenance is dependent on β catenin signaling. Moreover, because Wnt/β-catenin signalling is not essential for normal epidermal homeostasis, such a mechanistic difference may thus be targeted to eliminate CSCs and consequently eradicate squamous cell carcinomas. It is therefore hypothesized that inhibition of Wnt signaling may provide an effective way to reduce the unwanted stem cell renewal which results in cancers.

Inhibition of Wnt signalling may prove to be an effective road to inhibit the uncontrolled cell renewal that drives cancer. Acting as novel and pivotal regulators of protein-encoding genes, miRNAs will have great potential in regulating CSCs' biological functions by targeting CSCs-related signal pathway molecules.

We have performed various analyses of CSCs especially for PCa. This is a critical area for ongoing research and most likely will prove quite useful.

3.3.3.3 Multiple miRNAs

There are a large number of miRNAs and many of them work in concert. Thus, there can be a great degree of correlation between them and as such any use of classifiers may have some problematic issues. As Hayes et al have noted:

MicroRNA dysregulation in cancer was first reported in 2002, when a cluster of two microRNAs, miR-15 and miR- 16, was identified at 13q14.3, a frequently deleted region in chronic lymphocytic leukemia (CLL). This microRNA deletion was shown to act at least in part through allowing higher expression of the miR-15/16 anti-apoptotic target Bcell lymphoma 2 (BCL2). Since then, it has been documented that microRNAs have roles in all of the cancer hallmarks defined by Hanahan and Weinberg, and are implicated in the clinical management of cancers at every stage.

Although many specific examples have been reported, microRNA functions fall into two broad major functional categories:

(i) homeostatic regulation of gene expression, through 'fine-tuning' of translation according to cellular requirements; and

(ii) robustness in cellular responses, which is important in cell fate decisions in which groups of microRNAs can dictate the cellular differentiation state, acting as 'locks' to maintain cell identity, often via complex reciprocal negative-feedback loops.

This is seen in some cancers, in which microRNAs associated with terminal differentiation are weakly expressed in order to promote a proliferative state. Robustness is also important in responses to stress, in which microRNAs may function as 'switches' to allow cells to adapt to transient changes in their microenvironment.

For example, in glioblastoma, low levels of glucose lead to a reduction in levels of miR-451, which is necessary for AMP-activated protein kinase (AMPK) pathway activation and cell survival. Conversely, when energy levels are sufficient, higher levels of miR-451 act to suppress

AMPK signaling, and to promote mammalian target of rapamycin (mTOR) activation and cell proliferation.

Importantly, each tumor type has a distinct microRNA signature that distinguishes it from normal tissues and other cancer types. Most cancers can be further subclassified into prognostic groups based on these signatures. MicroRNA expression, like the expression of other cancer associated genes, can be altered by chromosomal amplification/deletion, promoter methylation, and transcription factor activation.

The importance of microRNA alterations in cancer is further highlighted by the observation that many cancer cells have genetic alterations that are microRNA mechanism-specific: that is, altered target binding, processing, and post-transcriptional editing. Binding site variation in the 30UTR of the target mRNA is a common feature of cancer cells. Single nucleotide polymorphisms (SNPs) and mutations have been identified, as well as deletions of 30UTRs during mRNA splicing in cancer cells, rendering mRNAs insensitive to microRNA regulation.

Hayes et al listed targets for 2014 time period. These targets are target genes which the driving miRNA has influence over. We present some of these below.

MicroRNA	***Mechanism***	***Targets***
miR-1792	Oncogene/tumor suppressor gene	E2F1, HBP1, CDKN1A, NCOA3, ERa, PTEN, MECP2, HOXA5, VPS4B, MYCN, RAB14, DPYSL2, TGFBR2, TSG101, ARHGAP12, BACE1,
miR-21	Oncogene	PDCD4, PTEN, RECK, PPARa, TIMP3, FasL, TGFBR2, SERINB5, CDK2AP1, TPM1
miR-221/222	Oncogene	CDKN1B, KIT, PPP2R2A, p27kip1, CDKN1C, ERa, KIT, DDIT4, BNIP3L, ZEB2, TBK1, CREBZF, MYBL1, DKK2
let-7	Tumor suppressor gene	NIRF, NF2, CASP3, TRIM71
miR-15/16	Tumor suppressor gene	BACE1, DMTF1, C22orf5, BCL2, ARL2, CCNT2, TPPP3, VEGFA, RARS, FGF2, ZNF622, DNAJB4, PURA, SHOC2, LUZP1, FNDC3B, ITGA2, ATG9A, CA12, TMEM43, YIF1B, TMEM189, VTI1B, RTN4, TOMM34, NAA15, PNP, SRPR, IPO4, NAPg, PFAH1B2, SLC12A2, SEC24A, NOTCH2, PPP2R5C, KCNN4, UBE4A, KPNA3, RAB30, ACP2, SRPRB, EIF4E, ABCF2, TPM3, ARHGDIA, GALNT7, LYPLA2, CHORDC1, TMEM109, LAMC1, EGFR, GPAM, ADSS, PPIF, RFT1, TNFSF9, IGF2R, TXN2, GFPT1, SLC7A1, SQSTM1, PANX1, UTP15, NPR3, SLC16A3, PTGS2, HARS, LAMTOR3, HSPA1B
miR-200	Tumor suppressor gene	ZEB1, CTNNB1, BAP1, GEMIN2, PTPRD, WDR37, KLF11, SEPT9, HOXB5, ERBB2IP. KLHL20, FOG2, RIN2, RASSF2, ELMO2, TCF7L1, VAC14, SHC1, SEPT7, FOG2
miR-34	Tumor suppressor gene	SIRT1, BCL2, YY1, MYC, CDK6, CCND1, FOXP1, HNF4a, CDKN2C, ACSL4, LEF1, ACSL1, MTA2, AXL, LDHA, HDAC1, CD44, BCL2, E2F3

We examine some more recent data latter. The difficulty with the above is twofold. First it appears for any and all cancers. Second, the apparent downstream impacts are extensive. It raises the issue of just how the downstream impacts are activated.

As Croce noted:

MicroRNA genes, unlike other genes involved in cancer, do not encode proteins. Instead, the products of these genes consist of a single RNA strand of about 21 to 23 nucleotides; their function is to regulate gene expression.

A microRNA molecule can anneal to a messenger RNA (mRNA) containing a nucleotide sequence that complements the sequence of the microRNA. In this way, the microRNA blocks protein translation or causes degradation of the mRNA. Examples of the role microRNA plays in cancer pathophysiology involve miR-15a and miR-16-1, which are deleted or down-regulated in most indolent cases of chronic lymphocytic leukemia, suggesting an early event in the pathogenesis of this disease.

Mapping of numerous microRNA genes has shown that many occur in chromosomal regions that undergo rearrangements, deletions, and amplifications in cancer cells. The regions of the genome that are consistently involved in chromosomal rearrangements in cancer cells but that lack oncogenes or tumor-suppressor genes appear to harbor microRNA genes. Expression profiling of microRNA genes has revealed signatures associated with tumor classification, diagnosis, staging, and progression, as well as prognosis and response to treatment.

For example, microRNA expression profiling can distinguish between indolent and aggressive forms of chronic lymphocytic leukemia, and expression of a small panel of microRNA genes correlates with prognosis in stage 1 lung cancer. Some microRNA genes that are deregulated in chronic lymphocytic leukemia have germ-line or somatic mutations in a microRNA precursor that affect the processing of short single-stranded microRNA molecules.62 MicroRNA genes can be up-regulated or down-regulated in cancer cells.

The up-regulated genes function as oncogenes by down-regulating tumor-suppressor genes, whereas the down-regulated genes function as tumor suppressor genes by down-regulating oncogenes. The function of microRNA genes depends on their targets in a specific tissue. A microRNA gene can be a tumor suppressor if in a given cell type its critical target is an oncogene, and it can be an oncogene if in a different cell type its target is a tumor-suppressor gene. Up-regulation of microRNA genes can be due to amplification, deregulation of a transcription factor, or demethylation of CpG islands in the promoter regions of the gene.

For example, the ALL1 (MLL) fusion proteins of acute lymphoblastic leukemia or acute myeloblastic leukemia carrying chromosome 11q23 translocations target the Drosha nuclease complex to specific microRNA genes, including miR191, thereby enhancing the processing of their microRNA precursors. The miR191 gene is also up-regulated in numerous types of solid cancers, suggesting that it is the downstream target of signal-translocation pathways involved in cancer.

MicroRNA genes functioning as tumor suppressors can be down-regulated because of deletions, epigenetic silencing, or loss of the expression of one or more transcription factors.

Esquela-Kerscher and Slack further detail the functioning of miRNAs as drivers and inhibitors as follows:

microRNAs can function as tumour suppressors and oncogenes.

a. In normal tissues, proper microRNA (miRNA) transcription, processing and binding to complementary sequences on the target mRNA results in the repression of target-gene expression through a block in protein translation or altered mRNA stability. The overall result is normal rates of cellular growth, proliferation, differentiation and cell death.

b. The reduction or deletion of a miRNA that functions as a tumour suppressor leads to tumour formation.

A reduction in or elimination of mature miRNA levels can occur because of defects at any stage of miRNA biogenesis (indicated by question marks) and ultimately leads to the inappropriate expression of the miRNA-target oncoprotein (purple squares). The overall outcome might involve increased proliferation, invasiveness or angiogenesis, decreased levels of apoptosis, or undifferentiated or de-differentiated tissue, ultimately leading to tumour formation.

The amplification or overexpression of a miRNA that has an oncogenic role would also result in tumour formation. In this situation, increased amounts of a miRNA, which might be produced at inappropriate times or in the wrong tissues, would eliminate the expression of a miRNA-target tumour-suppressor gene (pink) and lead to cancer progression.

Increased levels of mature miRNA might occur because of amplification of the miRNA gene, a constitutively active promoter, increased efficiency in miRNA processing or increased stability of the miRNA (indicated by question marks). ORF, open reading frame.

We depict these three cases as follows. First, miRNA acting in a normal manner. This is below:



Pre miRNA generated in nucleus and sent out to cytoplasm where Dicer cuts it to miRNA which in turn moves to align with RNA and blocks translation

Notice above the miRNA is assumed to be a normal part of the control mechanism of the control of the conversion of the mRNA into a protein. It blocks the conversion.

Now consider the second case. Here we have an oncogene which is not blocked by the miRNA and it results in many oncoproteins as shown below.



The miRNA fails to block a tumor suppressor translation

Results:
Tumor Formation
Proliferation
Invasion
Angiogenesis
No apoptosis

The oncogene not being blocked generates excess oncoproteins thus resulting in growth etc.

Finally in case 2 we have a massive explosion of miRNAs acting as onco activators as shown below.



These methods demonstrate in a somewhat simple manner how the miRNA functions in the case of certain cancers. It also demonstrates how the miRNA can become a target for therapeutics.

miRNA and its ability to block mRNA functions can thus directly block a multiplicity of cancer related gene products and thus activate malignant pathways. The following figure depicts some specific gene interference.



Finally, the following diagram depicts these processes. From the generation to the actual inhibition.



3.3.4 Metastatic Control

Finally, miRNAs have been identified as major participants in metastatic processes. As Sole and Lawrie have noted:

The first reports associating miRNAs with metastasis came in 2007, with the demonstration that miR-10b was induced by Twist1 binding and could promote metastasis in breast cancer in vitro and in vivo through targeting of Homeobox D10 (HOXD10). In the same year, also in breast cancer, let-7 was identified as a suppressor of metastasis acting to target the GTPase H-RAS and High Mobility Group AT-Hook 2 (HMGA2) gene in tumor-initiating cells, resulting in reduced proliferation and mammosphere formation in vitro and decreased metastasis in a NOD/SCID murine model.

In subsequent studies, breast cancer has remained the main focus of research investigating miRNAs in metastasis, and many studies have shown that miRNAs can act as both promoters or inhibitors of metastasis in cancer and modulate many steps of the metastatic pathway, including migration, invasion, adhesion, the epithelial–mesenchymal transition (EMT), niche conditioning and proliferation in secondary site.

3.3.4.1 Promotion

We can now provide some specific examples. From the perspective of promotion, we have from Sole and Lawrie who categorize these as:

In common with miR-10b, many of the metastasis-promoting miRNAs that have been characterized have been identified in breast cancer. For example, miR-105 has been identified as being up-regulated in tumor cells and exosomes derived from breast cancer cells were demonstrated to breakdown vascular endothelial barriers and induce vascular permeability, thereby promoting metastasis by targeting of ZO-1, a component of cell–cell adhesion complexes in endothelial and epithelial cells. Furthermore, these authors used exosomes to reduce tight junction formation in endothelial monolayers and induce vascular permeability and metastasis in vivo. MiR-181b-3p was demonstrated to promote EMT in vitro, with its inhibition reducing the expression of mesenchymal markers, migration and invasion in highly metastatic cell lines

3.3.4.2 Suppressing

Secondly Sole and Lawrie discuss the suppressing function of miRNAs:

In addition to miRNAs that promote metastasis, other miRNAs negatively regulate this process and are consequently found to be down-regulated in cancer tissues and/or cell lines. For example, members of the miR-200 family (i.e., miR-200a, miR-200b, miR-200c, miR-141 and miR-429) as well as miR-205 have been shown to inhibit the expression of transcription repressors ZEB1 and ZEB2 to enhance E-Cadherin expression, thereby inhibiting EMT in breast cancer.

In a study that looked at miRNA expression in 59 of the NCI60 cell lines that had a E-Cadherin high and vimentin low (EMT inhibitory) phenotype, they observed a strong negative correlation with miR-200 expression, suggesting that this miRNA is a universal regulator of metastasis in many cancer types including lung, kidney, colon and ovarian cancer.

Specifically, miR-200b was shown to be down-regulated in triple negative breast cancer (TNBC) as a result of the recruitment of DNMT3A by MYC, which in turn binds to the miR-200b promoter region, resulting in promoter methylation and silencing, thereby inhibiting migration, invasion and mammosphere formation in TNBC cells. Part of the miR-200 family, miR-141 is also down-regulated in prostate cancer (PC), and its ectopic expression was shown to inhibit invasion and metastasis and to convey a strong epithelial phenotype with a partial mesenchymal phenotype

3.3.4.3 Tumor Micro Environment

The tumor micro environment is something we have examined in detail. Whether it is the extracellular matrix or the tumor associate macrophages, these extracellular complexes are now known to play significant roles in the support of tumors and their proliferation. Again, as Sole and Lawrie then focus on the TAM. Namely they note:

MiRNAs contained in exosomes have also been shown to influence non-tumor cells in the tumor microenvironment such as tumor-associated macrophages (TAMs) that promote invasion and metastasis in cancer. For example, pancreatic cancer cells under hypoxic conditions were shown to release exosomes that contained miR-301a-3p, which was demonstrated to induce TAM polarization resulting in increased pancreatic cell migration and EMT in vitro and lung metastasis in vivo. This polarization was induced by activation of the PTEN/PI3Kγ signaling pathway.

In contrast, TAMs themselves have also been shown to secrete exosomes containing functional miRNAs that can promote metastasis. For example, exosomal miR-223 derived from TAMs of breast cancer patients were demonstrated to promote tumor cell invasion through targeting of the Mef2c-β-catenin pathway. In colon cancer, activated TAMs were shown to release exosomes containing miR-21-5p and miR-155-5p, which were demonstrated to regulate migration and invasion of colorectal cancer cells through targeting of BRG1. In addition to TAMs, cancer-associated fibroblasts (CAFs), which initiate remodeling of the extracellular matrix, thereby facilitating metastasis, can also release and respond to miRNA-containing exosomes.

This is the case for example in prostate cancer, where EV-associated miR-409 was demonstrated to promote EMT both in vitro and in vivo through down-regulation of RSU1 and STAG2. In breast cancer, tumor cells were demonstrated to secrete exosomes containing miR-122 that could induce glucose reallocation in pre-metastatic sites in fibroblast and astrocyte populations, thereby making sites more conducive to metastasizing cancer cells

3.3.4.4 Exosomes

We have separately examined the potential for miRNAs to be themselves a means for metastatic transfer via exosomes[6]. Specifically, we have postulated a reasonable mechanism for this transmission[7].

---

[6] https://www.researchgate.net/publication/334429457_miRNAs_Genes_and_Cancer_Cytology

[7] https://www.researchgate.net/publication/331318495_Exosomes_and_Cancer

Jiang et al have also recently noted the relationship between exosomes and miRNAs. They state:

> *Through intercellular transfer of exosomal miRNA, tumor parenchymal cells can confer drug resistance to each other and enhance the invasiveness of recipient cells. Tumor cells can promote angiogenesis of endothelial cells, and endothelial cells can promote tumor cell proliferation. Immune cells are able to regulate tumor metastasis under different conditions, and tumor cells may induce immune cell dysfunction and pro-inflammatory cytokine release.*
>
> *Tumor cells are capable of inducing CAF phenotype transformation of mesenchymal stem cells, and mesenchymal stem cells can be transferred to the tumor site to promote tumor metastasis or dormancy, but they also inhibit tumor growth in some cases. Adipocytes play an important role in promoting tumor cell invasion, while the effect of tumor-secreted exosomes on adipocytes has not been reported to date. Exosomal miRNA can convert normal fibroblasts into CAFs for tumor survival, and CAFs can promote tumor progression*

3.3.4.5 Examples

Sole and Lawrie summarize their results in the following Table. As we shall note as we examine several significant malignancies these may vary from study to study. The important factor is to understand the targets. As we noted previously, targets are suppressed for the most part and thus either blocking the miRNA or up expressing the target may be a reasonable therapeutic.

miRNA	**Cancer**	**Express.**	**Sample**	**Target**
Let-7	Breast	Low	Cells & Tissue	*RAS & HMGA2*
miR-7	Breast	Low	Cells & Tissue	*FAK*
miR-10b	Breast	High	Cells & Tissue	*HOXD10*
miR-26a/b	HNSCC	Low	Cells & Tissue	*LOXL2*
miR-29 family	HNSCC	Low	Cells	*LAMC2 & ITGA6*
miR-29 family	HNSCC	Low	Cells & Tissue	*LOXL2*
miR-29 family	ccRCC	Low	Cells & Tissue	*LOXL2*
miR-29a	Breast	High	Cells & Tissue	*SUV420H2*
miR-29c	Lung	Low	Cells	*Integrin* β1 *& MMP2*
miR-31	Breast	Low	Cells	*Integrin* α *subunits*
miR-31	Breast	Low	Cells & Tissue	*WAVE3*
miR-33b	Breast	Low	Cells & Tissue	*HMGA2, SALL4 & Twist1*
miR-34	CRC	Low	Cells	*ZEB1 & Slug*
miR-34a/b/c	CRC	Low	Cells	*Snail*
miR-34a	Breast	Low	Cells & Tissue	*CXCL10*
miR-34c	Breast	Low	Cells & Tissue	*GIT1*
miR-93	Endometrial	High	Cells & Tissue	*FOXA1*
miR-96	Breast	High	Cells & Tissue	*PTPN9*
miR-96	HCC	High	Cells & Tissue	*ephrinA5*
miR-101	Ovarian	Low	Cells	*ZEB1 & ZEB2*
miR-101	NSCLC	Low	Cells & Tissue	*ZEB1*
miR-105	Breast	High	Cells, Tissue & Serum	*ZO-1*
miR-124	Breast	Low	Cells & Tissue	*ZEB2*
miR-124	Breast	Low	Cells & Tissue	*IL-11*

---

miRNA	Cancer	Express.	Sample	Target
miR-124	CRC	Low	Cells & Tissue	*ROCK1*
miR-128-3p	ESCC	Low	Cells & Tissue	*ZEB1*
miR-130a	Breast	Low	Cells	*FOSL1*
miR-132	NSCLC	Low	Cells & Tissue	*ZEB2*
miR-132	CRC	Low	Cells & Tissue	*ZEB2*
miR-135a	Breast	High	Cells & Tissue	*HOXA10*
miR-135a	HCC	High	Cells & Tissue	*FOXO1*
miR-135a	Gastric	Low	Cells & Tissue	*ROCK1*
miR-135b	Breast	High	Cells & Tissue	*APC*
miR-138	Breast	Low	Cells & Tissue	*ROCK1*
miR-139-5p	Glioblastoma	Low	Cells & Tissue	*ZEB1 & ZEB2*
miR-141	Breast	Low	Cells & Tissue	*HIPK1*
miR-141	Prostate	Low	Cells & Tissue	*Rho GTases, CD44 & EZH2*
miR-150	Breast	Low	Cells & Tissue	*HMGA2*
miR-154	Breast	Low	Cells & Tissue	*E2F5*
miR-181b	Breast	High	Cells & Tissue	*YWHAG*
miR-182	HCC	High	Cells & Tissue	*ephrinA5*
miR-186-5p	CRC	Low	Cells	*ZEB1*
miR-190	Breast	Low	Cells	*STC2*
miR-190	Breast	Low	Cells & Tissue	*SMAD2*
miR-194	Ovarian	High	Cells & Tissue	*PTPN12*
miR-197	HCC	High	Cells & Tissue	*Axin-2, NKD1 & DKK2*
miR-200	Breast	Low	Cells & Tissue	*ZEB1 & ZEB2*
miR-200a/b	Breast	Low	Cells	*ZEB1 & ZEB2*
miR-200c	Breast	Low	Cells	*CRKL*
miR-200c	Breast	Low	Cells	*ZEB1*
miR-200c	Breast	Low	Cells & Tissue	*HIPK1*
miR-203	HNSCC	Low	Cells & Tissue	*LASP1, SPARC & NUAK*
miR-203	Breast	Low	Cells	*Slug*
miR-203	CRC	Low	Cells & Tissue	*EIF5A2*
miR-203	Melanoma	Low	Cells & Tissue	*Slug*
miR-203	Ovarian	Low	Cells & Tissue	*BIRC5*
miR-203	Gastric	Low	Cells & Tissue	*Annexin A4*
miR-205	Breast	Low	Cells	*ZEB1*
miR-205	Breast	Low	Cells & Tissue	*ZEB1 & ZEB2*
miR-210	Breast	High	Cells & Tissue	*E-Cadherin & Snail*
miR-215	NSCLC	Low	Cells & Tissue	*ZEB2*
miR-218	HNSCC	Low	Cells & Tissue	*LOXL2*
miR-374a	Breast	High	Cells & Tissue	*WIF1, PTEN & WNT5A*
miR-409-3p	Osteosarcoma	Low	Cells & Tissue	*ZEB1*
miR-429	Breast	Low	Cells	*ZEB1 & ZEB2*
miR-504	NSCLC	Low	Cells & Tissue	*LOXL2*
miR-508-3p	Breast	Low	Cells & Tissue	*ZEB1*
miR-520c	Gastic	High	Cells & Tissue	*IRF2*
miR-574-5p	NSCLC	High	Cells, Tissue & Serum	*PTPRU*
miR-577	Gastric	High	Cells & Tissue	*SDPR*
miR-641	Cervical	Low	Cells & Tissue	*ZEB1*
miR-708-3p	Breast	Low	Cells & Tissue	*ZEB1, CDH2 & Vimentin*
miR-1204	Breast	High	Cells & Tissue	*VDR*
miR-1269a	Colorectal	High	Cells & Tissue	*Smad7 & HOXD10*
miR-8084	Breast	High	Cells, Tissue & Serum	*ING2*

3.4 LONG CODING RNA

Long non-coding RNA, lncRNA, are the long RNAs recently discovered, most of which whose function is yet unknown, which can actually control gene transcription. The lncRNAs range from 200 to well over 100,000 nucleotides. In Weinberg's latest edition of Cancer, he presents about one page only to lncRNAs, and such is an example of their newness and lack of understanding[8].

We know that there are over 25,000 genes expressible in the human genome but that these genes comprise about 2% of the total DNA. The question always has been; what does the rest of the DAN do, if anything? lncRNA may be one of many answers to this question.

3.4.1 lncRNA Overview

We begin with a brief summary of some of the details of lncRNA. From the recent book by the Kovalchuks, the authors state that lncRNA have several functions:

1. Regulation of expression of neighboring genes
2. Blocking of splicing proteins-coding genes using antisense transcripts
3. Interaction with proteins making them more or less capable of fulfilling specific functions
4. Serving as precursors for smaller ncRNAs.

Kornienko et al present an excellent overview of these functions and we summarize here in their words some key elements of them:

Regulation of transcription is considered to be interplay of tissue and developmental-specific transcription factors (TFs) and chromatin modifying factors acting on enhancer and promoter sequences to facilitate the assembly of the transcription machinery at gene promoters. With a growing number of lncRNAs implicated in transcriptional gene regulation, this view may need refinement to include networks of tissue and developmental-stage specific lncRNAs that complement known regulators to tightly control gene expression and thereby organism complexity.

Transcriptional regulation by lncRNAs could work either in cis or in trans, and could negatively or positively control pc gene expression. lncRNAs work in cis when their effects are restricted to the chromosome from which they are transcribed, and work in trans when they affect genes on other chromosomes.

They continue:

lncRNAs can inhibit general protein-coding (pc) gene expression in trans

(a) by preventing transcription factor (TF) activity (7SK lncRNA) or

---

[8] Weinberg, 2013, p 26.

(b) by inhibiting RNAPII binding to DNA (B2 lncRNA). Xist lncRNA is transcribed from the X inactivation center (XIC) and inactivates a whole chromosome in cis

(c) by recruiting epigenetic modifiers (EM). lncRNAs can regulate specific genes, acting in trans like HOTAIR

(d) or in cis like HOTTIP

(e) by directly recruiting epigenetic modifiers to certain genomic loci.

In both cases the lncRNA binds EMs via a specific sequence or structure and targets them to promoter regions via DNA/RNA interaction elements to affect expression of the respective pc gene. Transcription of a lncRNA through a pc gene promoter or a cis-regulatory element (RE) affects pc gene expression in cis independent of the lncRNA product (f) by mechanisms discussed in the text. Both DNA strands are shown as separate boxes to indicate lncRNA transcription over the pc gene promoter in the antisense orientation.

Thus, the lncRNAs have become an interesting target for examination especially as we learn more about why certain cancers return after targeted pathway control. lncRNAs are one of the many epigenetic elements which make understanding the process of cancer development and metastasis so complex.

3.4.2 Functions of lncRNA

lncRNA are complex in their function and are being discovered at a rapid pace. We present herein some details that may assist in gaining a better understanding of how they operate and how they are classified. The lncRNAs have many functions. Although they do not encode into proteins, they have the ability to interfere and facilitate many other intra-nuclear processes. It must be remembered that this is still a work in progress, the understanding of lncRNAs.

We rely upon some of the recent summary literature which describes these newly observed entities in some detail. From Kornienko et al we have an overview of classification:

Transcriptional regulation by lncRNAs could work either in cis or in trans, and could negatively or positively control gene expression. lncRNAs work in cis when their effects are restricted to the chromosome from which they are transcribed, and work in trans when they affect genes on other chromosomes.

Thus, the classification of cis and trans is a critical distinction. In addition, they may activate or suppress, and do so directly or via agents. The authors then proceed to define cis and trans. They state as follows:

Regulation in trans: *Some significant examples of lncRNAs that act in trans are those that can influence the general transcriptional output of a cell by directly affecting RNAPII activity …Regulation in trans can also act locus-specifically. While the ability of lncRNAs to act locus-*

specifically to regulate a set of genes was first demonstrated for imprinted genes where lncRNA expression was shown to silence from one to ten flanking genes in cis

Regulation in cis: *In contrast to trans-acting lncRNAs, which act via their RNA product, cis-acting lncRNAs have the possibility to act in two fundamentally different modes:*

(i) The first mode depends on a lncRNA product.

(ii) The second mode of cis regulation by lncRNAs involves the process of transcription itself, which is a priori cis-acting

The authors describe several mechanisms for its action. We report their comments as follows which are mechanisms by which lncRNA transcription silences gene expression**.**

Mechanism	*Description*
Transcription-mediated silencing, also referred to as 'transcriptional interference' (TI)	This defined here as a case in which the act of transcription of one gene can repress in cis the functional transcription of another gene.
Mechanisms by which lncRNA transcription silences gene expression	Transcription-mediated silencing, also referred to as 'transcriptional interference' (TI), is defined here as a case in which the act of transcription of one gene can repress in cis the functional transcription of another gene.
Transcriptional interference acting by promoter nucleosome repositioning	DNA in the nucleus is organized into chromatin with the organizational scaffold consisting of nucleosomes, each with two copies of H3, H4, H2A and H2B histones. Nucleosomes can be densely packed, interfering with protein-DNA interactions, or relaxed, facilitating these interactions. The transcription process, which generates single-stranded DNA as RNAPII progresses along a gene locus, can directly affect nucleosome positioning.
Transcriptional interference acting by promoter histone modifications	Promoter associated nucleosomes carry post-translational histone tail modifications that reflect the activity state of the promoter and also influence accessibility of DNA binding factors involved in transcription.
Transcriptional interference acting by promoter DNA methylation	In mammalian genomes DNA methylation is generally associated with silent CpG island promoters, but the majority of CpG island promoters remain methylation free independent of their expression status.
Transcriptional interference in the absence of chromatin changes at the silenced promoter	In addition to RNAPII acting as a carrier of chromatin modifying enzymes, other TI models predict that RNAPII from one promoter traversing across another promoter can interfere with its activity without introducing chromatin changes.
lncRNA transcription creating a permissive chromatin environment	Enhancers are genetic elements that bind transcription factors facilitating transcription machinery assembly at nearby promoters.
lncRNA transcription and locus activation	Other examples indicate that lncRNA transcription activates gene expression by blocking access of repressor complexes to chromatin.

They continue as follows:

Modes of action include cotranscriptional regulation (e.g., through either the interaction of factors with the nascent lincRNA transcript or the act of transcribing through a regulatory region), regulation of gene expression in CIS or in TRANS through recruitment of proteins or molecular complexes to specific loci, scaffolding of nuclear or cytoplasmic complexes, titration of RNA-binding factors, and pairing with other RNAs to trigger posttranscriptional regulation.

The two latter mechanisms are illustrated in the cytoplasm (where they are more frequently reported) but could also occur in the nucleus. Additional mechanisms will presumably be proposed as additional functions of lincRNAs are discovered.

The following are two examples of how lncRNA may either activate or suppress gene transcription. Case 1 is an activation shown below.



Case 2 is a suppression mode of operation as shown below.



Now from Nie et. al. we have the following summary of lncRNAs. This is but a short list of what is currently known.

lncRNA Name	***Function/Characterization***
AIR	Imprinted, monoallelically expressed from the paternal allele, interacts with histone methyltransferase G9a
AK023948	Antisense transcribed from the intron of SIR-like adaptor gene (SLA), significantly downregulated in most of papillary thyroid carcinoma
ANRIL	Antisense transcript of INK4n/ARF/INK4a and p15/CDKN2B, required for the PRC2 recruitment to and silencing p15INK4b tumor suppressor gene
BACE1AS	Antisense transcript for beta-secretase-1, directly implicated in the increased abundance of Abeta 1-42 in Alzheimer's disease
CCND1/	Transcribed from 5' end of Cyclin D1 gene, induced by DNA damage and
CUDR	Upregulated in drug-resistant human squamous carcinoma, regulates drug sensitivity, cellular transformation and apoptosis
Cyclin D1	binding to TLS protein, leading to allosteric changes and repression of Cyclin D1 and anti-sense transcripts of tie-1 related to vascular malformation
DHFR	Transcribed from upstream of DHFR gene, regulates DHFR expression by forming triple helix with the promoter and disassociating pre-initiation complex
Evf-1	Activates transcriptional activity by directly influencing Dlx-2 activity
Evf-2	An alternatively spliced form of Evf-1 activates transcriptional activity by di-
GAS5	Growth arrest-specific transcripts, controls apoptosis and cell cycle, down-regulated in breast cancers
H19	Imprinted at the lgf2 locus; controls igf2 expression *in cis*, implicated in both tumor suppressors and oncogenes
HAR1	REST target gene, decreased in the neurons of Huntington's disease
HOTAIR	Intergenic transcript of HoxC locus, gene silencing in trans through interacting with PCR2 and LSD1 complex, involved in breast cancer metastasis
HOTAIRM1	Antisense intergenic RNA myeloid 1, transcribed antisense to the HOXA genes, plays a role in the myelopoiesis through modulation of gene expression in the HOXA cluster
KCNQ1OT1	Tissue-specific imprinted genes within the Kcnq1 domain, interacting with both PRC2 and G9a leading to gene silencing in a lineage-specific manner
KRAS1P	Transcript of KRAS pseudogene, overexpression of KRAS1P 3'-UTR, increases KRAS mRNA abundance and accelerates cell growth
LincRNA ROR	Expressed in the induced pluripotent stem cells (iPSCs), involved in the conversion of lineage-committed cells by interacting with reprogramming complexes
MALAT-1/NEAT2	Expressed in many cancers, regulates alternative splicing of pre-mRNA and promotes cell motility through transcriptional and post-transcriptional regulation of motility related gene expression
MEG3	Imprinted transcripts, highly expressed in human pituitary, stimulates p53-mediated transactivation and suppresses tumor growth in the absence of p53
Myc	Antisense transcript to myc gene, may be targeting the sense transcripts for immediate degradation
P15AS	Antisense transcript of p15, highly expressed in leukemia, epigenetically silences the tumor suppressor gene p15 directly influencing Dlx-2 activity
p21NAT	Antisense to cdkn1a/p21, requires Ago1 for epigenetic silencing of Cdkn1a/p21
PCGEM1	Prostate tissue-specific and prostate-associated, overexpressed in prostate cancers, regulates cell proliferation and apoptosis, promotes colony formation
PTENP1	Transcript of PTEN tumor suppressor pseudogene, PTENP1 3'-UTR exerts a tumor suppressive function by acting as a decoy for PTEN-targeting miRNAs
SRA-1	Alternative splicing of SRA-1, loss of coding frame, an increased expression is associated with tumor metastasis
TERRA	Telomeric UUAGG repeat-containing RNA, inhibits telomerase activity, also regulates Xist and HOTAIR
Tie-1AS	Expressed temporally and spatially in vivo with its native gene tie-1, binds tie-1 mRNA, regulating tie-1 transcripts; imbalance of sense

Tsix	Antisense transcript to Xist , prevents Xist stabilization and inhibits the interaction between Rep A and PRC2, silencing Xist expression
TUG1	Ubiquitously expressed in human and mouse cell types and tissues, involves eye development, upregulated by p53, repressed cell proliferation via bound to PRC2
UCA1	Urothelial carcinoma-associated transcript, upregulated in bladder carcinoma and embryo, influences cell growth and promotes invasion
VL30-1	A mouse noncoding retroelement RNA, binds and releases PSF from a proto-oncogene, thus activating Rab23 proto-oncogene transcription
Xist	Mosaic expression, spreads on Xi *in cis*, interacts with BRCA1, correlated with breast cancer, cervical, ovarian, and testis tumors
Zeb2NAT	Antisense to Zeb2, regulates splicing of the IRES-containing intron of Zeb 2, involved in EMT

A similar result is from Ulitsky and Bartel which shows the number of identified lncRNAs determined by a number of investigators. The numbers go from just over 3,000 to almost 15,000. The functions of these lncRNAs are still less well understood than for example the miRNAs. They do however play a significant role in epigenetic control, especially in cancer dynamics.

Reference	***Data for Transcript Reconstruction***	***Genomic Features and Filters***	***Coding-Potential Filters***	***Number of lincRNAs***
Khalil et al., 2009	Chromatin marks, tiling arrays	Collection of approximate exonic regions, chromatin domain > 5kb	CSF	3,289 loci
Jia et al., 2010	cDNAs	Overlap with mRNAs allowed		5,446 transcripts
Orom et al., 2010	cDNAs	Restricted to loci >1 kb away from known protein-coding genes, > 200 nt mature length	Manual curation based on length, conservation and other characteristics of the ORFs	3,019 transcripts from 2,286 loci
Cabili et al., 2011	RNA-seq	Multi-exon only, > 200 nt mature length	PhyloCSF, Pfam	8,195 transcripts (4,662 in the stringent set)
Derrien et al., 2012	cDNAs	Overlap with mRNAs allowed (intergenic transcripts reported separately), > 200 nt mature length	Manual curation based on length, conservation and other characteristics of the ORFs	14,880 transcripts from 9,277 loci, including 9,518 intergenic transcripts

Sigova et al., 2013	RNA-seq, cDNAs, chromatin marks,	Antisense overlap with mRNA introns allowed, > 100 nt mature length	CPC	3,548 loci from embryonic stem cells, and 3,986 loci from endodermal cells

3.5 DNA

DNA can be a powerful biomarker. However, it can be fragile and oftentimes found in broken parts. The DNA may be within a cell and well preserved, it may be in an exosome and somewhat preserved and it may be cell free. As Martins et al note:

*Currently, **cell-free DNA (cfDNA) is one of the most studied analytes in liquid biopsies.***

*Both the quantity and the integrity of cfDNA in circulation have shown the **ability to distinguish cancer patients from healthy individuals**. The **total levels of cfDNA tend to be higher in cancer patients than in healthy subjects**, and seem to increase with stage and metastasis. The increased concentration of cfDNA in these patients is thought to reflect the additional release of genetic material from tumor cells, but it could also be a result of the defective clearance of circulating DNA by phagocites.*

*However, **high cfDNA levels are not specific of cancer and have been identified in other pathological and non-pathological conditions, including exercise, trauma and surgery, which might hamper their direct application for cancer diagnosis**.*

Regarding integrity, cancer patients seem to display higher cfDNA fragmentation (<100 bp) than healthy controls, although a study in thyroid carcinoma revealed the contrary, once more disclosing that this type of analyses still lack the sensitivity and specificity needed for diagnosis.

*Nevertheless, through the analysis of tumor-specific alterations, including **single nucleotide variants (SNVs), insertions, deletions, copy number variations (CNVs), and methylation alterations,** one can identify tumor-derived DNA—ctDNA, among the total pool of cfDNA, providing a much more accurate form of cancer genotyping and, consequently, of diagnosis.*

Importantly, these (epi)genetic alterations seem to be highly concordant in blood ctDNA and in corresponding tumor tissues in a variety of cancers, including lung, breast, colorectal, pancreatic, liver , esophageal , gastric, and ovarian cancers. In this sense, these minimally invasive and less risky liquid biopsies could be used as an alternative to tissue biopsies in cases in which the latter cannot be performed or when these do not gather enough high-quality DNA.

In fact, since 2016, non-small cell lung cancer (NSCLC) patients who are unable to provide tumor specimens can be tested for EGFR mutations in plasma, using the U.S. Food and Drug Administration (FDA)-approved cobas EGFR Mutation Test v2. Since then, several other liquid biopsy-based tests have been approved by this agency: plasma samples are now being used to *detect specific gene mutations and rearrangements in patients with ovarian, lung, breast, and metastatic castration resistance prostate cancers. These tests are mainly used as companion diagnostic tests to identify patients who are eligible for targeted treatments. However, the concordance of alterations found in ctDNA and tumor tissues varies not only according to the type of cancer, since different tumors have different probabilities of shedding DNA into the bloodstream , but also depending on the stage of the disease. In fact, cfDNA levels tend to be lower in earlier stages, suggesting a limited role of liquid biopsies for the early detection of cancer, although increased technological sensitivity might help overcome these problems.*

Even though the use of liquid biopsies for cancer screening is still largely undeveloped, a liquid biopsy test based on the detection of abnormal methylation of the SEPTIN9 gene in blood has already been approved to screen for colorectal cancer (CRC). In addition, other blood tests that use ctDNA to screen for several cancer types, including ovarian, liver, stomach, pancreatic and esophageal, which, to date, do not have screening tests available, are currently being studied. In addition to accurately representing the tumor profile, ctDNA also captures tumor heterogeneity.

This is particularly relevant in metastatic disease, in which multiple tissue biopsies might not be viable and are associated with increased cost and risks to the patients. Correctly profiling all tumor sites is especially important for the detection of actionable mutations and, as mentioned above, for the selection of patients that might benefit from targeted therapies. Still, ctDNA analysis might be less sensitive to detect some alterations that are found in tumor tissues, since these are diluted in a background of germline DNA and some might be present in small subsets of cells and, thus, exist in lower quantities in circulation.

Therefore, currently, liquid biopsies seem to have a more complementary rather than alternative role to tissue biopsies for diagnostic and profiling purposes. Besides blood, other biofluids, such as urine, cerebrospinal fluid (CSF) , and gastric washes , have been shown to harbor ctDNA. Depending on the type of cancer, tumors might more closely contact with different fluids that, consequently, might contain higher ctDNA concentrations than blood. For example, urinary ctDNA has been detected in bladder and other urothelial cancers. Moreover, transrenal DNA, resulting from the clearance of bloodstream cfDNA by the kidneys, has also been detected in non-urological tumors, such as NSCLC and CRC.

Notably, urinary ctDNA also presents cancer-specific mutations , CNVs and methylation alterations that are highly concordant with the ones found in tumor tissues. Given this, the use of urine for liquid biopsies is particularly promising considering that its collection is totally non-invasive, resulting in improved patient compliance for serial sampling for diagnosis or follow-up.

Nevertheless, although there seems to be a positive correlation between plasma and urine cfDNA levels, mutation detection in urine is usually limited in comparison to blood. Regarding CSF, this is a specially relevant source of information in brain tumors, such as gliomas, as an alternative to surgical tissue biopsies. Importantly, CSF-derived ctDNA has also been shown to display tumor-concordant mutations, CNVs, and structural rearrangements. In addition to ctDNA, other components with diagnostic potential can be investigated in liquid biopsies, such as messenger RNA (mRNA) and micro-RNAs (miRNAs). For instance, Malczewska et al. evaluated gene *expression in the blood of patients with bronchopulmonary carcinoid (BPC) tumors and revealed that the levels of target transcripts were significantly increased in comparison to healthy controls and enabled to distinguish metastatic and localized disease.* ***Importantly, gene expression was highly correlated in tumor tissue and blood.***

The challenge of course is determining the source of this DNA. Just having an aberrant DNA sequence may mean nothing more than it is from somewhere and may just be sloughed off from that location.

3.6 Proteins

Proteins have been a useful target for a long period. PSA for example is a well-used marker for prostate cancer.

3.7 Genes

There are a variety of genes which are useful for various cancers. We demonstrate a sample of these below.

Cancer types	Biological source	Isolation method	Detection method	Markers	Potential application
Prostate	Plasma	UC	ELISA	PSA	Diagnosis/ Prognosis
	Urine	UC/SUC	ELISA/WB	PSA. PSMA	Diagnosis/ Monitoring
	Plasma/ Serum	UC/ ExoQuick	ELISA/WB	Survivin	Diagnosis/ Monitoring
	Urine	UC	IP/WB	6-catenin	Diagnosis
	Serum	UC	WB	MDR-l/P-gp. MDR-3. PABP4	Predict chemoresistance (Docetaxel)
	Plasma	-	FCM	PSMA	Monitoring/Predict chemoresistance
Bladder cancer	Urine	UC	MS/WB	EH-domain-containing protein 4. EPS8L1. EPS8L2, GTPase NRas Mucin 4. retinoic acid-induced protein3, resistin. alpha subunit of GsGTP binding protein	Diagnosis
	Urine	UC	ELISA	TACSTD2	Diagnosis
	Urine	UC	MS	a-l-antHrypsin, H2B1K	Diagnosis
	Urine	UC	WB	HEXB. S100A4, SND1. TALDOl, and EHD4	Diagnosis
	Urine	UC	WB	Periostin	Diagnosis
	Urine	UC/SUC	WB	EDIL3	Diagnosis
	Urine	UC/SUC	FCM	CD36, CD44,5T4. CD73. MUC1.	Diagnosis

Cancer types	Biological source	Isolation method	Detection method	Markers	Potential application
Renal cancer	Urine	UC	MS/WB	MMP9, DKK4, EMMPRIN. CP, POO XL. CAIX. CD10, AQP1,	Diagnosis
Breast cancer	Serum	ExoQuick	ELISA	Survivia Surviving	Diagnosis/Prognosis
	Serum/Plasma	ExoQuick	ELISA/WB	CD82	Diagnosis
	Ascites	UC/SUC	WB	CD24, EpC AM	Diagnosis
	Plasma	UC	FCM	TRPCS	Prognosis/Predict chemoresistance
	Serum	UC	FCM	UCH-L1	Predict chemoresistance (Anthracycline/ taxane)
	Serum	UC	FCM/WB	HER2	Predict chemoresistance (Trastuzumab)
	Plasma	UC	ELISA/FCM	TGFpl	Predict chemoresistance (Trastuzumab)
Ovarian	Plasma	-	Exosearch chip	CD24, EpCAM, CA-12S	Diagnosis
	Plasma	UC	WB	TGFpl. MAGE3/6	Diagnosis
	Plasma	UC/SUC	WB	Claudin-4	Diagnosis
	Ascites	UC/SUC	WB	E-cadherin	Diagnosis/Prognosis
	Ascites	UC	WB	MMP2.MMP9.uPA	Diagnosis
	Ascites	UC/SUC	WB	CD24, L1CAM, ADAM10, EMMPRIN	Diagnosis/Prognosis
Digestive cancer					
Pancreatic	Serum	UC	FCM	GPC1	Diagnosis/Prognosis
	Serum	UC/SUC	ELISA	CKAP4	Diagnosis
	Serum	UC	ELISA	MIF	Diagnosis/Prognosis
	Plasma	-	ELISA	EpCAM	Prognose
Colorectal	Serum	ExoQuick	ELISA	CEA	Diagnosis
	Serum	-	ExoScreen	CDM7.CD9	Diagnosis
	Ascites	UC	WB	daudan-3	Diagnosis
Gastric cancer	Serum	UC	FCM/WB	HER-2/neu, CCR6, EMMPRIN. MAGE-1. c-MET	Diagnosis
Lung cancer (NSCLC)	Serum	UC	ELISA	EGFR	Diagnosis
	Serum	UC	ELISA/WB	AHSG. ECM1 (with serum CEA)	Diagnosis
	Serum	-	EV array	30 Proteins	Diagnosis
	Plasma	-	EV array	CD171, NY-ESO-1. PLAP. Flotilinl	Diagnosis
	Urine	UC	WB	IRG1	Diagnosis

Cancer types	Biological source	Isolation method	Detection method	Markers	Potential application
Melanoma	Plasma	UC	ELISA (Exo Test/FCM/WB	Caveolin-1, CD63	Diagnosis/Prognosis
	Plasma	UC	WB	TYRP2L VLA-4, HSP70. HSP90	Prognose
	Plasma	UC/Total Exosome isolation Kit	ELISA/FCM/ WB	PDL-1	Predict immunotherapy resistance (Pembrolizumab)

The above abbreviations are as follows: NSCLC: Non-small cell lung cancer; LSCC: laryngeal squamous cell carcinoma; UC: ultracentrifugation; SUC: sucrose cushion; ELISA: enzyme-linked immuno-sorbent assay; FCM: flow cytometry; WB: western blotting; IP: immunoprecipitation; MS: mass spectrometry; miRNA: microRNA; tRNA: transfer RNA; circRNA: circular RNA; lncRNA: long non-coding RNA.

3.7.1 Mutations

Mutations are just changes in a gene resulting generally from an exogeneous source such as radiation, reactive oxygen species, viruses, and the like. As Nature notes[9]:

A single base change can create a devastating genetic disorder or a beneficial adaptation, or it might have no effect. How do mutations happen, and how do they influence the future of a species? Although the haploid human genome consists of 3 billion nucleotides, changes in even a single base pair can result in dramatic physiological malfunctions.

For example, sickle-cell anemia is a disease caused by the smallest of genetic changes. Here, the alteration of a single nucleotide in the gene for the beta chain of the hemoglobin protein (the oxygen-carrying protein that makes blood red) is all it takes to turn a normal hemoglobin gene into a sickle-cell hemoglobin gene. This single nucleotide change alters only one amino acid in the protein chain, but the results are devastating. Beta hemoglobin (beta globin) is a single chain of 147 amino acids. As previously mentioned, in sickle-cell anemia, the gene for beta globin is mutated. The resulting protein still consists of 147 amino acids, but because of the single-base mutation, the sixth amino acid in the chain is valine, rather than glutamic acid.

*While a mutation is defined as any alteration in the DNA sequence, … the term "single nucleotide polymorphism" (SNP) to refer to a single base pair alteration that is **common** in the population. Specifically, a polymorphism is any genetic location at which at least two different sequences are found, with each sequence present in at least 1% of the population. Note that the term "polymorphism" is generally used to refer to a normal variation, or one that does not directly cause disease. Moreover, the cutoff of at least 1% prevalence for a variation to be classified as a polymorphism is somewhat arbitrary; if the frequency is lower than this, the allele*

---

[9] https://www.nature.com/scitable/topicpage/genetic-mutation-441/

is typically regarded as a mutation. SNPs are important as markers, or signposts, for scientists to use when they look at populations of organisms in an attempt to find genetic changes that predispose individuals to certain traits, including disease. On average, SNPs are found every 1,000–2,000 nucleotides in the human genome, and scientists participating in the International HapMap Consortium have mapped millions of these alterations.

Mutations can result from a number of events, including unequal crossing-over during meiosis. In addition, some areas of the genome simply seem to be more prone to mutation than others. These "hot spots" are often a result of the DNA sequence itself being more accessible to mutagens. Hot spots include areas of the genome with highly repetitive sequences, such as trinucleotide repeats, in which a sequence of three nucleotides is repeated many times. During DNA replication, these repeat regions are often altered because the polymerase can "slip" as it disassociates and reassociates with the DNA strand.

To better understand a polymerase slip, imagine you are reading a page of text that is a repeat of a simple sequence. Say that the whole page is just copies of the word "And" ("And And And..."). Now, imagine that while reading the page, you briefly glance away and then look back at the text. It's quite likely that you will have lost your place. As a result, you may read the wrong number of copies from the page. Similarly, DNA polymerase sometimes slips and makes mistakes when reading repeats. In other cases, mutations alter the way a gene is read through either the insertion or the deletion of a single base.

In these so-called frameshift mutations, entire proteins are altered as a result of the deletion or insertion. This occurs because nucleotides are read by ribosomes in groups of three, called codons.

Thus, if the number of bases removed or inserted from a gene is not a multiple of three, the reading frame for the rest of the protein is thrown off. To better understand this concept, consider the following sentence composed entirely of three-letter words, which provides an analogy for a series of three-letter codons.

As previously mentioned, DNA in any cell can be altered by way of a number of factors, including environmental influences, certain chemicals, spontaneous mutations, and errors that occur during the process of replication. Each of these mechanisms is discussed in greater detail in the following sections. Oxidizing agents, commonly known as free radicals, are substances that can chemically modify nucleotides in ways that alter their base-pairing capacities.

Mutations can also occur spontaneously. For instance, depurination in which a purine base is lost from a nucleotide through hydrolysis even though the sugar-phosphate backbone is unaltered, can occur without an explicit insult from the environment. If uncorrected by DNA repair enzymes, depurination may result in the incorporation of an incorrect base during the next round of replication.

3.8 METHYLATION

DNA methylation is a process whereby the cytosine is changed by the insertion of a methyl group on the 5 carbons of the ring[10]. It is a process which is epigenetic and can dramatically modify gene expression. In fact, many of the methylation issue in humans are also common to plants, see the work by Zilberman. There has been a great deal of work demonstrating the impact of methylation on cancer progression; specifically, the recent summary by Herman and Baylin, that of Palii and Robertson, that of Robertson and Wolffe, Strathdee and Brown, Calin and Croce, are all worth reviewing.

In this section we examine methylation and its impact on several cancers. We will also examine briefly the causes of methylation as well as the therapeutics in use to modulate cancers that cause or persistence is supported by methylation related products, either directly or indirectly.

In the paper by Das and Singal, the authors define epigenetics in a quite clear manner:

Epigenetics can be described as a stable alteration in gene expression potential that takes place during development and cell proliferation, without any change in gene sequence.

DNA methylation is one of the most commonly occurring epigenetic events taking place in the mammalian genome. This change, though heritable, is reversible, making it a therapeutic target.

Epigenetics has evolved as a rapidly developing area of research.

Recent studies have shown that epigenetics plays an important role in cancer biology, viral infections, activity of mobile elements, somatic gene therapy, cloning, transgenic technologies, genomic imprinting, developmental abnormalities, mental health, and X-inactivation

This is one of the clearest definitions of epigenetics and especially the linking of methylation to epigenetics. The classic Watson and Crick model, now some 60 years old, we had the paradigm of DNA, RNA and protein. It was the proteins which did the work. In the 1953 world the proteins stood one by one and the clarity of gene to protein was unquestioned. Yet as we have come to better understand the details, and the details always count, there are many interfering epigenetic factors that all too often get in the way. Methylation is but one of those factors.

Basic cytosine is shown below. It has two NH groups at opposite poles and single oxygen.



---

[10] See Armstrong. This is an excellent introduction but now a bit dated.

Now when the 5 carbon is replaced by a methyl group we obtain the form below. This is methylated cytosine.



Thus, this small change in C, by adding the methyl group, can make for a dramatic difference in the expression of genes. For example, a well-controlled gene for proliferation, such as PTEN, may have its control over-ridden by the methylation of Introns of CpG islands, namely collections of C, cytosine nucleotides, and G, guanine nucleotides. The introns may be down from the gene, they may even be on a promoter section. The impact could be an aberrant cell proliferation and growth.

We examine the process; we then look at three types of cancers, a glandular, an epidermal, and a hematopoietic form and then examine some means used to control those cancers through the understanding or methylation and the control of it by therapeutics designed just for that purpose.

What is important about understanding methylation and especially all epigenetic changes are that it may perhaps be simpler to control them rather than a gene mutation. As Brower states:

The move from a purely genetic to an epigenetic model is crucial for prevention strategies. As numerous gene therapy trials have shown, it is very difficult to treat a genetic disease by re-activating the dormant, mutated gene or by replacing it with a non-mutated one. "Epigenetic changes are reversible, and therefore have an edge over genetics," says Mukesh Verma, an epigeneticist at the National Cancer Institute's division of cancer control and population sciences in Bethesda, Maryland. Furthermore, epigenetic changes in cancer occur before genetic mutations. "If you can prevent methylation of those tumour suppressor genes, you might have a valuable prevention strategy," says Baylin.

Thus, if we see cancers when they are driven by methylation, then can we actually anticipate reversing the process by reversing the methylation changes. Thus, with prostate cancer can we anticipate a preventative measure as one increasing certain methylation preventative therapeutics, can we do the same with say MDS, and can we attempt to do the same with say a melanoma. This is what we examine herein.

3.8.1 Some DNA Basics

We begin with some simple facts about DNA and then we lead to the methylation of cytosine. But first, the basics of DNA.

DNA is composed of just five basis elements; a ribose backbone with phosphates, and four different nucleotides (C, G, A and T). They align in a double stranded classic DNA pattern.

The base pairs and their ribose/phosphate backbone parts are shown below.



Adenine



Cytosine



Guanine



Thymine

Now we connect these in the one side of the double helix as is shown below:



Then from here we can connect the A-T and G-C pairs which make up the DNA as we know it.





The key observation of Watson and Crick was the hydrogen bonding between base pairs. As Watson and Crick stated in 1953:

The novel feature of the structure is the manner in which the two chains are held together by the purine and pyrimidine bases. The planes of the bases are perpendicular to the fiber axis. They are joined together in pairs, a. single base from ***one chain being hydrogen-bonded to a single base from the other chain****, so that the two lie side by side with identical z-co-ordinates. One of the pair must be a purine and the other a pyrimidine for bonding to occur. The hydrogen bonds are made as follows: purine position 1 to pyrimidine position 1; purine position 6 to pyrimidine position 6.*

The CG bonding is shown below:



Hydrogen Bonding between C and G



This model is the basis of what we now know as our DNA. The DNA is divided into chromosomes, different strands, and then in the chromosomes we have Introns, non-expressing parts of DNA, and Exons, the expressing parts. The current view is that although the non-expressing parts do not yield proteins, they strongly affect that process. That is what methylation does.

3.8.2 Methylation and DNA

We have now described methylation, a rather simple process, and now we seek to discuss its influence on DNA. We start first at the top level of DNA, namely the chromosome. Consider below the wrapped DNA around histones. The histones are themselves proteins that facilitate the compression of DNA in the nucleus.



Note: Histones H1, H2A, H2B, H3 and H4 are shown arranged. Genes inside the wrapped segments around a histone cannot be transcribed.

Methylation occurs when we have methyl groups attached to the DNA. We demonstrate this graphically below:



Finally, the methyl groups can block the expression of certain genes as we demonstrate below. This is the impact of epigenetic modifications. Thus, methyl groups and similar such groups resulting from the epigenetic processes can dramatically alter genome expression.





Now we can use the above to understand the impact of these epigenetic factors via the interactions between Sirt1 and diet. In a recent paper by Labbe et al the authors examine dies and PCa. In particular they discuss the effect of Sirt1[11]. We show a modification of the Figure in the paper below. Glucose is converted to pyruvate via the action of NAD+ to NAH. Likewise this activates citrate to Acetyl-Co A and acetylates the histone changing its code but Sirt1 then deacetylates it to the ground state again. Thus, loss of Sirt1 can potentially allow excess acetylated states which in turn does not allow the related genes to be expressed. Now from our discussions of miRNA exosomes we also understand that perhaps this down regulation of Sirt1 could be a result of metastatic spread of deregulating miRNAs. Although conjecture, the spread of miR34 via exosomes would result in suppression of Sirt1 as well as many other critical genes.

---

[11] http://www.nature.com/onc/journal/vaop/ncurrent/pdf/onc2014422a.pdf



The authors state as flows in their paper:

SIRT1 activity depends on the NAD+/NADH ratio modulated by glycolysis, while O-linked N-acetylglucosamine transferase uses GlcNAc produced by the hexosamine pathway. Pyruvate entering the tricarboxylic acid (TCA) cycle produces alpha-ketoglutarate, a critical cofactor for Jumonji domain-containing histone demethylase and TET. Acetyl-CoA is converted from the citrate generated by the TCA cycle and used as a donor by histone acetyltransferases.

Finally, the increase in ATP/ADP ratio from the TCA cycle also inactivates AMPK…. Under low-nutrient conditions, the NAD+/NADH ratio increases, activates SIRT1, which in turn de-acetylates and triggers ACECSs activity. Therefore, the pool of acetyl-CoA, which is governed by nutrient availability, controls the acetylation of metabolic enzymes as well as of histones at any given time.

As Melo et al state:

Exosomes are secreted by all cell types and contain proteins and nucleic acids. Here, we report that breast cancer associated exosomes contain microRNAs (miRNAs) associated with the RISC-Loading Complex (RLC) and display cell-independent capacity to process precursor microRNAs (pre-miRNAs) into mature miRNAs. Pre-miRNAs, along with Dicer, AGO2, and TRBP, are present in exosomes of cancer cells. CD43 mediates the accumulation of Dicer specifically in cancer exosomes.

Cancer exosomes mediate an efficient and rapid silencing of mRNAs to reprogram the target cell transcriptome. Exosomes derived from cells and sera of patients with breast cancer instigate nontumorigenic epithelial cells to form tumors in a Dicer-dependent manner. These findings offer opportunities for the development of exosomes based biomarkers and therapies.

It would be expected that this may be found elsewhere, especially in PCa, since both PCa and Breast Cancer have great similarity[12].

Moreover, Braicu et al have presented a more comprehensive understanding of exosomes. Their observations are as follows:

Exosomes are key elements that facilitate intercellular communication; depending on their vesicular content (‘cargo’), they can modulate tumor cells by influencing major cellular pathways such as apoptosis, cell differentiation, angiogenesis and metastasis. This communication can involve the exchange of molecules such as small noncoding RNAs (e.g., miRNAs) between malignant, non-transformed and stromal cells (in all directions). Exosomal miRNAs represent ideal candidates for biomarkers, with multiple applications in the management of an array of pathologies such as cancer. Manipulating exosomal miRNAs suggests new alternatives for patient-tailored individualized therapies.

They continue:

MiRNAs are short single-stranded (19–25 nucleotides in length) nonprotein-coding RNA transcripts (ncRNA) that are initially produced in the nucleus and then transported into the cytoplasm, where they undergo a series of steps to acquire maturation. Mature miRNAs regulate gene expression by binding (through watsonian complementarity) to the sequence of a target mRNA. This interaction results in translational repression and/or mRNA cleavage, which consequently decreases the levels of the mRNA coding protein. MiRNAs have been found to be aberrantly expressed in many diseases. For example, in cancer, the tumor microenvironment contains deregulated miRNA levels, and a reason for their altered levels is because they are being actively secreted as membrane-bound vesicular content.

Finally, they state:

Immediately after their synthesis, exosomes are released and can remain in the extracellular space near the cell they originated from. Alternatively, they can also travel through body fluids such as blood, urine, amniotic fluid, saliva, lung surfactant, malignant effusions or breast milk. The end result of this dynamic process is a variety of regulative molecules being transported to different tissues in different places, and influencing cellular processes. Exosomes have been shown to carry proteins, many of which have the potential to influence multiple regulatory mechanisms. For example, exosomes can transport annexins that have the ability of altering the dynamics of the cytoskeleton.

Thus, it is well understood that exosomes have not only the potential to allow one to see inside the cell, not only to transport to other cells but more importantly to act and a distributed means of control.

---

[12] See Telmarc White Paper 112 Prostate Cancer: miR-34, p53, MET and Methylation for detailed analysis.

3.9 The Histone Code

The Histone Code was described by Strahl and Allis in 2000 and it can be simply explained as follows[13]. We examine it in a bit more detail here. It is a critical factor in opening and closing genes. First, we layout below the relationship of a histone and its tail, the region for attachments.



In the above we have a tail and tail locations and respective amino acids for each location. Now on the top there are no methylations or acetylations. We have then done so on the one below. We can assert that in the top condition we have the base state and then the one below some active state. Thus, we go from off to on whatever that may mean. Thus, as Strahl and Allis note in their presentation we have:

N	*1*	*2*	*3*	*…*	*27*	*28*	*Modification State*	*Associated Protein*	*Function*
	M						Methylated	SIRT	Silencing
		M					Methylated	SMC	Transcription
				M	M		Methylated	RCAF	Mitosis
	A						Acetylated	Bromodomain	Transcription
		A		P	M		Complex	TWIST	Silencing

Namely the histone code postulates what reaction will ensue when we have some form of epigenetic change on a specific tail of a specific histone and it indicates what protein is necessitated to effect this epigenetic change.

---

[13] From Armstrong, pp 72-73, the authors states: *"…the histone code hypothesis … states that the multiple histone modifications, acting in a combinatorial or sequential fashion on one of multiple histone tails, specify unique downstream functions."*

Now the histone code relates to the state of the tail as described by methylations or other related attachments and the resulting actions related thereto.

The above demonstrates the tail composed of a collection of amino acids and the extension of that from each of the histone elements. These tails allow for reactions which in turn result in changes of gene expression. As we shall see, the protein we are focusing on, NSD2, is a histone modifying protein and it targets a specific amino acid on the histone. In this case it targets H3K36me3.

This nomenclature states:

1. Histone H3
2. K for lysine
3. Location 36 on the tail
4. methylated
5. tri methylated

Thus, the notation can be specific as to the tuple:

{*histone:amino acid:location:modification:degree*} =- H3K36me3.

As Jenuwein and Allis had noted in 2000:

Chromatin, the physiological template of all eukaryotic genetic information, is subject to a diverse array of posttranslational modifications that largely impinge on histone amino termini, thereby regulating access to the underlying DNA. Distinct histone amino-terminal modifications can generate synergistic or antagonistic interaction affinities for chromatin-associated proteins, which in turn dictate dynamic transitions between transcriptionally active or transcriptionally silent chromatin states. The combinatorial nature of histone amino-terminal modifications thus reveals a "histone code" that considerably extends the information potential of the genetic code.

From Tollefsbol we have:

Equally important in the fine tuning control of chromatin organization is the interplay between the histone modifications, DNA methylation and ATP-dependent chromatin remodeling. The large number of histone modifications and the possible interplay between them led to the proposition of the so-called "histone code hypothesis" in which "multiple histone modifications, acting in a combinatorial or sequential fashion on one or multiple histone tails, specify unique downstream functions". This hypothesis led the scientific community to adopt some metaphors to describe it such that the code is written by some enzymes ("writers"), removed by others ("erasers"), and is readily recognized by proteins ("readers") recruited to modifications through the binding of specific domains.

More complicated versions are available, in 2000 Strahl and Allis noted:

The `histone code' hypothesis.

Histone modifications occur at selected residues and some of the patterns shown have been closely linked to a biological event *(for example, acetylation and transcription). Emerging evidence suggests that* ***distinct H3 and H4 tail modifications act sequentially or in combination to regulate unique biological outcomes****. How this hierarchy of multiple modifications extends (depicted as `higher-order combinations') or how distinct combinatorial sets are established or maintained in localized regions of the chromatin fiber is not known.*

Relevant proteins or protein domains that are known to interact or associate with distinct modifications are indicated. The CENP-A tail domain might also be subjected to mitosis-related marks such as phosphorylation; the yellow bracket depicts a motif in which serines and threonines alternate with proline residues

From Tollefsbol we have another slightly more complicated version:

Chromatin Modification	***Residues modified***	***Function regulated***
Acetylation	Lysine	Transcription, DNA repair, replication and condensation
Methylation (Lysine)	Lysine me1, me2, me3	Transcription, DNA repair
Methylation (Arginine)	Arginine-me1, Arginine-me2a Arginine-me2s	Transcription
Phosphorylation	Serine, Threonine, Tyrosine	Transcription, DNA repair and condensation
Ubiqutination	Lysine	Transcription, DNA repair
Sumoylation	Lysine	Transcription
ADP ribosylation	Glutamic	Transcription
Deimination	Arginine	Transcription
Proline isomerization	P-cis, P-trans	Transcription

In summary we can articulate this as follows:

1. A base state is present and in the base state the genes follow the base state expression.

2. A methyltransferase or equivalent is introduced. This means that it is activated by some means. We leave that to the side for the moment.

3. The methyltransferase targets a specific histone tail element. It then methylates that element.

4. The methylated tail then reconfigures the histone arrangement, opening or closing sections of DNA.

5. DNA expression is altered as a result of the change in the histone configurations. Proteins are produced which are then sent from the nucleus or kept there.

6. The new proteins commence the actions for which they function. Cells then proliferate, go through epithelial-mesenchymal transitions and the like.

Conceptually this is a simple process but in actuality there are a multiplicity of questions as to what and why.

As Lu and Thompson have noted regarding the interaction between the histones and SIRT1 we have:

Histone acetylation*—Histone acetylation is catalyzed by HATs. Mammalian HATs are divided into five families which share a similar enzymatic reaction: HATs transfer the acetyl group of the acetyl-CoA to the lysine residues of histones and produce CoA as an end product. As demonstrated in yeast, elevated levels of acetyl-CoA can be sufficient to instruct cells to enter growth by promoting histone acetylation and expression of growth-related genes, suggesting that the availability of acetyl-CoA is a major metabolic input into histone acetylation. Indeed, it was shown that depending on the metabolic state, intracellular acetyl-CoA concentration shows a ~10-fold variation. Since the Km of most HATs is within the range the activities of HATs are likely sensitive to the fluctuation of intracellular acetyl-CoA levels.*

Histone deacetylation*—Enzymes that catalyze the removal of histone acetylation can be in principle divided into two groups based on structural and mechanistic similarities: classical HDACs and NAD+-dependent sirtuin family deacetylases. The deacetylation reaction is energetically favorable. Therefore, sirtuins are intriguing as they catalyze the reaction in a seemingly wasteful way: one NAD+ molecule is hydrolyzed to yield nicotinamide and O-acetyl-ADP-ribose. The substrates of sirtuins are diverse and among seven members of the mammalian sirtuin family, SIRT1 and SIRT6 have been shown to localize to the nucleus and exhibit HDAC activities.*

DNA and histone methylation*—DNMTs and HMTs add methyl groups to DNA or lysine/arginine residues of histones, respectively. Although structurally diverse and possessing high substrate specificities, DNMTs and HMTs share a similar reaction mechanism: transferring a methyl group from S-adenosyl methionine (SAM) to the substrate with the formation of the by-product S-adenosyl homocysteine (SAH). SAM is derived from the essential amino acid methionine through methionine adenosyltransferase (MAT). It is possible to alter SAM levels through diets. However, SAH is a very potent inhibitor of DNMTs and HMTs and the key metabolic determinant of methyltransferase reactions is the rate of SAH clearance. SAH can be hydrolyzed to homocysteine. Homocysteine can be used to regenerate methionine, a step catalyzed by methionine synthetase and dependent on one-carbon metabolism. Alternately, homocysteine can enter the transulfuration pathway to generate cysteine, the precursor for glutathione synthesis.*

DNA and histone demethylation*—A covalent methyl group is chemically stable. Therefore, DNA and histone methylation were considered as relatively static epigenetic marks. However,* *during embryonic development there is extensive remodeling of the cellular methylome, suggesting the existence of enzymes that actively remove methylation marks. Indeed, in recent years, a variety of HDMs and DNHDs have been identified. The first identified HDM is LSD1. The histone demethylation reaction catalyzed by LSD1 involves the reduction of co-factor flavin adenine dinucleotide (FAD) to FADH2 and the release of formaldehyde as a by-product. As recycling of FAD requires converting molecular oxygen to hydrogen peroxide*

The histone code regarding the methylation is shown below[14]. Here we show what specific methylations by histones can result in activation or repression. From the Judd Rice Lab in the Histone Code web site we have the following definition:

The histone code hypothesis predicts that the post-translational modifications of histones, alone or in combination, function to direct specific and distinct DNA-templated programs.

It has been known for over 45 years now that histones can be post-translationally modified by specific enzymes that write a histone code by adding or removing a number of different chemical modifications, including acetyl, phosphoryl and methyl groups. Since these modifications occur only on specific amino acid residues on specific histones in various eukaryotic organisms, these observations strongly linked the modifications involvement in nuclear processes.

For example, the acetylation of key lysine residues of histone H3 and H4 by enzymes known as histone acetyltransferases (HATs) was known to play a pivotal role in transcriptional activation. Conversely, the removal of the acetyl groups by enzymes known as histone deacetylases (HDACs) was known to be associated with transcriptionally inactive chromatin.

More recent findings demonstrate that certain histone modifications can actually block or recruit additional histone modifications. For example, methylated H4 can directly block the enzymatic activity of HATs resulting in a histone H4 that is methylated but devoid of acetylation this is associated with transcriptionally inactive regions.

In contrast, during mitogenic stimulation, the phosphorylation of H3 can recruit HATs to acetylate H3 resulting in a histone H3 that is both phosphorylated and acetylated ?this is associated with highly transcribed regions.

The details of the Histone Code are below:

---

[14] http://www.histonecode.com/

	H3K4	H3K9	H3K14	H3K27	H3K79	H4K20	H2BK5
Mono-meth	Active	Active		Active	Active	Active	Active
Di-meth		Repress		Repress	Active		
Tri-meth	Active	Repress		Repress	Active		Repress
Acetyl		Active	Active		Repress		

From Jenuwein and Allis we have:

The ***histone code hypothesis predicts that the modification marks on the histone tails should provide binding sites for effector proteins.***

In agreement with this notion, the bromodomain has been the first protein module to be shown to selectively interact with a covalent mark (acetylated lysine) in the histone NH 2-terminal tail. In addition to the proteins discussed above, the bromodomain is also present in many transcriptional regulators having intrinsic histone acetyltransferase (HAT) activity (e.g., GCN5, PCAF, TAFII250).

Consistent with the second prediction of the histone code (that there be combinatorial readout), TAFII250, which itself harbors several histone-modifying activities, contains two tandem copies of the bromodomain*.*

In this configuration it preferentially binds diacetylated histone peptides presenting acetyl-lysine moieties that are appropriately spaced.

Use of the Simple Modular Architectural Research Tool (SMART; http://smart.embl-heidelberg.de) indicates that there are ;75 bromodomain-containing proteins in humans. Several of these proteins, such as human poly-bromodomain protein 1, exhibit many copies (six) of regularly spaced bromodomains, which could conceivably bind to a specific combination of acetyl groups presented on one or several histone tails.

Chromodomains, on the other hand, appear to be targeting modules for methylation marks. The chromodomain of HP1 is highly selective for methylated H3 at Lys9, and little if any binding is observed with H3 peptides containing a methylated Lys4 position. Thus, although chromodomains are highly conserved, it seems likely that not all chromodomains—nor their methyl targets—behave similarly. In support, chromodomain swapping experiments have not uniformly indicated functional conservation in silencing assays.

Interestingly, Su(var)3-9 HMTase family members also contain a chromodomain, whose integrity is critical for silencing in vivo. Several repressive chromatin-remodeling complexes comprise components such as the Mi-2/CHD ATPase subunit of the NuRD complex , which harbors two chromodomains and might conceivably recognize dimethylated histone tails in a manner analogous to double bromodomains. In this regard, we note that Lys9 and Lys27 in the

H3 tail are embedded in similar sequence motifs, and both positions are "hot spots" for methylation by the SET domain– containing HMTase G9a.

Finally, a hallmark property of all HP1 proteins is the combination of a chromodomain with a chromoshadow domain that are separated by a short but variable hinge region. Because the chromoshadow domain of HP1 appears to self-dimerize in solution , it is tempting to infer that full-length HP1 may assemble intermolecular chromodomains, thereby generating a bifunctional cross-linker that is likely to stabilize the more rigid higher order structure of heterochromatin

However, Hassler and Egger have noted:

The coiling of DNA around nucleosome particles is the basis for the organization of eukaryotic genomes. A multitude of different posttranslational modifications of the core histone proteins (H2A, H2B, H3 and H4) allows for demarcation of specific chromatin regions and states, as illustrated by recent genome-wide chromatin modification mapping studies.

Histone modifications can be dynamically added or removed and associate with both active and repressed regions of chromatin. To date more than a dozen different histone modifications have been detected, which can modify more than 150 conserved residues within histone proteins.

This number of different modifications has a high combinatorial potential, which would yield a hugely complex histone code and it is under debate, whether such a code exists or whether histone modifications are a consequence and mere reflection of dynamic processes altering DNA accessibility such as transcription factor or RNA polymerase II (RNAPII) binding or chromatin remodeling.

Generally, certain histone modifications such as acetylation or phosphorylation are thought to change chromatin structure by altering the net positive charge of the histone proteins, thereby rendering the underlying DNA sequence information more accessible.

Alternatively, histone modifications can be recognized by specific protein domains (e.g., bromodomains, Tudor domains, chromodomains), which in turn might enforce or stabilize the chromatin signature and provide a platform for the recruitment of additional factors. Intriguingly, chromatin regulators encompassing histone modifiers and histone modification binding proteins are present in a combinatorial fashion at distinct genomic loci and frequently bring together regulators associated with opposing activities.

This might occur counterintuitive, but could provide a dynamic system for fine-tuning gene expression programs or rapid response to altered signals and highlights the importance of a balanced level of chromatin regulators for normal cell function. ...

The H3K4me1 appeared to represent a generalmark presenton enhancers irrespective of their activity state and cell type specificity, which was in contrast to earlier reports , but is in line with a recent report demonstrating that Polycomb repressed genes tend to keep permissive enhancers in differentiated cells, which are marked by the histone variant H2AZ and H3K4me1.

… Active genes have characteristic nucleosome depleted regions (NDRs) flanked by positioned nucleosomes upstream of their transcription start sites, which contain binding sequences for transcription factors. Repressed genes usually lack an NDR, but DNA sequence, binding of transcription factors and the action of chromatin remodeling complexes has been suggested to act in a multistep process to determine local nucleosome composition and density

We now want to discuss methylation and gene expression. Reference will be made to the work of Herman and Baylin, Jones and Takai, McCabe et al, Allis et al, and Issa and Kantarjian. We begin with Herman and Baylin and their description of the diagram below:

In most of the mammalian genome, which is depicted here as exons 1, 2, and 3 of a sample gene (boxes 1, 2, and 3), introns of the gene (line between the exons), and regions outside the gene, the CpG dinucleotide has been depleted during evolution, as shown by the small number of such sites (circles).

Small regions of DNA, approximately 0.5 to 4.0 kb in size, harbor the expected number of CpG sites and are termed CpG islands. Most of these are associated with promoter regions of approximately half the genes in the genome (numerous circles surrounding and within exon 1 of the sample gene). In normal cells, most CpG sites outside of CpG islands are methylated (black circles), whereas most CpG-island sites in gene promoters are unmethylated (white circles).

This methylated state in the bulk of the genome may help suppress unwanted transcription, whereas the unmethylated state of the CpG islands in gene promoters permit active gene transcription (arrow in upper panel). In cancer cells, the DNA-methylation and chromatin patterns are shifted.

Many CpG sites in the bulk of the genome and in coding regions of genes, which should be methylated, become unmethylated, and a growing list of genes have been identified as having abnormal methylation of promoters containing CpG islands, with associated transcriptional silencing (red X at the transcription start site).

Although there are possible explanations and findings from ongoing investigations, it is not known why the DNA-methylating enzymes fail to methylate where they normally would and which of these enzymes are mediating the abnormal methylation of CpG islands in promoters.

3.9.1 Methylation at the Molecule

What is methylation? Simply, the attachment of a methyl group to the cytosine molecule creates a methylated C. This is not a complicated process but one which happens frequently and may have significant effects. Cytosine gets methylated and is converted to 5-methyl cytosine. This is accomplished by means of two enzymes as depicted below. This occurs when we have a C and G adjacent. It occurs to the C in that pair. We depict that transition below. Note also that by using 5-Azacytadine we can block that transition.



From: Herman and Baylin, NEJM,

Now there are the CpG islands. These are C, cytosine, and G, guanine, adjacent nucleotides which are connected via a phosphodiester bone between the two, and multiple collections of these paired nucleotides. The CpG island is then an area dense in these CG pairs connected by the phosphodiester bond, but the “island” may contain nucleotides other than the CG pairs, but generally are high in CG pair concentration, usually more than 50%.

One should note that the statistical probability of such large CG pairings would normally be quite low. One would anticipate equal probability for any nucleotide and any nucleotide pairing. Furthermore, such a high concentration is statistically extremely rare but if often existentially quite common.

The CpG islands may be from 300 to over 3,000 base pairs in total length, and are frequently found in gene promoter regions. Thus, when the CpG islands are methylated, namely the C is methylated, then the island gets silenced as does the corresponding gene. Namely methylation of CpG islands can result in gene silencing. This then becomes a critical issue if the gene is a control gene such as PTEN, p53, or many of the critical pathway control genes. The CpG islands are also propagated to cell progeny during mitosis, thus a methylated island remains so in the cell’s progeny.

However, understanding methylation of islands, and having a means to demethylate the islands may present a reasonable way to develop therapeutics for cancers resulting from methylated regions. We shall examine that shortly.

As Laird and Jaenisch state:

The normal pattern of 5-methylcytosine distribution DNA methylation in mammals is found as a covalent modification at the fifth carbon position of cytosine residues within CpG dinucleotides. Most of the CpG dinucleotides in the human genome are methylated.

However, 5-methylcytosine makes up less than 1% of all nucleotides, since CpG dinucleotides are under-represented about five-fold in the mammalian genome. The paucity of CpG dinucleotides in the mammalian genome is attributed to a higher mutation rate of methylated versus unmethylated cytosine residues.

CpG dinucleotides and 5-methylcytosine are unevenly distributed in the genome. Most of the genome is heavily methylated with a corresponding deficit in CpG dinucleotides. About 1 to 2% of the genome consists of islands of non-methylated DNA and these sequences show the expected frequency of CpG dinucleotides.

CpG islands are about 1 kb long and are not only CpG-rich, but generally G/C-rich as well and are found at the 5' end of genes. All known housekeeping genes and some tissue-specific genes have associated CpG islands.

3.9.2 Methylation and Gene Expression

We now want to discuss methylation and gene expression. Reference will be made to the work of Herman and Baylin, Jones and Takai, McCabe et al, Allis et al, and Issa and Kantarjian.

We begin with Herman and Baylin and their description of the diagram below:

In most of the mammalian genome, which is depicted here as exons 1, 2, and 3 of a sample gene (boxes 1, 2, and 3), introns of the gene (line between the exons), and regions outside the gene, the CpG dinucleotide has been depleted during evolution, as shown by the small number of such sites (circles).

Small regions of DNA, approximately 0.5 to 4.0 kb in size, harbor the expected number of CpG sites and are termed CpG islands. Most of these are associated with promoter regions of approximately half the genes in the genome (numerous circles surrounding and within exon 1 of the sample gene). In normal cells, most CpG sites outside of CpG islands are methylated (black circles), whereas most CpG-island sites in gene promoters are unmethylated (white circles).

This methylated state in the bulk of the genome may help suppress unwanted transcription, whereas the unmethylated state of the CpG islands in gene promoters permits active gene transcription (arrow in upper panel). In cancer cells, the DNA-methylation and chromatin patterns are shifted.

Many CpG sites in the bulk of the genome and in coding regions of genes, which should be methylated, become unmethylated, and a growing list of genes have been identified as having abnormal methylation of promoters containing CpG islands, with associated transcriptional silencing (red X at the transcription start site).

Although there are possible explanations and findings from ongoing investigations, it is not known why the DNA-methylating enzymes fail to methylate where they normally would and which of these enzymes are mediating the abnormal methylation of CpG islands in promoters.

We depict a modified version of their Figure below:



Thus methylation in this case blocks the expression of the targeted gene.

3.9.3 Methylation and Deamination (C to T)

Methylation may also progress to more dramatic changes. We discuss here the change of C to T, a serious change in a DNA base pair which can result in dramatic changes in gene expression.

As Herman and Baylin state:

Although only four bases — adenine, guanine, cytosine, and thymine — spell out the primary sequence of DNA, there is a covalent modification of postreplicative DNA (i.e., DNA that has replicated itself in a dividing cell) that produces a "fifth base." Reactions using S -adenosyl-methionine as a methyl donor and catalyzed by enzymes called DNA methyltransferases (DNMTs) add a methyl group to the cytosine ring to form methyl cytosine.

In humans and other mammals, this modification is imposed only on cytosines that precede a guanosine in the DNA sequence (the CpG dinucleotide). The overall frequency of CpGs in the genome is substantially less than what would be mathematically predicted , probably because DNA methylation has progressively depleted the genome of CpG dinucleotides over the course of time.

The mechanism of the depletion is related to the propensity of methylated cytosine to deaminate, thereby forming thymidine. If this mutation is not repaired, a cytosine-to-thymidine change remains.

The depletion of CpG dinucleotides in the genome corresponds directly to sites of such nucleotide transitions, and this change is the most common type of genetic polymorphism (variation) in human populations.



From Robertson (2001) we have some of the genes influenced by methylation or as he states:

CpG-island-associated genes involved in cell growth control or metastasis that can become hypermethylated and silenced in tumors.

We depict the Table below from Robertson on some of the genes impacted by this type of methylation. Most of these are significant regulatory genes.

Gene	*Function*
pRb	Regulator of G1/S phase transition
$p16^{INK4a}$	Cyclin-dependent kinase inhibitor
$p15^{INK4b}$	Cyclin-dependent kinase inhibitor
ARF	Regulator of p53 levels
hMLH1	DNA mismatch repair
APC	Binds β-catenin, Regulation of actin cytoskeleton?
VHL	Stimulates angiogenesis
BRCA1	DNA repair
LKB1	Serine/threonine protein kinase
E-cadherin	Cell-cell adhesion
ER	Transcriptional activation of estrogen-responsive genes
GSTPI	Protects DNA from oxygen radical damage
0^{6}-MGMT	Repair/removal of bulky adducts from guanine
TIMP3	Matrix metalloproteinase inhibitor
DAPK1	Kinase required for induction of apoptosis by y interferon
p73	Apoptosis structurally similar to p53

For example, we show below some typical pathways and the above genes are seen targeted by methylation.



Methylation may then interfere with many of the genes in the above pathways.

3.9.4 Causes of Methylation

The major question which is often asked is what causes methylation. In Allis et al on p 460 the authors discuss some of the putative cause of methylation and methylation related cancers. Although not confirmative it is consistent with clinical correlations as well.

As Issa and Kartarjian state:

Much remains to be learned about the causes of DNA methylation abnormalities in cancer; for the most part, methylation seems to be gene specific. In some cases, a rare methylation event appears in cancer because of selection , while in others methylation anomalies are downstream of an oncogenic event …

As McCabe et al state:

DNA methylation patterns in human cancer cells are considerably distorted. Typically, cancer cells exhibit hypomethylation of intergenic regions that normally comprise the majority of a cell's methyl-cytosine content. Consequently, transposable elements may become active and contribute to the genomic instability observed in cancer cells.

Simultaneously, cancer cells exhibit hypermethylation within the promoter regions of many CpG island-associated tumor suppressor genes, such as the retinoblastoma gene (RB1), glutatione S-transferase pi (GSTP1), and E-cadherin (CDH1). As a result, these regulatory genes are transcriptionally silenced resulting in a loss-of-function. Thus, through the effects of both hypo- and hyper-methylation, DNA methylation significantly affects the genomic landscape of cancer cells, potentially to an even greater extent than coding region mutations, which are relatively rare

McCabe et al continue:

Although the precise molecular mechanisms underlying the establishment of aberrant DNA hypermethylation remain elusive, recent studies have identified some contributing etiologic factors.

For example, chronic exposure of human bronchial epithelial cells to **tobacco-derived carcinogens drives hypermethylation** *of several tumor suppressor genes including CDH1 and RASSF2A.*

Stable knockdown of DNMT1 prior to carcinogen exposure prevented methylation of several of these genes indicating a necessary role for this enzyme in the molecular mechanism underlying hypermethylation.

The reactive oxygen species (ROS) associated with chronic inflammation is another source of DNA damage with the potential to affect DNA methylation as halogenated pyrimidines, one form *of ROS-induced damage, mimic 5-methylcytosine and stimulate DNMT1-mediated CpG methylation in vitro and in vivo.*

Indeed, study of the glutatione peroxidase 1 and 2 double knockout model of inflammatory bowel disease found that 60% of genes that are hypermethylated in colon cancers also exhibit aberrant methylation in the inflamed noncancerous precursor tissues. Although the mechanisms by which DNA damage mediates DNA methylation are not fully understood, O'Hagan and colleagues have examined the process with an engineered cell culture model in which a unique restriction site was incorporated into the CpG island of the E-cadherin promoter.

Thus, the actual molecular mechanics leading to methylation are not fully understood but like most cancers inflammation appears to be a driving factor. What the cause of that inflammation may be is not yet clear.

We begin with a discussion of the definition of epigenetics. From Holliday we have a classic definition[15]:

Classical genetics has revealed the mechanisms for the transmission of genes from generation to generation, but the strategy of the genes in unfolding the developmental programme remains obscure. Epigenetics comprises the study of the mechanisms that impart temporal and spatial control on the activities of all those genes required for the development of a complex organism from the zygote to the adult. Epigenetic changes in gene activity can be studied in relation to DNA methylation in cultured mammalian cells and it is also possible to isolate and characterize mutants with altered DNA methylase activity.

Although this experimental system is quite far removed from the epigenetic controls acting during development it does provide the means to clarify the rules governing the silencing of genes by specific DNA methylation and their reactivation by demethylation. This in turn will facilitate studies on the control of gene expression in somatic cells of the developing organism or the adult.

The general principles of epigenetic mechanisms can be defined. There are extreme contrasts between instability or switches in gene expression, such as those in stem-line cells, and the stable heritability of a specialized pattern of gene activities. In some situations cell lineages are known to be important, whereas in others coordinated changes in groups of cells have been demonstrated. Control of numbers of cell divisions and the size of organisms, or parts of organisms, is also essential. The epigenetic determination of gene expression can be reversed or reprogrammed in the germ line. The extent to which methylation or demethylation of specific DNA sequences can help explain these basic epigenetic mechanisms is briefly reviewed.

There seems to be a continuous flow of genes, miRNAs, epigenetic factors including methylation, SNPs and the like all both diagnostic and prognostic for various cancers. A decade ago one looked for a gene, some gene that somehow got broken, changed, deleted, or the like. The paradigm was the Philadelphia chromosome of a cut and paste example. With the

---

[15] DNA Methylation and Epigenetic Inheritance, Philosophical Transactions B of the Royal Society, Published 30 January 1990,

understanding we now have of methylation we see the same occur here, and methylation can be acquired and/or genetically inherited (see imprinting examples). However methylation is still somewhat poorly understood; what causes it, why does it work positively in some cases and negatively in others?

Methylation is but one of the many facets of what we now see as causes of Cancer. We depict a short summary below.



We examine the work of Wojno et al which has received recent interest. They examine the impacts of methylation upon 3 genes and see their presence as prognostic of potential aggressive prostate cancer. Specifically they conclude:

The diagnosis of prostate cancer is dependent on histologic confirmation in biopsy core tissues. The biopsy procedure is invasive, puts the patient at risk for complications, and is subject to significant sampling errors.

An epigenetic test that uses methylation-specific polymerase chain reaction to determine the epigenetic status of the prostate cancer–associated genes GSTP1, APC, and RASSF1 has been clinically validated and is used in clinical practice to increase the negative predictive value in men with no history of prostate cancer compared with standard histopathology. Such information can help to avoid unnecessary repeat biopsies.

The repeat biopsy rate may provide preliminary clinical utility evidence in relation to this assay's potential impact on the number of unnecessary repeat prostate biopsies performed in US urology practices.

DNA methylation normally can result in the silencing of genes by interrupting the normal process of promoters. CpG islands are often hypermethylated and thus the gene which may regulate cell proliferation is silenced. This may result in uncontrolled cell growth. For example genes controlling MYC are not produced and MYC may then result in excess cell cycle proliferation. Methylation is hypermethylated in the regions of intergenic regions and in repetitive elements and this hypermethylation silences these regions and facilitates normal cell DNA transcription of the gene. Disruption of DNA, namely hypomethylation, in the intergenic and repetitive regions may result in possible loss of imprinting. This hypomethylation is also related to the production of lncRNAs which may in turn interfere with normal gene transcription.

Decitabine is a DNMT inhibitor. Namely, it inhibits the DNA methyltrasferases that facilitate methylation (such as DNMT3 which are de novo and DNMT1 which is maintenance). Decitabine thus has then tendency on the specific hematologic cell lines in MDS to remove methylations which have caused the aberrant cell line proliferations and allow for the return of homeostasis. MDS is a quasi-malignant condition originating in the bone marrow which may in many cases result in Acute Myelogenous Leukemia. With the use of decitabine or a similar DNMTI azacitidine, demethylation of these rapidly reproducing cells may be achieved and possible a normal state of homeostasis achieved.

The use of pharmaceuticals that alter the methylation patterns of DNA can have lasting effects because those patterns may last through subsequent mitotic changes. On the one hand that may be beneficial as is the case with MDS but such broad demethylation may also alter other segments of the DNA altering essential control elements and pathways. In cell development there are two sensitive periods; germ cell development and early embryonic development. It is during these periods that methylation is cleared and reset and that a drug-like a DNMTI would pose a serious risk to the proper resetting of the marks and could result in substantial DNA expression damage.

In summary we will examine the three gene methylation proposition with this test. We summarize this below:



3.10 SNP

SNP, or single nucleotide polymorphism, is a single nucleotide change. We see these frequently in viral mutations but we really do not want to see these in coding regions of cells. As defined by NCI[16]:

The most common type of change in DNA (molecules inside cells that carry genetic information). SNPs occur when a single nucleotide (building block of DNA) is replaced with another. These changes may cause disease, and may affect how a person reacts to bacteria, viruses, drugs, and other substances. Also called single nucleotide polymorphism.

Simply stated an SNP is a single nucleotide change in a gene. Thus an A to a T or G or C. Likewise for each of the other nucleotides. This change then changes the mRNA coding and in turn the resulting proteins. SNPs may occur in intros or exons; they may have an effect or not. One need simply view the COVID mutations which result in multiple SNP changes and in then impact the results of the infecting virus.

Medline states[17]:

Single nucleotide polymorphisms, frequently called SNPs (pronounced "snips"), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA. SNPs occur normally throughout a person's DNA. They occur almost once in every 1,000 nucleotides on average, which means there are roughly 4 to 5 million SNPs in a person's genome. These variations occur in many individuals; to be classified as a SNP, a variant is found in at least 1 percent of the population.

Scientists have found more than 600 million SNPs in populations around the world. SNPs differ from substitution variants, which replace one DNA building block (nucleotide) with another.

Substitution variants usually cause disease and are generally not found in 1 percent of any population. Additionally, SNPs differ from copy number variants (CNVs), which occur when a whole gene (or other large section of DNA) is duplicated or deleted. Most commonly, SNPs are found in the DNA between genes. They can act as biological markers, helping scientists locate genes that are associated with disease.

When SNPs occur within a gene or in a regulatory region near a gene, they may play a more direct role in disease by affecting the gene's function. Most SNPs have no effect on health or development. Some of these genetic differences, however, have proven to be very important in

---

[16] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/snp

[17] https://medlineplus.gov/genetics/understanding/genomicresearch/snp/

the study of human health. SNPs help predict an individual's response to certain drugs, susceptibility to environmental factors such as toxins, and risk of developing diseases.

SNPs can also be used to track the inheritance of disease-associated genetic variants within families. Research is ongoing to identify SNPs associated with complex diseases such as heart disease, diabetes, and cancer.

3.11 MEASUREMENT TECHNIQUES

Now there are techniques whereby one can measure the previously mentioned targets in blood or urine. These are thus the biomarkers of interest. We summarize FISH here since it is the most used method at this time..

As Young et al note:

RNA-fluorescence in situ hybridization (FISH) is a powerful tool to visualize target messenger RNA transcripts in cultured cells, tissue sections or whole-mount preparations. As the technique has been developed over time, an ever-increasing number of divergent protocols have been published. There is now a broad selection of options available to facilitate proper tissue preparation, hybridization, and post-hybridization background removal to achieve optimal results.

Here we review the technical aspects of RNA-FISH, examining the most common methods associated with different sample types including cytological preparations and whole-mounts. We discuss the application of commonly used reagents for tissue preparation, hybridization, and post-hybridization washing and provide explanations of the functional roles for each reagent. We also discuss the available probe types and necessary controls to accurately visualize gene expression. Finally, we review the most recent advances in FISH technology that facilitate both highly multiplexed experiments and signal amplification for individual targets. Taken together, this information will guide the methods development process for investigators that seek to perform FISH in organisms that lack documented or optimized protocols. ...

FISH is a powerful technique that can interrogate the spatial patterns and mechanisms of gene expression in biological systems on scales ranging from the single cell to tissue sections to whole organisms. When coupled with other modern methods that afford broad molecular insight (e.g., genomics, transcriptomics and gene editing), FISH can increase the precision of genetic information that can be ascertained from unconventional model organisms. However, establishing any kind of ISH method in an understudied system can be extremely time-consuming. This problem is compounded for the inexperienced user whose first step may be to consult an extremely varied, and at times contradictory, technical literature.

In this review, we have attempted to summarize some of the main principles of FISH, and to emphasize those steps that are critical to success. As a starting method, we recommend 4% PFA or 3.7% formalin for fixation with 10 µg/mL proteinase K for permeabilization. The hybridization solution should contain at least formamide (generally 50%), dextran sulfate, and *competitor DNA, but other ingredients and the duration of the hybridization are probe-dependent.*

Non-specific hybrids can then be removed during the post-hybridization washes using formamide and Tween-20 in SSC at the hybridization temperature, while progressively decreasing salt concentration. Finally, we have also highlighted some of the recent advances in the field and hope that in bringing these points to the attention of the reader, the process of FISH method development and optimization may be expedited.

From Sinnamon and Czaplinski:

The ability to detect RNA molecules in situ has long had important applications for molecular biological studies. Enzyme or dyelabeled antisense in vitro runoff transcripts and synthetic oligodeoxynucleotides (ODN) both have a proven track record of success, but each of these also has scientific and practical drawbacks and limitations to its use. We devised a means to use commercially synthesized oligonucleotides as RNA-FISH probes without further modification and show that such probes work well for detection of RNA in cultured cells.

This approach can bind a high concentration of fluorescent ODN to a short stretch of an RNA using commercial DNA synthesis outlets available to any laboratory. We call this approach for creating in situ hybridization probes Fluorescence In Situ Hybridization with Sequential Tethered and Intertwined ODN Complexes (FISHSTICs). We demonstrate that one FISH-STIC probe can detect mRNA molecules in culture, and that probe detection can be improved by the addition of multiple probes that can be easily adapted for robust mRNA quantification.

Using FISH-STICs, we demonstrate a nonoverlapping distribution for β-actin and γ-actin mRNA in cultured fibroblasts, and the detection of neuronspecific transcripts within cultured primary hippocampal neurons

From O’Connor:

Principles of fluorescence in situ hybridization (FISH).

(a) The basic elements of FISH are a DNA probe and a target sequence.

(b) Before hybridization, the DNA probe is labeled by various means, such as nick translation, random primed labeling, and PCR. Two labeling strategies are commonly used: indirect labeling and direct labeling. For indirect labeling, probes are labeled with modified nucleotides that contain a hapten, whereas direct labeling uses nucleotides that have been directly modified to contain a fluorophore.

(c) The labeled probe and the target DNA are denatured.

(d) Combining the denatured probe and target allows the annealing of complementary DNA sequences.

(e) If the probe has been labeled indirectly, an extra step is required for visualization of the nonfluorescent hapten that uses an enzymatic or immunological detection system.

Whereas FISH is faster with directly labeled probes, indirect labeling offers the advantage of signal amplification by using several layers of antibodies, and it might therefore produce a signal that is brighter compared with background levels.



From Burke et al we demonstrate the detection of the desired sequences using a FISH mechanism:



Schematic of method to detect ribosome–mRNA interactions in situ. Multiple DNA oligonucleotide probes are hybridized to ribosomes via rRNA and two different mRNA regions. For illustration purposes, only a single probe per ribosome and mRNA region is shown. When an mRNA is bound by ribosomes, the linker probe can hybridize across the extension sequences of both the ribosome probes and the mRNA interaction probes, and thereby produce a fluorescence signal via HCR. Bottom: When an mRNA is not bound by ribosomes, the linker probe hybridizes weakly to extensions on the ribosome probes and the mRNA interaction probes and can be washed out of cells. See Burke et al.

The following is a summary of methods for isolation of the biomarkers.

Isolation Methods	Time	Indication	Advantages	Disadvantages
Ultracentrifugation/ differential centrifugation	3 h-12h	Large volume of biofluids	Most commonly used, could be combined with other methods such as size exclusion, immune affinity isolation and sucrose gradient method	Need of expensive equipment, time consuming, low efficiency, deformity, impurity and protein co-aggregation, limit in processing sample quantity, low RNA yield
Size exclusion filtration+ chromatography	2 h	Large volume of biofluids, could be combined with nano-membrane ultrafiltration concentrators	Feasible, quick, inexpensive, low risk of contamination/deformity , yields functional EVs	EV dilution, yield variation
Immune affinity isolation (antibody against EVs surface proteins)	4-6 h	High purity isolation of EVs, isolation of sub-set of EVs, isolation of EVs from viruses and LPP	High specificity and selectivity, reproducibility, isolating special sub-set of EVs and possibility of negative selection	Cross reactivity of antibody, costly, low yield, expensive equipment
Microfluidic technologies	5-14 pL/min	Low volume of input biofluids	Can be combined by immune affinity methods	Early stage of development, low throughput, high cost
Participation with hydrophilic polymers	1 h (some protocols overnight)		Relatively low cost and high yield of EVs and biomolecules, simplicity, no need for expensive equipment	Contamination of EVs with protein complexes and lipoproteins, polymer retention
Porous structures (Capturing EVs through in ciliated micropillar sfmrtnrpl	2 h	Selectively trap particles in the range of 40-100 nm based on the research nnpstinn	Purity, rapidness	Not suitable for isolation of larger particles, not validated with clinical samples, can handle only

4 METRICS

Having chosen a target, having them measured the target, we then ask what metrics do we used to make it a reasonable measure to ascertain a malignancy.

4.1 A METRIC

We discussed the possible items to be measured and then used in a biomarker. Let us begin with a simple example. Let us assume we measure the presence or absence of n measurements, such as mRNA. We thus measure the presence or absence. Thus we have:

$$x_i = \begin{cases} 1 \text{ if mRNA}_i \text{ present} \\ 0 \text{ otherwise} \end{cases}$$

Then we create a metric as follows:

$$m = \sum_{k=1}^{n} a_k x_k$$

We then have the rule:

$$\begin{array}{l} \mathit{If} \;\; \text{m>m}_0 \text{ then disease present} \\ \text{otherwise absent} \end{array}$$

The coefficients or weights "a" must be selected based upon a robust data set. Note that since x is 0 or 1 we have no need for anything other than this linear metric.

4.2 AN OLD EXAMPLE (PSA)

Let us consider a classic example. Namely using PSA in prostate cancer assessment[18]. The data that can be provided is as follows:

1. PSA
2. %Free PSA
3. PSA history and thus velocity
4. Age
5. Prostate size
6. Family history

Briefly we have:

---

[18] See McGarty, The PSA Controversy: Details, Models, Analysis and Recommendations, November 2010.

PSA velocity is defined by:

PSA velocity in ng/mL per year was calculated for each subject (n = 788) as the running average of the rate of change over three consecutive visits (the index visit and the two preceding visits), when more than two PSA measurements were available , or as the simple rate of change, if only two measurements were available.

Or we can use the following:

$$V_{PSA}(k) = \frac{\sum_{n=k-3}^{k} \frac{PSA(n) - PSA(n-1)}{Date(n) - Date(n-1)}}{3}$$

And %Free is:

The percent free PSA is a measure of the PSA generated by benign luminal cells which is unbound to proteins in the circulation. The majority of PSA in the blood stream is bound to proteins, primarily α-antichymotrypsin. The remaining amount, from about 5% to 35%, is free. PSA released from cancer cells is generally bound and not free. Thus the increase in PSA with a concomitant reduction in percent free is an implication of PCa. On the other hand, if PSA slightly rises and free PSA also rises, or stays at peak, then one would suspect a benign process of hyperplasia or benign or non-malignant neoplasia. As we progress to PCa, the luminal cells which are malignant clones do not have free PSA and thus the percent free drops.

Now we have six data points on a patient. In fact, the velocity does bring in some past history. We can now ask the following question:

If we want to determine the probability that a patient has PCa based upon the set of six above measurements, then how do we incorporate them into a metric and how well does that metric perform? Namely the sensitivity vs specificity chart and the resulting AUC, or area under the curve?

Thus we have the following data:

PSA, PFPSA, Vel, Age, Vol, Fam.

We then want a function such that:

$M = f(x_1, \ldots x_6)$
such that
if $M < M_0$ then we can confirm no PCa
with
Sensitivity=y%
Specificity=z%

Where the x values are each of the above six values. Now let us approach this with a thought experiment. Namely:

PSA increases with age. Thus we should try to normalize the PSA accordingly.

PSA increases with volume. Thus this too should be normalized.

%Free is generally an independent variable

Velocity is also an independent variable

Family history is likewise independent.

Thus we can reduce this to four independent variables, normalized PSA and the remaining three as above. Namely:

$$f(x) = f\left(\frac{PSA}{Volume * Age}, \%Free, Vel, Fam\right)$$

In classic tests we just use PSA. Namely if PSA<4 then OK and if not then may be a problem. In reality we have probability densities such that:

$$p(x \,|\, no \text{ PCa}) = \frac{1}{\sigma\sqrt{2\pi}} \exp\left(-\frac{1}{2\sigma^2}(x - x_0)^2\right)$$
$$and$$
$$p(x \,|\, \text{PCa}) = \frac{1}{\sigma\sqrt{2\pi}} \exp\left(-\frac{1}{2\sigma^2}(x - x_1)^2\right)$$

Where the variances are equal and the means are known. Clearly negative values are not acceptable but we can use this as a simplification. Note that this simplistic model assumes we know means and standard deviations and that the distributions have some Gaussian form. Frankly none of this is correct.

4.3 SENSITIVITY AND SPECIFICITY

Now recall that:

$$Sensitivity = \frac{Number(\,TestPositive;Disease\,Pr\,esent\,)}{Number(\,Disease\,Pr\,esent\,)}$$

$$Specificity = \frac{Number(\,DiseaseAbsent;TestNegative\,)}{Number(\,DiseaseAbsent\,)}$$

We can relate these to our statistical model as follows. Assume we have only PSA and the probability densities are as above. Then we have to choose a selection point of PSA to say PCa or not. For each such choice of decision point we obtain as respective sensitivity and specificity doublet. Namely let us assume that we select m as the decision point. Then we have:

$$Sensitivity = \int_m^\infty \frac{1}{\sigma\sqrt{2\pi}}\exp(-\frac{1}{2\sigma^2}\left(x-x_1\right)^2)dx$$

$$and$$

$$Specificity = \int_0^m \frac{1}{\sigma\sqrt{2\pi}}\exp(-\frac{1}{2\sigma^2}\left(x-x_0\right)^2)dx$$

Now:

$$x_0 \le m \le x_1$$

If the variance is low then Specificity and sensitivity is high. Also as we move the me value we see the following:

1. As we decrease m the Sensitivity increases but the Specificity decreases

2, Likewise as we increase m the Sensitivity decreases and the Specificity increases.

As we have noted previously the curves are as follows:

In July 2003 Punglia et al in the New England Journal of Medicine published a study which demonstrated that the then current set point for PSA missed many cancers. They stated:

"Adjusting for verification bias significantly increased the area under the ROC curve (i.e., the overall diagnostic performance) of the PSA test, as compared with an unadjusted analysis (0.86 vs. 0.69, P<0.001, for men less than 60 years of age; 0.72 vs. 0.62, P=0.008, for men 60 years of age or older). If the threshold PSA value for undergoing biopsy were set at 4.1 ng per milliliter, 82 percent of cancers in younger men and 65 percent of cancers in older men would be missed. A digital rectal examination that is abnormal but not suspicious for cancer does not affect the

overall performance characteristics of the test….A lower threshold level of PSA for recommending prostate biopsy, particularly in younger men, may improve the clinical value of the PSA test."

They presented the following Figure:



Namely we see plotted Sensitivity vs 1-Specificity. This is the classic curve from which we can obtain the AUC, area under the curve. The above shows how the curve can be adjusted for various other variables. We have argued that we can adjust the PSA with knowledge of age, size, and possibly %Free. Namely we create an effective PSA as follows:

$$PSA_{eff} = (PSA)(Vol)^{\alpha}(Age)^{\beta}(\%Free)^{\delta}$$

Just how this can be accomplished is somewhat straightforward but data collection intensive.

4.4 MULTIPLE METRICS

We can now assume we have multiple metrics. Let us assume we have the following type metrics:

$$
\begin{aligned}
&x = \{x_i : i = 1, \ldots, N\} \\
&where \\
&x_1 = PSA \\
&x_2 = age \\
&x_3 = volume
\end{aligned}
$$

We can assume that they are independent variables, although perhaps not. Then we ask, how do we combine these three variables to generate a decision metric? In our previous discussion it was one where we assumed some form of relatedness, thus normalizing PSA by age. In contrast, what is we did not, and just used some linear decision algorithm? Would this work?

4.5 BINARY VS ANALOG METRICS

Now as we shall see as we go through this analysis, some data is binary, namely present or absent, or analog, namely we have some continuous number representing the target in question such as density.

Consider the following example. We believe that the five genes, miRNA or otherwise are appropriate targets. Thus we take a fluid sample and test for targets A, B, C, D, and E. Now the results could be:

A is present or absent
A if present is measure at some concentration CA.

Likewise for the other 4 metrics. They could be all binary, all analog, or any possible mix.

We now need a classifier algorithm that takes each into account, weighs them appropriately and establishes a classification metric to optimize the sensitivity and specificity. This is a non-trivial problem!

5 BLADDER CANCER

We first briefly review bladder cancer, BCa, and then consider some of the currently available biomarkers. Our focus is on understanding of what the biomarkers represent, and how they can relate to the more classic way of identifying bladder cancer via pathology slides. Bladder cancer is usually identified after a patient presents with symptoms, prime amongst them is gross hematuria. However, gross hematuria may be a result of many other factors such as prostatitis. Thus it becomes necessary to perform a cystoscopy and then examine any suspicious lesions.

The question then is; can we do as well with a biomarker as with a pathology exam?

5.1 ANATOMY

The urinary bladder is formed by four layers: (a) urothelium, (b) lamina propria, (c) muscularis propria, and (d) adventitia or serosa. The following is a normal structure for a healthy benign bladder wall.



Below we see a papillary bladder cancer.



The following is an aggressive BlCa:



The following is an example of an aggressive pleomorphic cancer.



5.2 ONCOGENES

All cancers have some collection of oncogenes. As NIH defines it[19]:

An oncogene is a mutated gene that has the potential to cause cancer. Before an oncogene becomes mutated, it is called a proto-oncogene, and it plays a role in regulating normal cell division. Cancer can arise when a proto-oncogene is mutated, changing it into an oncogene and causing the cell to divide and multiply uncontrollably. Some oncogenes work like an accelerator pedal in a car, pushing a cell to divide again and again. Others work like a faulty brake in a car parked on a hill, also causing the cell to divide unchecked.

Now from Sanli et al we have a list of such genes for bladder cancer:

Gene	**Chromosome**	**Frequency (%)**	**Alteration**
Low Grade tumors			
TERT	5p15	73–83	Point mutation
FGFR3	4p16	60–70, 80	Point mutation Upregulated expression
PIK3CA	3q26	16–25	Point mutation
HRAS	11p15	~10	Point mutation
KRAS	12p12	5	Point mutation
MDM2	12q14–q15	3	Amplification
AKT1	14q32	1–3	Point mutation
Muscle Invasive			
E2F3	6p22	20	Gain or amplification
PIK3CA	3q26	9–20	Point mutation
FGFR3	4p16	5–20	Point mutation Upregulated expression
MDM2	12q14–q15	5–15	Amplification
HRAS	11p15	5–12	Point mutation
ERBB3	12q13	11	Point mutation
CCND1	11q13	10	Amplification
RXRA	9q34	9	Mutation
HER2 (ERBB2)	17q12	7 4.5 42	Gain or amplification Mutation Amplification
EGFR	7p12	6	Gain or amplification
FGFR1	8p12	6	Amplification
KRAS	12p12	6	Point mutation
AKT1	14q32	1–3	Point mutation

Now the challenge is to determine what gene alteration is of significance and more importantly which ones combined can provide a reliable test.

---

[19] https://www.genome.gov/genetics-glossary/Oncogene

5.3 MARKERS

As Dudley et al note :

Bladder cancer is the sixth most common cancer in the United States, with an estimated 79,030 new cases in 2017. After diagnosis and treatment for localized disease, the National Comprehensive Cancer Network guidelines recommend that patients undergo cystoscopy and urine cytology evaluation to monitor for recurrence every 3 to 6 months for 2 years and then at increasing intervals.

Unfortunately, cystoscopy is invasive, and cytology has a low sensitivity, ranging from 20% to 53%. As a result of the need for this procedure-based, long-term follow-up, bladder cancer management costs more per patient lifetime than any other cancer. Many attempts have been made to overcome these challenges by developing biomarkers for bladder cancer surveillance.

The FDA has approved six different urine-based tests for bladder cancer recurrence, but they achieve modest sensitivities (55%–70%) and specificities (71%–83%), and none of the available tests have achieved widespread adoption.

The lack of acceptance is clearly due to the low performance of the test. A sensitivity of say 60% says we miss a great many as does the specificity in terms of saying we do when we don't.

Recent work has demonstrated the promise of analyzing circulating tumor DNA (ctDNA) in plasma to detect minimal residual disease (MRD) in a variety of tumor types. For example, recent work from our group has shown that hybrid capture–based ctDNA analysis using Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) can achieve 94% sensitivity and 100% specificity for detecting MRD posttreatment in plasma from patients with localized lung cancer. In the case of localized bladder cancer, analysis of tumor DNA in urine has been explored as a potential approach for detection and surveillance using amplicon-based high-throughput sequencing (HTS) approaches, with sensitivities and specificities ranging from 68% to 85% and 80% to 100%, respectively.

In this study, we developed a novel HTS-based hybridcapture method for detection of ***urine tumor DNA (utDNA)*** *called uCAPP-Seq and applied it to urine supernatant specimens. We hypothesized that assessment of utDNA would have superior performance characteristics compared with cytology for detecting early-stage bladder cancer and posttreatment residual disease.*

Development of a Novel Assay for utDNA Detection Given the practical challenges posed by purifying nucleic acids from large volumes of fluid, we adapted and optimized a previously described resin-based cell-free DNA (cfDNA) extraction protocol for urine samples, which performs as well as commercially available kits but allows analysis of larger volumes of urine.

We next established that in the presence of EDTA, urine cfDNA concentrations remain stable for at least 7 days at 4°C but not at room temperature. Applying our optimized protocol to 185 urine samples with a median urine volume of 50 mL, we observed a median urine cfDNA concentration *of 7.7 ng/mL and yield of 348.1 ng per sample. We next designed a custom capture panel for bladder cancer targeting recurrent single-nucleotide variants (SNV), insertions/deletions, and copy-number alterations.*

We began by including genomic regions covering known driver mutations in bladder cancer. We then applied our previously described algorithm to maximize patient coverage in the smallest possible genomic space using data from 412 bladder cancer cases … The final panel covered ~311 kb of genomic space, included regions from 460 genes, and was predicted to identify a median of 7 mutations per patient with bladder cancer …

We consider here several biomarkers for bladder cancer. From Ng et al:

Commercial Test	Genes Involved	Sensitivity	Specificity	Additional Notes
		mRNA tests		
Cxbladder	1GFBP5, HOXA13, MDK, CDKl and CXCR2	82% in patients with haematuria	90%	Large study comparing Cxbladder with FDA approved markers showed superior sensitivity and NPV
XpertBC	UPKIB, 1GF2, CRH, ANXA10, and ABL	46.2% DNA-based tests	77%	Study of 140 patients showed Xpert BC outperforms cytology at sensitivity and NPV even in low grade tumor, with no reduction of specificity
		DNA Tests		
Assure MDx	PGFR3, TERT, and HRAS in combination with methylation analysis ofOTXI, ONECUT2, and TWIST 1	97%	83%	Follow-up validation study demonstrated 93% sensitivity and 86% specificity
UroSEEK	Mutations in 11 genes or presence of abnormal number of chromosomes	96%	88%	
Uromonitor	FGFR3 hotspot and TERT promoter mutatioas	73.5% DNA methylation assays	93.2%	
EpiCheck	15 proprietary DNA methylated genes	68.2%	88.0%	

From Sugeeta et al:

Biomarker	Description	Method	Comment
UBC	Detects the presence of fragments of cytokeratin 8 and 18 in urine	ELISA or immunoradiometric assay	UBC values higher in high-grade tumours and able to distinguish from low-grade. Higher specificity in combination with cytology or survivin assay
CYFRA21-1	Quantifies soluble fragments of cytokeratin 19	ELISA	Significantly higher levels in patients with metastatic disease vs. locally invasive unable to differentiate between histological grades
BLCA-4	Measures protein components of the nuclear matrix which are present in the urothelium of BC patients	ELISA	Meta-analysis mainly retrospective studies showing potential to detect early tumours. No positive correlation between tumour stage and levels measured.

CellDetect	Composed of a unique plant extract which interacts with malignant cells due to their increased metabolic activity	Immunostaining	Two studies have shown higher sensitivity in low grade tumours in comparison to urine cytology (82% vs 59%) and similar specificity (86 vs 94%) It was also found not be affected by haematuria.
Hyaluronic acid	HA is a glycosoaminoglycan and HAse is endoglucosidase involved in tumour metastases and breakdown of HA into fragments for angiogenesis	ELISA and RT-qPCR	In comparison to BTA stat, UBC and cytology in two studies shown superior SS and SR SS and SP not affected by tumour grade but levels are not indicative of tumour grade. More studies required to evaluate this promising marker.
sFas	Anti-apoptotic protein released by BC cells to protect from anti-tumour activity	ELISA	Lower sensitivity. Higher levels associated with higher risk of recurrence.
Survivin	Overexpression in BC as a protein which inhibits apoptosis pathways	Bio-dot test	Limited data available in follow up setting or in comparison to other biomarkers
MCM5 - ADXBladder	Detects MCM5 shed by replicating BC cells	ELISA	Findings in prospective study in comparison to UC with SS 16.9% and SP 98%. Low sensitivity for low grade tumours. 99% NPV for high risk NMIBC
UR017	Detects oncoprotein Keratin 17 involved in the replication of cancer cells	Immunocyto-chemistry	Consistently high sensitivity and specificity from 3 independent studies. Good potential as simple incorporation to existing equipment

Also from Tamura et al we have a long list of miRNA and other RNA based markers as well as genes.:

Cancer	***Biological Source***	***Isolation methods***	***Detection methods***	***RNA types***	***Markers***	***Potential application***
Bladder Cancer	Urine	UC	ddPCR	miRNA	miR-21. miR-93, miR-200c. miR-940	Diagnosis
	Urine	-	ddPCR	miRNA	miR-21-5p, miR-4454, miR-720, miR-200c-3p, miR-29b-3p, miR-200b-3p	Diagnosis
	Urine	UC	RT-qPCR	miRNA	miR-375.miR-146a	Diagnosis
	Urine	unknown	RT-qPCR	miRNA	miR-146t, miR-I55-Sp	Diagnosis
	Urine	UC	RT-qPCR	lncRNA	HOTA1R. HOX-AS-2. MALATl. SOX2. OCT4	Diagnosis/Prognosis
	Serum	Exo Quick	RT-qPCR	lncRNA	PCAT1, UEC1. SNHG16	Diagnosis/Prognosis
	Serum	UC	RT-qPCR	lncRNA	UCA1	Diagnosis
	Urine/ Serum	UC	RT-qPCR	circRNA	PRMTS	Diagnosis/Prognosis

In the above the urine only genes are:

HOTA1R[20]: It functions through an RNA product, which binds lysine specific demethylase 1 (LSD1) and Polycomb repressive complex 2 (PRC2), and serves as a scaffold to assemble these regulators at the HOXD gene cluster, thereby promoting epigenetic repression of HOXD. This gene is highly expressed in multiple tumors.

MALATl[21]: This gene produces a precursor transcript from which a long non-coding RNA is derived by RNase P cleavage of a tRNA-like small ncRNA (known as mascRNA) from its 3' end. The resultant mature transcript lacks a canonical poly(A) tail but is instead stabilized by a 3' triple helical structure. This transcript is retained in the nucleus where it is thought to form molecular scaffolds for ribonucleoprotein complexes. It may act as a transcriptional regulator for numerous genes, including some genes involved in cancer metastasis and cell migration, and it is involved in cell cycle regulation. Its upregulation in multiple cancerous tissues has been associated with the proliferation and metastasis of tumor cells.

SOX2[22]: This intronless gene encodes a member of the SRY-related HMG-box (SOX) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate. The product of this gene is required for stem-cell maintenance in the central nervous system, and also regulates gene expression in the stomach. Mutations in this gene have been associated with optic nerve hypoplasia and with syndromic microphthalmia, a severe form of structural eye malformation. This gene lies within an intron of another gene called SOX2 overlapping transcript (SOX2OT).

OCT4[23]: This gene encodes a transcription factor containing a POU homeodomain that plays a key role in embryonic development and stem cell pluripotency. Aberrant expression of this gene in adult tissues is associated with tumorigenesis. This gene can participate in a translocation with the Ewing's sarcoma gene on chromosome 21, which also leads to tumor formation. Alternative splicing, as well as usage of alternative AUG and non-AUG translation initiation codons, results in multiple isoforms. One of the AUG start codons is polymorphic in human populations.

5.3.1 DNA

DNA is a possible target as free DNA, exosome DNA or CTC DNA. In all cases one must extract the DNA and examine it for target sequences. As Santoni et al note :

Tumors release DNA fragments into circulation, called circulating tumor DNA (ctDNA) containing tumor-specific mutations, variations of copy number and alterations in DNA methylation status. *This ctDNA reflects the heterogeneity of tumor subclones. In BC patients, ctDNA is detectable in over 70% of urine samples and it allows to discriminate between BC patients and control subjects.*

---

[20] https://www.ncbi.nlm.nih.gov/gene/100124700

[21] https://www.ncbi.nlm.nih.gov/gene/378938

[22] https://www.ncbi.nlm.nih.gov/gene/6657

[23] https://www.ncbi.nlm.nih.gov/gene/5460

CtDNA measures about 180 and 200 base pairs. It is easily accessible, but it is rapidly cleared from circulation following systemic therapy*. PCR based approaches, and more recently, digital-PCR and genome sequencing, represent the methods of choice for cell-free DNA (cfDNA) analysis.*

Thus the DNA target does have some difficulties in usage.

5.3.2 Methylation

We provided a review of methylation and its dramatic impact upon gene expression. As Sugeeta et al note :

Epigenetic alterations are part of the carcinogenesis. DNA hypermethylation of the CpG islands play a role in the promoter regions of tumour-suppressor genes. This mediates silencing of the affiliated gene which is a known phenomenon in BC. *The hyper or hypomethylation of these genes can be detected in tumour cells that are shed into urine and aid diagnosis of BC. This has been reviewed in both primary and recurrent tumours.*

Bosschieter et al. evaluated 42 studies and identified 8 with high sensitivity and specificity with varying methodologies and heterogenous patient groups. Studies with promising results, had no independent validation data and Costa et al. with 94% specificity and 90% sensitivity did not report on tumour grade or stage. This is relevant as similarly to other reported biomarkers; results will vary with disease spectrum. …

… used a combination of this technique along with DNA mutation analysis with FGFR3 and TERT mutation analysis to improve detection rates showed similar results as increased sensitivity in high grade tumour cells likely due to increased shedding of BC cells. There is an insufficient amount of data due to variability in methodology, patient groups and gene panel selection. Studies have used it in combination with DNA mutation analysis.

As Ng et al note :

The most well characterized epigenetic phenomenon is DNA methylation.

Hyper- and hypomethylated regions of DNA are identified in BC and in premalignant lesions*.*

DNA methylation status can be assessed in cell free DNA fragments and tumor cells shed in urine. A significant prevalence of methylated genes, for example, APC and cyclin D2, was elevated compared to benign cases.

Hypermethylation of selected genes, including GSTP1, APC, and RARb2 have been identified in patients with urothelial BC ….. some of the key DNA-based urine biomarkers investigated in recent years, along with their accompanying sensitivities and specificities. Although the specificities of these markers are highly encouraging, the molecular genetic techniques required to detect these are expensive, time consuming, and highly specialized.

Histone tail modifications

Histone modifications represent a diverse set of epigenetic markers involved in both dynamic cellular processes and the stable maintenance of chromatin. In BC, the levels of histone methylation are lower in advanced tumor and correlated to poor survival. For instance, high levels of H3K27me3 correlated with poorer prognosis post cystectomy in pT1-3 and node negative patients with BC.

Genetic alterations

DNA mutational analysis

Analysis of tumor-derived DNA via cell-free DNA can reveal mutations and serve as noninvasive biomarkers. Amongst the mutations which have been analyzed include urinary telomerase reverse transcriptase (TERT) promoter mutations, FGFR3 and telomere length. TERT maintains the integrity of telomeres and mutations in the TERT promoter are frequent in BC. ...

the TERT promoter mutation in urine showed an overall sensitivity of 80.5% and specificity of 89.8% in diagnosis of BC, and that TERT mutations significantly predicted recurrence of NMIBC (P<0.0001). TERT, in combination with FGF3 and OTX1 also showed high sensitivity of diagnosis of NMIBCs as well as in pT1 tumor. Mutations in FGF-3 are seen in approximately half of BC patients, with an elevated incidence (60%−70%) in low-grade tumor. Recent studies have suggested that partial replacement of cystoscopy with FGFR3 mutational analysis during surveillance can be safe and cost effective.

5.3.3 circRNA

Circular RNA also has a significant role. As Sun et al note :

The role of circular RNAs has made breakthroughs in understanding the mechanisms of tumor development. Bladder cancer has an increasing incidence, high recurrence rate, high metastatic potential, poor prognosis, and susceptibility to chemotherapy resistance. Thus, it is essential to identify molecules related to the tumorigenesis of bladder cancer. In this review, we summarize current knowledge about the expression of circular RNAs in bladder cancer and their implications in vesical carcinogenesis.

We further discuss the limitations of existing studies and provide an outlook for future studies in the hopes of better revealing the association between circular RNAs and bladder cancer.

Bladder cancer (BC) is among the top ten most common cancer types worldwide and is a serious threat to human health. ***Circular RNAs (circRNAs) are a new class of non-coding RNAs generated by covalently closed loops through back-splicing.*** *As an emerging research hotspot, circRNAs have attracted considerable attention due to their high conservation, stability, abundance, and specificity of tissue development.*

Accumulating evidence has revealed different form of circRNAs are closely related to the malignant phenotype, prognosis and chemotherapy resistance of BC, suggesting that different circRNAs may be promising biomarkers and have therapeutic significance in BC. The intention of this review is to summarize the mechanisms of circRNA-mediated BC progression and their diagnostic and prognostic value as biomarkers, as well as to further explore their roles in chemotherapy resistance. ...

Circular RNAs (circRNAs) are single-stranded, closed-loop structures lacking 50 caps and 30 tails of linear RNA, which enable them to resist the degradation of Ribonuclease R (RNase R) and thus are more stable than linear RNA. CircRNAs are an important part of non-coding RNA that are emerging as key new members of the gene regulatory milieu. ***The regulatory functions of circRNAs in physiological and pathological environments have been the focus of previous studies. Recently, the role of circRNAs has been revealed in a variety of cancers, such as prostate cancer, glioma, breast cancer, colorectal cancer, and more.***

A large number of studies have shown that circRNAs play a significant role in the progression of BC, including cell proliferation, migration and invasion, metastasis, cell cycle, apoptosis and drug resistance. Furthermore, it has also been demonstrated that the abnormal expression of circRNA is related to its pathological characteristics in bladder cancer tissue, which can be used as a potential biomarker for early screening, diagnosis and prognosis of bladder cancer.

CircRNAs possess potential modes of specific action, serving as sponges for miRNAs and RNA-binding proteins, or acting as transcriptional regulators. The aim of this paper is to discuss the latest knowledge on the role of circRNAs in bladder carcinogenesis, including proliferation, invasion, metastasis, and therapeutic resistance, and to propose circRNAs that conserve as ideal biomarkers and/or therapeutic targets

5.3.4 mRNA

Liu et al note the use of mRNA as follows:

*Based on the detection of five mRNA targets in urine (****CRH, IGF2, UPK1B, ANXA10, and ABL1****), Xpert Bladder Cancer (Xpert BC) is a recently developed detector for the detection of bladder cancer, which is non-invasive and highly economical.*

It can automatically complete the task of sample preparation, amplification of nucleic acid and detection of the target sequence, etc..

Xpert BC assay provided a “negative” or “positive” result based on the results of a linear discriminant analysis (LDA), which depended on a regression algorithm that utilizes the cycle threshold (Ct) results of the five mRNA targets.

In recent years, researches on the diagnostic accuracy of Xpert BC in the follow-up of bladder cancer have been carried out in full swing. Pichler et al. for the first time reported Xpert BC Monitor and documented that even in LG and pTa diseases, it could monitor with high *sensitivity. Hurle et al. discovered that 33.4% of cystoscopy can be avoided if Xpert BC is applied.*

One of the research of D'Elia et al. suggested that the sensitivity of the Xpert BC monitoring test was significantly higher than that of the cytological test, while its specificity failed to reach the cytological level. Valenberg et al. pointed out that Xpert BC improved NPV in bladder cancer patients during follow-up compared with urology and cytology

5.3.5 miRNA

As Piao et al note :

Numerous studies have shown that exosomal contents, such as double-stranded DNA, various RNA species, and proteins, can be used as predictive biomarkers for cancer diagnosis and prognosis. Studies regarding the biomarkers have revealed that several RNAs possess advantages over DNA, due to their dynamic and fluctuating expression pattern (such as lncRNAs) corresponding with the internal needs of cells, thereby indicating that those RNAs have a high tissue- or disease-state-specific feature.

*Furthermore, paradoxically, **the DNAs existing in exosomes vary along with the different detection methods, which makes an elusive whether genomic DNA exists in exosomes**.*

Among exosomal RNA species, miRNAs, a class of small, single-stranded, noncoding RNA molecules, play a role in virtually all biological pathways, including cell growth, proliferation, and differentiation, as well as immune responses, apoptosis, metabolism, and tumorigenesis. Exosomes provide a protective and highly stable source of miRNAs in body fluids, protecting them against degradation even under non-physiological conditions. ExomiRs are reportedly resistant to multiple freeze-thaw cycles, are stable during longterm storage at room temperature, and remain stable for up to five years when stored at −20 ◦C. Their enhanced stability compared to proteins and other nucleic acids, both in the circulation and in fixed tissues, makes exomiRs well-suited to sampling and analysis.

Moreover, exosome secretion from malignant tissue is much higher than that from the corresponding normal tissue, and higher concentrations of exomiRs are typically detected in tumor liquid biopsy samples such as plasma, urine, and ascites.

Coupled with the stability of miRNAs, this increased load of circulating exosomes in the malignant state has enabled the identification of several potential exomiR biomarkers. Another attractive RNA molecule exists in exosome is lncRNA, which is larger in size and has less been studied than exomiRs…

Nevertheless, granting exosomal lncRNA seems to be a promising biomarker for cancer; its application has some limitations, including an analysis only on the known lncRNAs, the false positives derived from nonspecific hybridizations, high variability for little expressed genes, and the sealed lncRNAs sequence variants.

On the basis of these findings, the obvious superiority for the exomiRs as a noninvasive biomarker in liquid biopsies has been confirmed.

miRNAs are taken up by nearby or distal target recipient cells as a cargo of exosomes, reflecting a cell-to-cell communication method that can influence the pathogenesis of cancer.

Therefore, miRNAs carried by exosomes can provide information about dominant cells from which they are derived, as well as the target and cellular state, including potential therapy resistance. Recent evidence suggests that the transmission of onco-miRNAs via tumor cell-derived exosomes can promote tumor cell proliferation and invasion, as well as angiogenesis, distant metastasis, and remodeling of the tumor microenvironment.

miRNAs are key regulators of gene expression in cancer, functioning as either tumor suppressors or oncogenes depending on the target mRNA, and play a constructive role in tumorigenesis, metastasis, and resistance to diverse treatments. Cancer cell released exomiR-21, exomiR-23, exomiR-29, exomiR-103, and exomiR-210 promote tumor proliferation, angiogenesis, and migration. ***In particular, exo-miR-21 may be a promising biomarker for many types of cancer.***

5.4 CXBLADDER

CxBladder uses 5 mRNA measures to assess the likelihood of a patient having bladder cancer, BCa[24]. The targeted mRNA are:

MRNA	*Control Factor*
IGFBP5	IGF genes are insulin growth factor related genes.
HOXA13	
MDK	
CDK1	CDK genes are cycling dependent kinases involved in the cell reproduction process.
CXCR2	

As Darling et al had noted:

Using a single voided urine sample, Cxbladder measures the expression of five genomic markers (IGF, HOXA, MDK, CDC and IL8R gene expression) in its Detect modality, while data from these genomic markers and clinical variables (age, gender, frequency of macrohematuria and smoking history) are considered in its Triage clinical modality. Cxbladder is used to identify patients who have a low risk of UC and may not require a full urological work-up (Triage clinical modality), and patients with a high probability of UC (Detect clinical modality).

---

[24] https://www.cxbladder.com/us/what-is-cxbladder/how-it-works/

Cxbladder has been validated for ruling out UC in 40% of patients with macrohematuria when used in the Triage modality (sensitivity 0.95; negative predictive value 0.98) , and has proven effective at separating samples from healthy patients and those with UC in the Detect modality (specificity 0.85; sensitivity 0.82)



5.4.1 IGFBP5

IGF is the insulin growth factor. IGFBP is the IGF bound protein which can modulate the effects of IGF. There are six IGFBP proteins and IGFBP5 is a significant one.

From NCBI[25]:

Enables insulin-like growth factor I binding activity. Involved in several processes, including cellular response to cAMP; regulation of smooth muscle cell migration; and regulation of smooth muscle cell proliferation. Part of insulin-like growth factor ternary complex.

From Duan and Allard:

Insulin-like growth factor (IGF) signaling is regulated by a conserved family of IGF binding proteins (IGFBPs) in vertebrates. Among the six distinct types of IGFBPs, IGFBP-5 is the most highly conserved across species and has the broadest range of biological activities. IGFBP-5 is expressed in diverse cell types, and its expression level is regulated by a variety of signaling pathways in different contexts. IGFBP-5 can exert a range of biological actions including prolonging the half-life of IGFs in the circulation, inhibition of IGF signaling by competing with the IGF-1 receptor for ligand binding, concentrating IGFs in certain cells and tissues, and potentiation of IGF signaling by delivery of IGFs to the IGF-1 receptor.

IGFBP-5 also has IGF-independent activities and is even detected in the nucleus. Its broad biological activities make IGFBP-5 an excellent representative for understanding IGFBP functions. Despite its evolutionary conservation and numerous biological activities, knockout of IGFBP-5 in mice produced only a negligible phenotype.

---

[25] https://www.ncbi.nlm.nih.gov/gene/3488

Recent research has begun to explain this paradox by demonstrating cell type-specific and physiological/pathological context-dependent roles for IGFBP-5. In this review, we survey and discuss what is currently known about IGFBP-5 in normal physiology and human disease. Based on recent in vivo genetic evidence, we suggest that IGFBP-5 is a multifunctional protein with the ability to act as a molecular switch to conditionally regulate IGF signaling….

IGFBP-5 has been found to be altered in various disease states (120–123), providing the possibility of using this protein as a marker of disease progression, and hinting that altered IGFBP- 5 expression may have pathophysiological relevance. Altered levels of IGFBP-5 have been detected in many types of cancer. Ding et al. have identified over 20 non-synonymous IGFBP- 5 mutations in a variety of cancer cell lines.

These include frame-shift and non-sense mutations. Several of them, including G223R and W242∗ were speculated to have lost IGF binding ability. IGFBP-5 has been found to indicate a poor prognosis in patients with several types of cancer. IGFBP-5 levels are significantly elevated in osteosarcoma cells that exhibit high metastatic potential. However, others found that IGFBP-5 expression inhibited osteosarcoma tumor growth and metastasis.

In gastric cancer, upregulation of IGFBP-5 was found to partially mediate the action of the PBX/Knotted Homeobox 2 tumor suppressor (128). In papillary thyroid carcinoma, IGFBP-5 was reported to promote cell growth, and miR-204-5p, which inhibits growth by suppressing IGFBP-5, was downregulated in these cells.

In MCF-7 breast cancer cells, IGFBP-5 promoted cell survival and adhesion via an IGF independent mechanism. A genome wide association study found an SNP allele associated with reduced IGFBP-5 expression and this SNP conferred increased susceptibility to breast cancer, which is consistent with the role of IGFBP-5 in mammary gland discussed above.

IGFBP-5 has been found to both inhibit and promote cancer cell growth in vitro. It is possible that the expression of IGFBP-5 protease(s) may be important for determining the context-specific effects of IGFBP-5. IGFBP-5 may play a role in the pathogenesis of atherosclerosis, which is a process of inflammatory tissue remodeling within the matrix of the arterial wall that is the top cause of cardiovascular disease and aging-related mortality in humans. A cross-sectional case-control study found a positive association between circulating IGFBP-5 levels and coronary heart disease. Overexpression of PAPP-A, whose only known substrates are IGFBP-2, -4, and -5, in the arterial smooth muscle of mice enhanced the progression of atherosclerotic lesion development. PAPP-A knockout mice are protected from atherosclerosis as well.

Conflicting results have been found in mouse models in which other components of the IGF system have been manipulated, and there are indications that circulating IGF may be protective rather than pro-atherosclerotic. Local IGF signaling plays an important role in atherosclerosis by stimulating the proliferation of vascular smooth muscle cells and their migration into the arterial intima where they contribute to the formation of atherosclerotic plaques.

Local IGF signaling in the arterial wall and in atherosclerotic plaques is regulated by multiple IGFBPs including IGFBP-5. IGFBP-2 and -4 inhibit IGF signaling in VSMCs but IGFBP-5 enhances it. IGFBP-5 expression is upregulated in atherosclerotic plaques and IGFBP-5 protein is found in large quantities associated with ECM within atherosclerotic plaques. IGFBP-5 is known to bind to ECM components PAI-1 and osteopontin, which have both been found in atherosclerotic plaques and have been shown to promote atherosclerosis in loss of function studies.

ECM associated IGFBP-5 potentiates IGF signaling, and IGF signaling can upregulate expression of IGFBP-5, so it is possible that a positive feedback loop could contribute to atherogenesis.

5.4.2 HOXA13

From NCBI[26]:

the genes encoding the class of transcription factors called homeobox genes are found in clusters named A, B, C, and D on four separate chromosomes. Expression of these proteins is spatially and temporally regulated during embryonic development. This gene is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation.

From Botti et al:

There is also growing evidence that HOXA13 has a role in liver cancer. HOXA13 is over-expressed in primary hepatocellular carcinoma (HCC) and is strongly associated with hepatitis B and C virus infection. In addition, its expression has been detected in HCC cell lines originating from liver stem-like cells, suggesting the HOXA13 role in the differentiation and tumor evolution of hepatic stem cells. The profile of the whole HOX network in a large cohort of paired liver biopsies, HCC versus their non-neoplastic counterparts, has identified the locus A HOX gene as the most dysregulated locus among the HOX loci and HOXA13 is systematically over-expressed in HCCs versus normal/non-neoplastic livers.

The study has demonstrated that HCC samples with high HOXA13 expression manifest the dysregulation of a gene set associated to poor prognosis, according to HCC transcriptome classification. Furthermore, HOXA13 homeoprotein physically interacts with the cap-binding protein eIF4E, deregulated in HCC. HOXA13 expression in HCC patients is also strongly correlated with the expression of angiogenic markers, such as VEGF, microvessels density and alpha-fetoprotein (AFP) serum levels.

In addition, serum HOXA13 levels have been detected in 90 HCC patients suggesting that its circulating level could be used for early HCC diagnoses and prediction of the outcomes. In HCC in vitro model, HOXA13 further correlates with poor differentiated HCC modulating sorafenib response. The deregulation of HOXA13 has been also described in lung cancer.

---

[26] https://www.ncbi.nlm.nih.gov/gene/3209

The expression data of HOXA13 have been collected from different databases, highlighting its aberrant expression mainly in lung adenocarcinoma progression. In addition, Kang and collaborators have described a frequent gain of copies number on the short arm of chromosome 7 containing the whole locus HOXA, suggesting its critical role in lung adenocarcinoma evolution.

HOXA13 deregulation has been sporadically associated to other cancer phenotypes, such as ovarian cancer associated with poor clinical outcome , in glioma associated with tumor progression thought Wnt and TG-Beta pathways modulation and thyroid cancers where HOXA13 nuclear expression is associated with different histotypes

5.4.3 MDK

From NCBI[27]:

This gene encodes a member of a small family of secreted growth factors that binds heparin and responds to retinoic acid. The encoded protein promotes cell growth, migration, and angiogenesis, in particular during tumorigenesis. This gene has been targeted as a therapeutic for a variety of different disorders. Alternatively spliced transcript variants encoding multiple isoforms have been observed.

As Filippou et al note :

Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration, and angiogenesis.

Several studies have investigated the role of midkine as a cancer biomarker for the detection, prognosis, and management of cancer, as well as for monitoring the response to cancer treatment. Moreover, several efforts are also being made to elucidate its underlying mechanisms in therapeutic resistance and immunomodulation within the tumor microenvironment.

---

[27] https://www.ncbi.nlm.nih.gov/gene/4192



Cancer cell survival and proliferation

They continue:

MDK is a protein that initiates signaling through ligand dependent receptor activation for a biological response. To date, there have been key advances made on elucidating the functional MDK-mediated mechanisms, including diverse receptors and complicated intracellular signaling pathways. The glycosaminoglycan (GAG)-recognizing activity of MDK is important for this mechanism of action. For this reason, proteoglycans including receptor-like protein tyrosine phosphatase- ζ (PTP-ζ) , syndecans , and glypican-2 , demonstrate a strong affinity for MDK. Other proteins, such as low-density lipoprotein receptor-related protein (LRP) , α4β1-integrin, and α6β1-integrin also serve as putative MDK receptors, which, together with PTP-ζ form a receptor complex for MDK binding.

In general, the interactions of MDK with the above mentioned receptors or receptor complexes promote cancer cell growth, migration, metastasis, and angiogenesis via the activation of downstream signaling cascades.

As already explained, MDK is a growth factor overexpressed in various human malignancies , and the downstream signaling events may be linked to a vast plethora of phenotypic characteristics leading to cancer development and progression. In this chapter, we describe the involvement of MDK in cancerrelated signaling from the viewpoint of the well-described hallmarks of cancer…

Bladder cancer (BCa) is the most common malignancy of the urinary tract in the elderly population and the sixth most common cancer in men worldwide. Although a great effort was performed to investigate putative urinary biomarkers suitable for the noninvasive diagnosis of BCa, a routine application of these tests is not recommended for the primary detection of BCa.

MDK protein expression in BCa and its correlation with a poor outcome in invasive bladder carcinomas has been reported , and increased MDK protein levels in urine specimens from BCa patients was demonstrated. Importantly, the correlation between MDK protein concentration in urine and disease progression in terms of tumor stage and grade has been previously investigated. MDK protein showed a substantial elevation in the urine of patients, although not in the urine of those with early-stage low-grade tumors.

In another study, increased MDK levels were normalized to urinary creatinine, indicating that MDK may potentially be suitable marker for the identification of patients with high risk BCa

The tumor proliferation impact is shown below:



5.4.4 CDK1

From NCBI[28]:

---

[28] https://www.ncbi.nlm.nih.gov/gene/983

The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is a catalytic subunit of the highly conserved protein kinase complex known as M-phase promoting factor (MPF), which is essential for G1/S and G2/M phase transitions of eukaryotic cell cycle. Mitotic cyclins stably associate with this protein and function as regulatory subunits. The kinase activity of this protein is controlled by cyclin accumulation and destruction through the cell cycle. The phosphorylation and dephosphorylation of this protein also play important regulatory roles in cell cycle control.

The cyclin dependent kinases, CDKs, are key elements in the operation of the cell cycle and thus key to functional proliferation. Any suppression of them would suppress proliferation and any significant activation would putatively result in excess proliferation. Thus cells have an over activated path controlling these genes would have a proliferation advantage and could arguably be the basis for metastatic growth.

As we have demonstrated previously the cell cycle shown below uses a variety of CDKs in its processing. CDK1 is used in G2 and M and it is essential for the final phase.



It is also useful as shown in the Figure below to understand that CDKs are controlled as well by FOXM and in turn by SPDEF. We have examined this in detail elsewhere[29].

---

[29] See http://www.telmarc.com/Documents/White%20Papers/117SPDEF.pdf



CCNB1 cyclin B1; Essential for the control of the cell cycle at the G2/M (mitosis) transition

CCNB2 cyclin B2; Essential for the control of the cell cycle at the G2/M (mitosis) transition

CDK1 cyclin-dependent kinase 1; Plays a key role in the control of the eukaryotic cell cycle.

CDK2 cyclin-dependent kinase 2; Involved in the control of the cell cycle. Interacts with cyclins

The SPDEF relationship is of merit but not essential in the current analysis. We also have the following.

The Figure below details a putative pathway element between SPDEF and AR[30]:



http://www.pathwaycommons.org/pc/record2.do?id=64346

There is a connection between SPDEF functioning and AR as well as CDK1. Whether this is a connection of merit between CHK2 functioning and AR is apparently unknown at this time.

---

[30] See also: https://targetexplorer.ingenuity.com/gene/EG/25803/pathways



The above is a significant exhibition of cause and effect with regards to the genes and their expression on overall cell stability.

5.4.5 CXCR2

From NCBI[31]:

The protein encoded by this gene is a member of the G-protein-coupled receptor family. This protein is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor.

Knockout studies in mice suggested that this receptor controls the positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. This gene, IL8RA, a gene encoding another high affinity IL8 receptor, as well as IL8RBP, a pseudogene of IL8RB, form a gene cluster in a region mapped to chromosome 2q33-q36.

From Korbecki et al we have:

---

[31] https://www.ncbi.nlm.nih.gov/gene/3579

In tumors, particularly in melanoma, CXCR2 is activated in an autocrine manner. CXCR2-induced NF-κB activation increases the expression of the CXCR2 ligands which activate CXCR2. Activation of NF-κB via CXCR2 happens through a process dependent on Ras, mitogen-activated protein kinase kinase kinase 1 (MEKK1), and p38. Moreover, CXCR2-induced NF-κB activation occurs via the PI3K-PKB/Akt pathway and via transforming growth factor (TGF)-β-activating kinase 1 (TAK1). At the same time, activation of this pathway may not so much directly depend on CXCR2 but rather on the transactivation of EGFR.

This activation of NF-κB leads to the expression of pro-inflammatory genes, including ligands for CXCR2. Moreover, the activation of NF-κB by CXCR2 causes cancer cell migration. CXCR2 increases tumor cell proliferation in cancer.

First of all, this happens via EGFR as a result of metalloprotease activation that cleaves heparin-binding epidermal growth factor-like growth factor (HB-EGF) , an EGFR ligand. HB-EGF, probably released via the actions of enzymes a disintegrin and metalloproteinase 17 (ADAM17) or cathepsin B , induces the transactivation of EGFR, which leads to increased proliferation of epithelial ovarian cancer cells.

Second, the activation of CXCR2 results in increased expression of early growth response-1 (EGR-1) in esophageal cancer , which increases proliferation by elevating the expression of cyclin-dependent kinase 4 (CDK4).

Third, CXCR2 activates PKB/Akt, which affects the action of p53 via the activation of murine double minute 2 (Mdm2), an enzyme causing the ubiquitination and subsequent degradation of p53.

Decreased expression of p53 results in decreased expression of p21, a cell cycle inhibitor—in this way CXCR2 activation results in decreased p21 expression and thus increased cell proliferation. CXCR2 appears to inhibit proliferation in normal cells, which is associated with senescence dependent on p53 and p38 MAPK. Senescence itself causes an increase in the expression of CXCR2 and ligands for this receptor and thus autocrine enhancement of senescence.

If there is a mutation in the TP53 gene or a decrease in p53 expression, then the described mechanism will not cause growth arrest but will stimulate proliferation , which is significant in cancer cell proliferation where p53 dysfunction is common.

The association of CXCR2 with senescence is important in the tumor microenvironment, as CXCR2 ligands secreted by cancer cells induce senescence of cancer-associated fibroblast (CAF). Then, these cells exhibit a senescence-associated secretory phenotype (SASP) that enhances cancer tumor growth. In the absence of CXCR2 activation on CAFs, these cells become myofibroblasts

5.5 XPERTBC

XpertBC is a second miRNA targeted test that is used to monitor Bladder Cancer.

From Liu et al:

*Xpert Bladder Cancer is a detection method developed in recent years, designed with the functions of integrating sample automatically, nucleic acid amplification, and target sequence detection. It is a urine assay targeting five mRNAs (**CRH, IGF2, UPK1B, ANXA10, and ABL1**). The purpose of this article is to review the accuracy of Xpert Bladder Cancer in the follow-up diagnosis of bladder cancer and evaluate the role of Xpert Bladder Cancer in detecting the recurrence of non-muscle-invasive bladder cancer in the round …*

*Xpert Bladder Cancer presents high accuracy and specificity in monitoring bladder cancer compared with cystoscopy… Xpert BC is highly valued in monitoring bladder cancer. Although cystoscopy and the cytological test are still adopted as the gold standard to monitor the recurrence of bladder cancer, each of the two methods has its own limitations: **cystoscopy is an invasive detection method, which causes uncomfortable feelings to the examinees as well as damage that may induce secondary infection, and as for the cytological test, the sensitivity of the results is not high, and the results are greatly affected by the subjective interpretation of the tester, which deprives the cytological test of authoritative objectivity** …*

5.5.1 UPK1B

From Wang et al:

The expression of UPK1B in BCa tissues was remarkably higher than that of adjacent normal tissues (p<0.05). Compared with BCa patients with lower UPK1B expression, those with higher UPK1B expression exhibited higher tumor stage, lymph node metastasis and distant metastasis. In vitro experiments indicated that cell proliferation, invasion and metastasis were remarkably decreased in cells transfected with siUPK1B when compared with those transfected with negative controls. Western blot showed that the expression of key proteins in the Wnt/β-catenin signaling pathway in cells transfected with si-UPK1B was significantly down-regulated compared with those transfected with negative controls, including β-catenin, c-myc and cyclinD1. In addition, rescue experiments found that UPK1B was regulated by β-catenin. …

UPK1B can promote the proliferation, invasion and metastasis of tumor cells and regulate the development and progression of tumors11,12. It has been shown that UPK1B is differentially expressed in multiple tumors with tissue specificity, including colorectal cancer, hepatocellular carcinoma, breast cancer and non-small cell lung cancer13. However, the specific mechanism of UPK1B in tumors has not been fully elucidated. Generally, UPK1B participates in various biological processes, such as chromosomal recombination, gene imprinting, nuclear transport, mRNA splicing and translation9, 10. However, the role of UPK1B in BCa has not been explored.

Therefore, we investigated the effect of UPK1B on the Wnt pathway, EGFR pathway, TGF-β inhibition, β-catenin mutation and epithelial-mesenchymal transition (EMT) in BCa

5.5.2 IGF2

From Chiu et al:

In this study, we found SOX2 expression signifies poor recurrence-free survival and correlates with advanced pathological grade in bladder cancer.

SOX2 silencing attenuated bladder cancer cell growth, while its expression promoted cancer cell survival and proliferation. Under low serum stress, SOX2 expression promoted AKT phosphorylation and bladder cancer cells' spheroid forming capability.

Furthermore, pharmacological inhibition of AKT phosphorylation, using MK2206, inhibited the SOX2-mediated spheroid formation of bladder cancer cells.

Gene expression profiling showed that SOX2 expression, in turn, induced IGF2 expression, while SOX2 silencing inhibited IGF2 expression. Moreover, knocking down IGF2 and IGF1R diminished bladder cancer cell growth.

Lastly, pharmacological inhibition of IGF1R, using linsitinib, also inhibited the SOX2-mediated spheroid formation of bladder cancer cells under low-serum stress.

Our findings indicate the SOX2–IGF2 signaling affects the aggressiveness of bladder cancer cell growth. *This signaling could be a promising biomarker and therapeutic target for bladder cancer intervention….*

Insulin-like growth factor 2 (IGF2), a mitogenic peptide hormone, is highly expressed during embryonic development19, and overexpressed in tumors associated with more aggressive status20*.*

Previous studies suggest that IGF2 binds to its receptor, IGF1R, to initiate tumorigenesis of breast and lung cancers21,22 and promote progression of endometrial and gastric cancers23,24*.*

Loss of imprinting contributes to overexpression of IGF2 in cancers of the prostate and colon and cancers with stem cell-like features25–28, while deregulation of IGF2 in cancers is also attributable to abnormal expression of transcription factors29–31. Insulin-like growth factor-binding protein 1 (IGFBP1) is a secreted protein serving as a negative regulator that competes with IGF ligands, thus preventing ligand–receptor activation32–34.

Although IGF2/IGF1R signaling enhances tumor progression in several cancers, it is unclear whether IGF2/IGF1R signaling contributes to bladder cancer progression.

In this study, we found SOX2 is a prognostic marker in bladder cancer patients, signifying poor survival. We also found SOX2 promotes AKT phosphorylation in bladder cancer cells by inducing IGF2 and IGF1R expression and suppressing IGFBP1.

We further characterized the potential of IGF1R signaling as a biomarker and therapeutic target in treating bladder cancer.

5.5.3 CRH

As NCBI state[32]:

This gene encodes a member of the corticotropin-releasing factor family. The encoded preproprotein is proteolytically processed to generate the mature neuropeptide hormone. In response to stress, this hormone is secreted by the paraventricular nucleus (PVN) of the hypothalamus, binds to corticotropin releasing hormone receptors and stimulates the release of adrenocorticotropic hormone from the pituitary gland.

Marked reduction in this protein has been observed in association with Alzheimer's disease. Autosomal recessive hypothalamic corticotropin deficiency has multiple and potentially fatal metabolic consequences including hypoglycemia and hepatitis. In addition to production in the hypothalamus, this protein is also synthesized in peripheral tissues, such as T lymphocytes, and is highly expressed in the placenta. In the placenta it is a marker that determines the length of gestation and the timing of parturition and delivery.

A rapid increase in circulating levels of the hormone occurs at the onset of parturition, suggesting that, in addition to its metabolic functions, this protein may act as a trigger for parturition.

5.5.4 ANXA10

From NCBI[33]:

This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways.

As Zhang et al note regarding melanoma mets :

Annexins are a superfamily of calcium- and phospholipid-binding proteins involved in many cellular processes, including calcium signalling, growth regulation, cell division, and cell differentiation. The dysregulation of annexins is associated with the development and progression of several types of human malignancies. Annexin A10 (ANXA10) is the most recently identified member of the annexin family, and its aberrant expression is observed in malignant tumours, including hepatocellular carcinoma, pancreatic cancer, oral cancer, and epithelial ovarian cancer.

---

[32] https://www.ncbi.nlm.nih.gov/gene/1392

[33] https://www.ncbi.nlm.nih.gov/gene/11199

ANXA10 expression holds differential prognostic value depending on tumor types. Reduced expression of ANXA10 is associated with vascular invasion, tumour progression, and poor prognosis of hepatocellular carcinoma.

A decrease in ANXA10 expression also correlates with the increase in proliferation and migration in cancers of prostate, gastric, and bladder cancers.

Conversely, upregulated expression of ANXA10 is associated with poor survival of colorectal cancer, oral squamous cell carcinoma, and head and neck squamous cell carcinoma, especially for patients with metastasis.

Although ANXA10 is involved in the regulation of cellular proliferation, differentiation, and the assembly of cell cytoskeleton, the molecular mechanism by which ANXA10 affects tumour progression, and thus, patient prognosis, remains unknown.

The last sentence is most important. The process is as yet unknown. The authors then assert:

1. ANXA10 is upregulated in melanoma and associated with melanoma progression

2. ANXA10 promotes the metastatic ability in melanoma

3. ANXA10 induces E− to N-cadherin switch via TGF-β/SMAD Pathway

SMAD6 is an inhibitory SMAD (I-SMAD) in TGF-β/SMAD signalling pathway. The upregulation of Smad6 mRNA expression in ANXA10-KO cells was observed in a qRT-PCR assay, whereas the downregulation of SMAD6 was detected in B16F10 cells overexpressing ANXA10, indicating a negative regulation of SMAD6 by ANXA10 (Supplementary Fig. S5). Importantly, ANXA10-KO cells exhibited higher E-cadherin expression and lower N-cadherin expression, which was coordinated with an increased SMAD6 expression (Fig. 3H). The changes in N- to E-cadherin expression in ANXA10-KO cells were confirmed using an immunofluorescence assay, and SMAD6 siRNAs reverted the E− to N-cadherin switch (Fig. 3I). Thus, ANXA10 appears to promote the E− to N-cadherin switch by downregulating SMAD6 in the TGF-β/SMAD signalling axis.

4. Effect of ANXA10 on SMAD6 via PKD1 signalling

5. ANXA10 regulates PKD1 degradation by interacting with it

6. ANXA10 inhibits E3 ligase TRIM41-mediated PKD1 degradation

7. ANXA10 promotes metastatic potential via PKD1–SMAD6 pathway

Now Munksgaard et al note:

The ANXA10 gene expression levels in tumours from 150 patients were reported previously. A gene expression signature including ANXA10 was validated as being able to predict the presence *of concomitant CIS, and progression to muscle-invasive bladder cancer. In the present study, we focused on the ANXA10 gene expression and in patient cohort 1, we found a 3.2-fold higher ANXA10 expression in tumours without concomitant CIS compared to tumours with concomitant CIS …*

Furthermore, low expression of ANXA10 correlated with shorter progression-free survival. … A high expression of ANXA10 in tumours without concomitant CIS compared to tumours with concomitant CIS was also shown at the protein level by western blotting. Immunostaining revealed strong but heterogeneous nuclear staining and medium cytoplasmic staining of ANXA10 in tumours without concomitant CIS and weak or no staining in tumours with concomitant CIS and in CIS lesions. Antibody specificity was validated by western blotting and by peptide competition assays.

Expression of ANXA10 in non-muscle-invasive bladder cancer

For validation of the prognostic value of ANXA10 at the protein level, we immunostained a bladder cancer tissue microarray. The patients had a median age of 68 years. …

Univariate Cox proportional hazards analysis of progression-free survival showed that ANXA10 and established prognostic factors including tumour stage, histological grade, age, and tumour growth pattern were significant risk factors for progression.

Multivariate analysis showed that low ANXA10 expression was an independent predictor of progression free survival.

In addition, we found a highly significant association between tumours with concomitant CIS and low ANXA10 expression (Po0.0001, w2-test). Down-regulation of ANXA10 and p53-positive immunostaining has been described to act synergistically towards high-grade and high-stage cancer and poor prognosis in hepatocellular cancer.

We therefore investigated the prognostic value of p53 alone and together with ANXA10. p53 immunostaining was significantly associated with shorter progression-free survival. Furthermore, an inverse correlation between ANXA10 and p53 expression was observed.

Combining ANXA10 and p53 expression resulted in a highly significant prediction of progression.

ANXA10 expression in muscle-invasive bladder cancer

We also investigated the prognostic value of ANXA10 in more advanced tumours. … The patients had a median age of 62 years (range: 46–73 years) and the median follow-up time was 24 months.

In this patient cohort, 15 of 97 patients (15%) had tumours with low ANXA10 expression, whereas 82 patients (85%) showed high ANXA10 expression.

We observed that in the ANXA10-positive tumours, the cancer cells generally revealed a strong but heterogeneous nuclear staining and medium cytoplasmic staining, similar to the non-muscle-invasive tumours. Kaplan–Meier survival curves showed that patients with low ANXA10 expression had an unfavourable prognosis. Metastatic disease was the only clinical variable that was significantly associated with ANXA10 expression in muscle-invasive tumours.

Furthermore, low ANXA10 expression was significantly associated with metastatic-free survival in univariate Cox regression analysis. All other clinical and histopathological parameters showed no correlation to survival.

5.5.5 ABL

As NCBI notes[34]:

This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons.

As Jones and Thompson note:

The Abelson (ABL) family of tyrosine kinases contains proteins ABL1 and ABL2 that regulate a multitude of cellular processes. These kinases garnered major attention in 1982, when de Klein and colleagues identified their involvement in the Philadelphia chromosome translocation that drives chronic myeloid leukemia (CML). This translocation results in an oncogenic fusion, BCR-ABL1, between the BCR gene (chromosome 22) and the ABL1 gene (chromosome 9).

ABL1 and ABL2 (also known as ABL-related gene, or ARG) have since been recognized for their roles in cytoskeletal reorganization, cell survival/proliferation, and disease pathology. ABL kinases are now implicated in a variety of disorders outside CML including diabetes, Niemann-Pick type C disease, and chronic pain. Elevated expression or activation of ABL kinases have also been found in several solid tumors.

Furthermore, ABL kinase fusions (like BCR-ABL1) have been identified as drivers of non-CML leukemias including B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), and acute myeloid leukemia (AML). Unsurprisingly, ABL kinase inhibition has proven an interesting therapeutic target in oncology. Imatinib mesylate, a first-generation,

---

[34] https://www.ncbi.nlm.nih.gov/gene/25

non-allosteric ABL inhibitor, has transformed the CML treatment landscape by improving 10-year overall survival in CML to over 80%, a nearly 50% reduction in annual age-adjusted mortality ,,,,,

ABL kinases are bilobal proteins with large C-terminal domains. The two members of the Abelson family in vertebrates, ABL1 and ABL2, share several catalytic and regulatory lobes but differ subtly in function. ABL1 contains nuclear localization motifs, whereas ABL2 is primarily found in the cytoplasm and at F-actin-rich sites in cells. An ATP-binding pocket rests between the N- and C-terminals of ABL1/ABL2 and contains a "gatekeeper" (threonine) residue, which regulates inhibitor binding and specificity. ABL kinase activity is controlled through such intramolecular/intermolecular interactions and through posttranslational modifications. A critical intramolecular interaction of ABL kinase activity is myristate binding. ABL kinases are inhibited when a myristoylated residue in the N-lobe binds a hydrophobic pocket in the C-lobe, locking ABL1/ABL2 into a "closed," or catalytically inactive, conformation (Fig. 1).

A major issue with ABL fusion proteins, like BCR-ABL1, is that their chromosomal translocation removes the Nlobe (and its myristate binder) from ABL1/ABL2. This leads to constitutive ABL kinase activity and helps drive leukemias like CML, because the autoinhibitory mechanism of ABL kinases is compromised when the N-terminal cap region is lost. The removal of this N-lobe, however, does not affect the myristate binding pocket in the C-lobe of ABL1/ABL2. This observation led researchers to question the utility of allosteric ABL kinase inhibitors, which can mimic the intrinsic myristate of the ABL N-lobe by binding in the C-lobe myristoyl pocket that is retained after chromosomal translocation

From Gu et al we have:



Now as Wang states:

ABL is not a master switch kinase.

(A) Receptor tyrosine kinase (RTK) is a master switch kinase that is activated by a specific signal—its extracellular ligand—and amplifies that signal by phosphorylating a whole host of intracellular proteins.

(B) ABL tyrosine kinase is not a master switch kinase. ABL binds to different trans inhibitors (depicted as a crescent) that partition this nonreceptor tyrosine kinase into different signaling complexes.

Signal-regulated release of ABL from a trans inhibitor may not be sufficient for kinase activation if that release does not disrupt the autoinhibitory kinase assembly established by intramolecular inhibitory interactions (the autoinhibited ABL is depicted as a full pie in this diagram). In order to become phosphorylated by ABL, a substrate must disrupt autoinhibition.

Many ABL substrates identified thus far are ABL-SH3-binding proteins, which disrupt the internal SH3/PXXP interaction to activate ABL (the substrate-bound and activated ABL is depicted as a three-quarter pie in this diagram).

Other ABL substrates interact with the SH2 domain or the PRL, and those interactions may also disrupt autoinhibition. The molecular design of ABL is more similar to an electric socket (upper right) than a master switch (see the text for discussion of this two-step mechanism of restricted ABL activation in signal transduction) …

The biological functions of a protein kinase can be deduced from its upstream activators and downstream substrates. The most familiar example is that of a receptor tyrosine kinase (RTK)—it is allosterically activated by ligand binding to the extracellular domain; it then phosphorylates its own intracellular domain and other intracellular proteins. By design, RTK functions as a master switch that turns on a complex network of pathways in response to a specific extracellular signal*...*

Other examples of master switch kinases are protein kinase A (PKA), which is activated by cyclic AMP (cAMP), and protein kinase B (PKB/AKT), which is activated by phosphotidyl-inositol-3,4,5-phosphate (PIP3). These serine/threonine protein kinases can transduce a variety of extracellular signals that cause the upregulation of second messengers such as cAMP or PIP3. In this master switch paradigm, a protein kinase is activated by a specific signal and proceeds to amplify that signal by phosphorylating a whole host of substrates.

*While this paradigm provided the rationale for most of the early studies on ABL****, the results obtained on ABL kinase regulation have been at odds with it being activated by a specific growth factor, a specific second messenger, or a specific upstream kinase. Instead, ABL kinase is activated by many different extrinsic ligands, including those that activate RTKs***

such as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), EPH, MET, and others.

ABL kinase is also activated by intrinsic signals such as DNA damage and oxidative stress. With each signal, the current results suggest that ABL kinase may be activated restrictedly, that is, each signal may activate only a fraction of the cellular ABL proteins to phosphorylate selective substrates

Finally, Luttman et al note:

The ABL kinases, ABL1 and ABL2, promote tumor progression and metastasis in various solid tumors. Recent reports have shown that ABL kinases have increased expression and/or activity in solid tumors and that ABL inactivation impairs metastasis.

The therapeutic effects of ABL inactivation are due in part to ABL-dependent regulation of diverse cellular processes related to the epithelial to mesenchymal transition and subsequent steps in the metastatic cascade. ABL kinases target multiple signaling pathways required for promoting one or more steps in the metastatic cascade. These findings highlight the potential utility of specific ABL kinase inhibitors as a novel treatment paradigm for patients with advanced metastatic disease. …

ABL kinases are activated by diverse stimuli including but not limited to growth factors, adhesion receptors, chemokines, oxidative stress, and DNA damage. Upon activation, ABL kinases can alter the cytoskeletal network necessary for cell migration, adhesion, polarity, phagocytosis and motility. In solid tumors, activated ABL kinases can promote invadopodia formation, invasion, and diverse cellular processes implicated in the epithelial–mesenchymal transition (EMT) and subsequent steps in the metastatic cascade. ABL1 was initially identified as a driver of leukemia in mice and humans.

Subsequently, ABL1 and ABL2 were shown to promote solid tumor progression and metastatic dissemination. In the context of solid tumors, ABL kinases are upregulated due to enhanced gene expression and/or enzymatic activation by oncogenic drivers, such as receptor tyrosine kinases (RTKs) and chemokine receptors. Upon activation, ABL kinases can potentiate cancer cell survival, proliferation, migration, and invasion, depending on the cellular context.

6 PROSTATE

In this Chapter we examine first the normal histology of the prostate and then we examine various types of dysplasia and malignancies. The intent here is not to become expert in the histological specificities of the prostate in both benign and malignant state but to have a fundamental understanding of how on a microscopic scale a malignancy develops and progresses. This will then allow us to, on the one hand look deeper into the genetic mechanism, and on the other hand, be able to look upward to cancer as a system level disease. The ultimate objective is to develop that system model for prostate cancer which aligns with the genetic underpinnings as well as being reflective of the histological development.

6.1 ANATOMY

We first examine the normal prostate. The prostate is normally about 40 cc in dimension with the prostate surrounding the urethra below the bladder.

The basic structure of the prostate is shown below. It consists of three major zones; peripheral (dominant zone), central zone which is around the urethra), and the transition zone.



The cellular structure is depicted below. There are approximately 35-50 glands in the prostate, mostly in the peripheral zone and the glands have a lumen in which the prostatic secretions flow and the glands have basal cells and luminal cells as shown below. The basal cells are dark and the luminal cells are somewhat lighter.

Between the cells is the stroma which includes the blood flow from veins and arteries, the muscle and other stroma elements. Simply stated, the prostate is a collection of the basal/luminal glands scattered about veins, arteries, muscles and nerves.



The figure below depicts a second view of the prostate glands. Again this is with HE stain and under low magnification. The basal cells are clearly seen with their dark stains and the luminal stand above them. The stroma is fairly well articulated in this slide.



The normal prostate then is merely a collection of glands, glands composed of basal and luminal cells, with open glandular portions, the white areas above. As we noted before these glands emit various proteins and are an integral part of the male reproductive system.

6.2 SUMMARY OF PROSTATE STATES

We now provide a high level summary of the changes in the prostate histologically as PCa is developed. We do this to lay out the various changes we will examine and to better understand what we may be looking for when developing pathways. We believe that it is essential that we always go back and forth between abstractions of pathways, and the reality of the cell histology.

There is a general agreement, with of course many exceptions, as to the progression of prostate pathology and its related causes. A graphic from a recent NEJM article is shown below[35]:



Not the progression from normal prostate with basal and luminal cells and then through PIA and then PIN and finally PCa. The PIN demonstrates a complex but contained development of cells. As one moves o PCa, that is when the cells move away from the existing gland, and they are for the most part luminal cells establishing de novo glandular like structures.

An excellent tabular summary from Taichman et al follows:

---

[35] See Nelson et al, Prostate Cancer, NEJM, July 24, 2003. p 376.

Disease State	***Histology***	***Details***
Normal Prostate		Large glands with papillary infoldings that are lined with a 2-cell layer consisting of basal and columnary secretory epithelial cells (luminal) with pale cytoplasm and uniform nuclei. Susceptibility genes or events related to hereditary PCa: RNASEL: regulates cell proliferation through the interferon regulated 2-5 oligoadenylate pathway ELAC2/HPC2: Loss of function of tRNA-3 processing endoribonuclease MSR1: Macrophage scavenger receptors process negatively charged macromolecules.
PIA		Atrophic glands have scant cytoplasm, hyperchromic nuclei and occasional nucleoli and are associated with inflammation Susceptibility genes or events: NKX3: Allelic loss of homeobox protein allowing growth of prostate epithelial cells PTEN: Allelic loss of phosphatase and tensin homolog allowing decreased apoptosis and increased cell proliferation. CDKN1B: Allelic loss of cyclin dependent kinase inhibitor p27 allowing increased cell proliferation
PIN		Intermediate to large size glands with proliferation changes contained within the gland and having nuclear abnormalities that resemble invasive carcinoma. Susceptibility genes or events: GSTP1: Hypermethylation of the upstream regulatory region inactivates the Pi class gluthionine S transferase enzyme which detoxifies carcinogens. Hepsin: Increased expression of this serine protease leads to increased invasiveness and disruption of the basement membrane. AMACR: Increased expression results in increased peroxisomal b-oxidation of branched chain fatty acids from red meat thereby increasing carcinogen exposure. TMPRSS2: Fusion of this androgen regulated gene with ETS family of transcription factors in late stages of PIN results in in increased breakdown of the extracellular matrix. Telomerase: Activation leads to maintenance of telomere length and immortalization of cells.
Prostate Cancer		Small irregular glands with cells having abnormal nuclei and nucleoli and lacking basal cells. Susceptibility genes or events: MYC: Overexpression leads to cell proliferation and transformation RB: Loss of expression leads to cell proliferation and transformation

Disease State	***Histology***	***Details***
Metastatic PCa		Nests of cancer cells within the bone Susceptibility genes or events: TP53: Mutation results in loss of multiple tumor suppressor functions E-cadherin: Aberrant expression leads to increased invasive and metastatic phenotype NM23: loss of this NDP kinase leads to increased metastasis EZH2: Histone methyltransferase PcG protein whose activation causes repression of genes that suppress invasion and metastasis
AR PCa		Cancer cells that grow in androgen depleted environment Susceptibility genes or events: AR: may remain active through amplification, phosphorylation by other steroids or non-androgen growth factors BCL2 Increased expression leads to protection from apoptosis Stem cells: potential repopulation by progenitor cells

Note in the above, Taichman et al make mention of the separate gene elements that are putatively assumed to have caused the subsequent event. These genetic changes then will become a key factor in how we view PIN transitions.

Also note in the above, it implies a set of sequences of genetic changes that moves from benign to malignant. The question then is; if a genetic change is necessary for a morphological change, then is the genetic change reversible or are the genetically changed cells killed off by some other process, and if so what process?

To understand this question, and hopefully set a path to answering it, we lay out the known elements in the path towards malignancy, look at the gene maps and dynamics, and then attempt to establish a model for examining the dynamic processes which move the cell forward to malignancy or backwards towards a benign state.

We shall now examine each of these in some detail.

6.3 PROSTATIC INTRAEPITHELIAL NEOPLASIA

Prostatic Intraepithelial Neoplasia, PIN, is considered a precursor to PCa. High Grade PIN, HGPIN, is often considered almost certainly a precursor. However as we shall discuss this is at times not the case and HGPIN is known to regress. One must be careful, however, since we are generally discussing biopsy samples which may be subject to substantial sampling deficiencies as we have already discussed.

Let us now provide a simple overview of the development of models. We develop it in the following manner:

First, we look at the histological structure of PIN and PCa. Cell changes occur and the changes morphologically are dependent upon the expression of or lack thereof of certain genes. The linking of morphology and gene expressions seems to fall short at this stage. Thus the nexus is missing.

Second, we look at some simple models for the development of HGPIN. As we have stated, the reason for this is twofold. First HGPIN is often assumed to be a natural precursor of PCa and as such one can assume that genetic changes necessary for PCa are first seen in HGPIN. Second we know that HGPIN can suddenly regress and the cells revert to benign state. If that is the case and indeed it is one may ask if the genetic changes were the cause also of the regression or was there some exogenous cause. We focus primarily on the Goldstein et al model because it demonstrates both HGPIN and PCa and the relationship to morphological and genetic changes.

Third, we examine the cancer stem cell, CSC, model. The CSC is an interesting paradigm which may explain the less than rapid growth of certain cancers. PCa may be dominated in many cases by indolent slow reproducing CSC. Understanding the dynamics of the CSC is therefore essential.

Fourth, we look at the many specific genetic drivers such as PTEN and the other first and second order products in the pathway chain. This is an extensive discussion which we will rely upon to build pathway models.

Fifth, we examine the epigenetic factors such as miRNA and methylation. These may be the most significant factors in cell change and genetic expression alteration that we see in PCa progression.

Sixth, we present and examine in some high level detail the many complex pathway models currently presented.

Seventh, we examine the various models for reaction kinetics. This will be essential when we attempt to model the dynamics. The classic approaches are significant and their simplifications are useful. By looking at linear models we often can find reasonable insight but it is often by examining the nonlinear models that we can ascertain the tipping points with more clarity.

Eighth, we examine pathway controls that are what components such as PTEN play the most significant role.

Ninth, we look at the three dominant modeling techniques; Boolean, Bayesian, and System model using reaction rates and complex time varying differential equations. We do not in this analysis examine the spatial models (as initially developed by Turing and detailed by Murray).

Tenth, we examine how the constants in these models may be obtained by means of system identification methods. We have accomplished this in other pathway systems and we believe it is directly applicable here as well.

6.3.1 HGPIN Characterization

HGPIN is represented by morphological changes in prostate cells in the acinar or glandular locations. It generally is a complex set of growth patterns of new cells whose morphological appearance is similar to but not identical to the existing cells in the gland. The new cells clearly have form and shape that demonstrates pre-malignant morphology, with enlarge and prominent nucleoli.

From the paper by Putzi and DeMarzo we have:

The high-grade form of prostatic intraepithelial neoplasia (PIN) has been postulated to be the precursor to peripheral zone carcinoma of the prostate. This is based on zonal co-localization, morphologic transitions, and phenotypic and molecular genetic similarities between high-grade PIN and carcinoma. Although high-grade PIN is thought to arise from low-grade PIN, which in turn is thought to arise in normal or "active" epithelium, little is known whether truly normal epithelium gives rise to PIN or whether some other lesion may be involved.

Focal atrophy of the prostate, which includes both simple atrophy and postatrophic hyperplasia, is often associated with chronic, and less frequently, acute inflammation. Unlike the type of prostatic atrophy associated with androgen withdrawal/ blockade (hormonal atrophy), epithelial cells in simple atrophy/postatrophic hyperplasia have a low frequency of apoptosis and are highly proliferative. In addition, hormonal atrophy occurs diffusely throughout the gland and is not usually associated with inflammation.

To simplify terminology and to account for the frequent association with inflammation and a high proliferative index in focal atrophy of the prostate, we introduced the term "proliferative inflammatory atrophy" (PIA).

In a similar manner in a review paper by O'Shaughnessy et al on multiple intraepithelial neoplasia the authors state the following regarding HGPIN:

The evidence that PIN is a morphological and genetic precursor to prostate cancer is extensive and conclusive...

When examined microscopically, PIN lesions are characterized by collections of proliferative prostatic epithelial cells confined within prostatic ducts that exhibit many morphological features of prostate cancer cells, including architectural disorganization, enlarged cell nuclei and nucleoli. ...

In addition to the similarity of the cellular morphologies of HGPIN and invasive lesions, evidence that HGPIN is a precursor of prostatic adenocarcinoma includes the multifocality of both lesions and the presence of carcinoma in foci of PIN; among older men, foci of PIN are found in 82% of prostates with carcinoma but in only 43% of normal prostates.

PIN is frequently located in the peripheral zone of the prostate, the site at which 70% of prostatic carcinomas occur. Additional similarities include enhanced proliferative activity of both PIN and carcinoma (3-fold that of benign tissue), cytokeratin immunoreactivity, lectin binding, and loss of blood group antigen with both PIN and carcinoma.

Prevalence of PIN and its temporal association with invasive cancer are illustrated by the known 40–50% PIN incidence in men 40–60 years of age, evolving into the 40–50% incidence of prostate cancer in men 80 years of age. Autopsy data reveal that PIN lesions appear in the prostates of men in their 20s and 30s in the United States, preceding the appearance of prostate cancer lesions by as many as 10 years …

African-American men, who are at higher risk of prostate cancer mortality, appear to have a greater extent of PIN at any given age. PIN and prostate cancer lesions share a number of somatic genome abnormalities, including loss of DNA sequences at 8p and increased GSTP1 CpG island DNA methylation, among others.

Finally, transgenic mouse strains prone to developing prostate cancers typically develop PIN lesions in advance of the appearance of invasive cancer. PIN lesions are always asymptomatic and cannot currently be diagnosed or detected by any reliable means other than examination of prostate tissue histologically. In autopsy studies, the incidence and extent of PIN increases with age, as does the incidence of prostate cancer.

Notwithstanding the correlation, there does not seem to be causality. In addition, the authors do indicate that HGPIN can be reduced but they seem to fail to speak to the issue of total remission without any treatment. The question is therefore, is PIN a precursor of PCa? If it is or is not, is PIN the result of a genetic change as has been postulated by many? It would seem clear that the existence of remission of PIN would imply that it is not at all necessarily a precursor and furthermore that it is not necessarily a genetic change for all PIN. That is can there be a morphological PIN that is genetic and not remissionable and one which is remissionable. Remissionable implies the existence of apoptosis that is a natural cell death or perhaps a cell death due to some immune response.

6.3.2 PIN Morphology

Prostatic Intraepithelial Neoplasia, PIN, is a growth within the normal glands of more cells than should normally be there. The slide below depicts high grade PIN, HGPIN. Note the PIN in the center shows significant cell growth in the existing gland as compared to the gland at the bottom which shows normal thinner growth.



The PIN shows papillae which are shooting out within the gland and there is also significant basophillic staining of the papilla cells whereas the normal gland has limited staining of the luminal cells. The key question is one of whether PIN is a precursor to PCa. Many articles state that it is but when one looks at the data there is still a significant area of doubt.

6.3.3 Some HGPIN Models

There has been an extensive amount of work in trying to create HGPIN from normal prostate cells. There are questions as to what cells the HGPIN derives from, for example basal or luminal, and then there are questions as to what genetic changes result in PIN. As with so many parts of the puzzle there are no single set of answers. We start with the recent Goldstein model and use it as a basis. Then we look at other models and specific genes expressed. We defer until later the issue of pathways.

6.3.3.1 The Goldstein Model

A novel set of experiments on prostate cancer were based on the work by Goldstein et al at UCLA. Understanding this work is useful in understanding both HGPIN and PCa. Goldstein et al demonstrate that one set of elements in the intracellular pathways if disturbed in a certain manner can result in morphological changes that first become HGPIN and then mode to PCa. The essential usefulness of this work is that it allows for a demonstrable relationship first between genetic change and histological change and second that changes in pathway elements lead to progression.

Simply what they did was to take two types of prostate cells, the basal and the luminal, tag them with surface tags, inject them into a mouse, and saw that only the basal cells grew, then they added two genes encoding for putative cancer pathways, and they saw that the basal cells grew to basal and luminal, like PIN, and then finally they added an AR, androgen receptor gene, and voila, prostate cancer. Result, showing how a specific pathway can generate cancer.

Let us go back and look at this a bit more.

1. First the prostate has cell collections which act as glands with basal cells at the base and luminal cells on top. The luminal cells secret to the gland, the luminal space. This we show below.



2. The normal prostate looks like what we show below, about 35-50 of these glands, and then surrounding material of muscle, blood supply, nerves, and lymphatics. The glands stand apart and they secret fluids into the lumen, the open parts of the gland. In between is the stroma composed of nerves, blood vessels and other connective tissues.



3. Now sometimes we see PIN, prostatic intraepithelial neoplasia, which is a growth of normal cells but not where they are to be. We may see the basal cells growing outwards and even some more luminal cells as well. The sign may be an increase in PSA since we have more luminal cells but the percent free PSA may stay high since the luminal cells are health ones. We show this below:



4. Then we may get prostate cancer, PCa, where the luminal cells types start to appear and grow without bound. The question is, where did these cells come from, other luminal cells or basal cells, or what. This is the question that the authors addressed with this elegant experiment. There is also the key question of whether it is just one cell that starts it or if the changed basal cells grow and if the environment switches many on over time. The latter effect is similar to that which has been observed in melanoma. Below we show what happens next,



Looking at the prostate as a whole we then may see what appears below. Namely we may see low grade cancer cells and then clusters of high grade cancer cells, this leads to the Gleason grading system.



5. Thus the question posed by the authors was the one which asks from what cell does cancer begin? Their answer suggests the basal cell.



6. Pathways have been studied for PCa extensively and we shall discuss them in some detail.

But the authors took a simple approach and looked at three genes in the putative pathway process. This is shown below:



First they showed that only basal cell proliferate into both basal and luminal. Then they added ERG and Akt genes known as key in the pathways, and they obtained PIN, and then they added AR, the androgen receptor to drive the previous two genes and the result was PCa.

They were able to keep track of basal and luminal cells by tagging them with cell surface markers, as shown below. Basal was positive for both and luminal positive for one and negative for another, a good example of tracking the cells as the transform.

Tagging



As to the two initial genes we have:

(i) Akt: There are in humans three genes in the "Akt family": Akt1, Akt2, and Akt3. These genes code for enzymes that are members of the serine/threonine-specific protein kinase family. Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes. Akt1 is also able to induce protein synthesis pathways, and is therefore a key signaling protein in the cellular pathways that lead to skeletal muscle hypertrophy, and general tissue growth. Since it can block apoptosis, and thereby promote cell survival, Akt1 has been implicated as a major factor in many types of cancer.

(ii) ERK: Extracellular signal regulated kinases, ERK, are protein kinase signaling molecules involved in the regulation of meiosis, mitosis, and postmitotic functions in cells.

This study still leaves several open questions:

1. Is the clonal theory of cancer still standing or can a single cell transform and then induce other cells via chemical signaling.

2. Is the basal cell the only one. There appears to be some issues here and the review article looks at these.

3. Is PIN an artifact or a precursor. Clinically men with PIN have a slightly higher risk of PCa but not a substantially higher as would be argued in this model. In fact men with PCa do not always have PIN and men with PIN do not always get PCa.

4. Is this just an artifact pathway, the true pathway, one of many pathways.

5. If we can duplicate pathways can we than better control the disease.

6. What does this tell us about detection and staging.

6.3.3.2 Other Models

The Goldstein et al model is but one of several which have taken this approach. There are others and the results are not always consistent. Two of them are discussed as follows:

1. Yen et al (2003) have reported on a murine model which demonstrated that by implanting c-Myc genes into a mouse that it resulted in murine PIN and then shortly thereafter PCa. Yen et al also shown loss of NKX3.1, a tumor suppressor gene, which is putatively involved in PCa as well as PIN. NKX3.1 is an 8p21 gene whose function is to generate the Homeobox protein[36]. It is known to be suppressed in familiar prostate cancer and in the case of Yen it is reduced in its expression as well.

2. Lawton and Witte discuss the generation of PIN by means of lentivirus infection via an siRNA which is a knock out for PTEN.

6.3.4 HGPIN, A Precursor of PCa?

There has been an extensive amount of literature claiming that high grade prostatic intraepithelial neoplasia, HGPIN, is a precursor to prostate cancer, PCa. The research has gone as far as delineating genetic changes which ultimately lead to metastatic PCa. However, at the same time it is not uncommon for HGPIN to regress and totally disappear. This would seem to counter the theory of genetic change and resulting morphological change of the prostate acini cells.

Moreover there have been many murine models of HGPIN which have been induced with specific genetic changes in specific pathways which lead inexorably to PIN and then to PCa. Likewise there have been many microarray analyses of HGPIN demonstrating the presence or absence, enhancement or deactivation, of the same or similar genes. Yet again there is at time spontaneous remission.

Thus it begs the question; what causes the remission of HGPIN? Is it possibly akin to the remission seen in certain cancers, a remission generated by an immune response effect, as discussed by Rosenberg? Or is it a pathway apoptosis that occurs as a natural course of having aberrant genes?

6.3.4.1 Key Questions

Let us begin with what we assume is known:

---

[36] Pecorino, Cancer, p 114.

1. HGPIN is driven by underlying progressive and non-changeable changes in the genetic structure of benign cells in the prostate glands.

2. There is a putative association between HGPIN and PCa, reflected in an increased incidence of PCa when HGPIN is present.

3. PCa like most other cancers is characterized by the clonal model, namely one cell becomes aberrant and all other cancers cells are daughter cells of the aberrant clone.

4. PCa is known to result via a set of genetic changes resulting in the cell growth outside of the gland and the creation of malignant glandular structures wherein additional genetic changes occur and result in a less structured morphology and then metastasis.

5. HGPIN regression is seen. This means that the HGPIN cells totally disappear resulting in a purely benign appearance of the prostate glands. It begs the question of; do they cells die or are they attacked and destroyed or is there some reversion mechanism? PIN is a proliferation, so any continuation of cell existence would imply at best a morphological change of say the nucleus and nucleoli but not the total cell count, namely the clustering of many cells in the gland. Thus in regression we do not know what happens or how.

Thus these observations pose the following questions:

1. What causes the disappearance of multiple clusters of HGPIN? Is it apoptosis of some form, an immune response, a genetic switch, or something else?

2. Has there been any extensive studies of HGPIN regression to understand how it arises?

3. If HGPIN regression is based upon some to-be-understood mechanism, can that same mechanism be applied in some form to PCa?

4. Does HGPIN, which is regressionable, have certain cell surface markers which are presentable to the immune system and thus enable enhanced immune responses?

5. Is there a stem cell created when PCa evolves and is PIN lacking in such a stem cell?

The literature demonstrates how to create PIN. There are a few presentations on how to regress PIN[37]. However the nexus of forward PIN progression and backward PIN regression is not complete. We attempt herein to review this in some detail and then to place it in a structure for further analysis and study.

As a natural extension to these questions we can then ask similar ones regarding PCa. How does PCa progress and what are the pathway dynamics related to that progression.

---

[37] Narayanan et al using NSAID.

6.3.4.2 An Example

Let us begin with a simple example. A 68 year old male is examined due to an increase in PSA from 1.5 to 2.3 in a one year period. The DRE is normal but there is a family history of a first degree relative who died from an aggressive PCa, at 79 years of age. Re-measuring the PSA from two independent sources yields values of 1.8 and 1.9 two months after the raised PSA.

A 20 core biopsy is performed and the results are as follows:

A. Prostate, right apex, biopsy: Benign prostatic glands and stroma.
B. Prostate, left apex, biopsy: Prostatic intraepithelial neoplasia, high grade, focal. Glandular hyperplasia of prostate.
C. Prostate left peripheral zone, biopsy: Prostatic intraepithelial neoplasia, high grade, focal, Glandular hyperplasia of prostate.
D. Prostate, right peripheral zone, biopsy: Benign prostatic glands and stroma.
E. Prostate, transition zone, biopsy: Prostatic intraepithelial neoplasia, high grade, focal Glandular hyperplasia of prostate.

After an eight month period PSA was measured again and this time it was 2.0. A second biopsy was performed using 24 cores. The results are:

A. Prostate, right apex, needle core biopsy: Benign prostatic tissue with very focal and mild acute inflammation.
B. Prostate, left apex, needle core biopsy: Benign prostatic tissue.
C. Prostate, right mid, needle core biopsy: Benign prostatic tissue.
D. Prostate, left mid, needle core biopsy: Benign prostatic tissue.
E. Prostate, right base, needle core biopsy: Benign prostatic tissue.
F. Prostate, left base, needle core biopsy: Benign prostatic tissue.
G. Prostate, transition zone, needle core biopsy: Benign prostatic tissue.

This is a clear case of total HGPIN regression. The question then is, how common is this and what is its cause, and if regression can be obtained how it might be achieved clinically?

6.4 PCA HISTOLOGY AND GRADING

In this section we provide more detail on grading of PCa. The emphasis here is upon histological change and does not reflect any changes in specific gene pathways.

Prostate Cancer is simply the growth of abnormal glandular like structures outside of the normal prostate glands the resulting continued growth of the cells making up those structures both within and without the prostate. The PCa cells take over the stroma, pushing aside the normal stromal cells and then migrate in a metastatic fashion throughout the body.

We will use the Gleason grading score as a means to characterize the level of cancer progression within the prostate.

6.4.1 Grading

We present the grading system developed by Gleason. On the one hand this has been used as a gold standard for ascertaining future progress and yet it is still just a morphological tool. It fails to determine the pathways and regulators in a cell by cell basis.

6.4.1.1 Gleason 1

The following is a Gleason 1 grade tumor. Note that there are a proliferation of small glandular like clusters with dark basophillic stains and they are separate and have clear luminal areas. Gleason 1 is generally composed of many single and separate and closely packed glands of well circumscribed uniforms glands. One rarely sees Gleason 1 grade tumors, and they are often found as incidental findings when examining for other issues.



We show another view of a Gleason 1 below. This is especially descriptive of such a form because it appears almost as a single and isolated structure. The interesting question will be if this is PCa then if PCa is clonal is this cluster an aberrant outgrowth of a normal cells, if so which one, and if so is this just one cell growing. It appears that at this stage the intercellular signaling is still trying to function. However the clarity of cell form is being degraded.



6.4.1.2 Gleason 2 and 3

Gleason 2 shows many newer glandular like cells but now of varying larger sizes. As Epstein notes: "*Grade 2 … is still fairly circumscribed, at the edge of the tumor nodule there can be minimal extension by neoplastic glands into the surrounding non-neoplastic prostate. The glands are more loosely arranged and not as uniform as Gleason 1*." We see those in the figure below which combines Gleason 2 and 3.

Gleason 3 is often composed of single glands. The Gleason 3 infiltrates in and amongst the non-neoplastic glands. Gleason 3 still can be seen as a separate gland and there are no single cells starting to proliferate. In Gleason 3 we still have some semblance of intercellular communications and coordination, albeit with uncontrolled intracellular growth. Again in the figure below we see both the smaller 2 and the larger 3 with gland structure being preserved and no separate cells proliferating.



A Gleason 3 throughout is shown below.



6.4.1.3 Gleason 4

Gleason 4 consists mostly of cribiform cells (perforated like a sieve) or fused and ill-defined glands with poorly formed glandular lumina. The glands appear to start to "stick" together. A Gleason 4 with a Gleason 3 is shown below. Note the sieve like structure and the closing of the glands.



A Gleason all 4 is shown below. Note that the cells are sticking closed and the entire mass appears as a sieve like mass.



6.4.1.4 Gleason 5

Gleason 5 is a complete conversion to independent malignant cells. They have lost all intercellular coordination. As shown below it is a mass or mat or sheet of independent cancer cells and it has lost any of the sieve like structures. There may also appear to be some necrosis



6.4.2 *Gleason Summary*

The Gleason scores are then determined by taking the predominant type and adding it to the secondary type. Thus a 4+3 yields a Gleason combined 7 but it is 4+3 and that is more aggressive than say a 3+4 with the same total score.

We repeat the grading commentary below.

Gleason 1	Gleason 2	Gleason 3	Gleason 4	Gleason 5
Many acini with no basal layers and large nucleoli. Closely packed clumps of acini.	Many very small single separate glands (acini) with no basal layer and large nucleoli. Glands, acini, are more loosely arranged and not close packed.	Many small microglands extending throughout the stroma and out of the normal gland structure	Glands are now spread out and fused to one another throughout the stroma.	No gland structure seen, all luminal cells throughout the stroma with large nucleoli.

The following chart is a summary of the progression.

Gleason Grades



Gleason 1



Gleason 2



Gleason 3



Gleason 4



Gleason 5

6.4.3 Models From Grading

In looking at the grading one may also hypothesize a possible path of progression. The steps appear to be:

1. Movement from existing benign gland to a separate but glandular like proliferation. Cells which would normally remain dormant go through a replication cycle, apoptosis and cell proliferation control seems lost. New glands appear clustered but appear separate.

2. Growth of the new glands makes them expand but remain morphologically glandular. They close packing begins to disappear and glands start to stand on their own. It is as if they are expanding and growing and the basal layer begins to disappear. Luminal like cancer cells start to be predominant.

3. Many small micro-glands start expanding and cell growth accelerates and the cells appear more cancer like but there is still some morphological glandular structure left.

4. The many glands have dramatically different shaped and start closing in one another and appear sieve like with small openings. They look as if they are losing any intercellular communications resulting is a common mat of cells.

5. Cells have lost any morphological form related to glands and appear as a mat of cancer cells replacing the stroma totally. No intercellular communications is left and cellular growth control has been eliminated totally.

These five steps are consistent with the Gleason grading but they also parallel the way the intracellular and intercellular controls are lost. We will look at these mechanism later.

6.5 BIOMARKERS FOR PCA

We now examine biomarkers for PCa.

Alarcón-Zendejas et al have noted:

Several novel biomarkers for PCa have been proposed, however, their clinical utility remains to be discussed. Nevertheless, coding genes used as biomarkers such as AR, BRCA2, PTEN and the gene fusion TMPRSS2-ERG have predictive value for treatment response and are used in clinical practice. Although these molecular markers offer valuable prognostic information for clinical practice, they are only functional in a subset of patients and more clinical trials are needed to validate their utility.

On the other hand, several mechanisms involved in prostate tumorigenesis such as epigenetic changes, alternative splicing, and the presence of gene variants, are possible novel biomarkers based on coding-genes with potential clinical utility.

For example, regarding epigenetic regulators, the coding genes MGMT , DNMT1 , and JMJD3 , which are involved in DNA methylation, have been associated with the risk of PCa mortality (HR 0.90; p-value = 3.5 × 102) as well as prostate tumor development (p-values = 0.03 and 0.05, respectively).

Similarly, other proteins related to splicing process, such as KDM4B , CDK9 and SF3B2 have been recently associated with generation of androgen receptor variant AR-V7 (pvalue < 0.05).

Furthermore, the splicing variants by themselves are of particular interest for PCa research , androgen receptor variants have been described as important factors in PCa development and prognosis, such as variant AR-V3 and its prognostic value (p-value = 0.05).

Likewise, HRAS and PRUNE2 are novel variants related to PCa development with clinical utility yet to be confirmed. Therefore, research focused on finding new coding genes with clinical application as biomarkers, could improve PCa prognosis and treatment. Another example of coding genes that may have potential clinical utility for PCa correspond to gene mutations involved in hereditary cancer, where it represents the etiology of 5–10% of all neoplasms , in which PCa has been associated with family history of cancer. Paradoxically, few high-susceptibility genes consistently related to the hereditary of PCa have been identified, presenting a pattern of dominant autosomal inheritance , that has been linked to phenotypic variation and genetic heterogeneity, limiting its association with PCa predisposition.

Currently, the analysis of Pathogenic Variants (PV) in predisposition genes associated with defects in homologous recombination and mismatch repair which represents therapeutic targets to PARP1 inhibitors and chemotherapies with platinum compounds, particularly in patients with metastatic and castration-resistant disease. The use of multi-gene panels in germline diagnosis *has identified PV in 7% to 12% of PCa patients , highlighting BRCA1, BRCA2, ATM, BRIP1, CHEK2, NBN, BARD1, RAD51C, MRE11A and PALB2 (homologous recombination repair); MLH1, MSH2, MSH6 and PMS2 (mismatch repair) as high risk genes, which have clinical guidelines; option for risk reduction surgeries, and personalized treatment, which benefits the PCa patient.*

Although hereditary PCa does not imply a generalized molecular diagnosis, it does entail the identification of metastatic disease; early age of onset, and cancer family history, who will have benefit for the therapeutic options and family prevention as a result of the molecular approach. Although all these molecular biomarkers have a potential clinical application, current clinical trials have not been able to determine whether they have sufficient sensitivity and specificity to be considered for clinical purposes, as well as all the genes discussed above are coding genes. Therefore, it is important to focus on the search for new biomarkers, like non-coding genes, which can contribute to the diagnosis and prognosis of PCa patients.

Noncoding genes as molecular markers in prostate cancer

Most of molecular biomarkers in PCa are based in coding genes, but as previous studies have demonstrated; mRNAs tend to have less tissue- and stage-specific expression. In contrast, non-coding RNAs tend to have more tissue-specific and stage-specific expression in disease, which is one of the main reasons noncoding RNAs have been proposed as molecular biomarkers in cancer. In the following paragraphs we describe some of the newest candidates as specific molecular biomarkers in PCa clinical research. miRNA One of the most studied small ncRNAs are microRNAs (miRNAs), these are single stranded RNAs of 21–25 nucleotides in length that regulate the post-transcriptional degradation of messenger RNAs nod inhibit their translation into proteins.

Because of their high stability in body fluids as well as to changes of physical and chemical conditions, miRNAs are interesting molecules to be used as biomarkers in cancer.

Free miRNAs can be found in several bodily fluids, such as blood, urine, semen, among others and their expression levels are tissue-specific and have been found to be deregulated in cancer. Moreover, they exhibit differential expression between tumor and normal tissues and are useful for tumor classification according to the lineage of origin, differentiation stage, and tumor aggressiveness.

It has been reported that circulating miRNAs can be packed in extracellular vesicles (EV) or in association with proteins such as Argonaute2 or lipoproteins in bio-fluids including blood and urine [54–56]. Some miRNAs, such as miR-21, miR-221, miR-1290, and miR-375, have been overexpressed and associated with prognosis in CRPC patients. Yaman and collaborators quantified the levels of miR-21, miR-142, and miR-221 in PCa patients and reported that overexpression of these three miRNAs were associated with an advanced PCa stage. Other groups have identified miRNAs in plasma and serum of patients with locally advanced and metastatic PCa, with BPH and in healthy individuals, showing that differences between each group (i.e., higher levels of miRNAs in patients with locally advanced and metastatic PCa highlight the role of miRNAs as diagnostic biomarkers. Several groups have studied the *diagnostic, prognostic, and predictive characteristics of miRNAs circulating in the plasma and serum of PCa patients finding differentially expressed miRNAs according to the Gleason index , response to treatment with docetaxel , and high blood PSA values.*

*In another study, a panel consisting of four miRNAs was proposed as a biomarker for the diagnosis of PCa. The four miRNAs (**miR-4289, miR-326, miR-152-3p and miR- 98-5p**) were upregulated in plasma of PCa patients compared to healthy controls and was able to differentiate between PCa patients and control individuals with an area under the ROC curve of 0.88, proving their diagnostic accuracy.*

*In the study conducted by Sharova and collaborators , a circulating miRNA test consisting of measuring the level of 3 circulating miRNAs (**miR- 106a, miR-130b and miR-223**) was proposed to differentiate between localized PCa and BPH patients.*

In this test two ratios are calculated: miR-106a/miR-130b and miR-106a/miR-223 ratios, the results showed a better performance (specificity: 0.806, sensitivity: 0.833, accuracy: 0.821) in comparison to PSA (specificity: 0.065, sensitivity: 0.889, accuracy: 0.507), the area under the ROC curve for miRNA test was 0.84 while for PSA was 0.56. This test could be helpful for PCa screening to avoid unnecessary biopsies and assessment of PCa risk. Indeed, the use of miRNAs as biomarkers in PCa has shown promising results for risk assessment, diagnosis, and prognosis.

Implementation of miRNA-based tests in combination with gene-based biomarkers could improve the clinical management of PCa patients.

Long non-coding RNAs

As mentioned above, RNA molecules seem to have a critical role in cancer pathways including those within PCa. Long non-coding RNAs are known to be RNA transcripts longer than 200 nucleotides with no protein-coding potential , these two major differences distinguish them from mRNA transcripts and any other non-coding RNA. LncRNAs have been implicated in several biological processes such as chromatin-reprogramming, genomic imprinting, transcriptional regulation in cis and trans and post-transcriptional regulation of mRNAs. Among some pathological features in which lncRNAs are involved are cell proliferation, tumorigenesis and malignant transformation , this is why several studies have proposed lncRNAs as tumorsuppressor genes and oncogenes.

Lately, lncRNAs have drawn the attention not only because of their critical role in cancer, but because of their potential as molecular biomarkers due to their tissue-specific and tumor-specific expression. Some lncRNAs, such as PCA3, SChLAP1, and PCAT1 have been proposed as good candidates for biomarkers mainly due to their differential expression in PCa patients. PCA3 is an overexpressed PCa-specific oncogene discovered in 1999 by Bussemakers. PCA3 is already considered a PCa biomarker, and it is measured by the commercial test PROGENSA approved in 2012 by the FDA [74–76] helping to reduce ~40% of unnecessary biopsies providing a great utility in urological diagnosis.

PROGENSA PCA3 test has a ***sensitivity of 62% and a specificity of 75%*** *demonstrating why lncRNAs can be one of the molecular markers with clinical utility. Similarly, SChLAP1 is known for its high expression levels in PCa. This lncRNA antagonizes the SWI/SNF complex promoting aggressiveness and metastasis of the tumor. Its effectiveness as a biomarker has been proved by assays such as RNA in situ hybridization leading to the development of several tests based on the detection of SChLAP1 expression levels and linking them with the patient's clinical-stage. Therefore, SChLAP1 is considered as a promising biomarker of clinical utility and one of the best genes for prediction of metastasis and biochemical recurrence in PCa patients.*

Along with these, Luo and collaborators reported that lncRNA-p21 is overexpressed in neuroendocrine PCa (NEPC) and that a treatment based upon enzalutamide increases its expression, and thus, the neuroendocrine differentiation; all of this is caused by the alteration of the Enz/AR/lncRNA-p21/EZH2/STAT3 axis. PCAT1 is another upregulated oncogenic RNA originally identified in PCa by RNA sequencing analysis. It is related to cell proliferation, apoptosis, migration, and invasion as well as epithelial mesenchymal transition and cancer progression via the Wnt/β- catenin signaling pathway. Finally, PCAT1 negatively regulates BRCA2 tumor suppressor protein, positively regulates Myc oncoprotein and it might be also acting as a miRNA sponge involved in cell growth.

Hence, PCAT1 is considered as a potential biomarker for PCa prognosis and prediction, supporting the statement that lncRNAs represent potential molecular biomarkers in the management of PCa. Most of these candidates and a large number of transcriptional units were found due to the breakthrough of the high-throughput massive sequencing technology, specifically, RNA-Seq.

Finally, lncRNAs could be used in combination with gene-based biomarkers and gene fusions to increase the sensitivity and specificity of molecular diagnostic tests, which will improve clinical patient management including early detection, diagnosis, prognosis, and prediction of response to treatment.

Repetitive sequences

Repetitive sequences are large quantities of repeated elements throughout the haploid genome, meaning they are repeated DNA nucleotides found more than twice in the genome that comprises about 55% of the human genome or even more. Their classification can vary from author to author, and it can be based on the origin, function, structure, and genomic distribution of the DNA, but it is mainly based on the latter. The five categories are simple sequence repeats, segmental duplications, tandem repeats and satellite DNA sequences, processed pseudogenes, and transposable elements.

Repetitive sequences are also considered as potential molecular biomarkers in diseases like cancer because some of them are overexpressed in different types of tumors cells. Genome sequencing and transcriptome sequencing have improved the discovery and detection of repetitive DNA and RNA elements that cannot be identified by classic biochemical methods. Solovyov and collaborators determined that RNA repetitive sequences are not fully detected when using the poly(A) protocol in RNA-seq procedure, while on the other hand, analyzing the *expression of total RNA sequencing can not only identify the repetitive sequences more accurately but delimitate immune phenotypes in cancer and response to immunotherapy*

From Tamura et al:

Cancer	***Biological Source***	***Isolation methods***	***Detection methods***	***RNA types***	***Markers***	***Potential application***
Prostate cancer	Urine	UC+SUC	Nested PCR	mRNA	PSA, PCA-3, TMPRSS:ERG	Diagnostic/ Monitoring
	Urine		ExoDx Prostate	miRNA	PCA3, ERG, SPDEF	Diagnosis
	Urine	UP/UC	RT-qPCR	miRNA	let-7c, miR-21, miR-107, miR-145, miR-196a-5p, miR-204, miR-375, miR-501-3p, miR-574-3p, miR-2909	Diagnosis
	Serum/Plasma	UF/SEC/UC	RT-qPCR	miRNA	let-7i, miR-16, miR-21-5p, miR-24, miR-26a, miR-26b, miR-30c-5p, miR-34b, miR-92b, miR-93, miR-103, miR-106a, miR-107, miR-130b, miR-141, miR-181a-2, miR-195, miR-197, miR-200c-3p, miR-210-3p, miR-223, miR-298, miR-301a, miR-326, miR-328, miR-331-3p, miR-346, miR-375, miR-432, miR-574-3p, miR-625, miR-1290, miR-2110	Diagnosis
	Plasma	Uf/SfC/UC	RT-qPCR	miRNA	miR-17, miR-20a, miR-23a, miR-130b, miR-198, miR-200b, miR-375, miR-379, miR-513a-5p, miR-572, miR-577, miR-582-3p, miR-609, miR-619, miR-624, miR-1236, miR-1290	Prognosis
	Serum	UC	RT-qPCR	miRNA	miR-1246	Prognosis
	Urine		Urine Exosome RNA isolation Kit /RT-qPCR	lncRNA	p2l	Diagnosis
	Plasma	Total Exosome Isolation Kit	RT-qPCR	lncRNA	SAP30L- ASl, SChLAPl	Diagnosis

Cancer	***Biological Source***	***Isolation methods***	***Detection methods***	***RNA types***	***Markers***	***Potential application***
	Plasma/ Urine		cxoftNcasy kit/ddPCR	mRNA	AR-V7	Predict hormone therapy resistance Abiraterone

6.5.1 *Proteins*

From Hoey and Liu:

Prostate cancer antigen 3 (PCA3) is a predictive post-digital rectal exam (DRE) urine-based test used to help determine whether an elevated PSA test is likely caused by prostate cancer. PCA3 testing can help physicians decide whether a biopsy is required. Although this test is very useful in its ability to help distinguish patients who should be selected for biopsy compared to those who can be spared this invasive procedure, it cannot predict disease aggressiveness or prognosis.

The commercially available 4Kscore Test (OPKO Health Inc, Miami, FL, USA) is a prognostic blood test that evaluates a patient's risk of aggressive prostate cancer prior to biopsy, and poor clinical outcomes within 20 years. The 4Kscore Test uses an algorithm consisting of the levels of four markers in the serum – ***total PSA, free PSA, intact PSA, and human kallikrein 2 – in addition to the patient's age, DRE status, and history of prior biopsy to determine the probability of identifying clinically significant cancer*** *(Gleason 7 and above) from a biopsy. It can help determine which patients are high risk and would benefit from a biopsy, and those who are low risk and can avoid receiving a biopsy.*

The 4Kscore Test has been independently validated in large, multi-institutional studies showing its utility in predicting high-grade prostate cancer, and reducing the need for biopsies in low-grade cancer patients. However, it does not eliminate the need of biopsies for others; patients at high risk for prostate cancer (determined by either the PCA3 or 4Kscore tests) will still need to have a biopsy. Furthermore, these tests cannot guide treatment planning or identify which patients will have recurrence after treatment. Therefore, there is a need to identify noninvasive biomarkers that can be used for patient risk stratification at initial diagnosis and for serial monitoring of their disease throughout treatment, independent of biopsy or surgical tissue.

6.5.2 *miRNA*

From Hoey and Liu:

miRNAs (also represented as miR-) have recently gained interest as promising candidates for noninvasive circulating biomarkers. Circulating miRNAs have been shown to be stable in bodily fluids, expressed at detectable levels, and representative of cancer.

miRNAs are also thought to be superior to proteins as biomarkers, as they are more stable in biological fluids and yield more straightforward interpretations (i.e., miRNA expression level correlates with activity, miRNAs are not translated from mRNA like proteins, and they do not undergo posttranscriptional or posttranslational modifications).

miRNAs are small (~20–25 nucleotides in length), noncoding RNAs that downregulate expression of target genes.31 It is estimated that there are over 1,000 miRNAs encoded in the human genome, which regulate ~50% of all protein coding genes.

miRNAs regulate genes involved in all cellular processes, which highlights their widespread importance in gene regulation. miRNAs decrease gene expression by binding to the 3'-untranslated region of a target mRNA. This binding results in translation inhibition or transcript degradation. If transcriptional repression occurs, it will do so in one of four ways:

1) inhibition of translation initiation;

2) inhibition of translation elongation;

3) co-translational protein degradation; or

4) premature termination of translation.

Target degradation is recognized to be the major result of miRNA–mRNA binding.35 miRNAs are involved in all cell processes and have been an object of much interest due to their aberrant expression and role in cancer. They are particularly intriguing due to the fact that one miRNA can target and downregulate hundreds of gene transcripts. Since individual miRNAs can regulate multiple cellular pathways simultaneously,36 small perturbations in miRNA expression could lead to harmful downstream effects resulting in cancer development, progression, and recurrence.

Many miRNAs have been characterized for their role in prostate cancer. We have previously described various miRNAs for their role in cell cycle progression, metastatic potential, tumor aggression, and therapy resistance ***: miR-95,39 miR-106a,40 miR-330-3p,41 miR-620.42 miRNAs have been described to be preferentially enriched in extracellular vesicles*** *(EVs, also known as exosomes).*

Exosomes are small vesicles formed from the inward budding of endosomes, which therefore contain cellular components from the cytosol. Exosomes facilitate cell–cell communication in a paracrine or endocrine manner. It is thought that exosomal contents, such as miRNAs, may be involved in epigenetic reprogramming of the target cell.46 Urine exosomes are a particularly rich source of prostate cancer-specific transcripts when collected from post-DRE urine.

A clinically validated noninvasive test, ExoDx Prostate IntelliScore (Exosome Diagnostics, Waltham, MA, USA), assesses the expression of three genes from urine specimens to distinguish benign and low-grade prostate cancer from high-grade prostate cancer.48,49 This assay can help determine whether patients with elevated PSA require a biopsy. Although ExoDx is a urine-

based test and this review is focusing on circulating blood biomarkers, it is worthwhile mentioning since post-DRE urine samples are likely to be highly enriched with prostate cells and Evs.

Hoey and Liu have noted:

miRNAs (also represented as miR-) have recently gained interest as promising candidates for noninvasive circulating biomarkers. Circulating miRNAs have been shown to be stable in bodily fluids, expressed at detectable levels, and representative of cancer.

miRNAs are also thought to be superior to proteins as biomarkers, as they are more stable in biological fluids and yield more straightforward interpretations (i.e., miRNA expression level correlates with activity, miRNAs are not translated from mRNA like proteins, and they do not undergo posttranscriptional or posttranslational modifications). miRNAs are small (~20–25 nucleotides in length), noncoding RNAs that downregulate expression of target genes.

It is estimated that there are over 1,000 miRNAs encoded in the human genome, which regulate ~50% of all protein coding genes.32–34 miRNAs regulate genes involved in all cellular processes, which highlights their widespread importance in gene regulation. miRNAs decrease gene expression by binding to the 3′-untranslated region of a target mRNA. This binding results in translation inhibition or transcript degradation. If transcriptional repression occurs, it will do so in one of four ways: 1) inhibition of translation initiation; 2) inhibition of translation elongation; 3) co-translational protein degradation; or 4) premature termination of translation. T

arget degradation is recognized to be the major result of miRNA–mRNA binding. miRNAs are involved in all cell processes and have been an object of much interest due to their aberrant expression and role in cancer. They are particularly intriguing due to the fact that one miRNA can target and downregulate hundreds of gene transcripts. Since individual miRNAs can regulate multiple cellular pathways simultaneously,36 small perturbations in miRNA expression could lead to harmful downstream effects resulting in cancer development, progression, and recurrence.

Many miRNAs have been characterized for their role in prostate cancer. We have previously described various miRNAs for their role in cell cycle progression, metastatic potential, tumor aggression, and therapy resistance: miR-95, miR-106a,40 miR-330-3p,41 miR-620. miRNAs have been described to be preferentially enriched in extracellular vesicles (EVs, also known as exosomes).43 Exosomes are small vesicles formed from the inward budding of endosomes, which therefore contain cellular components from the cytosol.

Exosomes facilitate cell–cell communication in a paracrine or endocrine manner. It is thought that exosomal contents, such as miRNAs, may be involved in epigenetic reprogramming of the target cell. Urine exosomes are a particularly rich source of prostate cancer-specific transcripts when collected from post-DRE urine.

A clinically validated noninvasive test, ExoDx Prostate IntelliScore (Exosome Diagnostics, Waltham, MA, USA), assesses the expression of three genes from urine specimens to distinguish benign and low-grade prostate cancer from high-grade prostate cancer.48,49 This assay can help determine whether patients with elevated PSA require a biopsy. Although ExoDx is a urine-based test and this review is focusing on circulating blood biomarkers, it is worthwhile mentioning since post-DRE urine samples are likely to be highly enriched with prostate cells and EVs. miRNAs are likely enriched in EVs, regardless of whether they are collected in urine or other biofluids, such as plasma and serum. miRNAs are particularly promising biomarker candidates as they have the characteristics of an ideal biomarker.

A perfect biomarker must be specific to the tissue of interest and be able to distinguish the particular disease state of interest within that tissue; be sensitive so that the extent of the pathology is mirrored in the expression of the biomarker; have a long half-life; be easy, fast, and inexpensive to detect; and not be invasive for the patient.16,50 miRNAs are known to be highly stable in serum and plasma, and are very resistant to boiling, pH changes, repeated freeze–thaw cycles, and fragmentation by chemical or enzymes.

It is thought that miRNAs are highly stable in serum and plasma due to their incorporation in EVs or protein complexes. The future of prostate cancer risk stratification will likely entail the identification of unique circulating miRNA signatures that allow for treatment regimens to be tailored to each individual patient. In the following section we will be discussing the potential utility of circulating miRNAs to address two significant clinical problems

6.5.3 Glycans

Glycans are sugar molecules attached to proteins. As Scott and Munkley note:

The development and progression of prostate cancer from localised, organ-confined disease to biochemically progressive and then to metastasis is prolonged. To capture this evolving landscape, serial tissue biopsies are needed, which is difficult and costly to execute in the clinic. In addition, prostate cancer preferentially metastasizes to bone, which is a site that is very difficult to sample. Tumour heterogeneity can also lead to aggressive tumours being missed, or underestimation of the tumour landscape.

Liquid biopsies offer a potential solution to overcome the practical and technical challenges of the traditional tissue biopsy. The concept of a 'liquid biopsy' relies on the principle that cancer cells are shed directly into blood, urine, and other body fluids. These cancer cells can be captured and used to derive information to improve diagnosis, prognosis, or treatment. Liquid biopsies may also capture a more complete representation of a cancer, which encompasses tumour heterogeneity

Flow cytometry techniques were able to detect circulating prostate cancer cells in men with metastatic disease as early as the 1970s. Today, technologies can use bodily fluids to profile genomic mutations, copy number alterations, and obtain information about the tumour transcriptome, epigenome, proteome, metabalome, and glycome.

Among prostate cancer liquid biopsies, circulating tumours cells (CTCs) are the most extensively evaluated biomarkers, but other clinically relevant phenotypes have also shown promise.

These include detection of the androgen receptor variant V7 (AR-V7, circulating miRNAs, TMPRSS2:ERG, and prostate cancer antigen 3 (PCA3), circulating free DNA (cfDNA), detection of gene methylation, and the analysis of tumour-derived exosomes. Individual biomarkers in liquid biopsy can often not accurately predict disease state due to heterogeneity in phenotype across individuals and over time.

To address this challenge, effective diagnostics using liquid biopsies will require multiparameter strategies to combine information from multiple analytes. A recent study by Murphy et al. suggested that integrating biomarkers across multi-omic platforms (including changes to the epigenome, transcriptome, proteome, and glycome) can improve the stratification of patients with prostate cancer.

By the analysis of four types of DNA methylation, four coding and nine non-coding RNAs, 27 peptides, and 13 glycans (in a cohort of 158 radical prostatectomy patients), combined with clinical parameters, it was possible to effectively distinguish indolent and aggressive prostate cancer with area under the ROC curve (AUC) = 0.91 (age, PSA level, Gleason score, and DRE gave an AUC of 0.67).

This strongly suggests that multivariate models (built from different -omics data) will lead to superior accuracy over individual markers for prostate cancer diagnosis and disease stratification, and together with the data discussed in this review, clearly demonstrate that the inclusion of glycans in a multi-analyte liquid biopsy test for prostate cancer should help improve clinical utility

6.5.4 mRNA

As Visser et al note :

The PSA test is widely used as a risk marker for PCa. Increased use of the PSA test resulted in increasing controversy for its use, since the poor specificity of the PSA test results in overdiagnosis and overtreatment of low-risk cancers.

The last decade, various molecular biomarker tests have been developed as diagnostic tools for early and non-invasive detection of PCa. The SelectMDx test (MDxHealth, Nijmegen, The Netherlands) is one of these commercially available molecular tests, which predicts presence of high-grade PCa (Gleason score ≥ 7 (GS7)) upon biopsy. The used prediction model includes a molecular risk score based on

… ***post-DRE urinary-derived mRNA levels of the homeobox C6-gene (HOXC6) and Distal-Less Homeobox 1-gene (DLX1) combined with clinical variables digital rectal exam (DRE) result, age and PSA density****.*

The test is intended to be used in patients with an abnormal PSA level to help in patient stratification for biopsy, thereby avoiding biopsies. Moreover, using the SelectMDx test to select patients for multiparametric MRI (mpMRI) is another good strategy, especially in situations with limited accessibility to mp-MRI. Haese et al. validated the SelectMDx test in a multi-center cohort of men waiting for initial biopsy.

Of all patients, 35% had a negative SelectMDx result of whom in 95% of the biopsies showed no PCa or PCa GG1. In the subgroup including patients with PSA levels <10 ng/mL, 44% of all cases showed a negative SelectMDx result. Of these patients, again, 95% of the biopsies showed no PCa or PCa GG1. Therefore, 53% of the unnecessary biopsies (biopsies indicating no- or GG1 PCa) could have been avoided when using the SelectMDx test as a decisiontool for performing a biopsy.

Since the SelectMDx test is commercially available for a few years now, data is available on the patient group requesting the SelectMDx test. The aim of this study is to obtain insight into the clinical use of the SelectMDx test in daily practice based on 5157 samples from ten European countries

6.5.5 DNA

As Herberts et al note :

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genotyping and longitudinal disease monitoring1. However, owing to past emphasis on targeted and low-resolution profiling approaches, our understanding of the distinct populations that comprise bulk ctDNA is incomplete.

Here we perform deep whole-genome sequencing of serial plasma and synchronous metastases in patients with aggressive prostate cancer. We comprehensively assess all classes of genomic alterations and show that ctDNA contains multiple dominant populations, the evolutionary histories of which frequently indicate whole-genome doubling and shifts in mutational processes.

Although tissue and ctDNA showed concordant clonally expanded cancer driver alterations, most individual metastases contributed only a minor share of total ctDNA.

By comparing serial ctDNA before and after clinical progression on potent inhibitors of the androgen receptor (AR) pathway, we reveal population restructuring converging solely on AR augmentation as the dominant genomic driver of acquired treatment resistance. Finally, we leverage nucleosome footprints in ctDNA to infer mRNA expression in synchronously biopsied metastases, including treatment-induced changes in AR transcription factor signalling activity. Our results provide insights into cancer biology and show that liquid biopsy can be used as a tool for comprehensive multi-omic discovery …

Our study reveals that plasma ctDNA-based subclonal reconstruction is associated with a unique set of challenges and opportunities. Heightened subclonal diversity invalidates many simplifying assumptions on which contemporary subclonal reconstruction methods rely, and regionally *varying sequencing depth due to cfDNA nucleosome footprints may pose a challenge for ultra-sensitive copy number analysis.*

Conversely, serial ctDNA sampling also presents new opportunities, as the increased data dimensionality allows resolution of previously ambiguous scenarios, such as distinguishing between a WGD and a 50% CCF subclone. Notably, the fractal nature of clonal evolution means that the level of detail in reconstructions from bulk sequencing can vary according to sampling characteristics (for example, sequencing depth, breadth or number of samples).

We have generated a large repository of deep ctDNA WGS data, including data on patient-matched white blood cells. These data are available to researchers and will provide a resource for further discovery work using ctDNA.

6.5.6 SNPs

As Vaidyanathan et al have noted :

Prostate cancer (PCa) is one of the most significant male health concerns worldwide. Single nucleotide polymorphisms (SNPs) are becoming increasingly strong candidate biomarkers for identifying susceptibility to PCa.

***We identified a number of SNPs reported in genome-wide association analyses (GWAS) as risk factors for aggressive PCa in various European populations, and then defined SNP-SNP interactions, using PLINK software, with nucleic acid samples from a New Zealand cohort**. We used this approach to find a gene x environment marker for aggressive PCa, as although statistically gene x environment interactions can be adjusted for, it is highly impossible in practicality, and thus must be incorporated in the search for a reliable biomarker for PCa.*

We found two intronic SNPs statistically significantly interacting with each other as a risk for aggressive prostate cancer on being compared to healthy controls… Analysing the role of SNP-SNP interactions and epistasis10 is very appealing among researchers working on risk factors for various cancers11–13, including prostate cancer.

Here we have identified a SNP-SNP interaction as a risk factor for aggressive PCa, by comparing the data generated after carrying out SNP genotyping using the SEQUENOM MassARRAY iPLEX® assay, and the TaqMan® assay (depending on the gene of interest) from the DNA extracted from blood samples. These samples were taken from a New Zealand cohort of men with self-reported European ethnicity that have been clinically diagnosed with aggressive and non-aggressive PCa, and healthy controls with no reported symptoms of the disease. Symptoms include increased urination during night time along with a frequent urge to urinate problems maintaining a steady flow of urine, hematuria and dysuria. Our results indicate a strong influence of gene x environment interaction in overall gene expression and epistasis…

We suggest that the intronic SNP rs2121875 in the gene FGF10 may be causing alterations in gene expression, perhaps due to the prevalent external/environmental conditions in the elderly men with PCa.

Our theory is based on the recent discovery in a study by Zhang et al. (2007) that even intronic SNPs (such as the ones identified in FGF10 and CYP24A1) can change the outcome and usage of exons. This unique and novel epistatic finding emphasizes the fact that intronic SNPs (and SNP-SNP interactions) can also have a significant effect on the risk of diseases such as aggressive PCa, and need to be investigated further.

7 BREAST

Breast cancer is the most common cancer in women. It is highly pleiomorphic and generally broken down into receptor status; HR, HER2, and none or triple negative.

7.1 ANATOMY

From Schnitt,

The cellular lining throughout the ductal-lobular system is bilayered.

*It consists of an inner (**luminal**) epithelial cell layer and an outer **(basal)** myoepithelial cell layer.*

The importance of this double cell layer cannot be overemphasized, because it is one of the main guides used to distinguish benign from malignant lesions.

The luminal epithelial cells of the resting breast ducts and lobules are cuboidal to columnar in shape and typically have pale eosinophilic cytoplasm and relatively uniform oval nuclei. These epithelial cells express a variety of low-molecular-weight cytokeratins, including cytokeratins 7, 8, 18, and 19.

The outer or myoepithelial cell layer, although always present, is variably distinctive.

Myoepithelial cells range in appearance from barely discernible, flattened cells with compressed nuclei to prominent epithelioid cells with abundant clear cytoplasm. In some cases, the myoepithelial cells have a myoid appearance featuring a spindle cell shape and dense, eosinophilic cytoplasm, reminiscent of smooth muscle cells. Even when inconspicuous on hematoxylin and eosin-stained sections, myoepithelial cells can be readily demonstrated using immunohistochemical stains for a variety of markers including S-100 protein, actins, calponin, smooth muscle myosin heavy chain, p63, p40, and CD10 among others. However, these markers vary in both sensitivity and specificity for myoepithelium.

Myoepithelial cells also express high-molecular-weight cytokeratins 5/6, 14, and 17 with the expression of cytokeratin 14 restricted to myoepithelial cells of the extralobular ducts and terminal ducts; expression is not seen in myoepithelial cells of the lobular acini.

From Harbeck et al:

Basal-like TP53 mutations; genetic instability; BRCA mutations; medullary-like histology poorly differentiatied

Luminal A Activation of ERS1, GATA3, FOXA1, XBP1; NST, tubular cribriform and classic lobular histology

Luminal B PI3KCA mutations (40%); ESR1 mutations (30–40%) a; ERBB2 and ERBB3 mutations; NST, micropapillary and atypical lobular histology





© 2011 Terese Winslow LLC
U.S. Govt. has certain rights

From Schnitt we have the following. Normal cells then grades 1 through 3 BCa. Note in benign cells we have the ductal structures and a well-organized cellular profile. The nucleus of the cells is not enlarged and cytoplasm is reasonable.



The initial state of malignancy shows increasing disorganization of the cells.



The malignancy then progresses and structure begins to fade.



Finally below we see the total disorganization of cells.



7.2 CLASSIC MARKERS

Schnitt notes:

ER and PR represent weak prognostic factors for patients with breast cancer, but these receptors are the strongest predictive factors for response to endocrine therapy. ER and PR assays are determined by immunohistochemistry performed on paraffin sections and should be performed on all invasive breast cancers in accordance with the guidelines published by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP).241 An ER assay should also be performed on all cases of DCIS.242 The value of performing PR assays on DCIS is questionable.

The ASCO/CAP guidelines require that reports of ER and PR assays include the percentage of tumor cells showing nuclear staining and the intensity of staining (strong, medium, weak); combining these two parameters into a score (such as the Allred score)243 is optional. Carcinomas are considered positive for ER and PR when at least 1% of tumor cells show nuclear staining. An adequate internal positive control consisting of normal breast epithelial cells that show staining for the receptors is required, particularly for the interpretation of an ER or PR result as negative.

Recent studies have raised concerns about the categorization and management of breast cancers with low levels of ER expression (1% to 10%). Retrospective studies have indicated that these tumors have an outcome more similar to ER-negative cancers than to more strongly ER-positive tumors and do not appear to derive benefit from endocrine therapy. In addition, only a minority of these tumors are "luminal" by molecular profiling assays. Although such tumors constitute only a small proportion of breast cancers categorized as ER positive, additional studies are needed to define more clearly their biology and sensitivity to endocrine therapy.

HER2 is a prognostic factor for outcome in both node-negative and node-positive patients and is a predictive factor for response to certain chemotherapeutic and endocrine agents.

However, the major clinical reason to assess HER2 status in invasive breast cancers is to identify patients likely to benefit from treatment with HER2-targeted therapy with agents such as trastuzumab, lapatinib, and pertuzamab, among others.

Assessment of HER2 protein overexpression using immunohistochemistry and HER2 gene amplification using fluorescence in situ hybridization (FISH) are the methods most commonly employed in clinical practice.

A detailed discussion of the pros and cons of each of these techniques is beyond the scope of this text, and the interested reader should consult other references on this subject.248,249 HER2 assays should be performed on all invasive breast cancers and interpreted according to the guidelines published by ASCO/CAP, the most recent update of which was published in 2013.

Using these guidelines, ***a tumor is considered HER2 positive if at least 10% of the tumor cells show strong, circumferential membrane staining using a validated IHC method, shows ≥6***

HER2 signals/cell using a single-probe system *(i.e., one that includes a FISH probe for the HER2 gene only), or shows a HER2/CEP17 (centromere enumeration probe 17) ratio of 2.0 or greater using a validated dual-probe system (i.e., a system that includes FISH probes for the HER2 gene and CEP17). In addition, cases with a HER2/CEP17 ratio <2.0 but with an average HER2 copy number >6.0 are also considered positive.*

As Rossi et al note about circulating tumor cells, CTC,

Circulating tumor cells (CTCs) are rare cells found in the bloodstream of oncologic patients with a central role in the metastatic spread. In this study, we aim at exploring their heterogeneity levels in metastatic breast cancer patients focusing on single cell single nucleotide variant (SNV) and copy number aberration (CNA) analyses.

Our results show high levels of heterogeneity, especially concerning SNVs. Further analysis revealed the presence of CNAs associated with breast tumorigenesis, while longitudinal CNA profiling was demonstrated to track clonal selection of CTCs during treatment. Despite this heterogeneity, we found a group of CTCs from different patients sharing common genomic aberrations, such as losses on 15q.

Collectively, our findings demonstrate that single-cell molecular analyses could be exploited in future to better address therapeutic strategies. Further investigations to better characterize this mixed population are needed to understand its role in MBC. Abstract: Circulating tumor cells' (CTCs) heterogeneity contributes to counteract their introduction in clinical practice. Through single-cell sequencing we aim at exploring CTC heterogeneity in metastatic breast cancer (MBC) patients. Single CTCs were isolated using DEPArray NxT.

After whole genome amplification, libraries were prepared for copy number aberration (CNA) and single nucleotide variant (SNV) analysis and sequenced using Ion GeneStudio S5 and Illumina MiSeq, respectively. CTCs demonstrate distinctive mutational signatures but retain molecular traces of their common origin. CNA profiling identifies frequent aberrations involving critical genes in pathogenesis: gains of 1q (CCND1) and 11q (WNT3A), loss of 22q (CHEK2). The longitudinal single CTC analysis allows tracking of clonal selection and the emergence of resistance-associated aberrations, such as gain of a region in 12q (CDK4). A group composed of CTCs from different patients sharing common traits emerges.

Further analyses identify losses of 15q and enrichment of terms associated with pseudopodium formation as frequent and exclusive events. CTCs from MBC patients are heterogeneous, especially concerning their mutational status. The single-cell analysis allows the identification of aberrations associated with resistance, and is a candidate tool to better address treatment strategy. The translational significance of the group populated by similar CTCs should be elucidated. … In recent years, CTCs have been deeply investigated due to their pivotal role in the metastatic cascade, but their high heterogeneity still contributes to counteract their introduction in clinical practice. In fact, as a consequence of the dynamic changes in the bloodstream, CTCs can converge in distinct subpopulations with specific genomic and phenotypic features.

Up to now, CTC enumeration remains the only FDA-approved CTC-based assay in clinical practice with prognostic purpose, but the heterogeneous genetic features characterizing this cell population could no longer be neglected as they dramatically influence disease manifestation and outcome.

Hence, the identification of novel approaches to further exploit data from CTCs for translational purposes beyond CTC enumeration is imperative. The aim of this study is to explore the molecular landscape of CTCs in MBC patients. ***For this purpose, we exploited single-cell resolution NGS to assess CTC mutational status and CNA profile.***

However, this study has some flaws. Firstly, the limited number of patients makes challenging to achieve robust statistical data. However, this weakness is mitigated by high-quality single-cell data illustrated in this article, especially with whole-genome CNA profiling. Moreover, the availability of primary tumor and metastatic specimens would have been helpful to integrate the mutational profiling, and to better delineate the clonal selection of CTCs based on their CAN

Our results confirm that single-cell analysis of CTCs represents an accurate approach to unmasking genetic heterogeneity. In *our study, testing single CTCs for a panel of 60 cancer-relevant genes revealed a great intra-patient degree of variant heterogeneity, supporting the existence of distinct self-specific mutational signatures for each CTC. Our study is not the first to describe the detection of mutational heterogeneity in single CTCs from MBC patients [11,57–60]. At the same time, while no mutations were common among patients, we detected a limited number of alterations shared among CTCs within the same patient even at different time points.*

This finding, as observed by other researchers, highlights ***that the presence of shared molecular alterations reflects the common clonal origin of tumor cells in the bloodstream.*** *Overall, due to the high degree of heterogeneity, the translational significance of candidate alterations is still not univocal.*

One key example is represented by the AKT E17K variant which is reported as pathogenic and associated with resistance to therapies in BC but was retrieved in 50% of CTCs at timepoint A in patient CH32. Finally, we found a limited number of CTCs with called SNVs.

This result may be imputable to the tested panel, which includes a limited number of genes and covers hotspot mutations. Hence, we cannot exclude the presence of alterations occurring on other genes not included in this analysis. Concerning chromosomal aberration analysis, while confirming the heterogeneous portrait of CNAs in CTCs, we described the emergence of frequent alterations involving genes with a critical role in MBC in agreement with the literature.

This workflow was previously successfully exploited by our group for the longitudinal characterization of single CTCs from early BC and oesophageal cancer patients. Herein, we found that gain of the region 22q11.2 emerged as the most frequent aberration in CTCs.

This short aberration includes a unique gene, KIAA1671, which codifies for an uncharacterized protein involved in mitosis and chromosome segregation. Although its role is still unexplored, *KIAA seems to contribute to BC pathogenesis, since autoantibodies against the codified protein were detected in serum from BC patients.*

Moreover, emerging frequent aberrations included several gains (1q, 4p, 11q, 14q and 16p) and losses (13q and 22q), among which aberrations already described in BC and often hosting clinically-relevant genes.

One example is represented by WNT3A (1q42), whose protein product encompasses a wide range of roles, from oncogenesis to developmental processes. In vitro studies have demonstrated a role for WNT3A in BC proliferation and resistance to tamoxifen treatment. CCND1 (11q13) amplification is frequent in BC and associated with progression and resistance. The encoding product, Cyclin D1, is an oncogenic protein with a pivotal role in G1 to S phase transition during the cell cycle.

A high copy number of CCND1 was previously found to identify a subset of ER-positive patients with poorer prognosis [69]. Beyond its role in cell cycle regulation, Cyclin D1 harbours also non-canonical cdk-independent functions, among which the ability to interact with the hormone binding domain of ER. As a consequence, ER-mediated transcripts are upregulated even in absence of the canonical ligand. On the other hand, Checkpoint Kinase 2, codified by the CHEK2 (22q12.1) gene, acts as a tumor-suppressor in BC where gene loss is not infrequent.

7.3 BIOMARKERS

There has been a multiplicity of studies on biomarkers for breast cancer. The following from Jia et al list some of them along with the target genes they putatively effect:

miRNA/Protein	**Target genes**	**Physiological function**
miR-130a	TGB-β/Smad signaling	tumorigenesis
miR-328	CD44	reduce cell adhesion and enhance cell migration
miR-301a		a negative prognostic maker
miR-34a	p53	
miR-106b	BRMS1; RB	an early process of tumor metastasis
miR-10b	HOXD10; KLF4	transfer to non-malignant HMLE cells and promote cell invasion
miR-105	ZO-1	cell migration and metastasis
miR-127, -197, -222, and -223	CXCL12	suppress cell proliferation and elicit cell cycle quiescence
miR-23b		promote cell dormancy in a metastatic niche
miR-373		downregulate ER expression and inhibition of apoptosis
miR-122		inhibit glucose uptake in a premetastatic niche and promote metastasis

miR-9		transfer cancer-associated fibroblasts phenotype to normal fibroblasts
miR-223	Mef2c–β-catenin pathway	promote invasiveness of breast cancer
miR-16	VEGF	suppress angiogenesis
miR-210		key factors for the tumor angiogenesis and brain metastasis
miR-451, miR-326, miR-100, miR-222, and miR- 30a		drug resistance
miR-221/222		enhance tamoxifen resistance
miR-155, miR-21 and miR-1246	the shelterin component TERF1	cancer diagnose and predict a poor prognosis
miR-215, miR-299, and miR-411		lower expression in untreated patients with metastatic breast cancer
miR-155, miR-19a, miR- 181b, and miR-24		an early marker for breast cancer risk
miR-101, miR-939, miR- 373		breast tumor subtype and stage

Li et al have recently summarized blood based biomarkers focusing on breast cancer. The have noted:

Compared with imaging and biopsy cancer detection approaches, blood tests are not only convenient and non-invasive (or minimally invasive), but also widely acceptable, readily reproducible and cost effective. Cancer cells often produce specific proteins, nucleic acids or other cellular vesicles, and shed live cells or dead cell debris into the blood. Analyzing for the existence of those components in the blood may provide a method of detection of the cancer.

Circulating Carcinoma Proteins

Circulating carcinoma proteins are associated with proliferation, invasion, metastasis, aggressiveness, angiogenesis, oncogenic signaling, and immune regulation of tumor cells. Thus, they have the potential to serve as markers for cancer detection. A number of serum carcinoma protein markers in breast cancer have been identified, including CA15-3, CA27-29, CA-125, carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), circulating extracellular domain of human epidermal growth factor receptor 2 (HER2), and tissue polypeptide-specific antigen (TPS).

These markers are mainly used in monitoring response to therapy in patients with advanced disease and none of them has been used alone for screening because of low diagnostic sensitivity for early disease or lack of specificity.

Although a combination of several such biomarkers may increase the sensitivity and specificity, a study demonstrated that no combination of the selected ten breast cancer serum protein markers, including CA15-3, CA125, and CEA, could accurately predict early-stage breast *cancer. However, when combined with tumor-associated autoantibodies, serum protein biomarkers were able to achieve 81.0% sensitivity and 78.8% specificity for detection of breast cancer with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.89.*

Circulating Tumor Cells

Tumor cells may enter into the peripheral blood of cancer patients either through active intravasation or passive shedding from the primary or metastatic tumors. The presence of CTCs in early-stage breast cancer increases the risk of recurrence and death. However, the measurement of CTCs has not been recommended for breast cancer diagnosis because of low sensitivity and reproducibility. ***CTCs are rare and there is as few as one CTC per billion normal blood cells****.*

Circulating Cell-Free Tumor DNA

Circulating tumor DNA (ctDNA) in the bloodstream has emerged as a promising biomarker of disease status for breast cancer. An elevated level of ctDNA has been found to be associated with advanced-stage breast cancer and metastasis. Breast cancer patients had significantly higher levels of ctDNA than healthy controls. The ctDNA concentrations at levels ≥0.75% could be detected in breast cancer patients with a sensitivity of >90% and a specificity of >99%. Some ctDNA was also detected in 97% (29/30) women with metastatic breast cancer. It has also been demonstrated that analyses of mutations in ctDNA could detect early-stage tumors. For example, ctDNA assays targeting known tumor mutations using droplet digital PCR (ddPCR) assays demonstrated a sensitivity of 93.3% and a specificity of 100% in detection of early-stage breast cancer. Similarly, TP53 mutations detected in ctDNA may be useful for breast cancer screening for those with BRCA1 mutations. Chromosome instability is one of the hallmarks of tumors.

Circulating miRNAs

The miRNAs are small regulatory RNA molecules that mediate target mRNA expression by base pairing to complementary sequences in the 30 untranslated region. It was shown that circulation miRNAs in the serum and plasma of patients could distinguish patients with prostate cancer from healthy controls. In breast cancer, a large number of miRNAs have been observed to be significantly upregulated in the plasma of patients, although a small number of miRNAs were found to be downregulated when compared to healthy controls. Studies have demonstrated that a combination of certain circulating miRNAs were able to distinguish breast cancer from normal and healthy controls, as well as differentiate breast cancer from benign lesions.

Extracellular Vesicles

The term EV is a generic term used to refer to all types of vesicles that exist in the extracellular space, including microvesicles, microparticles, ectosomes, exosomes, oncosomes, prostasomes, and tolerosomes. EVs, secreted from normal and cancer cells, are a complex of lipids, proteins, DNAs, various RNAs, and other biomolecules enclosed by a lipid bilayer with transmembrane proteins. Because EVs can mirror the features of the origin and the state of the tumor, they have gained increasing attention as cancer biomarkers. An elevated number of EVs has been found in *the peripheral blood of breast cancer patients compared with healthy controls. However, the number of EVs alone is not specific enough for cancer diagnosis. As an alternative to EV count, their molecular cargos may be a better cancer biomarker, especially if the enclosed contents are cancer related, such as amplified oncogenes and oncoproteins.*

From Sauter:

There has been considerable effort to identify novel biomarkers that might offer clinical utility. Relatively few identified candidates have been subjected to rigorous validation. Validation requires the analysis of hundreds and sometimes thousands of samples to adequately survey the variability in biomarker expression that is present in patient samples. The evaluation of changes in both DNA and proteins in body fluids and tissue shows considerable promise in the diagnosis and management of breast cancer, but analysis of body fluids is preferred for diagnosis because sampling is minimally invasive and ongoing assessment is practical.

Analysis of fluids also has promise, either alone or in combination with tissue analysis, for determining if breast cancer will recur. Despite the potential already demonstrated, researchers have not delivered validated biochemical markers that can be used to optimally diagnosis and manage breast cancer.

Only four of the Food and Drug Administration (FDA)-approved markers (CA 15-3, CA 27.29, HER- 2/ neu, and circulating tumor cells analysis of EpCAM, CD45, CK8, 18, 19) can be measured and assessed longitudinally.

Notably, there are no FDA approved biomarkers for breast cancer diagnosis or screening. Biomarkers in tissue

1. Hormone receptor status: Cancers that express the estrogen receptor (ER) are estrogen dependent, whereas cancers that do not express ER are estrogen independent.

Two thirds of invasive breast cancers express ER and are classified ER+. The progesterone receptor (PR) becomes activated when it interacts with the hormone progesterone. Approximately 65% of breast cancers that are ER positive are also PR positive. Expression of both ER and PR are measured via immunohistochemical (IHC) assay. Tumors that are ER+ and/or PR+ generally respond to antihormonal therapy with tamoxifen or an aromatase inhibitor, whereas those that are ER/PR negative do not.

2. Cytokeratin (CK): IHC expression of CK7, CK8, CK18 and CK19 is observed in more than 90% of all breast carcinomas. Expression of CK5/6, CK14 and CK20 correlate with high tumor grade.

3. Heregulin (HER)2: Also known as epidermal growth factor receptor (EGFR) II, HER2 is overexpressed in 20% of breast cancers, most often due to HER2 gene amplification.

HER2 overexpression upregulates the cell signaling pathway leading to uncontrolled cell growth. HER2 positive breast cancers are generally aggressive and patients with HER2 *overexpression have a worse prognosis than patients whose breast cancers do not overexpress HER2.*

FDA approved agents targeting HER2 include transtuzumab, lapatinib, T-DM1 (adotrastuzumab emtansine) and pertuzumab.

4. Ki67: This protein is a marker of cell proliferation for many types of cancer. The fraction of cells that stain positive for this protein reflects the fraction of cells in G1, S, G2 or mitosis, but not those that are in G0. Higher levels of Ki-67 correlate with more rapid tumor growth and tumor aggressiveness.

5. Oncotype Dx: This is a 21 gene expression biomarker panel that ***uses formalin fixed tissue.*** *The test is valid for women with hormone sensitive breast cancer. It is most often used for women with early stage (DCIS, stages I and II node negative) disease. Results provide a statistical inference of chemotherapy benefit and likelihood of recurrence.*

6. Mammaprint: This ***70 gene biomarker panel uses fresh or fixed tissue to determine the likelihood of recurrence of breast cancer within 10 years*** *of diagnosis and response to treatment with chemotherapy.*

Mammaprint can be used to analyze both ER (-) and ER+ early stage (i.e. stage I or II) node negative (U.S. criteria; international criteria allow up to three positive nodes) invasive cancers.

7. Prosigna: The 50 gene assay, formerly called the PAM50 test, analyzes the activity of certain genes in node-negative (stage I or II) or node positive (stage II), hormone receptor-positive breast cancer patients. It provides individualized assessment of a patient's risk of recurrence at 10 years if given endocrine therapy alone. Biomarkers in body fluids The most common body fluid currently in use for biomarker detection is blood or its components. Three breast specific fluids that are being evaluated for predictive biomarkers are nipple aspirate fluid (NAF), breast milk and ductal lavage (DL). Each fluid contains proteins, carbohydrates and lipids, DNA and RNA. NAF, collected neat through breast massage +/- suction on the breast nipple, has a relative paucity of cells, but concentrated proteins, carbohydrates and lipids.

Breast milk contains high concentrations of certain proteins, including α-lactalbumin, lactoferrin, secretory IgA, lysozyme and albumin, whose primary function is feeding an infant, but there are also less abundant proteins, carbohydrates and lipids with potential cancer biomarker usefulness. DL is collected through the insertion of a micro catheter into the nipple, providing irrigating fluid, and analyzing the effluent. There are more cells in DL than NAF. The irrigant dilution factor for analysis of proteins, lipids and carbohydrates is somewhat uncertain, as often not all of the irrigant is collected.

Biomarkers in body fluids: serum

*1****. CA15-3 and CA 27.29****: For women diagnosed with breast cancer, assessment of the expression of both CA 15-3 (MUC1) and CA 27.29 in serum are FDA approved to monitor patients. American Society of Clinical Oncology guidelines recommend using these tumor* *markers in conjunction with imaging and clinical examination to assess treatment response/failure. A confirmed increase of >= 25% has been suggested as clinically significant.*

2. ***HER2/neu****: Reports suggest that the sensitivity of HER2/neu tissue testing may be enhanced by evaluating the external fragment of the HER2 protein, which is shed into the bloodstream. This assessment is referred to as the serum HER2 (sHER2) test.*

An increasing level of circulating HER2 is an early indicator of progression, particularly in HER2-positive patients. The rise and fall parallels the clinical course of disease, independent of therapy. HER2 status of the primary tumor may not accurately reflect the HER2 status of recurrent disease. As such, elevated serum HER2 levels may be an early signal of a HER2-positive metastatic tumor and therefore alert the physician to re-assess HER2 status using a tissue test.

3. Circulating tumor cells (CTCs): The CellSearch system was FDA approved in 2004 to detect the presence of CTCs and monitoring disease progression based on CTC level in patients with metastatic breast, colorectal, and prostate cancer. The CellSearch test has not yet been established as a means of selecting therapies for these patient populations, hampering its incorporation into treatment guidelines.

Breast Cancer Biomarkers Being Evaluated Biomarkers in tissue

1. p53 is the most commonly mutated gene in human cancers. Individuals who have germline mutations in TP53 have Li-Fraumeni syndrome. Li-Fraumeni syndrome is rare, with approximately 400 known families. Patients with Li-Fraumeni syndrome are at high risk for early onset breast cancer. The primary limitation of performing screening for germline p53 mutations is their rarity.

3. Ataxia Telangiectasia (AT) is caused by mutations in the AT mutated (ATM) gene which leads to the generation of defective AT protein. The normal AT protein detects DNA strand breaks, recruits proteins to fix the break, and prevents a cell from making new DNA until the repair is finished. People with AT are at an increased risk of multiple cancers, including lymphoma, leukemia, and breast cancer. Compared to the general population, women who are heterozygous or homozygous for AT have double the risk of developing breast cancer. The relative infrequency of the mutation limits its justification for screening the general population to identify individuals at increased risk.

4. Mutations in the Phosphatase and Tensin (PTEN) gene can contribute to the development of a variety of cancers, including breast cancer Approximately 50% of breast cancers have loss of PTEN expression, which is associated with lymph node metastases and poor survival. Individuals with Cowden's disease, who have germline mutations in PTEN, have a 25-50% lifetime risk of developing breast cancer.

5. Multiple gene analyses: There are a variety of hereditary breast cancer syndromes which have genetic mutations associated with them, and confer an increased risk of developing breast +/- other malignancies.

These include Hereditary Breast and Ovarian Cancer syndrome, with mutations in BRCA1 or BRCA2, Li-Fraumeni, with mutations in TP53, Cowden's syndrome, involving PTEN, Hereditary Diffuse Gastric Cancer syndrome, involving CDH1, Peutz-Jeghers, involving STK11, Lynch syndrome, involving MLH1, MSH2, MSH6, or PMS2, and Fanconi anemia, involving PALB2. Lifetime risk of breast cancer is over 20% for mutation carriers of these syndromes, ranging up to 80% for BRCA1 mutation carriers. Gene panels have been developed to evaluate patient samples for alterations in some or all of these genes. a. BROCA:

This panel from the University of Washington evaluates mutations in genes involved with a variety of human cancers. BROCA is most useful for analyzing patients with a suspected cancer predisposition. An advantage of the BROCA gene panel is that specific gene testing can be selected or the investigator can opt for the entire panel. The number of genes in the panel changes over time based on new information.

b. BreastNext: This 17 gene panel developed by Ambry Genetics is very similar to the BROCA panel in that it analyzes cancer risk and is best suited for patients with a suspected hereditary predisposition to breast or ovarian cancer. Like BROCA, this panel offers the option of specific gene testing or analysis of the entire panel. A further advantage to BreastNext is that it includes duplication and deletion gene analysis

From Colomer et al present a summary of several recent assessments of each of the tests available as we show below:

	ASCO 2016			NCCN 2016		ESMO 2015			SEOM 2015		
	Prognosis		CT benefit prediction	Prognosis	CT benefit prediction	Prognosis		CT benefit prediction	Prognosis		CT benefit prediction
	5 yr	10 yr				5 yr	10 yr		5 yr	10 y	
Oncotype DX[38]	Yes	NA	Yes	Yes	Yes	+++	+++	Yes	IA (low RS) IB (other RSs)	IB	IA (low RS) IB (other RSs)
Prosigna[39]	Yes	Yes	Yes	Yes	NA	++	++	Yes	IB	IB	NA
MammaPrint[40]	Yes	-	-	Yes	NA	+++	NA	Yes	IB	NA	NA
EndoPredict[41]	Yes	Yes	Yes	Yes	NA	++	++	Yes	IB	IB	NA

From Harbeck as modified:

---

[38] https://precisiononcology.exactsciences.com/healthcare-providers/treatment-determination/breast-cancer/oncotype-dx-breast-dcis-score

[39] https://www.prosigna.com/en/why-prosigna/?gclid=Cj0KCQjwxb2XBhDBARIsAOjDZ35DnepxEdIq7dHDVKb41ujuc73IdoYgqRVcTh1NfU0FFpnHNduMKWYaAm28EALw_wcB&gclsrc=aw.ds

[40] https://agendia.com/mammaprint/

[41] https://myriad.com/managed-care/products/endopredict/



7.3.1 miRNA

From Richard et al:

Breast cancer is an ideal model of a heterogeneous disease that is triggered by genetic changes in the normal mammary epithelial cells and manifest as variants of breast tumor subtypes in individuals. Advancement in molecular and genomic profiling techniques, in particular the microRNA profiling have improved the ambiguity related to the presence of multiple breast tumor subtypes.

This review discusses in detail, the efficient categorization of breast tumor subtypes based on expression of microRNAs and also highlights the significant role of microRNAs in regulating both the tumor cells and the host microenvironment in driving tumor initiation, progression, chemoresistance and eventual spread of the disease.

***MicroRNAs may be rightfully deemed as excellent biomolecules deserving a detailed investigation**. The current clinical practice of breast tumor classification relies on the routine immunohisto chemistry-based expression analysis of hormone receptors, which is inadequate in addressing breast tumor heterogeneity and drug resistance.*

MicroRNA expression profiling in tumor tissue and in the circulation is an efficient alternative to intrinsic molecular subtyping that enables precise molecular classification of breast tumor variants, the prediction of tumor progression, risk stratification and also identifies critical regulators of the tumor microenvironment. This review integrates data from protein, gene and miRNA expression studies to elaborate on a unique miRNA-based 10-subtype taxonomy, which *we propose as the current gold standard to allow appropriate classification and separation of breast cancer into a targetable strategy for therapy …*

Failure of treatment modalities leading to recurrence in breast tumors has been attributed to the presence and survival of a small fraction of tumor cells that retain the properties of adult stem cells and the potential to regenerate a whole new tumor. Stem-like cancer cells that express the (CD44+CD24−/lin−) cell surface marker phenotype and share the molecular regulatory features of normal mammary stem cells (MaSCs) are termed breast cancer stem cells (BCSCs). The differential expression of miRNAs and miRNA clusters located on distinct chromosomal regions also provides an additional layer of regulatory control on oncogenes during the malignant transformation of cells.

*Three miRNA clusters (**miR-200c-141, miR-200b-200a-429 and miR-183**) are proven to be downregulated in human BCSCs and the proto-oncogene BMI1 is a validated target of miR-200c. MicroRNAs are also capable of regulating the distinct inter-cell state transitions, epithelial–mesenchymal transition (EMT) and mesenchymal–epithelial transition (MET), in both normal and malignant breast stem cells, thus facilitating the co-existence of multiple stem cell states, interpreted as biological heterogeneity in tumors …*

Differential expression of microRNAs also enables the clear distinction of cell types evidenced by high expression of miR-let7c, miR-125b, miR-126, miR-127-3p, miR-143, miR- 145, miR-146-5p and miR-199a-3p in normal mammary epithelial basal cell types, whereas miR-200c and miR-429 are upregulated specifically in the luminal cell type. MicroRNA profiling experiments revealed consistent low expression of three clusters, the miRNA- 200c-141 cluster, the miR-200b-200a-429 and the miR-183-96-182 cluster, in human BCSCs as compared to mature epithelial cells.

Diminished expression of miR-200c inversely elevated the expression of BMI1 gene, ZEB1 and ZEB2 (the two transcriptional repressors of E-cadherin), thereby enhancing the self-renewal, differentiation and EMT pathways, respectively, that are crucial in the maintenance of normal MaSCs and tumorigenic BCSCs alike Interactions between cancer cells and the TME usually occur via cytokines, hormones, growth factors and secreted microRNAs. Pathway analysis of the genes targeted by miRNAs in the greater part of tumors positively correlated with miRNA-mediated gene regulation among stromal cells, mainly the myofibroblast phenotype and vascular smooth muscle cells inhabiting the tumor space.

Sequentially, cancer-associated fibroblasts (CAFs) also regulate the TME and tumor cells by secreting microRNAs encapsulated as endosomal vesicles, which strongly promote the development of an aggressive breast cancer cell phenotype. A differential expression profile identified miRs-21, -378e and -143 to be augmented in exosomes from CAFs in comparison to normal fibroblasts and this induced stemness and an EMT phenotype, promoting the development of an aggressive breast cancer cell phenotype. The measures adopted by tumor cells to counter immune cell infiltration are via the secretion of tumoral exosomes that act as carriers of miRNAs, targeting mRNAs with a role in immune-suppressive pathways, the promotion of tumor cell communication, invasion, metastasis and induced drug resistance by targeting antiapoptotic genes.

Tumor-cell-secreted microRNAs in the circulation may either be protected in micro-vesicles containing mature miRs or pre-miRs with RNA-induced silencing complexes (RISCs) or as exosome-free microRNA complexes with argonaute proteins or bound by high-density lipoprotein (HDL). Most often, the exosome acceptor/receiver cells would be the immediate stromal microenvironment, the immune and endothelial cells that adapts its responses to the needs of the transforming tumor clones.

Metastatic human breast cancer cell lines secreted exosomes containing miR-200 that are absorbed by non-metastatic tumor cells and promote EMT and colonization at distant sites. High plasma levels of miR-200c/141 are indicative of metastatic breast cancers rather than localized breast tumors, suggesting its potential role as a biomarker for detecting metastatic spread.

The influence of steroid hormones in modulating the tumor environment via microRNAs is evidenced wherein progesterone treatment and irradiation stimulated the expansion of radiation-resistant tumor-initiating CSC compartment followed by the downregulated expression of miR-22 and miR-29c both in (PR+) BC cells and in (PR-) normal cells.

MiR-9, miR-15b, miR-17, miR-19a and miR-30d are identified to be the most interconnected differentially expressed (DE) ci-miRs that are highly abundant in tumor interstitial fluids (TIFs) of the basal subtype than in patients with luminal and Her2-enriched cancer and are also suggestive of high-grade metastatic tumors with poor prognosis

Halvorsen et al noted the following miRNAs:

	Luminal A	Luminal B	HER2	TNBC
miR-1282	Down	Up	Up	Up
miR-190b	Up	Up	Down	Down
miR-224-5p	Down	Down	Up	Up
miR-27a-5p	Up	Down	Up	ns
miR-342-3p	Up	Up	Down	Down
miR-342-5p	Up	Up	Down	Up
miR-375	Up	ns	Up	Down
miR-376a-5p	Up	Up	Down	Down
miR-432-3p	Down	Up	Down	Up
miR-524-3p	Up	Down	Up	Up
miR-671-3p	Down	Down	Up	Down
miR-9-5p	Down	Down	ns	Up

From Tamura et al we have the following summary table:

Cancer	***Biological Source***	***Isolation methods***	***Detection methods***	***RNA types***	***Markers***	***Potential application***
Breast cancer	Plasma	FC/UC/ Exo Quick	RT-qPCR	miRNA	miR-21, miR-1246	Diagnosis
	Plasma	UC	RT-qPCR	miRNA	miR-105	Diagnosis
	Serum	unknown/ Total Exosome Isolation Kit	RT-qPCR	miRNA	miR-21, miR-222, miR-155	Prognosis/ Predict chemo-resistance (miR-21, miR-155): Doxorubicin. Paclitaxel)
	Serum	UC+IP	RT-qPCR	miRNA	miR-200a. miR-200c. miR-205	Diagnosis
	Blood/ Milk/ Ductal fluids	UC	RT-qPCR	miRNA	miR-16, miR-1246, miR-45t mlR-205	Diagnosis
	Serum	Exo Quick	RT-qPCR	lncRNA	HOTAIR	Prognosis/Monitoring
	Serum	Exo Quick	RT-qPCR	lncRNA	SNHG14	Predict chemoresistance Trastusumab
	Plasma	UC	RT-qPCR	mRNA	TrpC5. rndrl. MUCl and flotillin2	Predict chemoresistance Anthracycline/ taxane
	Serum	Total Exosome Isolation Kit	RT-qPCR	mRNA	GSTP1	Predict chemoresistance Anthracycline/ taxane

7.3.2 DNA

As Turner et al have noted:

In this large, prospective trial of ctDNA testing in advanced breast cancer, we found that ctDNA testing was highly accurate, with high agreement between different ctDNA testing techniques, and high sensitivity for mutations identified in advanced breast cancer tissue biopsies.

ctDNA testing identified patients with rare targetable mutations and these patients were recruited into cohorts that were given targeted therapies (matched to mutations) without confirmatory tumour testing, with activity comparable to previous studies involving tumour tissue testing.

We enrolled more than 1000 patients across the UK in less than 3 years, and the dynamic trial platform design allowed for the simultaneous evaluation of multiple targeted treatment options. The availability and accuracy of ctDNA testing shown in this study compares favourably with *tissue-based mutation testing. Nearly all patients (99%) received a result from ctDNA testing, contrasting with previous tumour sequencing studies where results were typically received in only 70–90% of patients. In addition, previous tumour sequencing studies generally only included patients with disease that could be biopsied, which is not a constraint for ctDNA testing. Results were received relatively quickly after blood draw, compared with results for tissue-based testing, and this led to a high conversion rate of patients with ctDNA mutations into the corresponding treatment cohort.*

The accuracy of ctDNA testing was also similar to that achieved with tissue sequencing.17 Discordance between ctDNA results was still observed for patients at low allele frequency mutations, suggesting further potential for assay development. ESR1 mutations had lower percent-negative agreement, probably reflecting the subclonality of acquired ESR1 mutations, with ctDNA detecting mutations present in metastastic sites other than the one biopsied. Nevertheless, the degree of sensitivity observed in this study suggests that, within the patient population of advanced disease patients recruited, ctDNA testing could replace tissue-based mutation analysis.

However, we note that tissue biopsy will remain important for immunohistochemistry, and for copy number-based assessment. Digital PCR offered similar accuracy to sequencing, with substantial cost efficiency, although this comparison was limited to the specific mutations analysed.

The academic clinical laboratory doing the digital PCR assay achieved the trial target turnaround time of results within 14 days.

*A shorter turnaround time could easily be achieved if required in clinical practice, resulting in a cost-efficient method of ctDNA analysis. 533 (51·1%) of 1044 patients who underwent ctDNA testing had a potentially targetable mutation (**PIK3CA, ESR1, HER2, AKT1, or PTEN**), indicating a potential value for ctDNA testing.*

Our results confirm clinically relevant activity of targeted therapies against rare activating mutations in breast cancer. In a previous phase 1 study with an expansion cohort of those with HER2-mutant breast cancer identified in tissue, who were given neratinib, there was a 32% unconfirmed response rate after 8 weeks of treatment. In our study, neratinib for HER2-mutant breast cancer identified by ctDNA testing had comparable activity to that observed when guided by tissue testing, with durable responses.

Similarly, capivasertib had high activity in patients with ctDNA-identified AKT1 mutations, Our study did not show benefit from increasing the dose of fulvestrant in patients with ESR1 mutations in ctDNA. Previous research has suggested that fulvestrant at standard doses does not maximally inhibit or degrade mutated ESR1, and we assessed whether more frequent administration of fulvestrant would increase therapeutic utility. Although exposure was increased in later cycles, this was insufficient to enhance activity, with the response rate remaining similar to that previously reported. We note however that our study recruited a heavily pretreated population, and this might have reduced the activity of fulvestrant. More *potent oestrogen receptor inhibitors, such as novel oral oestrogen receptor degraders and modulators, are also likely to be required.*

***We found that patients with Tyr537Ser ESR1 mutations were no less sensitive to fulvestrant than those with other ESR1 mutations**, and that ESR1 mutations were frequently subclonal, with detection of ESR1 mutations in ctDNA that were not present in contemporaneous single site tissue biopsies, reflecting the limited sampling of single site tissue biopsies.*

Fulvestrant activity was similar in patients with and without ESR1 mutations in tissue sequencing. Our study has limitations. Inclusion of relatively heavily pretreated patients might reduce activity of the targeted drugs, especially in cohort A, and future ctDNA selection trials might benefit from more restrictive entry criteria.

The study was designed to assess the activity of therapies against specific genomic events, but it did not target PIK3CA mutations,1 and as a result relatively few of the patients registered to the trial had a response to therapy. However, mutation-directed therapy with alpelisib is now approved to target PIK3CA mutations, and our study shows the clinical validity of using ctDNA to direct therapy. Cohort D was designed as a basket cohort from the outset, to explore the activity of capivasertib against different AKT pathway activating mutations. Only cohort D allowed entry of patients with previous tissue sequencing results, as it was anticipated that ctDNA testing alone might not recruit sufficient patients.

*Although we identified low activity of capivasertib in **PTEN-mutant** cancers when used as a single agent, AKT inhibition in combination with paclitaxel chemotherapy might be efficacious in PTEN mutant cancers.22,23 Capivasertib plus fulvestrant might be efficacious in endocrine-resistant oestrogen receptor positive breast cancer without mutation selection, as shown in the FAKTION trial.24 It is not possible to robustly compare plasmaMATCH with FAKTION, as patients enrolled in plasmaMATCH had more previous lines of treatment, and AKT1 mutations were not assessed and would be few in number in FAKTION.24*

In conclusion, we show that ctDNA testing, with the assays employed in this study, has sufficient accuracy for widespread adoption in routine clinical practice to identify patients with breast cancer who are suitable for licensed targeted therapies, such as PIK3CA-mutant breast cancer, with the transformative potential of efficient and rapid screening for clinical trials.

*A high proportion of patients with specific targeted mutations were able to enroll on the matching treatment cohort, with clinically important activity observed with therapies matched to **AKT1 and HER2** mutations. With mutation matching therapy now approved in breast cancer, with alpelisib for **PIK3CA-mutant disease**, ctDNA testing can be seen as a standard-of-care test for both common and rare targetable genetic events.*

7.4 ONCOTYPE DX

From Oncotype DX we have the following genes[42]:

---

[42] https://precisiononcology.exactsciences.com/healthcare-providers/treatment-determination/breast-cancer/oncotype-dx-breast-recurrence-score/interpret-the-results

16 Breast Cancer-Related Genes				
Estrogen	**Proliferation**	**HER2**	**Invasion**	**Others**
ER	Ki-67	GRB7	Stromelysin 3	CD68
PR	STK15	HER2	Cathepsin L2	GSTM1
Bc12	Survivin			BAG1
SCUBE12	Cyclin B1			
	MYBL2			
5 Reference Genes				
Beta-actin	GAPDH	RPLPO	GUS	TFRC

8 THYROID

Our intent here is not to present a pathologists view but just to highlight some of the pathological histological features and they attempt a nexus to the underlying genetic cause. Examining the histology, we can ask such questions as:

1. Why do the cells lose their relational aspects?

2. Why do the cells proliferate?

3. What drives vascularization?

4. What are the causes of the morphological changes such as notching and clear nuclei?

By examining the histology of the cell and especially of the cancerous variants it begs the question; what are the genetic factors which cause or facilitate these changes. Some of these are understood while others remain questionable. This section is in no way an attempt to present the histology of thyroid cancers. It is merely an attempt to raise the question of shape versus cause versus therapeutic.

8.1 THE THYROID CELL

Basically the thyroid cells is the outer side of a thyroid follicle. It is the boundary. This is shown below for a simple thyroid boundary. The cells on the boundary are well behaved and connected. Cell interfaces such as E-cadherin stabilize these cells. Internally to this glandular structure is a collagen internal fill. From this colloid under the pituitary control the T3 and T4 hormones are released. From this is the basis of the thyroid control path.



Now the thyroid gland is a compilation of these follicles as shown below. There are blood organs between the follicles and also C cells, cells separate from those that form the effective gland. The highly simplistic view is seen below.



Inside is the collagen material used by the cells to produce T3 and T4.

The normal thyroid cells are shown below (From *Epstein, Biopsy Interpretation of the Thyroid*). The separate cells for enclosures which contain colloid and then it is processed and released by the cell. Surrounding the cell is and there are blood networks throughout the thyroid providing the cells with their requirements and transporting the cell products.



Further specific detail of a follicle is shown below (again from Epstein). Note the clarity and simplicity as well as structure of the cells in each small gland portion:

Note that the cells are well demarcated and organized. Now as we shall see, several variations occur as the cell becomes malignant. Growth results in a proliferation of cells, everywhere, loss of adhesion via EMT results in cell dislocation, and the morphology of individual cells change as well.

8.2 PAPILLARY GROWTH

Now papilla are the small bumps or perturbances of the normal cells which generally are somewhat uniform as we have depicted.

The papillary like cells are shown as below:



The above show the papilla, the bumps or offshoots. It can be argued that this papilla formation is a result of a quasi-EMT process where the E-cadherin bond structure is starting to deteriorate. Namely the genetic control of this is breaking down because of the suppression of the pathways that control epithelial like structure[43]. Now as Nucera and Pontecorvi have noted:

---

[43] See McGarty, EMT and Cancers, January 2019, https://www.researchgate.net/publication/330222973_EMT_and_Cancers

Most human thyroid cancers are differentiated papillary carcinomas (PTC). Papillary thyroid microcarcinomas (PTMC) are tumors that measure 1 cm or less. This class of small tumors has proven to be a very common clinical entity in endocrine diseases. PTMC may be present in 30-40% of human autopsies and is often identified incidentally in a thyroid removed for benign clinical nodules.

Although PTMC usually has an excellent long-term prognosis, it can metastasize to neck lymph nodes; however deaths related to this type of thyroid tumor are very rare. Few data exist on molecular pathways that play a role in PTMC development; however, two molecules have been shown to be associated with aggressive PTMC.

S100A4 (calcium-binding protein), which plays a role in angiogenesis, extracellular matrix remodeling, and tumor microenvironment, is over-expressed in metastatic PTMC. In addition, the BRAFV600E mutation, the most common genetic alteration in PTC, is present in many PTMC with extra thyroidal extension and lymph node metastasis.

The above observation is interesting. Namely that almost 40% of people will be harboring small PTCs which unless sampled by a good ultrasound examiner would never be found. Furthermore they would never grow. They also note regarding the papillary growth above:

BRAFV600E triggers a cascade that leads to human papillary thyroid microcarcinoma (PTMC) proliferation. The constitutive kinase activity of BRAFV600E phosphorylates and activates MEK1/2. Phospho-MEK1/2 induces hyperphosphorylation of ERK1/2 which translocates into the nucleus, triggering cell cycle progression, and abnormal cell proliferation by up-regulating cyclins (e.g., Cyclin D1) crucial for the checkpoint machinery in G1-S phases and inhibiting anti-cell cycle cyclins (e.g., p27). Up-regulation of cyclins (e.g., Cyclin D1) leads to hyper-proliferation of papillary thyroid microcarcinoma cells and increase in papillae size.

In contrast, as Das notes[44]:

Psammoma bodies (PBs) are concentric lamellated calcified structures, observed most commonly in papillary thyroid carcinoma (PTC), meningioma, and papillary serous cystadenocarcinoma of ovary but have rarely been reported in other neoplasms and nonneoplastic lesions. PBs are said to represent a process of dystrophic calcification.

Despite numerous ancillary studies over a span of three and half decades, formation of PBs remains a poorly understood mechanism. Ultrastructural study of PTC has shown that thickening of the base lamina in vascular stalk of neoplastic papillae followed by thrombosis, calcification, and tumor cell necrosis leads to formation of PBs. Studies on serous cystadenocarcinoma of ovary and meningioma, however, revealed that collagen production by neoplastic cells and subsequent calcification was responsible for the formation of PBs.

---

[44] Note: A psammoma body is a round collection of calcium, seen microscopically. The term is derived from the Greek word ψάμμος (psámmos), meaning "sand".

The existence of some precursor forms of PBs was reported in meningiomas and more recently in PTC, which were mostly in the form of extracellular hyaline globules surrounded by well-preserved neoplastic cells or in a smaller number of cases intracytoplasmic bodies liberated from intact tumor cells.

Cellular degeneration and necrosis, leading to the disappearance of neoplastic cells, were noticed by us only around PBs but not around the precursor forms. Based on the above findings, it is suggested that rather than being the outcome of dystrophic calcification of dead or dying tissue, PBs may indeed represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm. It may also serve as a barrier against the spread of neoplasm.

We show psammoma bodies below.



An additional example is one with clear nuclei as shown below:



An example of one type of papillary carcinoma is one with "Orphan Annie" eyes, the wide open white eyes of the nucleus in the cells below.



Note also the well demarcated papillary form with outstretches of the otherwise well-structured cell.

Nuclear grooves is another characteristic that is part of this diagnosis as shown below:



These are small notches seen in the side of the nucleus.

8.3 FOLLICULAR GROWTH

In contrast to follicular carcinoma, where the boundary patency gets deformed, follicular carcinoma is where there is a proliferation of the follicular cells.

Baloch and LiVolsi have noted:

Follicular carcinoma comprises about 5% of thyroid cancers; however, in iodide-deficient areas, this tumor is more prevalent making up 25-40% of thyroid cancers. The true incidence of follicular carcinoma is difficult to determine since the follicular variant of papillary carcinoma may still be placed into this category. Risk factors include iodine deficiency, older age, female gender, and radiation exposure (although the relationship of radiation to follicular carcinoma is far less strong than with papillary cancer).

Clinically, follicular carcinoma usually presents as a solitary mass in the thyroid. Follicular carcinoma has a marked propensity for vascular invasion and avoids lymphatics; hence, true embolic lymph node metastases are exceedingly rare. Follicular carcinoma disseminates hematogenously and metastasizes to bone, lungs, brain, and liver …

What are the minimum criteria for making this diagnosis? Invasion of the capsule, invasion through the capsule, and invasion into veins in or beyond the capsule represent the diagnostic criteria for carcinoma in a follicular thyroid neoplasm. The criterion for vascular invasion applies solely and strictly to veins in or beyond the capsule, whereas, the definition of capsular invasion is controversial. Some authors require penetration of the capsule to diagnose a follicular tumor as carcinoma, while others need tumor invasion through the capsule into the surrounding normal thyroid.

Is capsular invasion insufficient for the diagnosis of follicular cancer? Distant metastases have been reported in follicular carcinoma diagnosed only on the basis of capsular and not vascular invasion, however, in some cases, metastases were already present at initial diagnosis. The *presence of vascular invasion is also indicative of malignancy in a follicular tumor. Invasion of vessels within or beyond the lesional capsule is necessary for a definitive diagnosis of vascular invasion. The lesions with vascular invasion should be separated from the minimally invasive follicular carcinomas that show capsular invasion only, because angio-invasive lesions have a greater probability of recurrence and metastasis.*

Thus a simplistic view of a follicular cancer is shown below.



We depict a follicular cancer below:



Note the extensive infiltration. Again in simplistic terms, papillary is a form where we lose shape, namely a putative EMT transition and follicular is where we see extensive proliferation. Clearly both forms may occur.

8.4 NEUROENDOCRINE GROWTH AND MEDULLARY THYROID CANCER

Medullary thyroid cancer is basically a neuroendocrine cancer. Neuroendocrine cancers are an interesting subset of many cancers and it worth reviewing the overall paradigm of their growth.

8.4.1 Neuroendocrine Paradigm

Namely we look at neuroendocrine type effects and thus it requires a slightly more detailed understanding of the prostate As NCI notes[45]:

Neuroendocrine: Having to do with the interactions between the nervous system and the endocrine system. Neuroendocrine describes certain cells that release hormones into the blood in response to stimulation of the nervous system.

We then, in a rationalistic manner, can try and connect the other empirical facts and see if the initial observation can also be logically correct and from that logic ascertain a new therapeutic approach.

A simplistic view of a neuroendocrine system is shown below. Basically the neuro cell activates the endocrine cell which in turn sends out signals to other collections of cells to do whatever they are supposed to do.



The above is simplistic but based upon a substantial base of validated cellular signalling factors. Namely these results are empirical in a broad sense. Now when examining various cancers we often look at the cancer cell as being the driving factor. However in a neuroendocrine

---

[45] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neuroendocrine

environment, the cancer cell may be getting its signalling from a cancer initiating cell which in turn is being signaled by a neuro cell. The cancer initiating cell may be blocked by blocking the signalling between it and the causative neuro cell. That is the logical or rationalistic part of this exercise.

The questions now are;

(i) If the malignancy occurs in the neuroendocrine cell, then does it create an environment for proliferation of other cells?

(ii) If the malignancy occurs in the neuroendocrine cell does it send out signals that either block other homeostatic processes or does it accelerate angiogenesis in the new malignancy?

(iii) If the malignancy starts in a non-neuroendocrine cell, are there processes that effectively "turn on" the neuroendocrine cell to facilitate such effects as proliferation, angiogenesis, gene suppression or activation in other cells?

These are but a few of the questions which may be posed. Again we indicate that this is a bit simplistic but it does present the key issues related hereto.

We have examined neuroendocrine driven cancers when examining the prostate. They are simply cancers where a local neuroendocrine cell starts controlling the proliferation process.

As Franz notes:

Medullary thyroid cancer (MTC) is a tumor of the parafollicular C cells that accounts for approximately 10% of all thyroid malignancies. An estimated 75% of MTC cases are sporadic, and the remaining 25% are familial. Embryologically, these cells originate within the neural crest and function similarly to other neuroendocrine cells within the amine precursor uptake and decarboxylation system. C cells are distributed throughout the entire thyroid gland, although they tend to predominate in the upper poles. Calcitonin, a hormone active in calcium metabolism, is synthesized and secreted by C cells and therefore serves as a useful serum marker for the presence of MTC. Calcitonin levels are most useful in screening individuals who are genetically predisposed to the disease and in following patients who already have been treated. The recent identification of the gene responsible for heritable forms of MTC has allowed earlier identification of individuals at risk for the disease

8.4.2 Medullary carcinoma

Kim and Kuo have noted:

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin. MTC accounts for 0.6% of all thyroid cancers and incidence of MTC increased steadily between 1997 and 2011 in Korea. It occurs either sporadically or in a hereditary form based on germline rearranged during transfection (RET) mutations. MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases.

The most appropriate treatment is still less clear in patients with residual or recurrent disease after initial surgery or those with distant metastases because most patients even with metastatic disease have indolent courses with slow progression for several years and MTC is not responsive to either radioactive iodine therapy or thyroid-stimulating hormone suppression. Recently, two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, are approved for use in patients with advanced, metastatic or progressive MTC.

Baloch and LiVolsi note:

Medullary thyroid carcinoma comprises less than 10% of all thyroid malignancies. This tumor is of great diagnostic importance because of its aggressiveness, its close association with multiple endocrine neoplasia syndromes (MEN2A and 2B), and a relationship to a C cell hyperplasia, a probable pre cursor lesion.

While the majority of medullary carcinomas are sporadic, about 10-20% are familial. Since these familial cases have been identified, a gene associated with medullary carcinoma has been identified on chromosome 10 and involves mutations in the RET oncogene.



and below:



8.5 ANAPLASTIC

This is a highly aggressive cancer with nearly 100% mortality in 6 to 12 months. It is also quite rare but seems to be a sequella to a Graves diseased thyroid. Given its rarity and complexity it is worth just a mention.

8.6 GENOMICS

Over the past two decades the details of the genomics of many cancers have been developed. In the case of thyroid cancer we now have a substantial base.

From Wells and Santoro we have the chart below which depicts the genetic disturbances for various thyroid cancers.



We will now explore several genes which are alleged to play a role in thyroid cancers. We first look at those examined in fusion panels and then those examined for somatic mutations.

			FA	HCA	NIFTP	FTC	HCC	PTC	PDTC	ATC	MTC[a]
Point mutations and indels		*BRAF* V600E, %					0	40-45	5-30	10-45	<5
		RAS, %	20-30	10-20	30-40	40-50	10-20	20	20-40	20-40	10-15
		EIF1AX, %	10-20	10-15	5-10	10-15	10-15	<5	10	10	
		PTEN, %	10-15		-5	10-15	10-15	<3	5-20	10-15	
		DICER1, %	10-15		-5	10-15		<5			
		7P53, %				<10	15-20	<5	10-30	50-70	<5
		TERT, %				15	10-20	5-10	30-50	70	
		PIK3CA, %	<5			<5		<5	5-20	5-18	
		AKT1, %							<5	<5	
		RET, %									40-50
Large-scale alterations	Fusions	*RET/PTC*, %						5-10	<5	<1	
		PPARG, %	5-10		20-30	10-20		<5	5-7	<1	
		NTRK1/3, %						<5	1-5		
		ALK, %						<5	5-10	<5	2
		THADA, %	5-10		20-30	<5		5			
	Somatic copy number alterations, %		20-40	40-50	20	40-50	70	5-10	50	90	20

NOTE: ATC, anaplastic thyroid carcinoma; FA, follicular adenoma; FTC, follicular thyroid carcinoma; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma; MTC, medullary thyroid carcinoma; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma. aSporadic MTC.

8.7 FUSION PANEL

Fusion panels are also a frequent element in searching for malignancies. As Haley et al, note:

Somatic gene fusions are common in leukemias/lymphomas and solid tumors. The detection of gene fusions is crucial for diagnosis. NanoString fusion technology is a multiplexed hybridization method that interrogates hundreds of gene fusions in a single reaction. This study's objective was to determine the performance characteristics and diagnostic utility of NanoString fusion assays in a clinical diagnostics laboratory.

Validation using 100 positive specimens and 15 negative specimens by a combined reference standard of fluorescence in situ hybridization (FISH)/RT-PCR/next-generation sequencing (NGS) assays achieved 100% sensitivity in leukemias/lymphomas and 95.0% sensitivity and 100% specificity in solid tumors. Subsequently, 214 consecutive clinical cases, including 73 leukemia/lymphoma specimens and 141 formalin-fixed, paraffin-embedded solid tumor specimens, were analyzed by gene fusion panels across 638 unique gene fusion transcripts.

A variety of comparator tests, including FISH panels, conventional karyotyping, a DNA-based targeted NGS assay, and custom RT-PCR testing, were performed in parallel. The gene fusion assay detected 31 gene fusions, including 16 in leukemia/lymphoma specimens and 15 in solid tumor specimens.

The overall ***sensitivity, specificity, and accuracy of gene fusions*** *detected by the gene fusion panel in all 329 specimens (validation and consecutive clinical specimens) tested in this study were 94.8%, 100%, and 97.9%, respectively, compared with FISH/RT-PCR/NGS assays. The gene fusion panel is a reliable approach that maximizes molecular detection of fusions among both fresh and formalin fixed, paraffin-embedded cancer specimens.*

Some of the common gene fusions examined for thyroid cancer are listed in the Table below[46].

Gene	*Function*
ALK[47]	This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, a hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer.
AXL[48]	The protein encoded by this gene is a member of the Tyro3-Axl-Mer (TAM) receptor tyrosine kinase subfamily. The encoded protein possesses an extracellular domain which is composed of two immunoglobulin-like motifs at the N-terminal, followed by two fibronectin type-III motifs. It transduces signals from the extracellular matrix into the cytoplasm by binding to the vitamin K-dependent protein growth arrest-specific 6 (Gas6). This gene may be involved in several cellular functions including growth, migration, aggregation and anti-inflammation in multiple cell types.
BRAF[49]	This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung.

---

[46] These samples are from tests that were performed at Columbia University Med Ctr Path, https://www.pathology.columbia.edu/diagnostic-specialties/personalized-genomic-medicine/oncology-testing/columbia-targeted-fusion-panel-ctfp

[47] https://www.ncbi.nlm.nih.gov/gene/238

[48] https://www.ncbi.nlm.nih.gov/gene/558

[49] https://www.ncbi.nlm.nih.gov/gene/673

Gene	*Function*
EGFR[50]	The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer.
FGFR1[51]	The protein encoded by this gene is a member of the fibroblast growth factor receptor (FGFR) family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds both acidic and basic fibroblast growth factors and is involved in limb induction.
FGFR2[52]	The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform.
FGFR3[53]	This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation.

---

[50] https://www.ncbi.nlm.nih.gov/gene/1956

[51] https://www.ncbi.nlm.nih.gov/gene/2260

[52] https://www.ncbi.nlm.nih.gov/gene/2263

[53] https://www.ncbi.nlm.nih.gov/gene/2261

Gene	*Function*
MET[54],[55]	This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion.
MYB[56]	This gene encodes a protein with three HTH DNA-binding domains that functions as a transcription regulator. This protein plays an essential role in the regulation of hematopoiesis. This gene may be aberrantly expressed or rearranged or undergo translocation in leukemias and lymphomas, and is considered to be an oncogene.
NRG1[57]	The protein encoded by this gene is a membrane glycoprotein that mediates cell-cell signaling and plays a critical role in the growth and development of multiple organ systems. An extraordinary variety of different isoforms are produced from this gene through alternative promoter usage and splicing.
NTRKI[58]	This gene encodes a member of the neurotrophic tyrosine kinase receptor (NTKR) family. This kinase is a membrane-bound receptor that, upon neutrophil binding, phosphorylates itself and members of the MAPK pathway. The presence of this kinase leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in this gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, cognitive disability and cancer.
NTRK2[59]	This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation. Mutations in this gene have been associated with obesity and mood disorders.

---

[54] Kenji TAKEUCHI* and Fumiaki ITO

[55] https://www.ncbi.nlm.nih.gov/gene/4233

[56] https://www.ncbi.nlm.nih.gov/gene/4602

[57] https://www.ncbi.nlm.nih.gov/gene/3084

[58] https://www.ncbi.nlm.nih.gov/gene/4914

[59] https://www.ncbi.nlm.nih.gov/gene/4915

Gene	*Function*
NTRK3[60]	This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation and may play a role in the development of proprioceptive neurons that sense body position. Mutations in this gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers. Several transcript variants encoding different isoforms have been found for this gene.
PDGRFA[61]	his gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
PPARG[62]	his gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described.
RET[63]	This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations.
ROS1[64]	This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor

---

[60] https://www.ncbi.nlm.nih.gov/gene/4916

[61] https://www.ncbi.nlm.nih.gov/gene/5156

[62] https://www.ncbi.nlm.nih.gov/gene/5468

[63] https://www.ncbi.nlm.nih.gov/gene/5979

[64] https://www.ncbi.nlm.nih.gov/gene/6098

Gene	Function
THADA[65]	This gene is the target of 2p21 choromosomal aberrations in benign thyroid adenomas. Single nucleotide polymorphisms (SNPs) in this gene may be associated with type 2 diabetes and polycystic ovary syndrome. The encoded protein is likely involved in the death receptor pathway and apoptosis.

8.7.1 ALK

As Murugan and Xing have observed:

Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor subfamily of receptor tyrosine kinases (RTKs), with its encoding gene located on the short arm of chromosome 2.

ALK was initially identified as part of an oncogenic fusion gene, NPM1-ALK (also known as NPMALK), in anaplastic large-cell non–Hodgkin's lymphomas (ALCL). It is also part of the fusion gene EML4-ALK in non–small-cell lung cancer (NSCLC).

There are a few other ALK fusion genes, such as TMP3/4-ALK and RANBP2-ALK, in inflammatory myofibroblastic tumors (IMT). The tyrosine kinase activities of these fusion ALK proteins are aberrantly activated and promote cell proliferation and survival. ALK fusion proteins have also been shown to activate various signaling pathways, among which are the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the Ras-Raf-MEK- extracellular signal regulated kinase (ERK)/mitogen-activated protein (MAP) kinase pathway with multiple interaction points to mediate the ALK signaling.

8.7.2 EGFR

The epidermal growth factor, EGF, is another GF associated with malignancies. As NCBI notes[66]:

This gene encodes a member of the epidermal growth factor superfamily. The encoded preproprotein is proteolytically processed to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding with high affinity to the cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4.

Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed.

---

[65] https://www.ncbi.nlm.nih.gov/gene/63892
[66] https://www.ncbi.nlm.nih.gov/gene/1950

8.7.2.1 EGF Functions

We begin with a simple overview of the EGF functions. As Singh et al note:

EGF is the prototypic and founding member of the EGFR ligand family, first identified from submaxillary gland extracts during nerve growth factor studies. The EGF-EGFR ligand-receptor system has greatly enhanced our understanding of receptor tyrosine kinase signaling, as evidenced by more than 70,000 publications for EGF alone. A recent review has distilled our current understanding of EGF and its actions.

More recently, a study uncovered that EGF-induced EGFR signaling enhances production of intracellular reactive oxygen species (ROS) by dual oxidase 1 (DUOX1) This nicely complements earlier studies in which ROS were shown to enhance EGFR signaling by modulating both positive and negative regulators of EGFR signaling (ADAMs and protein tyrosine phosphatases). In another recent study, urinary EGF has been shown to be an independent risk factor for progression of chronic kidney disease, substantiating earlier findings.

They then note its functioning:

Modes of signaling via epidermal growth factor receptor (EGFR) ligands.

Autocrine signaling occurs when a ligand is released from a cell and binds to EGFR on that same cell.

Paracrine signaling refers to the released ligand acting on a nearby cell, usually a different cell type.

Juxtacrine signaling occurs when a non-cleaved, transmembrane ligand binds to EGFR on an adjacent cell; this is best documented for heparin-binding epidermal growth factor-like growth factor (HBEGF). Amphiregulin (AREG), transforming growth factor-alpha (TGFA), and HBEGF, as well as EGFR, can be packaged into signaling competent exosomes. Uptake of exosomal AREG by recipient cells is, at least in part, dependent on EGFR, leading to the term exosomal targeted receptor activation (ExTRAcrine).

ExTRAcrine signaling has features of autocrine, paracrine, and juxtacrine signaling as well as possibly endocrine signaling since EGFR and AREG can be detected in human plasma exosome.

8.7.2.2 EGF and Cancer

Relationships between EGF and cancers are significant. From Yang et al we have the following:

EGF and its receptor (EGFR) have been associated with tumour cell invasion and metastasis initiation.

Dysregulation of EGFR signalling, including receptor over expression and/or activation has been shown to be a significant effector in the progression of human cancers including neoplasms of the brain, lung, breast, ovary, prostate, and pancreas.

A recent study investigated the relationship between EGFR and the adhesion molecule-integrin in human pancreatic carcinoma cells and demonstrated that the crosstalk between EGFR signalling and integrin in the cancer cell membrane is implicated in carcinoma cell invasion and metastasis. Integrins are a family of adhesion proteins that regulate cell migration.

The fact that EGF stimulated integrins-mediated carcinoma cell migration on vitronectin suggests that EGFR regulates cancer cell migration through the adhesion proteins, the integrins. EGFR inhibitors, such as erlotinib, provide clinical benefit in patients with advanced non-small cell lung cancer metastasis which suggests a critical role for EGF and its receptor in the initial steps of cancer metastasis. The mechanism of EGF activation of adhesion proteins in cancer cell remains to be elucidated.

Some studies indicate EGF induces tumour cell invasion and metastasis through de-phosphorylation and downregulation of focal adhesion kinase, while other studies suggest EGFR activates the Src family of kinases (SFK). The fact that activated Src kinase is involved in the rearrangement of the actin cytoskeleton, cell-matrix interactions, and cell-cell adhesion processes that promote cell invasion suggests a role for Src activity in tumour metastasis development.

Added insight is provided by Mendelsohn and Baselga who note:

Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments. In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed.

These MAbs have shown promising preclinical activity and `chimeric' and `humanized' MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC- C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy. In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.

Finally from Calderon and Prins[67]:

Epidermal growth factor (Egf), a secreted peptide, is produced by the luminal epithelial cells in the prostate, and is found at the highest concentration in human prostatic secretions compared to the rest of the body. Epidermal growth factor exerts its effects by binding to its tyrosine kinase receptor, epidermal growth factor receptor (EgfR).

Upon binding, EgfR can homo- or heterodimerize with erbB2 receptors, causing autophosphorylation of its tyrosine residues that in turn activate the phosphatidylinositol 3'-kinase (PI3K), mitogen activated protein kinase (MAPK), or phospholipase C-γ (PLC-γ) signaling cascades. In the developing murine prostate gland, Egf has been shown to mediate its actions through the PLC-γ signaling pathway.

Furthermore, rat UGS explants treated with exogenous Egf showed stimulation of prostate bud

8.8 GENES MUTATIONS

The common gene mutations examined for in thyroid cancer are listed below. We examine some in detail.

Gene	***Function***
GNAS[68] {7}	This locus has a highly complex imprinted expression pattern. It gives rise to maternally, paternally, and biallelically expressed transcripts that are derived from four alternative promoters and 5' exons. Some transcripts contain a differentially methylated region (DMR) at their 5' exons, and this DMR is commonly found in imprinted genes and correlates with transcript expression. An antisense transcript is produced from an overlapping locus on the opposite strand. One of the transcripts produced from this locus, and the antisense transcript, are paternally expressed noncoding RNAs, and may regulate imprinting in this region. In addition, one of the transcripts contains a second overlapping ORF, which encodes a structurally unrelated protein. Alternative splicing of downstream exons is also observed, which results in different forms of the stimulatory G-protein alpha subunit, a key element of the classical signal transduction pathway linking receptor-ligand interactions with the activation of adenylyl cyclase and a variety of cellular reponses. Multiple transcript variants encoding different isoforms have been found for this gene. Mutations in this gene result in pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, Albright hereditary osteodystrophy, pseudohypoparathyroidism, McCune-Albright syndrome, progressive osseus heteroplasia, polyostotic fibrous dysplasia of bone, and some pituitary tumors

---

[67] https://www.sciencedirect.com/science/article/pii/B9780128126363000055

[68] https://www.ncbi.nlm.nih.gov/gene/2778

Gene	*Function*
RET[69](10;11;13;15;16)	This **gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins.** Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This **proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations**. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis.
AKT1[70]	The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by **mutations in the pleckstrin homology domain of AKT1**. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome.
HRAS[71] {2;3)	This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, cognitive disability, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. **Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.**
NRAS[72] {2;3)	This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia

---

[69] https://www.ncbi.nlm.nih.gov/gene/5979
[70] https://www.ncbi.nlm.nih.gov/gene/207
[71] https://www.ncbi.nlm.nih.gov/gene/3265
[72] https://www.ncbi.nlm.nih.gov/gene/4893

Gene	***Function***
BRAF[73] (11;15)	This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome.
PIK3CA[74] {2;5;8;10;14;21)	Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdInsP2. This gene has been found to be oncogenic and has been implicated in cervical cancers.
TP53[75] {2;4;5;6;7;8;10}	This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms.
KRAS[76] {2;3;4)	This gene, a **Kirsten ras oncogene homolog** from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A **single amino acid substitution is responsible for an activating mutation**. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.
CTNNB1[77]	The protein encoded by this gene is part of a complex of proteins that constitute **adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells.** The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer

---

[73] https://www.ncbi.nlm.nih.gov/gene/673
[74] https://www.ncbi.nlm.nih.gov/gene/5290
[75] https://www.ncbi.nlm.nih.gov/gene/7157
[76] https://www.ncbi.nlm.nih.gov/gene/3845
[77] https://www.ncbi.nlm.nih.gov/gene/1499

Gene	***Function***
PTEN[78] {1;3;6;7;8)	This gene was identified **as a tumor suppressor that is mutated in a large number of cancers at high frequency**. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and **functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway**. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms

8.8.1 BRAF V600

BRAF is a RAF gene (protein) which plays a role in many pathways and has been a key player in many malignancies. Mutations in somatic cells of BRAF have resulted in multiple malignancies. These mutations have been found in many malignancies such as melanoma, prostate and breast.

As noted:

The management and treatment of malignant thyroid micro nodules (i.e., PTMC) can be a challenge for physicians. Most PTMC are indolent and have an excellent prognosis; however, a subgroup shows an aggressive biological and clinical behavior similar to PTC. While additional robust prospective studies are required, there is now a body of evidence suggesting that BRAF V600E-positive PTMCs show aggressive behavior, whereas BRAFV600E-negative PTMCs have a good prognosis. This suggests that it will be valuable to consider the BRAF V600E mutation as a prognostic marker of PTMC aggressiveness and to undertake prospective studies with systematic screening for the BRAF V600E mutation and long-term follow-up to validate this marker of tumor aggressiveness.

As Ascierto et al have noted:

BRAF is a serine/threonine protein kinase, encoded on chromosome 7q34, that activates the MAP kinase/ERKsignaling pathway. BRAF is the family member most easily activated by Ras. In addition, the basal kinase activity of BRAF is higher than that of other family members. This provides a potential rationale for the frequent mutational activation of BRAF observed in human tumors. In fact, approximately 50 % of melanomas harbor activating BRAF mutations.

Among the BRAF mutations observed in melanoma, over 90 % are at codon 600, and among these, over 90 % are a single nucleotide mutation resulting in substitution of ***glutamic acid for valine*** *(BRAFV600E: nucleotide 1799 T>A; codon GTG>GAG). The second most common mutation is BRAFV600K substituting* ***lysine for valine****, that represents 5-6 % (GTG>AAG),*

---

[78] https://www.ncbi.nlm.nih.gov/gene/5728

followed by BRAFV600R (GTG>AGG), an infrequent two-nucleotide variation of the predominant mutation, BRAF V600 'E2' (GTG>GAA), and BRAF V600D (GTG>GAT). The prevalence of BRAFV600K has been reported as higher in some populations

Note in the Figure below the BRAF functions:



p16: Also known as p16INK4, p16 binds to cyclin-dependent kinase 4 and 6, thereby preventing their interaction with cyclin D. It thus behaves as a negative regulator of proliferation and arrests cells in the G0/G1 phase of the cell cycle.

BRAF V600 blocking can be achieve as shown below:





Note: PLX4032 replaces the activating ATP and deactivates the V600E BRAF.

with the following details:



From Solit and Rosen Fig 1: *"the overexpression of RAF1 or the activation of RAS as a result of RAS mutation or upstream activation of a receptor tyrosine kinase promotes:*

(i) the formation of RAF dimers. In cells expressing RAF dimers, binding of RAF inhibitors to one member of the dimer transactivates the other, nonbound member.

(ii) In such cells, PLX4032 does not inhibit MAP kinase signaling, which leads to drug resistance.

(iii) Alternatively, the overexpression of mitogen-activated protein kinase kinase kinase 8 (MAP3K8, or COT) results in RAF-independent activation of MEK and ERK and thus resistance to PLX4032.

(iv) The activation of upstream receptor tyrosine kinases may also cause resistance to PLX4032 by activating RAS, as well as by activating parallel signaling pathways, which results in diminished dependence of the cell on RAF signaling. PDGFRβ denotes platelet-derived growth factor receptor β, and RAS-GTP RAS in its active, GTP-bound state."

8.8.2 RAS

From Mendelsohn et al

Point mutations in RAS genes are among the most common oncogenic abnormalities in all cancers, and DTC is no different. Mutations in the RAS protein lead to constitutive activation through alterations in the binding affinity of the kinase for GTP or through inactivation of its intrinsic GTPase activity. Thus, mutant RAS can signal downstream through both the MAPK and PI3K/Akt pathways without upstream activation derived from ligand-bound RTK. All three RAS genes (H-RAS, K-RAS, and N-RAS) are implicated in thyroid tumor formation from follicular cells, including 20% to 40% of benign follicular adenomas, 40% to 50% of FTC (including 15% to 20% of oxyphilic variants), 10% to 20% of PTC (almost exclusively follicular variants of PTC), and 25% of PDTC.

The presence of a RAS mutation may portend more aggressive disease with worse outcomes, but this has not been extensively examined.19,23 Each of these histologies has also been observed in transgenic mice expressing RAS mutations, although the presence of mutant RAS proteins alone is likely insufficient to cause tumor formation.24,25
PI3K/Akt Pathway

Inactivating germline mutations of the tumor suppressor gene PTEN cause Cowden syndrome, which carries a 50- to 70-fold increased risk for the development of DTC, especially FTC.26,27 Loss of this tumor suppressor function leads to activation of PI3K, Akt, and mTOR, thus *contributing to enhanced cell cycle progression, decreased apoptosis, and increased tumor proliferation. However, mutations in individual genes in this pathway are otherwise uncommonly reported as early oncogenic events.*

Instead, somatic mutations and/or overexpression of PIK3CA (which encodes the class I p110α catalytic subunit of PI3K), AKT, and PTEN are observed as frequent later events, especially in FTC, PDTC, and ATC.20,28,29 Gene amplification as well as activating point mutations are observed in 10% to 20% of PDTC and 40% of ATC and can be found in tumors also bearing either BRAF or RAS mutations. AKT activation is also characteristic of the invasive fronts of aggressive DTC and has been reported to trigger increased cellular motility.30
PAX8/PPARγ

A chromosomal translocation, t(2:3) (q13;p25), results in the PAX8/PPARγ mutation, which couples the DNA binding domains of the thyroid transcription factor PAX8 with the entire coding sequence of the nuclear peroxisome proliferator-activated receptor subtype γ1.31 The actual mechanisms by which the encoded fusion protein contributes to thyroid tumorigenesis remain unclear. However, several critical pathways may be affected, including reduced expression of PTEN leading to increased activation of Akt, and a dominant-negative effect on the normal PPARγ transcription factor permitting enhanced cellular proliferation and reduction of apoptosis. This mutation may be preferentially seen in younger patients with smaller tumors, which are generally better prognostic signs, but conversely are also seen in tumors with solid or nested histologies as well as with vascular invasion.

From Ruscica et al we have:

The neuropeptide Y (NPY) family of peptides, in addition to its many physiological actions, has also been involved in the modulation of tumor progression, with specific reference to endocrine-related cancers such as neuroendocrine tumors, breast and prostate cancers. These have been found either to express NPY receptors, or to secrete NPY-related peptides, or both.

The study of the role of the NPY family of peptides in the biology of endocrinerelated tumors, specifically concerning cell proliferation, angiogenesis, invasion and metastatization, may help to clarify some aspects of tumor pathophysiology, as well as to indicate novel diagnostic markers and therapeutical approaches…..

Proposed mechanisms of ERK1/2 activation by NPY in human prostate cancer cells. In PC3 cells, NPY activates ERK1/2 via PKC and, possibly, via RAS/RAF, whereas in DU145 cells, PKC activation is not required for NPY-induced ERK1/2 phosphorylation



From Ruscica et al

Sherr and Weber discuss the function of RAS as below. The first state regarding the Figure:

The ARF-regulated checkpoint connects the RB and p53 pathways. Mitogenic signals acting through Ras stimulate the formation of cyclin D/CDK complexes that phosphorylate RB in mid to late G1 phase. Accentuated by cyclin E/CDK2 (not shown), RB phosphorylation interrupts its interactions with both histone deacetylase and E2Fs, enabling E2Fs to promote S phase entry. Myc plays a similar role in the sense that it is also able to accelerate S phase entry.

By dampening cyclin D-dependent kinase activity, p16INK4a acts as a potent tumor suppressor. One of the oncogenic effects of adenovirus E1A is to interfere with RB function. Inappropriately increased E2F or Myc signals, stemming from oncogene activation, trigger ARF expression (the vertical barrel designates the checkpoint) and activate p53 to induce either cell-cycle arrest or apoptosis, depending on the biologic context. Although the known target of ARF action is the p53- negative regulator and p53-inducible gene product Mdm2, other targets for ARF action cannot be precluded.

Similarly, Mdm2 probably interacts with proteins other than p53. DNA damage (checkpoints collectively indicated by the horizontal barrel) is shown to access the Mdm2–p53 machinery independently of ARF. However, ARF loss enables Mdm2 to work more efficiently in countering p53 function in response to DNA damage.

From Sherr and Weber



The ARF-regulated checkpoint connects the RB and p53 pathways. Mitogenic signals acting through Ras stimulate the formation of cyclin D/CDK complexes that phosphorylate RB ….Accentuated by cyclin E/CDK2…, RB phosphorylation interrupts its interactions with both histone deacetylase and E2Fs [49^0], enabling E2Fs to promote S phase entry. Myc plays a similar role in the sense that it is also able to accelerate S phase entry…. Although the known target of ARF action is the p53- negative regulator and p53-inducible gene product Mdm2, other targets for ARF action cannot be precluded...

8.8.3 PTEN

PTEN is a major controlling gene. We show the overall pathway elements below.



PTEN is a significant gene which controls the Akt pathway which in turn controls the replication of cells. Loss of PTEN is often seen in metastatic prostate cancer. In many ways it is the hallmark of this change. As stated in NCBI[79]:

---

[79] http://www.ncbi.nlm.nih.gov/gene/5728

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.

First the PTEN pathway as shown below:



Note PTEN modulates the production of Akt which in turn modulates c-Myc which in turn controls cell reproduction. Any effect which causes PTEN to not be expressed will in turn result in unfettered cell growth.

http://www.ncbi.nlm.nih.gov/pubmed/19861688/



The phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10) antagonizes phosphoinositide 3-kinase (PI3K) signaling and is one of the most frequently mutated tumor suppressors in human cancers. Its regulation appears complex and is of great potential clinical importance. The protein P-REX2a (phosphatidylinositol 3,4,5-trisphosphate Rac exchanger 2a), better known as a regulator of the small guanosine triphosphatase Rac, has been identified as a direct regulator of PTEN activity and as a potential oncoprotein. P-REX2a can stimulate cell proliferation by inhibiting PTEN and stimulating downstream PI3K-dependent signaling. This suggests that aberrant control of PTEN by P-REX2a may represent a key tumorigenic mechanism, in agreement with recent studies supporting the pathological relevance of several other proposed PTEN regulators.

p16: Also known as p16INK4, p16 binds to cyclin-dependent kinase 4 and 6, thereby preventing their interaction with cyclin D. It thus behaves as a negative regulator of proliferation and arrests cells in the G0/G1 phase of the cell cycle.

PTEN has become a key gene in the development of prostate cancer. It controls a pathway leading up to c-myc control and once PTEN is lost the PCa can be considered as very aggressive. Its loss results in an activation of Akt and then c-myc causing uncontrolled cell growth. The pathway is shown below:



Receptor Tyrosine Kinase: Class of kinase receptors altered in cancer; eg, EGFR, MET, RET, ERBB2, HER2, FGFR1. When mutated or altered it overexpresses any ligand growth factor and drives pathway.

Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes. Akt1 is also able to induce protein synthesis pathways, and is therefore a key signaling protein in the cellular pathways that lead to skeletal muscle hypertrophy, and general tissue growth. Since it can block apoptosis, and thereby promote cell survival, Akt1 has been implicated as a major factor in many types of cancer.

As Jelovac and Park state[80]:

The phosphatase and tensin homolog gene (PTEN) is a tumor suppressor located on the human chromosome 10q arm and is an important mediator of carcinogenesis in a variety of human malignancies. By the strictest definition, a tumor suppressor is a gene whose loss confers an increased lifetime risk of developing tumors. The most illustrative examples of genes that fulfill this criterion are those associated with familial cancer syndromes whereby heritable inactivation of 1 allele and subsequent increased tumor risk is passed along to each generation in an autosomal-dominant fashion.

Using this as a framework, PTEN is a bona fide tumor suppressor gene in that heritable germline mutations have been described in Cowden syndrome (CS), giving rise to a number of human tumors and cancers, most notably thyroid and breast cancers. As is the paradigm of tumor suppressor genes, affected patients with CS inherit 1 mutant inactive copy of PTEN from either parent, and the ensuing loss of the second allele results in tumor formation with subsequent genetic events that eventually lead to cancer. Although there are notable exceptions to this model, most heritable cancer syndromes are believed to adhere to this pattern.

From the work of McMenamin et al we have the slides below. Here is a case where PIN is still expressing PTEN but as we increase the grade of PCa we see the elimination of PTEN expression. Thus we can say that PIN is a state prior to PTEN suppression and a corollary may be that PCa aggressiveness is reflective of loss of PTEN and activation of Akt pathway.

8.8.4 p53

p53 is one of the earliest gene products that has been correlated with cancers. First known as an oncogene it was found that its function actually inhibited cancerous growth. As Malaguarnera et al have noted:

At variance with other human malignancies, p53 mutations are not frequent in thyroid cancer and are believed to be responsible mainly for cancer progression to poorly differentiated and aggressive phenotype. p63 and p73, two proteins with a high degree of homology with p53, are overexpressed in thyroid cancer, but their role in cancer initiation or progression is controversial. Regulation of p53 family protein function depends on:

the balance between the expression of transcriptionally active (p53, TAp63, and TAp73) and inactive isoforms (DNp63 and DNp73);

their interaction and competition at DNA-responsive elements;

their interaction with regulatory proteins, either inhibitory or activating.

In thyroid cancer, therefore, although mutations of the p53 oncosuppressor protein family are rare, other mechanisms are present, including aberrant expression of p53 family dominant

---

[80] http://jama.ama-assn.org/content/304/24/2744.full

negative isoforms, up-regulation of inhibitory proteins, and functional inhibition of activating proteins. The overall result is a defective oncosuppressor activity.

These inactivating mechanisms may be present in the early stages of thyroid cancer and in different cancer histotypes. A better understanding of this complex network may not only ameliorate our comprehension of cancer biology, but also open the possibility of innovative diagnostic procedures and the development of targeted therapies.

Thus the p53 mutation may not be common its presence can be highly suggestive of a severe malignancy.

8.8.5 GNAS

GNAS appears to be a protein common to hormone glands. From the NLM database:[81]

The GNAS gene provides instructions for making one component, the stimulatory alpha subunit, of a protein complex called a guanine nucleotide-binding protein (G protein). Each G protein is composed of three proteins called the alpha, beta, and gamma subunits. In a process called signal transduction, G proteins trigger a complex network of signaling pathways that ultimately influence many cell functions by regulating the activity of hormones.

The G protein made with the subunit produced from the GNAS gene helps stimulate the activity of an enzyme called adenylate cyclase. This enzyme is involved in controlling the production of several hormones that help regulate the activity of endocrine glands such as the thyroid, pituitary gland, ovaries and testes (gonads),and adrenal glands. Adenylate cyclase is also believed to play a key role in signaling pathways that help regulate the development of bone (osteogenesis). In this way, the enzyme helps prevent the body from producing bone tissue in the wrong place (ectopicbone).

8.8.6 RET

RET appears to be an influential gene involved in thyroid malignancies. From NLM database:[82]

The RET gene provides instructions for producing a protein that is involved in signaling within cells. This protein appears to be essential for the normal development of several kinds of nerve cells, including nerves in the intestine (enteric neurons) and the portion of the nervous system that controls involuntary body functions such as heart rate (the autonomic nervous system). The RET protein is also necessary for normal kidney development and the production of sperm (spermatogenesis).

The RET protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning of the protein

---

[81] https://ghr.nlm.nih.gov/gene/GNAS

[82] https://ghr.nlm.nih.gov/gene/RET

allows it to interact with specific factors outside the cell and to receive signals that help the cell respond to its environment.

When molecules that stimulate growth and development (growth factors) attach to the RET protein, a complex cascade of chemical reactions inside the cell is triggered. These reactions instruct the cell to undergo certain changes, such as dividing or maturing to take on specialized functions.

From Mendelsohn we have:

About 20% of MTC occurs in one of several familial syndromes: multiple endocrine neoplasia (MEN) 2A (which also includes parathyroid tumors and pheochromocytomas); MEN 2B (which also includes pheochromocytomas, intestinal ganglioneuromatosis, neuromas of the tongue and subconjunctiva, and Marfanoid habitus); and familial MTC (FMTC, which lacks the other clinical features of MEN 2A).

Additional variants of MEN 2A have been reported that include cutaneous lichen amyloidosis and with Hirschsprung disease. Germline mutations in RET were identified as causative of these hereditary forms of MTC in two landmark 1993 studies.34,35 Today, more than 99% of all cases of hereditary MTC can be attributed to one of numerous point mutations in RET that cause activation of the tyrosine kinase function of the RTK (Table 43-1). Given the ubiquitous nature of the mutation, it is not surprising that the disease begins with diffuse hyperplasia of all of the C cells, with eventual development of one or more malignant foci.

The most common germline mutation, a cysteine-to-arginine substitution at codon 634 (denoted C634R), accounts for at least half of all cases of MEN 2A and has also been extensively studied in vitro in the well-characterized TT cell line.36 This mutation is found in the cysteine-rich extracellular domain of RET, a region responsible for ligand-dependent dimerization. However, in the setting of the C634R mutation, RET is capable of ligand-independent dimerization, leading to autophosphorylation of the intracellular tyrosine residues that are responsible for interaction with downstream signaling pathways.

In contrast, a methionine-to-threonine substitution at codon 918 (denoted M918T) is associated with the more aggressive phenotype of MEN 2B. The M918T mutation occurs in the intracellular domain of RET, changing the conformation of the tyrosine kinase domain and allowing marked enhancement of autophosphorylation in the absence of dimerization. In addition, allelic imbalance, due to either increased copy number of the mutant RET allele or deletion of part or all of the wild-type allele, has been reported in several cases of MEN 2A as well as the TT cell line itself.

Sporadic MTC, on the other hand, is not associated with germline changes in RET, but nonetheless, somatic RET mutations have been commonly reported in 25% to 50% of sporadic MTC cases. In this instance, the most frequent somatic mutation is the M918T alteration, but numerous other codon changes have also been observed, including selected deletions as well as point mutations. Of note, about 6% to 7% of patients with clinically sporadic MTC are found to carry germline mutations diagnostic of hereditary forms of the disease despite the absence of a *positive family history, thus leading to the consensus recommendation to recommend RET germline testing for all newly diagnosed cases of apparently sporadic MTC.37,38*

Extensive genotype:

phenotype correlations have been established in the two decades since RET was identified as causing MTC. In addition to identifying specific clinical syndromes associated with each mutation, these analyses have also demonstrated that disease penetrance, typical age of development of C-cell hyperplasia and malignancy, and the aggressiveness of the malignancy vary in a manner that is based to a large degree on the individual mutation. Thus, the intracellular domain mutations, which tend to be associated with the aggressive MTC characteristic of MEN 2B, are also found to cause aggressive sporadic MTC when they occur as somatic mutations. Patients who present with sporadic MTC associated with a somatic M918T mutation of RET have worse outcomes, including overall survival.39 These genotype:phenotype correlations are also useful in determining the role and outcomes of genetic screening in hereditary disease.

Recently published guidelines from the American Thyroid Association divide known RET germline mutations into four risk categories that guide earliest age for RET testing of potential familial carriers, earliest age for recommended first thyroid ultrasound and serum calcitonin testing to detect early presymptomatic evidence of disease, and role for potentially curative prophylactic thyroidectomy.38 Using this type of approach, most young patients identified by prospective genetic screening as carriers for FMTC or MEN 2A can be cured with prophylactic thyroidectomy, although a small percentage remain with biochemical evidence of residual disease.40
RAS

Mutations of RAS have recently been recognized as common in sporadic MTC in the absence of documented RET mutations.41,42 A wide range of frequency has been reported, however, between 10% and 80% of all RET–wild-type sporadic cases, using differing techniques for identifying RAS mutations. In the largest study, tumor samples from 108 sporadic disease patients without somatic RET mutations were subjected to RAS sequencing, yielding a frequency of 17% in that setting.42 Of the three potential genotype combinations, patients who were (mutant)RAS (wt)RET were more likely to be disease free after a median follow-up of 5 years than those who were (wt)RAS (wt)RET or (wt)RAS (mutant)RET.

As Subbiah et al note:

The receptor tyrosine kinase RET can be oncogenically activated by gene fusions or point mutations. RET fusions occur in a variety of malignancies, including 1%-2% of lung cancers, up to 10%-20% of papillary thyroid cancers, and rarely in many other solid tumors. RET mutations affect most medullary thyroid cancers (MTCs) , and next generation sequencing (NGS) analysis of large numbers of patient tumors has uncovered RET alterations at low frequency in other tumor types. Such alterations possess the hallmarks of cancer drivers: constitutive kinase and signaling activity, transformation of primary cells, and mutual exclusivity from other drivers. Until recently, only multikinase inhibitors (MKIs) with nonselective RET inhibitory activity have *been available for patients with RET-altered cancers. Clinical experience with these nonselective RET inhibitors has been disappointing, with only modest activity in RET-mutant MTCs and RET fusion-positive lung cancers.*

Other MKIs approved for other indications (e.g. sorafenib) possess similar, nonselective anti-RET activity preclinically. In part, this may be due to substantial 'off-target' side-effects that limit the degree of RET-specific inhibition and lead to frequent dose reductions. Together with weak anti- RET potency and poor pharmacokinetic (PK) properties, these limitations prevent potent RET pathway inhibition in patients.

8.9 BIOMARKERS

There are many biomarkers which have been investigated for thyroid cancer. As Wang et al have noted:

As we all know, chronic inflammation is related to the occurrence of cancer, and calprotectin is involved in the occurrence and development of various inflammations. Tabur et al found that the concentration of calprotectin in the serum of PTC patients increased significantly, and then decreased significantly after total thyroidectomy, besides, the level was similar to that of healthy people. Therefore, perhaps an increase in calprotectin may be a potential marker for oxidative stress in thyroid cancer. But again, the increase in calprotectin can occur in many diseases, so its specificity is not satisfactory.

Besides, Argyris summarized some searches and found that only malignant thyroid cancer which has aggressive characteristics would has increased calprotectin level.

In addition to anaplastic thyroid carcinoma, it has no significant role in non-neoplastic thyroid tissue and well-differentiated thyroid tumors. And as an important proinflammatory factor, platelets have also been studied as a biomarker. It will be rather convenient if the platelets could be the marker, since the test of it is such regular. However, the results are totally different and contradictory.

The study by Baldane et al in 2015 included 98 people shows the mean platelet volume (MPV) is higher in PTC patients, and gave a cut-off value as 7.81fl.

Yu et al investigated 280 people in 2017 attained a complete opposite result with PTC patients have lower MPV and higher platelet distribution width (PDW).

While in Dincel's study there's no significant difference in MPV, but PDW is lower and plateletcrit is higher in PTC patients.

These studies and their conflicting results is a frequent finding with many biomarkers. They continue:

For patients with tumor diseases, intact tumor cells and cell-free nucleic acids (cfDNA/cfRNA and circulating miRNA) can all appear in peripheral blood.

And given the tissue-specific expression pattern and stability of miRNAs, circulating miRNAs have become ideal biomarkers for many cancers. Among the most often mentioned and proven circulating substances in PTC patients are cfDNA,40,41 lnc-RNAs42 and various miRNAs. Among them, levels of miR-146, miR-221, miR-222 and let-7 were higher than those of the healthy control group43–48 and miR-222 and miR-146b can distinguish between PTC and benign nodules.

What's more, high-mobility group box-1 has also been proposed to be a marker, and as Mardente studied, its interact with RAGE enhances the level of ***miR221/222*** *that in turn* ***inhibits tumor suppressor gene PTEN****.*

Midkine is a pleiotropic growth factor that is significantly expressed during embryogenesis and regulates cell growth, survival, migration, angiogenesis, and antiapoptotic activities, but usually has low expression levels in adulthood. Some studies have shown that midkine expression in PTC is strong, and it is related to the clinicopathological characteristics and metastasis of PTC. …

But in fact, it has increased in more than 20 tumor diseases, so it needs to be assisted by other means.

Interleukin (IL) is a small protein signal molecule mainly synthesized by T cells, monocytes, macrophages and endothelial cells. It plays an important role in promoting communication between immune system cells, regulating transcription factors, controlling inflammation, differentiation, proliferation, and secreting antibodies etc. Various interleukins have been widely recognized as diagnostic, prognostic indicators and treatment methods.

In a validation test by Martins et al, the levels of IL-6, IL- 8, and IL-10 were higher in patients with thyroid nodules than in healthy people, but they could not distinguish between benign and malignant nodules.

In addition to the sensitivity of IL-2 reaching 98%, the others' sensitivity and specificity are not ideal. Matrix metalloproteinase (MMP) is a zinc-dependent endopeptidase, which has the function of digesting gelatin and a variety of collagens, and is involved in the development of many tumors. Shi et al affirmed its value as a diagnostic marker of thyroid cancer in their research.

The serum MMP-2 concentration of PTC patients is greater than of healthy people, and its level can be reduced after surgery. In addition, it may also have significant effects in prognostic evaluation and treatment….

At the same time, they also proposed that MMP-9 and TIMP-1, and TIMP-2 may have analogous effects, and the imbalance between MMP and TIMP may cause tumor progression. Vascular adhesion protein-1 (VAP-1) is an endothelial cell adhesion molecule that is involved in the process of leukocyte rolling, adhesion and transfer to inflammatory sites. Hu et al measured serum levels of VAP-1 in patients with thyroid cancer and benign thyroid adenomas, and found *that serum VAP-1 levels in the thyroid cancer group were significantly lower than those in the healthy control group and the benign nodule group.*

And it negatively correlated with serum thyroglobulin concentration in patients with thyroid cancer. The optimal cutoff value of VAP-1 for diagnosis of thyroid cancer was 456.6ng/mL, with a specificity of 77.4% and a sensitivity of 66.7%.58 Meanwhile, Baki's research in 2019 also confirmed its value as a potential marker. Galectin-3 is a protein that binds to β-galactosyl residues of cell surface glycoproteins.

Many studies have shown that its expression levels are different in benign and malignant thyroid tissues. The study of Saussez in 2008 showed that the level of Galectin-3 in the serum of patients with thyroid disease is higher than that of healthy people. Yilmaz's research in 2015 affirmed the statistical value of the difference, but in view of the inadequacy of existing studies, it was considered that it can only be used as a method of auxiliary diagnosis.64 β-2 microglobulin is the light chain of human leukocyte antigen (HLA).

Studies by Adil et al suggest that after excluding the deposition of β-2 microglobulin in the blood due to renal insufficiency, β-2 microglobulin elevated concentrations in serum can also be used as auxiliary diagnostic markers of thyroid cancer.65 CYFRA21-1 is a fragment of CK19, whose washout fluid shows great potential in diagnose the metastatic lymph nodes of DTC when combined with FNA.

Though its concentration in serum presents good value in diagnosing head and neck cancer, including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers, it does not perform well in discerning benign and malignant thyroid nodules.

Early to 2008 and 2010, someone has claimed that its level has no manifested difference between benign and malignant thyroid nodules. ***But like Tg, it may help in predicting the prognosis****. Besides, the higher level of it may indicate the poorly differentiated and anaplastic thyroid carcinoma, and worse prognosis of DTC.*

8.9.1 miRNA

As Dai et al note :

Several promising forms of biomarkers for liquid biopsy are currently available. For instance, cell-free DNA detection has achieved great success in several types of cancers, such as non-small-cell lung cancer.

However, this method is not suitable for PTC because the DNA mutation rate and the detection rate of cell-free DNA mutations are both extremely low in patients with PTC.

Further, RNA-type molecules in biofluids are unstable as they are readily hydrolyzed by nuclease, which also curbs the application of cell-free RNA molecules as biomarkers.

miRNAs in exosomes are very stable because exosomes have membranes that shelter miRNAs from hydrolysis by nuclease.

Exosomal miRNA profiles have been examined in several types of carcinomas. However, to date, only one study assessing the exosomal miRNAs of patients with PTC that reported the differentially expressed exosomal miRNAs in 50 patients with PTC and follicular TC by RT-qPCR. However, the study above implemented a small sample size, and the global signature of exosomal miRNAs for patients with PTC has not been thoroughly examined. In this study, we investigated the exosomal miRNA profiles of patients with PTC, using a large sample size with small RNA sequencing combined with RT-qPCR validation.

We identified 41 significantly upregulated miRNAs concurrently expressed in plasma and serum exosomes from patients with PTC, as compared with those from patients with benign thyroid nodules.

Among them, four exosomal miRNAs, including ***miR-376a-3p, miR- 4306, miR-4433a-5p, and miR-485-3p****, were determined to be significantly and steadily increased in plasma samples from patients with PTC in comparison with those from healthy controls and patients with benign thyroid nodules by RT-qPCR in two independent cohorts. miR-485-3p and miR-4433a-5p held relatively high diagnostic accuracy in sorting patients with PTC from healthy controls and patients with benign thyroid nodules. These results indicate plasma exosomal miR-485-3p and miR-4433a-5p have considerable potential as diagnostic biomarkers for PTC.*

Moreover, the high expression of exosomal miR- 485-3p correlated with tumor size greater than or equal to 1 cm, advanced clinical stage, extrathyroidal extension, BRAF mutation, and lymph node metastasis. miR- 485-3p exhibited the highest accuracy in discriminating PTC patients at the advanced stage from patients at the early stage, patients with extrathyroidal extension from patients without extrathyroidal extension, patients with BRAF mutation from patients without BRAF mutation, patients with lymph node metastasis from patients without lymph node metastasis. These results suggest that the high expression of plasma exosomal miR-485-3p is related to poorer prognoses.

Therefore, exosomal miR- 485-3p may serve as a promising biomarker to tell apart high-risk and low-risk PTC. Furthermore, we identified and confirmed exosomal miR-204-3p as a biomarker for PTC (tumor size ≥1 cm) diagnosis, and exosomal miR-4306 as a biomarker for PTC (tumor size <1 cm) diagnosis. miR-485 showed a significantly lower expression in PTC tissues as compared with normal tissues. As the targets of miR-485, 47 mRNAs were associated with several biological processes, especially pathways in cancer. Among these mRNAs, STAT3 and SP1 have been experimentally validated as a tumor promoter in PTC.

Reportedly, miR-485-3p is a tumor suppressor in breast cancer. Low serum level of miR-485-3p could predict poor survival in patients with glioblastoma.

Our data showed that miR-485-3p expression was markedly increased in plasma exosomes from patients with PTC as compared with healthy controls and patients with benign thyroid nodules, and the high expression of exosomal miR-485-3p was associated with high-risk factors, *indicating that exosomal miR-485-3p may play a key role in progression of PTC. A recent study showed that miR-204-3p was related to PTC progression, by acting as the target of lncRNA LINC00514. miR-204-3p has been reported to be specifically detected in exosomes from the cerebrospinal fluid of healthy human donors.*

However, we found that miR-204-3p was also detected in plasma or serum exosomes in this study. Saiselet et al. reported that miR- 204-3p was downregulated in PTC tissues as compared to those in normal tissues. Notably, miRNA levels in exosomes do not necessarily reflect that in tissues, since the miRNA sorting mechanism may affect the incorporation of miRNA into exosomes.

It was shown that miR-4306 served as a biomarker to predict survival and disease control of patients with head and neck cancer negative for human papillomavirus infection. miR-4306 was shown to be significantly upregulated in pancreatic cancer serum exosomes. Thus, the exosomal miRNAs identified in this study likely play essential roles in PTC. miR-4433a-5p was found to be significantly downregulated in peripheral blood from patients with vitiligo, which was not further validated. Because miR-4433a-5p was a newly identified miRNA, no study has reported the existence of miR-4433a-5p in exosomes. miR-204-3p, miR-4306, miR-4433a-5p, and miR-485-3p have never been found in plasma or serum exosomes from patients with PTC.

Thus, this study shows that small RNA sequencing is a valid method to identify novel exosomal miRNA-based biomarkers for PTC. Our study had several advantages. First, instead of measuring several miRNAs selected from different literature, we screened the genome-wide exosomal miRNA profiles of PTC via small RNA sequencing. Small RNA sequencing can measure the absolute abundance of miRNAs, enhancing the chance to identify differentially and steadily expressed exosomal miRNA.

Furthermore, we performed small RNA sequencing both in plasma and serum samples and screened the differentially expressed exosomal miRNAs that co-occurred in those samples. This approach enabled us to eliminate many miRNAs that were significantly increased due to technical and human errors that might have occurred during experimental handling. Besides, we validated the expression of putative exosomal miRNAs biomarkers in two independent and large cohorts.

In summary, we performed a detailed analysis of the plasma and serum exosomal miRNA profile in patients with PTC, and we validated plasma exosomal miR-485-3p and miR-4433a-5p as non-invasive biomarkers differentiate patients with PTC from healthy people and patients with benign thyroid nodules.

Moreover, plasma exosomal miR- 485-3p could serve as a biomarker to distinguish high-risk from low-risk PTC. These results suggest that miR-485-3p plays a pivotal role in the pathogenesis and development of PTC, and the functional role of exosomal miR-485-3p is an exciting subject requiring further study

Park et al also note regarding miRNA and TCa:

Thyroid nodules are frequently detected, but the majority of these nodules are benign. Molecular markers have become useful for diagnosing the minority of thyroid cancer.

*We performed high-throughput small RNA sequencing in a discovery cohort and identified three miRNAs (**miR-136, miR-21, and miR-127**) as potential biomarkers for thyroid cancer. We validated the diagnostic and prognostic utilities of three miRNAs in patients with thyroid cancer in an independent cohort.*

High expression of the three miRNAs could be used to differentiate thyroid cancers from benign tumors and tumors with extremely low malignant potential. In patients with thyroid cancers, a high expression of three miRNAs was associated with poor clinicopathological features and recurrent or persistent disease following surgery. Therefore, testing for high expression levels of these three miRNAs in thyroid nodules may be useful for diagnosing and assessing the recurrence of the thyroid cancer's risk stratification. The challenge in managing thyroid nodules is to accurately diagnose the minority of those with malignancy.

We aimed to identify diagnostic and prognostic miRNA markers for thyroid nodules. In a discovery cohort, we identified 20 candidate miRNAs to differentiate between noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) and papillary thyroid carcinomas (PTC) by using the high-throughput small RNA sequencing method.

*We then selected three miRNAs (**miR-136, miR-21, and miR-127**) that were differentially expressed between the PTC follicular variant and other variants in The Cancer Genome Atlas data. High expression of three miRNAs differentiated thyroid cancer from nonmalignant tumors, with an area under curve (AUC) of 0.76–0.81 in an independent cohort.*

In patients with differentiated thyroid cancer, the high-level expression of the three miRNAs was an independent indicator for both distant metastases and recurrent or persistent disease. In patients with PTC, a high expression of miRNAs was associated with an aggressive histologic variant, extrathyroidal extension, distant metastasis, or recurrent or persistent disease.

Three miRNAs may be used as diagnostic markers for differentiating thyroid cancers from benign tumors and tumors with extremely low malignant potential (NIFTP), as well as prognostic markers for predicting the risk of recurrent/persistent disease for differentiated thyroid cancer

8.9.2 circRNA

Zhang et al note:

Thyroid cancer (TC) is one of the most common malignant tumors, with high morbidity and mortality rates worldwide. The incidence of TC, especially that of papillary thyroid carcinoma (PTC); has increased rapidly in recent decades. Autoimmune thyroid disease (AITD) is closely related to TC and has an estimated prevalence of 5%. Thus, it is becoming increasingly important to identify potential diagnostic biomarkers and therapeutic targets for TC and AITD.

Circular RNAs (circRNAs) are a class of non-coding RNAs with covalently bonded circular structures that lack 5'-3' polarity and polyadenylated tails.

Several circRNAs play crucial roles in the development of various diseases, including TC and AITD, and could be important new biomarkers and/or targets for the diagnosis and therapy of such disorders. *Although there are four subtypes of TC, research on circRNA has largely focused on its connection to PTC. Therefore, this review mainly summarizes the relationships between circRNAs and PTC and AITD, including the molecular mechanisms underlying these relationships. In particular, the functions of "miRNA sponges" and their interactions with proteins and RNA are discussed. The possible targeting of circRNAs for the prevention, diagnosis, and treatment of TC and AITD is also described. CircRNAs could be potential biomarkers of TC and AITD, although validation will be required before they can be implemented in clinical practice. ...*

In recent years, several studies have shown that a number of circRNAs are abnormally expressed in tumor tissues and are related to cancer progression. Differential expression of these circRNAs can lead to changes in both biological processes and the flow of genetic information. CircRNAs play roles in TC signaling pathways and the invasion and migration of TC cells. In addition, the expression levels of circRNAs can be used for diagnosis of TC and monitoring the response to therapy. Table 1 summarizes the changes in expression levels (i.e., up-regulation or down-regulation) and regulatory functions of circRNAs in TC reported in recent studies. However, due to the high proportion of PTC among all thyroid cancers (about 80%) , recent studies on circRNA and TC have largely focused on PTC.

8.9.3 Genes

As Xu et al noted :

Thyroid cancer is the most common endocrine cancer, the incidence rate has continuously increased worldwide. However, there are still lack of effective molecular biomarkers for the diagnosis and treatment of the disease. The study was conducted to identify driver genes that may serve as potential biomarkers for the disease. The computational tools oncodriveCLUST, oncodriveFM, icages and drgap were used to detect driver genes in thyroid cancer using somatic mutations from The Cancer Genome Atlas database. Integrated analyses were performed on the driver genes using multiomics data from the TCGA database. ***A set of 291 driver genes were identified in thyroid cancer.***

BRAF, NRAS, HRAS, OTUD4, EIF1AX were the top 5 frequently mutated genes in thyroid cancer*. The weighted gene co-expression network analysis identified 4 coexpression modules. The modules 1-3 were significantly associated with patients' tumor size, residual tumor, cancer stage, distant metastasis and multifocality. SEC24B, MET and ITGAL were the hub genes in the modules 1-3 respectively. Hierarchical clustering analysis of the 20 driver genes with the most frequent copy number changes revealed 3 clusters of PRAD patients. Cluster 1 tumors exhibited significantly older age, tumor size, cancer stages, and poorer prognosis than cluster 2 and 3 tumors.*

16 genes were significantly associated with number of lymph nodes, tumor size and pathologic stage, such as ***IL7 R, IRS1, PTK2B, MAP3K3 and FGFR2.*** *The set of cancer genes and subgroups of patients shed insight on the tumorigenesis of thyroid cancer and open up avenues for developing prognostic biomarkers and driver gene-targeted therapies in thyroid cancer.*

9 MELANOMA

Melanoma is a highly virulent cancer which historically had poor results. However with the introduction of CTLA4 and PD-1 antibodies it has been mitigated in many cases. Yet a great deal depends on early identification and mitigation. In many cases attempts are made to ensure wide margins and attempts are made to determine if lymph node involvement has occurred. Biomarkers represent an interesting means to assess presence, progression and prognosis.

9.1 SKIN ANATOMY

The skin is the largest organ of the body. A skin cell is about 30 μm in diameter and the top layer of the skin, the epidermis, may be 5 to 15 cells thick and this 150 to 450 μm in thickness, about 0.5 mm at the deepest.

The dermatopathologist spends years of training to recognize and identify the multiplicity of skin disorders. This can be a very difficult process as exemplified by the ongoing debate on dysplastic nevi, are they pre-malignant or merely a condition unto themselves. One just needs to examine the years of work by Ackerman and colleagues in identifying melanocytic lesions. It is a complex and challenging process. It is a process which we will not even attempt to address herein.

However, our focus is on the specific intra and intercellular pathways. Examining the skin cellular structure provides a certain amount of insight and may be able to elucidate some of the extracellular flow issues including metastasis. However our goal in the chapter is not to provide details on dermatopathology but to provide a reasonable overview of its issues. Namely we want to be able to identify the melanocyte and to see what happens when a malignant condition is observed.

The challenge for the dermatopathologist in the coming years will be to not only use the visual clues, nor even the staining and immunohistological techniques, but to examine cells from a pathway distortion perspective both externally and internally. Namely do the cells express the desired or aberrant receptors and/or ligands and/or are the pathway elements normal or aberrant. Is the V600 BRAF present, for example? Currently there is a bifurcation of expertise in these areas and we may see an increase as time goes by and as we understand the pathway dynamics in a more complete manner.

The objectives of the Chapter are as follows:

1. Provide a general overview of the structure of the skin and the specific cells which compose this structure. The size of the cells and their “geographic” layout are essential to understanding the skin as an organ.

2. Provide a basic understanding of how the melanocyte integrates within that structure and what it appears to be in a health benign environment. This should provide a basis for understanding the importance of inter-cellular communications.

3. Identify the surrounding parts of the skin which interact with the melanocyte.

4. Identify abnormalities of the skin with emphasis on melanocytic disorders but also malignancies of other than melanocytes.

5. Identify and understand the simple melanocytic malignancy of melanoma and identifying and recognizing the typical morphological structures that are often found.

These objections, if met, will allow for a simple basis of understanding on how cells in a benign and malignant environment interact.

9.1.1 Skin Structure and Microscopy

The skin is composed of multiple layers. Simply, there is the epidermis in the top layer and the dermis the bottom, with a basal layer in between.

In the top epidermal layer we have the following type of cells:

1. Keratinocytes (92+% of total)

These are the most abundant cells, which are always growing and migrating upward where they die off and fall off the top layer. The very top layers of the akin are the stratum corneum which is at the very outermost surface. Just below that layer is the stratum granulosom, the layer of dying keratinocytes.

2. Langerhans cells (4% of total)

They are dendritic in shape and are exclusively in the epidermis. They function as the macrophage in the epidermis by processing contact antigens which they present to specific T cells. The Langerhans cells are thus a part of the immune system. They also provide a transport and contact mechanism to the lymphatic system.

3. Merkel cells (<1% of total)

These cells are considered to be touch receptors and reside in the basal layer and are generally unseen in normal microscopic observation.

4. Melanocytes (3% of the total)

The melanocytes remain at the basal layer of the epidermis and have long tentacles which spread upward to the upper layers and from these tentacles they emit the melanocytes, the pigment of the skin and the general pigment of a nevus. Any movement, up or down, from the basal layer, of the melanocytes is pathognomonic of a malignancy of some form. Stability of the melanocyte is the *sine qua non* of a benign cell. Unlike the keratinocytes, which are reproducing and dying, the melanocytes are generally non-reproductive and stable. Their major function is to produce melanosomes. A single melanocyte provides about 30 keratinocytes with melanosomes.

The melanocytes are seen as clear cells in normal staining and appear as wedged between the keratinocytes.

The figure below depicts the characteristics of the skin. The papillary dermis is about 0.4 to 0.6 mm in thickness and contains blood flow both from below and within the layer itself. It abuts the epidermis. It is composed of many collagen fibers and blood and never fibers. The blood flow to the basal layer and epidermal cells is via small capillaries that come up from the subcutis into this top layer. The blood flow provides for oxygen and other nutrients and also eliminates any internal waste products and provides a pathway for the immune system.



The details from Netter are below. This shows a considerable amount of anatomical detail as compared to the above. Quoting Ovalle and Nahirney:

The skin *"... consists of* ***stratified squamous keratinized epithelium*** *on its outer part, called the* ***epidermis,*** *and an inner layer of* ***fibrous connective tissue,*** *called the* ***dermis.*** *A loose layer of* ***subcutaneous connective tissue,*** *the* ***hypodermis,*** *attaches skin to underlying structures and permits movement over most body parts. Skin has a dual embryologic origin: epidermis and its appendages derive mostly from surface ectoderm; dermis originates from mesoderm. The epidermis consists primarily of cells called keratinocytes, which make up more than 90% of the cell population. Other epidermal cells are* ***melanocytes*** *and Merkel cells, which derive from neural crest, and Langerhans cells, which have a monocytic origin. During embryonic development, skin appendages deriving from the epidermis grow down into the dermis*."



▲ **Schematic of skin and its appendages that shows the epidermis, dermis, and subcutaneous tissue.**

© Elsevier. Ovalle & Nahirney: Netter's Essential Histology - www.studentconsult.com

The skin is generally considered to be composed of the following layers. The first four are effectively in the epidermis and the last two in the dermis.

1. Stratum corneum: The top layer of the epidermis where the dead keratinocytes are lost.

2. Granular layer: Also called the Stratum Granulosum is below the top layer.

3. Spinous layer: Also called the Stratum Spinosum is just above the basal layer.

4. Basal Layer:

5. Papillary layer: Part of the dermis which is *composed of thin, haphazardly arranged collagen fibers.*

6. Reticular layer: Part of the dermis which is *the thicker lower layer and extends from the base of the papillary layer to the subcutaneous tissue and is composed of thick collagen fibers that are arranged parallel to the surface of the skin.*

From Ovalle and Nahirney we also have the graphic and specific cellular slides presenting actual views of the details:



▼ **Strata of epidermis.**

▲ **LM of thick skin at the dermoepidermal junction.** A thick keratin layer characterizes the outermost stratum corneum. A dermal papilla that projects superficially into the epidermal region consists of loose connective tissue of the papillary layer. This layer contains many small blood vessels and a Meissner corpuscle (**MC**), which is an encapsulated touch receptor. 240×. *H&E.*



▲ **Higher magnification LM of the epidermis of thick skin.** The epidermis, a continually renewing epithelium, shows progressive differentiation and keratinization in a basal to superficial direction. Main features of its layers—strata basale (**SB**), spinosum (**SS**) (note prickle cells), granulosum (**SG**), and a small part of the corneum (**SC**)—are seen here. Part of the underlying dermis appears at the bottom. 575×. *H&E.*

© Elsevier. Ovalle & Nahirney: Netter's Essential Histology - www.studentconsult.com

The Figure above shows the detail of each of the respective layers.

We can now be more specific by each layer. Gartner and Hiatt have the following Table which gives detail on the cells from a histological perspective[83]:

---

[83] Gartner, L:., J. Hiatt, Color Textbook of Histology, Saunders (New York) 2007.

Layer	*Histological Features*
Epidermis	Derived from ectoderm; composed of stratified squamous keratinized epithelium (keratinocytes)
Stratum corneum	Numerous layers of dead flattened keratinized cells, keratinocytes, without nuclei and organelles (squames, or horny cells) that will be sloughed off.
Stratum lucidum	Lightly stained thin layer of keratinocytes without nuclei and organelles; cells contain densely packed keratin filaments and eleidin.
Stratum granulosum	A layer three to five cell layers thick; these keratinocytes still retain nuclei; cells contain large, coarse keratohyalin granules as well as membrane-coating granules.
Stratum spinosum	Thickest layer of epidermis, whose keratinocytes, known as prickle cells, interdigitate with one another by forming intercellular bridges and a large number of desmosomes; prickle cells have numerous tonofilaments and membrane-coating granules and are mitotically active; this layer also houses Langerhans cells.
Stratum basale (germinativum)	This single layer of cuboidal to low columnar, mitotically active cells is separated from the papillary layer of the dermis by a well-developed basement membrane; Merkel cells and melanocytes are also present in this layer.
Dermis	Derived from mesoderm; composed mostly of type I collagen and elastic fibers, the dermis is subdivided into two regions: the papillary layer and the reticular layer, a dense, irregular collagenous connective tissue.
Papillary layer	Interdigitates with epidermis, forming the dermal papilla component of the rete apparatus; type III collagen and elastic fibers in loose arrangement and anchoring fibrils (type VII collagen); abundant capillary beds, connective tissue cells, and mechanoreceptors are located in this layer; occasionally, melanocytes are also present in the papillary layer.
Reticular layer	Deepest layer of skin; type I collagen, thick elastic fibers, and connective tissue cells; contains sweat glands and their ducts, hair follicles and arrector pili muscles, and sebaceous glands as well as mechanoreceptors (such as pacinian corpuscles).

Let us now examine each layer more specifically. Our objective is first to understand what a normal skin looks like and then a malignancy.

9.1.1.1 Epidermis

The epidermis is the top layer of the skin.

It is composed of the following is composed of the following four layers (deep to superficial or from the bottom to the surface)[84]:

1. Basal layer: source of replacement cells and epidermal stem cells. The cells are generated here and the keratinocytes then migrate upward. Also the melanocytes are located here and send their tentacles and melanosomes upward from this layer. Normally melanocytes do not move from this point.

2. Spinous layer: center of epidermis that has a spiny appearance due to desmosomal junctions, area where keratinocytes produce keratin;

3. Granular cell layer: site of the epidermis' water barrier;

---

[84] http://missinglink.ucsf.edu/lm/DermatologyGlossary/index.html

4. Stratum corneum: thick outer layers of flattened keratinized non-nucleated cells that provide a barrier against trauma and infection. This layer shows dying or deal keratinocytes flaking off.

The details are below. Here we have the epidermis, composed of keratinocytes and the basal layer where we have melanocytes. The melanocytes have tentacles which grow through the keratinocyte layer and exude melanosomes, the dark pigmentation we see in colored skin patches. Below are the dermis and then the subcutis. The blood flow goes from arteries to veins and provides nutrients to the adjacent layers. A nevus will be seen as an agglomeration of melanocytes at the basal layer.



Habif defines the epidermis using a slightly different level of detail:

The epidermis is the outermost part of the skin; it is stratified squamous epithelium. The thickness of the epidermis ranges from 0.05 mm on the eyelids to 1.5 mm on the palms and soles. The microscopic anatomy of the epidermal-dermal junction is complex….

The innermost layer of the epidermis consists of a single row of columnar cells called basal cells. Basal cells divide to form keratinocytes, which comprise the spinous layer.

The cells of the spinous layer are connected to each other by intercellular bridges or spines, which appear histologically as lines between cells.

The keratinocytes synthesize insoluble protein, which remains in the cell and eventually becomes a major component of the outer layer (the stratum and corneum). The cells continue to flatten, and their cytoplasm appears granular (stratum granulosum); they finally die as they reach the surface to form the stratum corneum.

There are three types of branched cells in the epidermis: the melanocyte, which synthesizes pigment (melanin); the Langerhans cell, which serves as a frontline element in immune reactions of the skin; and the Merkel cell, the function of which is not clearly defined.

9.1.1.2 Dermis

In contrast the dermis is described as follows. The dermis is composed of cells, connective tissue, and ground substance and can contain blood and lymphatic vessels, nerves, glands, and hair follicles. It ranges from 1-4mm in thickness, making it much thicker than the epidermis. The dermis is divided into two layers: the papillary dermis and the reticular dermis. The papillary dermis is the region closest to the epidermis with papillae interdigitating with the epidermis; here, collagen fibers are thinner and loosely packed. In the deeper reticular dermis, collagen fibers are thicker and more densely and irregularly arranged. Elastin fibers are found in both the papillary and the reticular dermis, but they are more numerous within the latter.

Cutaneous appendages, like hair follicles, originate from the dermis. Blood vessels and nerves course through the dermis which supplies strength to the skin by its collagen and elastic fiber network. The vasculature to the skin is arranged in two plexi, the superficial plexus, located within the papillary dermis, and the deep plexus, located within the reticular dermis.

The basal layer is often seen as flowing in a wave like manner creating what are called Rete Ridges. We show them below:



Again quoting Habif we have:

The dermis varies in thickness from 0.3 mm on the eyelid to 3.0 mm on the back; it is composed of three types of connective tissue: collagen, elastic tissue, and reticular fibers.

*The dermis is divided into two layers: the thin upper layer, called the **papillary layer**, is composed of thin, haphazardly arranged collagen fibers; the thicker lower layer, called the **reticular layer**, extends from the base of the papillary layer to the subcutaneous tissue and is composed of thick collagen fibers that are arranged parallel to the surface of the skin.*

Histiocytes are wandering macrophages that accumulate hemosiderin, melanin, and debris created by inflammation. Mast cells, located primarily around blood vessels, manufacture and release histamine and heparin.

9.1.2 Some Basic Skin Architectural Elements

We now present some important specifics that will be incorporated in the description of melanoma.

9.1.2.1 Rete Ridges

Rete are a net or mesh of cells often at the bottom of the basal layer. As seen below they tend to extend downward and from time to time they may connect, anastamatose, but generally they are finger like extensions.

A microscopic description is as follows:

A. There are plump fibroblasts within the upper part of the dermis of this dome-shaped papule.

B. There is a proliferation of enlarged melanocytes arranged as solitary units and as nests within the epidermis, at the dermo-epidermal junction and down epithelial structures of adnexa.
There is marked solar elastosis.

If this biopsy captured the entire pigmented lesion this could be a junctional melanocytic nevus

9.1.2.2 Lentigenes

Lentigenes have a distinct histologic pattern of elongated, club-shaped rete ridges which often anastomose.



Lentigenes (which is the plural of lentigo) is a flat brownish spot on the skin resulting from excess melanin. Lentigo maligna is a macular (raised) patch. One can see the melanocytes in the basal layer as he clear cells.

9.1.2.3 Tumor Infiltrating Lymphocytes

Tumor infiltrating lymphocytes are lymphocytes which have left the blood stream and have infiltrated the cellular area. Melanomas frequently have TILs which is a good prognostic factor. We show from McKee and Calonje the examples of TILs.



We show a cell below demonstrating TILs. They are the dark spotted areas.



The following is the high power description.



9.1.2.4 Melanocytes

Melanoma is a cancer of the melanocyte. The normal condition of the melanocyte is to stay at the basal layer of the epidermis, with its dendritic arms moving upward and distributing melanosomes to the keratinocytes in response to ultra violet radiation. It is a protective function. The trouble starts when the melanocyte fails to stay put and to migrate and then to multiply.

We show a typical histological section below[85]:



This shows the typical structure comparable to what we have shown above.

The following is an example showing a prominent melanocyte[86]. Note at the basal layer, namely the bottom layer, we see a dark nucleolus with a clear cytoplasm. That is a single melanocyte, and there is another to its right. The melanocytes normally have a clear appearance, are at the basal layer and often have a prominent nucleus.



---

[85] http://pathology.mc.duke.edu/research/Histo_course/epi1.jpg

[86] http://pathology.mc.duke.edu/research/Histo_course/melanocyte.jpg

The above is a 200X magnification. One can see the keratinocytes building from the bottom of the basal layer and moving upward where they get squashed down and then slough off the surface. The melanocytes have a generally longer life cycle and they remain fixed.

In this section we look at the histology of the melanocyte. In many ways it differs from other cancers in that we can focus on the aberrant behavior of a single cell type, the melanocyte. In a benign state it belongs to the basal layer and should remain there. The melanocyte produces melanosomes for pigmentation. When it loses its normal control mechanism and starts to become a pre-malignant cell the melanocytes lose their location sense. They move from the basal layer to the epidermis and then can be called melanoma in situ. Then they spread outward from the basal layer and become superficial spreading melanoma. Then they start the vertical stage and that is when we see metastatic potential. We examine those stages herein.

We continue to examine the normal skin histology. The following slide details more structure of the normal skin[87]. It demonstrates the dermis structure as well, specifically the papillary and reticular dermis. :



The following shows another example of a melanocyte in normal skin[88]:

---

[87] http://missinglink.ucsf.edu/lm/DermatologyGlossary/normal_skin.html

[88] http://www.oucom.ohiou.edu/dbms-witmer/Downloads/Basic%20Skin%20Histology2-21-01.pdf

Again, in the above, we see the melanocyte in the basal layer, it has a clear cytoplasm and it has a prominent and round nucleolus.

9.2 HISTOLOGY

Melanoma is simply the uncontrolled growth, spread, and creation of immortal distorted melanocytes which have the capability to spread throughout the body and destroy the functioning of other normal benign cells. Malignant metastatic melanoma may spread to the lungs, brain, liver or other parts of the body, destroying the normal cells and in turn destroying the functions of the normal organ. In the brain the metastatic cells create clusters which push out the normal cells.

In a 1930 NEJM paper McKittrick states[89]:

Melanotic sarcoma. Melanotic sarcoma, or melanoma, may be quite varied in its clinical manifestations. It frequently arises in pigmented moles. Rarely is it noted in the intestinal tract. It may arise in any part of the body where there is pigmentation, and even in parts of the body where one does not commonly expect pigmentation.

Metastases as a rule are first to skin, later to the regional lymph nodes, lymph nodes elsewhere in the body, and ultimately, to nearly every organ in the body. Bony metastases are very rare. It is very difficult to determine which mole is sometime going to become a melanotic sarcoma and which one is not. Any pigmented lesion which shows any change in any way should be removed. Practically all of these lesions will show some change in character or in size before going into the malignant, metastasizing lesion, and if removed then, the patient may be cured. Another factor in deciding whether to remove or not is the location.

If the person has a pigmented mole or lesion which is located where constant irritation is unavoidable, I believe it should be removed unless it is so large that removal would be too

---

[89] McKittrick, L., Malignant Disease of the Skin, NEJM, Vol 202 No 15, pp 725-726, April 10, 1930.

disfiguring. There are two things to do for these pigmented moles on the skin. One is to leave them alone until there is some definite change or until something about them makes you feel

And the other is to take them suspicious out and to take them out well. Use no radium. No superficial cauterization. No diathermy. Take them out well with a wide margin of normal skin as though the lesion were already malignant. Leave them alone or else treat them right.

This recommendation is prescient. Namely, the physician should perform a wide area excision of any suspicious mole. There have been many cases, from then, even to the present, where the removal failed to be done properly. That of course has led to excess mortality.

As Crowson et al state:

Superficial spreading melanoma constitutes approximately 70% to 75% of all melanomas, and, though mainly found on the trunk and the sun-exposed areas of the upper arms and the lower legs, it may occur anywhere on the body surface... Therapeutic ultraviolet (UV) irradiation and use of tanning bed may play an etiological role. A Norwegian melanoma project carried out between 1989 and 1993 revealed that persons with red hair and skin type I/II were at increased risk of developing melanoma. Intermittent intense exposure to UV irradiation as in the context of beach vacation in adolescence, prior sun burns, or exposure to sunbeds and sunlamps is associated with increased risk, while chronic sun exposure may be protective.

Clinically, the incipient lesion is a dark-brown macule, a few milli-meters in size that gradually enlarges to reach an average size of 2.5 cm. However, marked variation in size may be noted with some lesions being as small as 4 mm and others as large as 8 to 10 cm. When fully evolved, the lesion has variegated color and irregular borders. The onset of the vertical growth phase is associated with the presence of a distinctive nodule.

Superficial spreading melanoma arises de novo in approximately 75% of the cases and, in the remainder, it is associated with a pre-existing nevus, including those of congenital and dysplastic nevus subtypes. Melanoma arising in a pre-existing dysplastic nevus is usually of superficial spreading type.

Cowden et al show the SSM radial phase as follows:



Regarding the above Cowden et al state:

Cells with an epithelioid cytomorphology grow in a haphazard, pagetoid fashion with single-cell dispersal through the epidermis to the cornified layer. The cells exhibit prominent nucleolation and high nuclear to cytoplasmic ratios. There is significant variability with respect to nuclear size and shape.

Note that pagetoid means upward spreading. One can see the large nucleoli clear melanocytes spreading upward to the top epidermal layer and we can see the irregular clusters and the irregular size as well as large nucleoli to cytoplasm ratios in all of these cells. This shows many of the general characteristics of all cancers; growth (increasing cell size), uncontrolled proliferation (mitotic activity), loss of location, namely the cells are not where they are supposed to be.

From Miller and Mihm we have the following Table which present examples of each type:

Histopathological Appearance	Description	Histologic Features
 Benign nevus	**Step 1** The first event is a proliferation of structurally normal melanocytes leading to the benign nevus. Clinically, these nevi present as flat or slightly raised lesions with either uniform coloration or a regular pattern of dot-like pigment in a tan or dark brown background. Histologically, such lesions have an increased number of nested melanocytes along the basal layer (arrows).	Proliferation of melanocytes Benign lesions
 Dysplastic nevi	**Step 2** The next step is the development of aberrant growth. This may occur within a preexisting benign nevus or in a new location. Clinically such lesions may be asymmetric, have irregular borders, contain multiple colors, or have increasing diameters. Histologically, such lesions have random and discontiguous cytologic atypia (arrows).	Dysplastic cells Random atypia
 Radial-growth phase	**Step 3** During the radial-growth phase, cells acquire the ability to proliferate intraepidermally. Clinically, they sometimes present as raised lesions. These lesions no longer display random atypia and instead show cytomorphologic cancer throughout the lesion. In addition to the intraepidermal cancer, the cells can penetrate the papillary dermis singly or in small nests but fail to form colonies in soft agar.	Intraepidermal growth Continuous atypia
 Vertical-growth phase	**Step 4** Lesions that progress to the vertical-growth phase acquire the ability to invade the dermis and form an expansile nodule, widening the papillary dermis. The cells can also extend into the reticular dermis and fat, are capable of growth in soft agar, and have the capacity to form tumor nodules when implanted in nude mice.	Dermal invasion
 Metastatic melanoma	**Step 5** The final step in the model is the successful spread of cells to other areas of the skin and other organs, where they can successfully proliferate and establish a metastatic focus. These cells can grow in soft agar and can form tumor nodules that may metastasize when implanted in nude mice.	Metastasis

Malignant Melanoma is a highly invasive cancer and has the propensity to metastasize to the brain as the primary site. This paper looks at the literature and evaluates the propensity of such metastases to result in psychotic behavior as the first presenting symptom. This paper focuses especially on those patients presenting after multiple recurrences of melanoma with extensive resection and with a recurrence on the head or neck. There is a significant body of literature linking the incidence of brain metastasis and extensive head and neck melanoma and there is also another body of literature linking brain tumors, including metastasis, to psychiatric changes.

We now look at several issues regarding malignant melanoma. These issues relate to the question of how frequently melanoma metastasizes to the brain and under what conditions and then in those metastasized lesions what are the presenting symptoms and finally how frequently the metastatic lesions may result in psychotic behavior. We approach this review by looking at each of the issues in some detail and then we proceed to review the literature to substantiate what is currently known in the field.

9.3 BIOMARKERS

Melanoma has several biomarkers. The challenge here is that initially the lesion is the prodrome and it is the target for initial treatment. However following up with a patient who has had an excision really requires biomarkers and we discuss a few here.

9.3.1 Genes

Melanoma has been studied for gene changes, mutations and activations. As Pinzani et al note :

Melanoma is one of the most aggressive cancers and is known for its rapid progression and poor prognosis in the advanced stages. Its incidence is steadily increasing among Caucasian populations.

Main risk factors include exposure to ultraviolet radiation, a history of sunburn, multiple common and atypical nevi, fair skin type, and genetic predisposition. Although it can be surgically cured if detected at early stages, survival rates are drastically low in the advanced disease. Melanoma arises through the gradual accumulation of molecular abnormalities and shows the highest mutation rate among all cancers.

The most significant driver mutations occur in BRAF, NRAS, NF1, and KIT genes.

Activating BRAF mutations are present in about 50% of cases, mainly at codon 600 with the V600E change, while oncogenic NRAS mutations are found in 15–25% of melanomas. Mutations in the other genes are less frequent. Treatment decision involves molecular analysis of driver mutations in the primary tumor or metastatic tissues, but the huge heterogeneity of the molecular changes occurring during the disease course make melanoma management difficult. Since 2011, few therapies approved for treatment of stage III and IV melanoma patients and in adjuvant setting have been introduced in clinical practice.

The use of target therapies (anti-BRAF and anti-MEK drugs) and immunotheraphies have improved the one year survival rate up to 75%. However, the emergence of drug resistance in the majority of patients for MAPK inhibitors and low but durable response rates for single-agent immune checkpoint inhibitors represent major limitations. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary.

Liquid biopsy has long been considered as a promising non-invasive method in melanoma management and might represent a valuable tool especially in high-risk patients with advanced stage tumor (IIc, III, and IV), particularly for patients with No Evidence of Disease (NED) or MRD status. The detection of CTCs and/or ctDNA in blood of melanoma patients might help in stratifying patients for therapies, predicting clinical outcomes, monitoring response, and progression. The existence of circulating melanoma cells was described for the first time in 1991 and since then many studies using different detection approaches have been performed, with conflicting results.

The main issue is that melanoma cells do not express EpCAM that is the classical marker of most CTC isolation strategies. Therefore, alternative approaches based on makerdependent-melanoma-specific antigens like MART-1, MAGE-A3, PAX-3, GalNac-T, HMW-MAA,CD146 (MelCAM), and MCAM- or marker-independent (based on large size or density of primary melanoma cells) strategies have been proposed.

The most innovative technologies of cellcapture include microfluidic chips and biosensors, the magnetic CellSearch® Circulating Melanoma Cell Kit, the dual-step protocol immune-magnetic sorting and subsequent dielectrophoretic DEPArray separation, and a new in vivo photoacoustic flow cytometry platform called "Cytophone". The presence of CTCs has been associated with tumor burden, as well as with decreased disease-free and OS rates in several studies.

More recently, the expression of PD-L1 on CTCs has been showed to predict the response to the anti-PD-1 pembrolizumab treatment in advanced melanoma. Instead, the utility of melanoma CTCs for the identification of actionable mutations is limited, since the use of enrichment methods can lead to the loss of CTC subpopulations, representing a bias in molecular definition of the disease. To date, 12 trials registered in the ClinicalTrials.gov database are evaluating the potential clinical application of melanoma CTCs. The majority of them are studying CTCs as biomarkers for monitoring therapy response and for predicting failure before clinical relapse, while the others are evaluating the association of CTCs with OS in patients with metastatic melanoma.

***Despite several experimental evidences, to date the utility of melanoma CTCs in clinical routine is still unclear due to the lack of robust and consistent results**.*

Indeed, the great diversity of markers used for enrichment, their low specificity, and the multiplicity of technical procedures reduces the significance of the obtained results.

In addition, as melanoma is a highly heterogeneous tumor, melanoma CTCs display different phenotypes and functional states resulting in expression of different markers.

Interestingly, Gorges et al. recently demonstrated that the mutational status of melanoma cells might influence the volume of CTCs and the expression of surface markers, representing a threatening bias for the clinical use. In addition to the direct detection of melanoma CTCs, indirect analysis of circulating nucleic acids has been studied. Indeed, the high prevalence of *oncogenic hot spot mutations and the availability of several highly sensitive technologies make melanoma an ideal candidate for the use of ctDNA as a biomarker.*

The analysis of ctDNA in melanoma patients, includes the detection of typical mutations in BRAF and NRAS genes, microsatellite alterations and epigenetic modifications such as DNA methylation. CtDNA evaluation has been proposed for the management and follow-up of patients with melanoma. Overall, the use of ctDNA for diagnostic purpose is not the priority in melanoma, since there is usually enough tumor tissue available for genetic analyses; therefore it is limited to cases of scarce material or when additional clinically relevant information, as clonality or tumor heterogeneity, need to be considered.

Monitoring melanoma course and predicting treatment outcomes represent the preferred uses of ctDNA for this cancer type. Several studies demonstrated a prognostic value, as high levels of ctDNA bearing the BRAFV600E mutation at melanoma diagnosis have been correlated with shorter PFS and OS.

9.3.2 Methylation

Methylation in melanoma cells has been identified. As Aleotti et al have noted:

DNA methylation, along with histone modifications and non-coding RNAs (ncRNAs), is classified as an epigenetic modification. Epigenetic modifications are defined as heritable alterations in gene expression that occur without modifying the DNA sequence. As is the case with several other physiological mechanisms, when improperly activated or silenced, it can affect the expression of oncogenes or tumor suppressor genes (TSGs), resulting in tumor initiation, development, and progression.

DNA methylation consists of the covalent addition of a methyl group (-CH3) to the fifth position of the pyrimidine ring of the cytosine nucleotide (5-methylcytosine, 5-mC). DNA methylation can putatively occur at any cytosine nucleotide in the genome, but its distribution is not random and is mostly restricted to the so-called CpG dinucleotides. CpGs are more abundant at gene promoters, where they tend to congregate and form CGIs.

Two main enzyme families are involved in a balanced and regulated manner in DNA methylation and demethylation processes. DNA methyltransferases (DNMTs), which establish and maintain methylation patterns , and ten-eleven translocation (TET) methylcytosine dioxygenases, which are involved in the demethylation pathway.

Under normal conditions, DNA methylation encompasses the entire genome, with the exception of short unmethylated regions within the CGIs. The deregulation of DNA methylation mechanisms, characterized mainly by hypermethylation of CGIs in TSG promoters or global loss of DNA methylation, is common in cancer. CGI hypermethylation in promoter regions has been shown to affect genes involved in the regulatory circuits that control cell proliferation and homeostasis, enabling malignant cells to sustain their abnormal growth. Cancer-associated promoter hypermethylation may affect between 5–10% of promoters containing CGIs. Global *loss of DNA methylation leads to molecular consequences that are advantageous to tumor development, including the generation of chromosomal instability…*

The authors then list the following genes which demonstrate hypermethylation:

Gene Symbol	Gene Name	Relevance to Melanoma
APC	Adenomatous Polyposis Coli	Decreased expression increases the proliferation potential of melanoma cells. Found in brain metastases in melanoma.
CDH11	Cadherin 11	The hypermethylated *CDH11* facilitates the scattering of tumor cells by loosening contacts between them. Increased proliferation following its inactivation may encourage further establishment at secondary sites, contributing to melanoma progression.
CDH13	Cadherin 13	The loss of CDH13 is involved in the development of malignant melanoma. Found in brain metastases in melanoma.
CDKN2A	Cyclin-Dependent Kinase Inhibitor 2A	The hypermethylated $pl6^{INK4A}$ promoter has been predominantly observed in NRAS-mutated metastatic melanomas.
CLDNU	Claudin 11	Its methylation level is a potential tool to help discriminate between malignant melanoma and nevus cell nevi.
DAPK	Death-Associated Protein Kinase	Detected in patients with both cutaneous and uveal melanoma: its epigenetic silencing is a common mechanism for tumor formation.
ESR1	Estrogen Receptor 1	The detection of methylated *ESR1* in tissues or sera correlates with tumor progression and is, therefore, of prognostic importance in melanoma patients. In addition, it may identify a population of patients with poor response to systemic therapy, for whom alternative treatment management should be considered.
FES	FES Proto-Oncogene, Tyrosine Kinase	Its downregulation correlates with poor OS. FES loss drives tumor progression of BRAF V600E-induced murine melanoma.
MAPK13	Mitogen-Activated Protein Kinase 13	Its epigenetic silencing contributes to melanoma progression: restoration of its expression in melanoma cells with *MAPK13* promoter methylation reduces these cells' proliferative capacity.
MEOX2	Mesenchyme Homeobox 2	This gene's degree of DNA methylation can predict the prognosis of melanoma patients. Its methylation is associated with melanoma progression and/or poor survival.
MGMT	06-Methylguanine-DNA Methyltransferase	Its epigenetic silencing was associated with a better response to DTIC/TMZ therapy and longer PFS in patients with stage IV melanoma and patients with stage III melanoma treated with melphalan locoregional chemotherapy.
M1TF	Melanocyte Inducing Transcription Factor	The *M1TF* gene body was found to be hypermethylated in primary tumors compared to metastases.
OLIG3	Oligodendrocyte Transcription Factor 3	This gene's degree of DNA methylation can predict the prognosis of melanoma patients. Its methylation is associated with melanoma progression and/or poor survival.
OVOL1	Ovo Like Transcriptional Repressor 1	Patients with high OVOL1 expression in the primary tumor had a significantly better prognosis than those with low expression.
PD-L1	Programmed Cell Death 1 Ligand 1	Decreased PD-L1 expression correlates with a shorter patient OS.

Gene Symbol	Gene Name	Relevance to Melanoma
PON3	Paraoxonase 3	This gene's degree of DNA methylation can predict the prognosis of melanoma patients. Its hypermethylation is significantly elevated in patients with metastatic melanoma.
PTEN	Phosphatase And Tensin Homolog	Reduced OS and DFS in stage III/IV patients. Found in brain metastases in melanoma.
RARp2	Retinoic Acid Receptor Beta 2	Correlated with Breslow thickness of the primary tumor: its silencing may be a key epigenetic factor in melanocyte transformation and progression of the primary lesion. Found in brain metastases in melanoma.
RASSF2A	Ras-Association Domain Family Member 1	Detected in patients with cutaneous and uveal melanoma. It can predict the response of patients with stage IV melanoma to biochemotherapy. Found in brain metastases in melanoma.
SOCS1/2	Suppressor of Cytokine Signaling 1/2	Frequently found hypermethylated in the serum of melanoma patients or melanoma cell lines.

It is then possible to examine the gene products or mRNA to assess the status of methylation.

10 OBSERVATIONS

This has been an extensive tutorial and overview. The intent of the tutorial portions was to provide a common framework for the details in the specific targets discussed. We know that as time goes by many more "targets" are found and putatively stated as key targets. The results are still problematic. We have focused upon five cancers in an attempt to provide some substance[90].

There are several observations worthy of note.

10.1 THERE IS A PLETHORA OF TARGETABLE MIRNAS. IT WILL BE ESSENTIAL TO UNDERSTAND THE IMPACT THAT EACH HAS LEADING TO A MALIGNANCY AND METASTASIS.

As we scan the previous miRNA targets we see that they are quite extensive. They can be relatively easy to detect but their functions in terms of the cancers involved are less that well understood. Are there just incidental findings and is there an overlap of miRNAs across various malignancies. The concern is that we may just have too many miRNAs.

10.2 IT APPEARS THAT MANY OF THE TARGETS HAVE BEEN DISCOVERED AS AN INCIDENTAL FINDING. THERE APPEARS TO BE A LACK OF WELL ACCEPTED DISCOVERY AND VALIDATION PROCESS.

Incidental findings are all too common. Namely we may see miRNAs in certain lesions but their presence is just incidental and neither causal or supportive.

10.3 THE SENSITIVITY AND SPECIFICITY OF ANY AND ALL OF THESE TESTS IS LESS THAN NECESSARY. HOW CAN THIS BE IMPROVED AND WHY ARE THEY SO POOR CURRENTLY.

Every one of the tests has less than sterling performance. A few may be reasonable but having a sensitivity of 60-70% means we are missing a great deal.

10.4 THE TARGETS WHICH RELATE TO A MALIGNANCY MAY ALSO BE THERAPEUTIC TARGETS. IF SO, HOW CAN THIS BE APPROACHED?

Targets can in some cases become vehicles to seek therapeutic targets as well. There does not seem to be a great deal of effort yet in this area.

---

[90] In 2019 we provided an update on exosomes and cancer https://www.researchgate.net/publication/331318495_Exosomes_and_Cancer and in 2016 we did a detailed analysis of biomarkers for PCa and in 2014 we did an analysis of biomarkers for melanoma https://www.researchgate.net/publication/325046957_ENDOSOMES_AND_MELANOMA and in 2013 we wrote about oncosomes and PCa on some of the early applications.

10.5 EPIGENETIC FACTORS HAVE A HISTORY OF BEING SIGNIFICANT, MANY IN CANCERS. CAN THESE FACTORS BE EVIDENT IN BODY FLUID BIOMARKER ANALYSIS.

Epigenetics is a powerful element in terms of understanding the biomarkers. It is complex, still a work in progress, and a driver for many cancers.

10.6 CAN AN EFFICIENT, EFFECTIVE, AND COMPREHENSIVE BIOMARKER ANALYSIS SYSTEM BE DEVELOPED. THE CHALLENGE IS THAT WITH SO MANY DISPARATE METRICS IT MEANS A HIGHLY COMPLEX, COSTLY AND LONG TIMED SET OF PROCESSES. HOW CAN THIS BECOME IMPROVED.

When sending blood for a CBC or CMP we have standard tests which can return results quickly and at low costs. However when examining biomarkers the tests are disparate, costly, and take considerable skill and time. Also there are no standardized reporting metrics. This may very well be the greatest issue we can see.

10.7 GENES, VS PROTEINS, VS MRNA, VS MIRNA, VS CIRCRNA, VS LNCRNA, VS METHYLATION, VS FUSION PANELS, ETC

As we went through the five malignancies we saw a massive number of putative markers. Some can be straightforward other are highly complex. Should one focus on a single one, a class, and complex grouping? Is just presence or absence appropriate or must one try to assess density or concentration?

10.8 METRICS FOR CLASSIFICATION ARE COMPLEX AND SOME OFFER ADVANTAGES, OTHERS UNCERTAINTIES.

Classification is a complex process and given the mass of data we have an even more complex issue. It is worth reviewing the classifiers that can be developed.

10.9 IS THERE A ROLE FOR SOME AI METHODOLOGY?

As I have noted previously, I am not a fan of AI. It is merely a sorting and weighting set of algorithms based upon some selected learning set. However in this case if one chooses the putative targets well enough then perhaps an AI methodology can assert the best classification metric.

11 REFERENCES

1. Abba, M., et al, MicroRNAs in the Regulation of MMPs and Metastasis, Cancers 2014, 6, 625-645; doi:10.3390/cancers6020625.
2. Abbas, A., A., Lichtman, Cellular and Molecular Immunology, 10th Ed, Elsevier (New York) 2022.
3. Abenoza, P., A. B. Ackerman, Neoplasms with Eccrine Differentiation, Lea & Febiger (Philadelphia) 1990.
4. Abraham et al, Autophagy as a Possible Target for Cancer Therapy, J Orthop Oncol 2018, 4:2
5. Abraham, R., Cell cycle checkpoint signaling through the ATM and ATR kinases, Genes & Development 15:2177–2196, 2001
6. Abrahamsson, P., D. Bostwick, The Biological Nature of Prostate Cancer, to be published 2010 (Univ Malmo Sweden).
7. Ackerman, A. B., et al, Differential Diagnosis in Dermatopathology, Lea & Febiger (Philadelphia) 1988.
8. Aggarwal. A., Histopathology of the Skin, Jaypee (New Delhi) 2007.
9. Ahn, K., Transcription Factor NF-kB, Ann NY Aca Sci, V 1056, 2005, pp 218-233.
10. Ailles, L., I. Weissman, Cancer Stem Cells in Solid Tumors, Curr Opp in Biotech, 2007, pp 460-466.
11. Alarcon-Zendejas et al, The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches, Nature, Prostate Cancer and Prostatic Diseases, 14 April 2022
12. Alberts et al, Molecular Biology of the Cell, Garland (New York) 2010.
13. Aleotti et al, Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy, Cancers 2021, 13, 6217
14. Ali and Cibas, The Bethesda System for Reporting Thyroid Cytopathology, Springer, 2018
15. Alix-Panabières and Pantel, Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy, May 2016, Cancer Discovery, , 479
16. Al-Johi et al, Diffusion weighted magnetic resonance imaging in bladder cancer, is it time to replace biopsy? Central European Journal of Urology, 2018: 71: 31-37.
17. Alles et al, An estimate of the total number of true human miRNAs, Nucleic Acids Research, 2019, Vol. 47, No. 7 3353–3364
18. Allis, C., et al, Epigenetics, 2nd Ed, CSH (Cold Spring Harbor) 2015
19. Allis, C., et al, Epigenetics, CSH (Cold Spring Harbor) 2007.

20. Alonzo, T., Verification Bias corrected estimators of relative true and false positives of two binary screening tests, Stat in Med 2005 pp 403-417.
21. Amiji and Ramesh, Diagnostic and Therapeutic Applications of Exosomes in Cancer, Academic, 2018
22. Amiri, K., A. Richmond, Role of nuclear factor-κB in melanoma, Cancer Metastasis Rev. 2005 June ; 24: 301–313.
23. Anastasiadou, E., F. Slack, Malicious exosomes, Science, 19 December 2014 Science Vol 346 ISSUE 6216, pp 1459-1460.
24. Andaloussi et al, Extracellular vesicles: biology and emerging therapeutic opportunities, Nature Reviews Drug Discovery volume 12, pages 347–357 (2013)
25. Ando, S., H. Iba, Quantitative Modeling of Gene Regulatory Network, Univ Tokyo.
26. Andriole, G., et al, Mortality Results from Randomized Prostate Cancer Screening Trial, NEJM, 2009 V 360 pp 1310-1319.
27. Appasani, MicroRNAs, Cambridge (New York) 2008.
28. Appasani, MicroRNAs. Cambridge, 2008
29. Araud, T., Overview of the miRNA Pathways, Thesis, U Geneva, 2008.
30. Armstrong, L., Epigenetics, Garland (New York) 2014.
31. Asadi, F., R. Sharifi, Effects of Sex Steroids on Cell Growth and C myc Oncogene Expression in LN-CaP and DU-145 Prostatic Carcinoma, Int Uro and Neph, V 27, 1995, pp 67-80.
32. Asangani, I. A. et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 49, 80–93 (2013).
33. Atefi, M., et al, Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway, PLoS ONE, www.plosone.org, December 2011, Volume 6, Issue 12.
34. Augustin, H., et al, Prostate Cancers in the Transition Zone Part II, BJU Inter V 94 2004 pp 1226-1229.
35. Austin, R., et al, Role of Hyperhomocysteinemia in Endothelial Dysfunction, Cell Death and Diff 2004 pp 556-564.
36. Ayala, G., et al, High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and No Neoplastic Prostate Tissues are Strong Predictors of Biochemical Recurrence, Clin Can Res, V 10, 2004, pp 6572-6578.
37. Aytes et al, NSD2 is a conserved driver of metastatic prostate cancer progression, Nature Communications, 2018, 9:5201
38. Azzato, E., et al, Common germ line polymorphisms of C1QA and breast cancer survival, Br Jrl Can 2010, pp 1294-1299.
39. Baas, A., et al, Complete Polarization of Single Intestinal Epithelial Cells upon Activation of LKB1 by STRAD, Cell, Vol. 116, 457–466, February 6, 2004.

40. Babchia, N., et al, The PI3K/Akt and mTOR/P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK, Investigative Ophthalmology & Visual Science, January 2010, Vol. 51, No. 1.
41. Bader, A. et al, Developing therapeutic microRNAs for cancer, Gene Therapy, 2011, V 18.
42. Bagheri et al, Advances in medical imaging for the diagnosis and management of common genitourinary cancers, Urol Oncol. 2017 July; 35: 473–491
43. Baker et al, MicroRNA profiling: separating signal from noise. Nature Methods 7, 687–692.
44. Baker, C.A.H., et al, GeneVis: Visualization Tools for Genetic Regulatory Network Dynamics, Univ Calgary.
45. Baker, M. Long noncoding RNAs: the search for function, Nature Methods, VOL.8 NO.5, May 2011, p, 379.
46. Balch, C., et al, Cutaneous Melanoma, Quality (St Louis) 1998.
47. Baldo, P., et al, mTOR Pathway and mTOR inhibitors as Agents for Cancer Therapy, 2008, Curr Can Drug Targets, pp 647-668.
48. Ballo, MT, Ross, MI, Cormier, JN, et al. Combined-modality therapy for patients withregional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 2006; 64:106.
49. Bankhead, C, Melanoma Survival Benefit Called 'Astounding' MedPage; http://www.medpagetoday.com/Oncology/SkinCancer/30413
50. Baquero, et al, Targeting quiescent leukemic stem cells using second generation autophagy inhibitors, Leukemia, Nature, https://doi.org/10.1038/s41375-018-0252-4
51. Barbar, I., F. Slack, MicroRNAs in Cancer, Clin Onco, 2007.
52. Bartel, D., MicroRNAs: Target Recognition and Regulatory Functions, Cell, V 136 Jan 23, 2009, p 215.
53. Bard et al, Image Guided Prostate Cancer Treatments, Springer, 2014
54. Barnett, S., et al, Identification and characterization of pleckstrin-homology-domain dependent and isoenzyme-specific Akt inhibitors, Biochem. J. (2005) 385, 399–408 (Printed in Great Britain) p 399.
55. Barnhill, R., et al, Pathology of Melanocytic Nevi and Malignant Melanoma, Springer (New York) 2004.
56. Barrett, What is multiparametric-MRI of the prostate and why do we need it?, Imaging Med. (2015) 7
57. Barry, M., Screening for Prostate Cancer among Men 75 Years of Age and Older, NEJM, 2008, V 359, pp 2515-2516.
58. Bartel, D., MicroRNAs: Genomics, Biogenesis, Mechanism, and Function, Cell 2004 pp 281-297.
59. Bartel, D., MicroRNAs: Target Recognition and Regulatory Functions, Cell, V 136 Jan 23, 2009, p 215.

60. Batchelor, J., MEK and BRAF Therapy Combo Promise for Advanced Melanoma, http://www.onclive.com/conference-coverage/asco-2011/MEK-and-BRAF-Therapy-Combo-Promising-for-Advanced-Melanoma , 2011
61. Bax et al, Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways, Cancers 2019, 11, 1244
62. Beaty et al, Bladder Endometriosis: Ultrasound and MRI Findings, Radiology Case Reports , Volume I, Issue 3, 2006
63. Becker et al, Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis, Cancer Cell 30, December 12, 2016
64. Beekman, J., P. Coffer, The ins and outs of syntenin, a multifunctional intracellular adaptor protein, Journal of Cell Science 121, 1349-1355 Published by The Company of Biologists 2008.
65. Begg, C., R. Greenes, Assessment of Diagnostic Tests when Disease Verification is Subject to Selection Bias, Biometrics 1983 V 39 pp 207-215.
66. Bellomo, N., et al, Selected Topics in Cancer Modelling, Birkhauser (Boston) 2008.
67. Bennett, D., How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21; 27–38, 2008
68. Bennett, R. L., Swaroop, A., Troche, C., & Licht, J. D., The role of nuclear receptor-binding SET domain family histone lysine methyltransferases in cancer. Cold Spring Harb. Perspect. Med. 7, a026708 (2017).
69. Benson D. L., Unraveling the Turing Bifurcation Using Spatially Varying Diffusion Coefficients, Jour Math Bio, Vol 37 1998, pp. 381-417.
70. Benvenuti, S., P., Comoglio, The MET Receptor Tyrosine Kinase in Invasion and Metastasis, J. Cell. Physiol. 213: 316–325, 2007
71. Berger, M., et al, Melanoma Genome Sequencing Reveals Frequent PREX2 Mutations, Nature, May 2012.
72. Berghe W., Epigenetic impact of dietary polyphenols in cancer chemoprevention: Lifelong remodeling of our epigenomes, Pharmacological Research 65 (2012) 565– 576
73. Berthelot and Terrat, Petri Nets Theory for the Correctness of Protocols, IEEE Trand Comm Dec 1982.
74. Biechele, T., et al, Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma, Sci. Signal., 10 January 2012 Vol. 5, Issue 206, p. ra3.
75. Binder RL. Neurologically silent brain tumors in psychiatric hospital admissions: three cases and a review. J Clin Psychiatry. 1983 Mar; 44:94-7.
76. Birkfeliner, Applied Medical Image Processing, CRC, 2011
77. Biro, A., Class III Phosphoinositide 3-kinase in Melanoma, Thesis, Univ Basel, 2011.

78. Bloomston, M., et al, TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo, Excerpta Medica, Am Jrl Surgery, 2005, pp 675-679.

79. Boiko, A., et al, Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor, Nature V 466 pp 133-137, 2010.

80. Bolouri, H., Computational Modeling of Gene Regulatory Networks, Imp Coll Lon Press (London) 2008.

81. Botti et al, Paralogous HOX13 Genes in Human Cancers, Cancers 2019, 11, 699

82. Bouchelouch et al, PET/CT and MRI in Bladder Cancer, Cancer Sci Ther 2012, S14

83. Boudeau J., et al, Analysis of the LKB1-STRAD-MO25 complex, Journal of Cell Science 117, 6365-6375 Published by The Company of Biologists 2004.

84. Boukerche H., et al., Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-κB, Oncogene. 29:3054-66, 2010 May 27.

85. Boukerche, H. et al, mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src, pp 15914–15919, PNAS, October 14, 2008, vol. 105, no. 41.

86. Boumber, Y., et al, Epigenetics in Cancer: What's the Future?, ONCOLOGY. Vol. 25 No. 3 March 16, 2011

87. Bourneuf, E. et al, Genetic and functional evaluation of MITF as a candidate gene for cutaneous melanoma predisposition in pigs, Mamm Genome, May 2011.

88. Bousquet , M., MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA, Haematologica , 2012; 97

89. Braicu et al, Clinical and pathological implications of miRNA in bladder cancer, International Journal of Nanomedicine 2015:10 791–800

90. Braicu, C., et al, Exosomes as divine messengers: are they the Hermes of modern molecular oncology?, Cell Death and Differentiation (2015) 22, 34–45

91. Brinster, N., et al, Dermatopathology, Elsevier (New York) 2011.

92. Brooks, C., W. Gu, How does SIRT1 affect metabolism, senescence and cancer?, Nature Reviews Cancer 9, 123-128 (February 2009)

93. Brooks, J., et al, CG Island Methylation Changes Near the GSTP1 Gene in Prostatic Intraepithelial Neoplasia, Can Epid 1998, pp 531-536.Donkena, K., et al, Oxidative Stress and DNA Methylation in Prostate Cancer, Ob & Gyn Internat 2010, pp .

94. Brower, V. Unravelling the cancer code, 24 March 2011, Vol 471, NATURE.

95. Brown and Semelka, MRI Basics, Principles and Applications, Wiley, 2003.

96. Buchsbaum, JC, Suh, JH, Lee, SY, et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002; 94:2265.

97. Buhmeida, A., et al, Prognostic Factors in Prostate Cancer, Diag Path 2006 pp 1-15.

98. Bunz, Principles of Cancer Genetics, Springer, 2008

99. Burke et al, A Fluorescence in Situ Hybridization Method To Quantify mRNA Translation by Visualizing Ribosome−mRNA Interactions in Single Cells, ACS Cent. Sci. 2017, 3, 425−433

100. Bushberg et al, The Essential Physics of Medical Imaging, Wolters, 3rd Ed, 2012

101. Bussemakers, M., et al, DD#: A New Prostate specific Gene, Am Assn Cancer Res, 1999.

102. Bustin et al, MIQE précis: Practical implementation of minimum standard guidelines for fluorescence based quantitative real-time PCR experiments, BMC Molecular Biology 2010, 11:74

103. Bustin et al, The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments, Clinical Chemistry 55:4, 2009

104. Cabili, M.N., Trapnell, C., Goff, L., Koziol, M., Tazon-Vega, B., Regev, A., and Rinn, J.L. (2011). Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25,1915-1927.

105. Calin, G., C. Croce, Chromosomal Rearrangements and Micro RNAs, Jrl Clin Inv 2007 pp 2059-2066

106. Calin, G., C., Croce, MicroRNA signatures in human cancers, Nature Reviews , Cancer Volume 6 , November 2006 , 857.

107. Campbell, A., L. Heyer, Genomics, Proteomics, and Bioinformatics, Benjamin Cummings (New York) 2003.

108. Campisi, J., et al, Cellular senescence, cancer and aging: the telomere connection, Exp Geront V 36 pp 1619-1637, 2001.

109. Cantley ey al, Signal Transduction, CSHL Press, 2014

110. Cardoso et al, Corticotropin-Releasing Hormone (CRH) Gene Family Duplications in Lampreys Correlate With Two Early Vertebrate Genome Doublings, Frontiers in Neuroscience , www.frontiersin.org 1 July 2020 , Volume 14 , Article 672

111. Carrecedo, A., et al, PTEN Level in Tumor Suppression, How Much is Too Little?, Cancer Res; 71; pp. 629–33. 2011.

112. Carter, H., et al, Recommended Prostate Specific Antigen Testing Intervals, JAMA 1997, V 277, pp 1456-1460.

113. Carthew and Sontheimer, Origins and Mechanisms of miRNAs and siRNAs, Cell, Feb 2009

114. Cassimeris, L., et al, Lewin’s Cell, 2nd Ed, Jones and Bartlett (Boston) 2011.

115. Catalona, W., et al, Prostate Cancer Detection in Men, JAMA, 1997 V 277, pp 1452-1455.

116. Causton, H. et al, Microarray Gene Expression and Analysis, Blackwell (Malden, MA) 2003.

117. Chandran, U., et al Gene Expression Profiles of Prostate Cancer Reveal Involvement of Multiple Molecular Pathways in Metastatic Process, BMC Cancer, 2007 1-21.

118. Chapman, P., et al, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, NEJM, 2011, pp 1-9.

119. Chario, A., et al, The NF-κB-independent functions of IKK subunits in immunity and cancer, Trends in Cell Biology Volume 19, Issue 8, August 2009, Pages 404–413.

120. Chen, H., et al, NKX3.1 Interacts with Prostate Derived ETS Factor and Regulates the Activity of PSA Promoter, Can Res, V 63, 2002, pp 330-340.

121. Chen, P., J. Chen, A Markovian Approach to the Control of Genetic Regulatory Networks, Bio Sys, 2007 PP 535-545.

122. Chen, T., et al, Modeling Gene Expression with Differential Equations, Pacific Symposium on Biocomputing, 1999 pp. 29-40.

123. Cheng, C. Y., et al, miR-34 Cooperates with p53 in Suppression of Prostate Cancer by Joint Regulation of Stem Cell Compartment, Cell Reports (2014), http://dx.doi.org/10.1016/j.celrep.2014.02.023

124. Chiu et al, Critical role of SOX2–IGF2 signaling in aggressiveness of bladder cancer, Scientific Reports, (2020) 10:8261

125. Chow, L. et al, PTEN Function in Normal and Neoplastic Growth, Cancer Ltr, V 241, 2006, pp 184-196.

126. Chudnovsky, Y., et al, Use of human tissue to assess the oncogenic activity of melanoma-associated mutations, Nat Genet. 2005 Jul;37:745-9. Epub 2005 Jun 12.

127. Ciechanover , A, Intracellular Protein Degradation: From a Vague Idea through the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting, Rambam Maimonides Medical Journal, January 2012, Volume 3, Issue 1.

128. Clarke, R., New Genomic Structure for Prostate Cancer Specific Gene PCA3 within BMCC1, Plus One March 2008.

129. Clevers, The Cancer Stem Cell: Premises, Promises, and Challenges, Nature Med V 17 March 2011, p 313.

130. Cloonan, Re-thinking miRNA-mRNA interactions: Intertwining issues confound target discovery, Bioessays 37: 379–388, 2015

131. Cohen, R., et al, A Proposal on the Identification, Histologic Reporting, and Implications of Intraductal Prostatic Carcinoma, Arch Path Lab Med, V 131, 2007. pp 1103-1109.

132. Coleman CN, Kelly L, Reise Daly N, Beard C, Kaplan I, Lamb C, Propert K, Manola J. Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects. IJROBP (2002 Sep 1) 54:191-4

133. Colomer et al, Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology, Clin Transl Oncol (2018) 20:815–826

134. Coppola, V., et al, MicroRNAs and Prostate Cancer, Endo Rel Canc 2010 pp F1-F17.

135. Costa, F., et al, Concise Review: Cancer Testis Antigens, Stem Cells and Cancer, Stem Cells 2007 pp 707-711.

136. Cox RL; Crawford ED Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology 1995 Jun;45:932-5)

137. Crampin, E., et al, Extracting Biochemical Reaction Kinetics from Time Series Data, LNAI 3214 pp 329-336 2004 Springer Verlag.

138. Cristofani et al, Dual role of autophagy on docetaxel sensitivity in prostate cancer cells, Cell Death and Disease (2018) 9:889

139. Croce, C., Causes and Consequences of microRNA Dysregulation in Cancer, Nature 2009 pp 704-714.

140. Croce, Oncogenes and Cancer, NEJM, Jan 31 2008

141. Cronin, A., A., Vickers, Statistical Methods to Correct for Verification Bias, BMC Med Res Meth 2008 V 8 pp 2-9.

142. Crosby, Delivering on the promise of early detection with liquid Biopsies, British Journal of Cancer, 2022

143. Crowson, A., et al, Biopsy Interpretation of the Skin, Lippincott (New York) 2012.

144. Cucchiara, et al, Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy, Cancers 2017, 9, 9;

145. Cumberbatch et al, Epidemiology, aetiology and screening of bladder cancer, Transl Androl Urol 2018

146. Curtin, J., et al, Distinct Sets of Genetic Alterations in Melanoma, NEJM, 2005 pp 2135-2147.

147. da Silva, H., et al, Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer, Hindawi Publishing Corporation Prostate Cancer Volume 2013, Article ID 920612, 23 pages

148. Dagvodorj, A., et al, Transcription Factor Signal Transducer and Activator of Transcription 5, Clin Can Res, V 14, 2008, pp 1317-1324.

149. Dahia, P., PTEN, a Unique Tumor Suppressor Gene, Endo Rel Can, V 7 2000, pp 115-129.

150. Dahlman, A., et al, Effect of Androgen Deprivation Therapy on the Expression of Prostate Cancer Biomarkers, Pros Can and Prost Dis 2010 pp 1-7.

151. Dai et al, Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing, European Journal of Endocrinology (2020) 182, 111–121

152. Dalerba, P., et al, Cancer Stem Cells: Models and Concepts, Stem Cells, 2008 pp 267-284.

153. Dalerba, P., Robert W. Cho, and Michael F. Clarke, Cancer Stem Cells: Models and Concepts, Annu. Rev. Med. 2007. 58:267–84.

154. D'Amico AV; Schnall M; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A. Endorectal Coil Magnetic Resonance Imaging Identifies Locally Advanced Prostate Cancer In Select Patients With Clinically Localized Disease. Urology 1998 Mar;51:449-54.

155. D'Amico, A., et al, Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy, NEJM, V 351, 2004, pp 125-135.

156. Dang and Kim, Convergence of Cancer Metabolism and Immunity: an Overview, Biomol Ther 26(1), 4-9 (2018)

157. Dang X, et al, MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells, Cancer Genet. 2012 Mar;205:113-23. doi: 10.1016/j.cancergen.2012.01.002.

158. Daraselia, N., et al, Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers, Am J Cancer Res, 2012.

159. Darling et al, Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma, Adv Ther (2017) 34:1087–1096

160. Das S., et al, MDA-9/syntenin: a positive gatekeeper of melanoma metastasis, Frontiers in Bioscience 17, 1-15, January 1, 2012.

161. Das, P., R., Singal, DNA Methylation and Cancer, Journal Of Clinical Oncology, Volume 22, Number 22, November 15 2004.

162. Das, S., et al, Therapeutics, Targets, and Chemical Biology Raf Kinase Inhibitor RKIP Inhibits MDA-9/Syntenin-Mediated Metastasis in Melanoma, Cancer Res Published Online First October 11, 2012.

163. Davies, M., The Role of the PI3K-AKT Pathway in Melanoma, The Cancer Journal & Volume 18, Number 2, March/April 2012.

164. de la Taille, A. et al, The Pca3 Assay Improves The Prediction Of Initial Biopsy Outcome And May Be Indicative Of Prostate Cancer Aggressiveness, 1 Chu Henri Mondor, Paris, France; 2 CHU.

165. De Long et al, A non-invasive miRNA based assay to detect bladder cancer in cell-free urine, Am J Transl Res 2015;7:2500-2509

166. de Souza et al, Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer, PLOS ONE, 14 Sept 2017

167. Dearnaley DP; Khoo VS; Norman AR; Meyer L; Nahum A; Tait D; Yarnold J; Horwich A. Comparison Of Radiation Side-Effects Of Conformal And Conventional Radiotherapy In Prostate Cancer: A Randomized Trial. Lancet 1999 Jan 23;353(9149):267-72

168. DeFranco, A., et al, Immunity, Sinauer (Sunderland, MA) 2005.

169. Dehaia, P, PTEN, a unique tumor suppressor gene , Endocrine-Related Cancer (2000) 7 115–129,

170. Deleyrolle, et al, Determination of Somatic and Cancer Stem Cell Self-Renewing Symmetric Division Rate Using Sphere Assays, PLOS January 2011,

171. DeMarzo, A., et al, Inflammation in Prostate Carcinogenesis, Nature Rev Cancer 2007 pp 256-269.

172. DeMarzo, A., et al, Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Theraputic Targets, Int Soc Uro Path 2008.

173. DeMarzo, A., et al, Pathological and Molecular Aspects of Prostate Cancer, Lancet, V 361, 2003, pp 955-964.

174. Demichelis, F., et al, Distinct Genomic Aberrations Associated with ERG Rearranged Prostate Cancer, Gene, Chromo, Cancer, V 48, 1999, pp 366-380.

175. Demichelis, F., et al, TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort, Onco 2007 pp. 1-4.

176. Denny et al, Exploring autophagy with Gene Ontology, Autophagy, 2018, Vol. 14, No. 3, 419–436

177. Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., Guer-nec, G., Martin, D., Merkel, A., Knowles, D.G., et al. (2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22, 1775-1789.

178. DeSemir, D et al, Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis, www.pnas.org/cgi/doi/10.1073/pnas.1119949109 PNAS Early Edition, 2012.

179. Detours, V., Opinion: Confounded Cancer Markers, http://the-scientist.com/2011/12/07/opinion-confounded-cancer-markers/

180. Deutsch, E., et al, Environmental. Genetic, and Molecular Features of Prostate Cancer, Lancet, 2004, pp 303-313.

181. DeVita, Hellman, and Rosenberg, Cancer: Principles & Practice of Oncology, 9e, Lippincott (New York) 2011.

182. DeVita, Hellman, and Rosenberg, Cancer: Principles & Practice of Oncology, 8th Ed, Lippincott (New York) 2008.

183. DeVita, Hellman, and Rosenberg, Cancer: Principles & Practice of Oncology, 10th Ed, Lippincott (New York) 2019

184. DeVita, Primer of the Molecular Biology of Cancer, Wolters Kluwer, 2011

185. Dhawan, Medical Image Analysis, IEEE, 2011

186. di Bernardo, D., et al, Chemogeneomic Profiling on a Genome Wide Scale Using Reverse Engineered Gene Networks, Nature Biotech, V 23, 2005, pp 377-383.

187. Di Sante, G., et al, Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria

188. Diamond, J., et al, The Use of Morphological Characteristics and Texture Analysis in the Identification of Tissue Composition in Prostatic Neoplasia, Human Path, V 35, 2004, pp 1121-1131.

189. Djebbari, A., J. Quackenbush, Seeded Bayesian Networks, BioMed Cent Sys Bio 2008 pp 1-13.

190. Dobi, A., et al, ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor, Open Cancer Jrl, V 3, 2010, pp 101-108.

191. Dominy, J., et al, The Deacetylase Sirt6 Activates the Acetyltransferase GCN5 and Suppresses Hepatic Gluconeogenesis, Molecular Cell 48, 900–913, December 28, 2012

192. Donkena K., et al, Oxidative Stress and DNA Methylation in Prostate Cancer, Obs & Gyn Int 2010, pp.

193. Dreesen, O., A., Brivanlou, Signalling Pathways in Cancer and Embryonic Stem Cells, Stem Cell Rev, 2007.

194. Driscoll, M., T. Gardner, Identification and Control of Gene Networks in Living Organisms, Jrl Proc Contrl 2006 pp 303-311.

195. Duan and Allard, Insulin-Like Growth Factor Binding Protein-5 in Physiology and Disease, Front. Endocrinol., 03 March 2020

196. Dudley et al, Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA, Cancer Discovery, April 2019

197. Eades et al, miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells, The Journal Of Biological Chemistry Vol. 286, No. 29, pp. 25992–26002, July 22, 2011

198. Easton, J., P. Houghton, mTOR and Cancer Therapy, Oncogene, 2006, pp 6436-6446.

199. Ebersdobler, A., et al, Prostate Cancers in the Transition Zone Part I, BJU Inter V 94 2004 pp 1221-1225.

200. Eisenhauer et al, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal Of Cancer 45 (2009) 228 – 247

201. Eisenmann, K., et al, Mitogen Activated Protein Kinase Pathway Dependent Tumor Specific Survival Signalling in Melanoma Cells, J Can Res 2003 pp 8330-8337.

202. El-Assmy et al, Diffusion-Weighted MR Imaging in Diagnosis of Superficial and Invasive Urinary Bladder Carcinoma: A Preliminary Prospective Study, The Scientific World Journal (2008) 8, 364–370

203. Ellis et al, Epigenetics in cancer: Targeting chromatin modifications, Mol Cancer Ther 2009;8(6). June 2009

204. El-Osta, H., BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes, PLoS ONE , www.plosone.org 1 October 2011 , Volume 6 , Issue 10.

205. Elston, D., T. Ferringer, Dermatopathology, Saunders (New York) 2009.

206. Elton and Yalowich, Experimental Procedures to Identify and Validate Specific mRNA Targets Of miRNAS, EXCLI Journal 2015;14:758-790

207. Enokida et al, The role of microRNAs in bladder cancer, Investig Clin Urol 2016;57 Suppl 1:S60-76.

208. Enokida et al, The role of microRNAs in bladder cancer, Investig Clin Urol 2016;57

209. Epstein, Biopsy Interpretation of the Bladder, 3rd Ed, LWW, 2016

210. Epstein, J., G. Netto, Biopsy Interpretation of the Prostate, Lippincott (New York) 2008.

211. Ergun, A., et al, A Network Biology Approach to Prostate Cancer, Mole Sys Bio, V 3, 2007, pp 1-6.

212. Ernst, T., et al, Decrease and Gain in Gene Expression are Equally Discriminatory Markers for Prostate Cancer, Am Jrl Path, V 160, 2002, pp 2169-2180.

213. Ernstoff, M., Been There, Not Done That — Melanoma in the Age of Molecular Therapy, 10.1056/nejme1105792 nejm.org,

214. Esgueva, R., et al, Prevalanece of TMPRSS2-ERG and SLC45A3-ERG Gene Fusions in a Large Prostatectomy Cohort, Mod Path, V 2010, pp 1-8.

215. Eslami-S et al, Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade, British Journal of Cancer, 2022

216. Esquela-Kerscher, A. and F, Slack, Oncomirs — microRNAs with a role in cancer, Nature Reviews , Cancer Volume 6 , April 2006 , 259.

217. Essaghir, A., et al, The Transcription of FOXO Genes is Stimulated by FOXO3 and Repressed by Growth Factors, Jrl Bio Chem 2009, pp 10334-10342.

218. Esserman, L., et al, Rethinking Screening for Breast Cancer and Prostate Cancer, JAMA 2009 V 302 pp 1685-1692.

219. Esteller, M., Epigenetics in Cancer, NEJM, 2008 V 358 pp 1148-1159.

220. Ewend, MG, Carey, LA, Brem, H. Treatment of melanoma metastases in the brain. Semin Surg Oncol 1996; 12:429 February 26, 2004.

221. Ewing, C., et al, Germline Mutations in HOX B 13 and Prostate Cancer Risk, NEJM, Jan 2012 V 366 N 2 pp 141-149.

222. Ezponda, T. et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 32, 2882–2890 (2013).

223. Fang, D. et al, A Tumorigenic Subpopulation with Stem Cell Properties in Melanoma, Can Res V 65 2005.

224. Farhang-Fallah, J., et al, The Pleckstrin Homology (PH) Domain-Interacting Protein Couples the Insulin Receptor substrate 1 PH Domain to Insulin Signaling Pathways Leading to Mitogenesis and GLUT4 Translocation, MOLECULAR AND CELLULAR BIOLOGY, Oct. 2002, p. 7325–7336.

225. Feero, W. G., et al, Genomic Medicine – An Updated Primer, NEJM, 2010, pp 2001-2011.

226. Feldman, B., D., Feldman, The Development of Androgen Independent Prostate Cancer, Nature Reviews Cancer, Vol 1, 2001, pp 34-45.

227. Fernández-Lázaro et al, Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers, Diagnostics 2020, 10, 215

228. Ferrone, E et al, Clinicopathological Features of and Risk Factors for Multiple Primary Melanomas, JAMA, October 5, 2005—Vol 294, No. 13 pp. 1647

229. Fesler et al, Circulating microRNA testing for the early diagnosis and follow up of colorectal cancer patients, Mol Diagn Ther. 2014 June ; 18: 303–308

230. Fife, KM, Colman, MH, Stevens, GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293.

231. Figueiredo, M., et al, Advances in Preclinical Investigation of Prostate Cancer Gene Therapy, Am Soc Gene Therapy 2007 V 15 pp 1053-1064.

232. Filippou et al, Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target, Oncogene (2020) 39:2040–2054

233. Fine, B., et al, Activation of PI3K Pathway in Cancer through Inhibition of PTEN by Exchange Factor P-REX2a, Science, 2009, pp 1261-1265.

234. Finn, O., Cancer Immunology, NEJM V 358, 2008 pp 2704-2715.

235. Flaherty, K., et al, Inhibition of Mutated Activated BRAF in Metastatic Melanoma, NEJM, 2010, pp 809-819.

236. Flockhart, R., et al, BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration, Genome Res. 2012 22: 1006-1014 originally published online May 11, 2012.

237. Floor, S., Cancer Cells in Epithelial to Mesenchymal Transition and Tumor Propagating Cancer Stem Cells: Distinct, Overlapping or Same Populations, Oncogene V 30, pp 4609-4621, 2011.

238. Foong et al, Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study , J Neurol Neurosurg Psychiatry 2000;68:242-244 (February)

239. Forloni et al, miR-146a promotes the initiation and progression of melanoma by activating Notch signaling, eLife 2014;3:e01460

240. Foster, C., D. Bostwick, Pathology of the Prostate, Saunders (Philadelphia) 1998.

241. Freytag, S., Prostate Cancer Gene Therapy Clinical Trials, Am Soc Gene Therapy V 15 2007 pp 1042-1052.

242. Friedman et al, Principles of MRI, McGraw Hill, 1989.

243. Frixa et al, Oncogenic MicroRNAs: Key Players in Malignant Transformation, Cancers 2015, 7, 2466–2485

244. Frohling, S., Chromosomal Abnormalities in Cancer, NEJM 2008, pp 722-734.

245. Fukuhara, H., et al, Maximum Tumor Diameter, Pros Canc and Prost Dis 2010 V 13 pp 244-247.

246. Gajos-Michniewicz and Czyz, Role of miRNAs in Melanoma Metastasis, Cancers 2019, 11, 326

247. Galasko D, Kwo-On-Yuen PF, Thal L. Intracranial mass lesions associated with late-onset psychosis and depression. Psychiatr Clin North Am. 1988 Mar; 11:151-66.

248. Garcia-Carpizo, V. et al. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Sci.Rep. 6, 32952 (2016).

249. Gardenes, J., et al, On the robustness of complex heterogeneous gene expression networks, Biophys Chem, 118 2005 pp. 225-228.

250. Garnick MB. Prostate Cancer Screening: Part I: The Screening Dilemma, Screening Tests and the Role of Prostate Specific Antigen Testing. Primary Care Reports. 2006; 12:1-12

251. Garnick MB. Prostate Cancer Screening: Part II: Treatment and Outcomes. Primary Care Reports. 2006; 12: 13-28

252. Gartner and Hiatt, Textbook of Histology, 3rd Ed, Saunders 2006

253. Gartner, L., J. Hiatt, Color Textbook of Histology, Saunders (New York) 2007.

254. Gehring, W., Y. Hiromi, Homeotic Genes and the Homeobox, Ann Rev Gen 1986 V 20 pp 147-173.

255. Gelman et al, Molecular Oncology, Cambridge, 2014

256. Ghai and Haider, Multiparametric-MRI in diagnosis of prostate cancer, Indian J Urol. 2015 Jul-Sep; 31: 194–201

257. Giza et al, Key principles of miRNA involvement in human diseases, Discoveries (Craiova). 2014 ; 2

258. Gkountela et al, Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding, Cell 176, 98–112, January 10, 2019

259. Glaser et al, Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors, Journal of Visualized Experiments, 2018

260. Glunde, K. et al. Molecular–functional imaging of cancer: to image and imagine, TRENDS in Molecular Medicine, Vol.13 No.7, 2007.

261. Goentoro, L., et al, The Incoherent Feedforward Loop Can Provide Fold Change Detection in Gene Regulation, Mol Cell 2009 pp 894-899.

262. Gogas et al, Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon , New England Journal Med. pp. 354;7 February 16, 2006.

263. Goldberg, A., Protein degradation and protection against misfolded or damaged proteins, NATURE, Vol 426, 18/25 December 2003.

264. Goldman and Schafer, Goldman's Cecil Medicine, 24th Ed, Elsevier, 2012

265. Goldstein, A. et al, Identification of a Cell of Origin for Human Prostate Cancer, Science, 2010 V 329, pp 568-571.

266. Goldstein, A., et al, Identification of a Cell of Origin for Human Prostate Cancer, Science, Vol 329, July 2010, p 568.

267. Gonzalgo, M., et al, Prostate Cancer Detection by GSTP1 Methylation Analysis of Post biopsy Urine Specimen, Clin Can Res, 2003, pp 2673-2677.

268. Goosens et al, Cancer biomarker discovery and validation, Trans Cancer Res, 2015 4

269. Gorlov, I., et al, Candidate pathways and genes for prostate cancer, BMC Med Gen 2009.

270. Goss, K., M. Kahn, Targeting the Wnt Pathway in Cancer, Springer (New York) 2011.

271. Gottwein, E., B. Cullen, Viral and Cellular MicroRNAs as Determinants of Viral Pathogenesis and Immunity, Cell Host 2008, pp 375-387.

272. Green, Cell Death, 2nd Ed, CSHP, 2018

273. Greenberg DB, Brown GL. Mania resulting from brain stem tumor. J Nerv Ment Dis. 1985 Jul; 173:434-6.

274. Gregg, J., EGF Mediated Regulation of EGR1 In Prostate Cancer Cells, PhD Thesis Kent State, Dec 2010.

275. Greider, C., Wnt Regulates TERT – Putting the Horse Before the Cart, Science, V 336 p 1519, 2012.

276. Grichnik, J., et al, Melanoma, a Tumor Based on a Mutant Stem Cell?, Jrl Inv Derm V 12 2006.

277. Griffith, D., Targeting aggressive prostate cancer, Eureka, http://www.eurekalert.org/pub_releases/2013-08/uoc--tap081213.php , 14 August 2013.

278. Grochow, J., M.. Kellis, Network Motif Discovery Using Subgraph Enumeration and Symmetry Breaking, Speed and Huang Ed, RECOMB Springer 2007 pp 92-106.

279. Grunkemeier, M, R. Vollmer, Predicting Prostate Biopsies, Ana Path 2006 V 126 pp 110-112.

280. Gu et al, Inactivation of ABL kinases suppresses non–small cell lung cancer metastasis, JCI Insight. 2016;1:

281. Guatente, L., Sirtuins, Aging, and Medicine, NEJM, Vol 364 June 2011

282. Gupta and Massague, Cancer Metastasis: Building a Framework, Cell 127 Nov 2006

283. Gupta, G, Robertson, AG, MacKie, RM. Cerebral metastases of cutaneous melanoma. Br J Cancer 1997; 76:256.

284. Gupta, P, et al, Cancer Stem Cells, Mirage or Reality, Nature Medicine, 2009, p. 1010.

285. Gupta, P., et al, Identification of Selective Inhibitors of Cancer Stem Cells by High Throughput Screening, Cell, V 138, pp 645-659, Aug 2009.

286. Gurel, B., et al, Molecular Alterations in Prostate Cancer as Diagnostic Prognostic, and Theraputic Targets, Adv Anal Path, V 15, 2008, pp 319-331.

287. Gut and Verdin, The nexus of chromatin regulation and intermediary metabolism, 24 October 2013 , Vol 502 , Nature , 489

288. Gutman, M., J, Rinn, Modular regulatory principles of large non-coding RNAs, Nature, V 462, 14 Feb 2012.

289. Hagen, NA, Cirrincione, C, Thaler, HT, DeAngelis, LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990; 40:158.

290. Haley et al, Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens, he Journal of Molecular Diagnostics, Vol. 23, No. 10, October 2021

291. Haller, Rudolf, Questions on Wittgenstein, University of Nebraska Press (Great Britain), 1988.

292. Halvorsen et al, Profiling of microRNAs in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer, Molecular Oncology 11 (2017) 220–234

293. Hammond, An Overview of microRNAs, Adv Drug Deliv Rev. 2015 June 29; 87: 3–14

294. Hanahan, D., R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, 2011, pp 646-674.

295. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46:823-32.

296. Hanley, J., B., McNeil, The Meaning and Use of the Area under a Receiver Operating Curve, Radiology 1982 V 143, pp 29-36.

297. Happel et al, Extracellular RNAs as potential biomarkers for cancer, J Cancer Metastasis Treat. 2020 ; 6

298. Harbeck et al, Breast Cancer, Nature Reviews Disease Primers · December 2019

299. Harmans, K., Unravelling of the Major Genetic Defects in Prostate Cancer, Doctoral Thesis, Erasmus Univ, Rotterdam, 2009.

300. Hassler and Egger, Epigenomics of cancer e emerging new concepts, Biochimie 94 (2012) 2219e2230

301. Hastie et al, The Elements of Statistical Learning, 2nd Ed, Springer, 2009

302. Hatzimanikatis, V., Dynamical Analysis of Gene Networks Requires Both mRNA and Protein Expression Information, Metabolic Engr, Vol 1, 1999, pp. 275-281.

303. Hay, N., The Akt-mTOR tango and its relevance to Cancer, Cancer Cell, V 8, 2005, pp 179-183.

304. Hayat, Autophagy, Academic, 2014

305. Hayden, E., Study links genes to melanoma development, Nature, 09 May 2012 Corrected: 21 May 2012

306. Hayes et al, MicroRNAs in cancer: biomarkers, functions and therapy, Trends in Molecular Medicine, August 2014, Vol. 20, No. 8

307. He, L., G. Hannon, MicroRNAs: Small RNAs with a Big Role in Gene Regulation, Nature, 2004 pp 522-532.

308. Hearing, V., S. Leong, From Melanocytes to Melanoma, Humana (Totowa, NJ) 2006.

309. Heiner, Petri Nets for Systems and Synthetic Biology, M. Bernardo, P. Degano, and G. Zavattaro (Eds.): SFM 2008, LNCS 5016, pp. 215{264, 2008.

310. Helin and Dhanak, Chromatin proteins and modifications as drug targets, Nature , Vol 502 , 24 October 2013

311. Helm, K., J. Marks, Atlas of Differential Diagnosis in Dermatopathology, Churchill (Philadelphia) 1998.

312. Hendig, D., et al, SPP1 Promoter Polymorphism, Mol Diag and Gen Clin Chem 2007 pp 829-835.

313. Herberts et al, Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer, Nature, July 20, 2022

314. Herman, J., S. Baylin, Gene Silencing in Cancer in Association with Promoter Hypermethylation, NEJM 2003, pp 2042-2034.

315. Hines, Z., et al, The cAMP/PKA Pathway Rapidly Activates SIRT1 to Promote Fatty Acid Oxidation Independently of Changes in NAD+, Molecular Cell 44, 851–863, December 23, 2011

316. Hirano, I., et al, Depletion of Pleckstrin Homology Domain Leucine rich Repeat Phosphatases 1 and 2 by Bcr-Abl Promotes Chronic Myelogenous Leukemia Cell Proliferation through Continuous Phosphorylation of Akt Isoforms, Jrl Bio Chem V 284, 2009.

317. Hiscutt, E., et al, Targeting X-Linked Inhibitor of Apoptosis Protein to Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy, Journal of Investigative Dermatology (2010), Volume 130.

318. Ho et al, Direct Quantification of mRNA and miRNA from Cell Lysates Using Reverse Transcription Real Time PCR: A Multidimensional Analysis of the Performance of Reagents and Workflows, PLOS Sept 2013

319. Ho, C., Stopping The Spread Of Melanoma By Removing Protein Affecting Metastasis, RedOrbit, November 15, 2012.

320. Ho, J., et al, Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy, JAMA 2009 V 302 pp 1557-1564.

321. Hoey and Liu, Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies, Research and Reports in Urology 2019:11 29–42

322. Hoffman, U., et al, Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression, British Journal of Cancer (1999) 81, 774–782.

323. Hoffmyer, K., et al, Wntβ-Catenin Signalling Regulates Telomeres in Stem Cells and Cancer Cells, Science, V 336 p 1549, 2012.

324. Hofmann and Clokie, Principles and Techniques of Biochemistry and Molecular Biology, Cambridge, 2018

325. Holmes, S., Graphs and Networks in Bioinformatics, Stanford Univ Notes.

326. Holst, L, et al, The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c, Experimental Dermatology, 2010, p 278.

327. Holst, L, et al, The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c, Experimental Dermatology, 2010, p 278.

328. Hong, D., A Fountain of Cancer, Sci Transl Med 4 May 2011: Vol. 3, Issue 81, p. 81

329. Horn, S. e al, TERT Promoter Mutations in Familial and Sporadic Melanoma, Sciencexpress, 24 January 2013.

330. Horowitz, MRI Physics for Physicians, Springer, 1989

331. Hoshino et al, Tumour exosome integrins determine organotropic metastasis , Nature, 19 Nov 2015

332. Hosmer, D., S., Lemeshow, Applied Logistic Regression, Wiley (New York) 2000.

333. Houben, M., et al, Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma, Journal of Investigative Dermatology (2006) 126, 1135–1142.

334. Houston, P., Chemical Kinetics and Reaction Dynamics, Dover (Mineola) 2001.

335. Howard, D. et al, The Problem of Brain Tumor in Psychiatric Diagnosis, Am J Psychiatry 98:720-726, March 1942

336. Hsu. P, David M. Sabatini1,2,3 Cancer Cell Metabolism: Warburg and Beyond, Cell 134, September 5, 2008.

337. Hu et al, Targeting Autophagy for Oncolytic Immunotherapy, Biomedicines 2017, 5, 5;

338. Huang, C., et al, A Study of Cancer Related MicroRNAs through Expression Data and Literature Search, World Acad Sci & Engr, 2009 254-256.

339. Huang, F., et al, Highly Recurrent TERT Promoter Mutations in Human Melanoma, Sciencexpress, January 2013.

340. Huang, H., PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer, Jrl Bio Chem, V 276, 2001, pp 38830-38836.

341. Huang, S., et al, Blockade of NF-kB Activity in Human Prostate Cancer Cells is Associated with Suppression of Angiogenesis, Invasion, and Metastasis, Oncogene, V 20, 2001, pp 4118-4197.

342. Huang, Z., Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients, Cancer Management and Research, 2021:13 587–593

343. Huang,P., A. Oliff, Signaling pathways in apoptosis as potential targets for cancer therapy, TRENDS in Cell Biology Vol.11 No.8 August 2001.

344. Huettel, S., et al, Functional Magnetic Resonance Imaging, Sinauer (Sunderland, MA) 2009.

345. Hunink, M., C. Begg, Diamond's Correction Method, A Real Gem or Just a Cubic Zirconium, Med Dec Making 1991 V 11 pp 201-203.

346. Hurt, E., et al, CD44+CD44- Prostate Cells are Early Cancer Progenitor Stem Cells that Provide a Model for Patients with Poor Prognosis, Brit Jrl Can 2008 pp 756-765.

347. Huse, J. et al, The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo, Genes Dev. 2009 23: 1327-1337.

348. Hwangbo, C. et al, mda-9/Syntenin Protein Positively Regulates the Activation of Akt Protein by Facilitating Integrin-linked Kinase Adaptor Function during Adhesion to Type I Collagen, Volume 286 Number 38 Journal Of Biological Chemistry, September 23, 2011.

349. Iljin, K., et al, TMPRSS2 Fusions with Oncogenes ETS Factors in Prostate Cancer, Cancer Res, V 66, 2006, pp 10242-10246.

350. Imoto, S., et al, Combining Microarrays and Biological Knowledge for Estimating Gene Networks via Bayesian Networks, IEEE Com Sys Bio 2000 pp.

351. Ip, J., Telomeres and Cancer: A New Approach to Therapy, Bio Teach Jrl, V 2 Fall 2004.

352. Issa, J., M. Hagop, Targeting DNA Methylation, Clin Cancer Res 2009; V 15: pp 3938-3946.

353. Ivanov, I., E. Dougherty, Reduction Mappings Between Probabilistic Boolean Networks, Jrl App Sig Pro 2004 pp 125-131.

354. Iwarta, T., et al, Myc Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells, Open Access, www.plosone.org ,V 5, 2010, pp e9427

355. Jacobsen, S., Gene Silencing: Maintaining Methylation Patterns, Curr Bio 1999, pp 617-619.

356. Jähnel M. Schizophreniform Psychosis in a Patient with Right Temporal-parietal Meningioma, Psychiatr Prax. 2003 May; 30(Suppl 2):66-69.

357. Jana et al, Nuclear Medicine Studies of the Prostate, Testes, and Bladder, Sem in Nuc Med, 2006

358. Jansen, R., et al, A Bayesian Networks Approach for Predicting Protein-Protein Interactions from Genomic Data, Science, 2003 pp 449-453.

359. Jaqmaspishvili, T., et al, Urine Markers in Monitoring Prostate Cancers, Pros Canc and Prost Dis, V 13, 2010, pp 12-19.

360. Jeet, et al, Modeling prostate cancer: a perspective on transgenic mouse models, Cancer Metastasis Rev (2010) 29:123–142.

361. Jelovac, D., B. Park, PTEN Promoter Silencing and Cowden Syndrome, JAMA, 2010, pp 2744-2745.

362. Jenuwein and Allis, Translating the Histone Code, Science, Aug 10 2001, p 1074

363. Jeong, J., et al, BRAF Activation Initiates but does not Maintain Invasive Prostate Adenocarcinoma, Plus One, 2008 pp 3949-.

364. Jia et al, Exosome: emerging biomarker in breast cancer, Oncotarget, 2017, Vol. 8, (No. 25), pp: 41717-41733

365. Jia, H., Osak, M., Bogu, G.K., Stanton, L.W., Johnson, R., and Lipovich, L. (2010). Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA 16, 1478-1487.

366. Jiang et al, Exosomal microRNA remodels the tumor microenvironnement, PeerJ, DOI 10.7717/peerj.4196, 2017

367. Johansson, P., et al, Confirmation of a BRAF mutation-associated gene expression signature in melanoma, Pigment Cell Res. 20; 216–221, 2007.

368. Johnson, JD, Young, B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337.

369. Jones and Thompson, Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer, Mol Cancer Ther; 19 September 2020

370. Jones, J., Prostate Biopsy, Humana (Totowa, NJ) 2008.

371. Jones, P., S. Baylin, The Epigenomics of Cancer, Cell, 2007 pp 683-692.

372. Jordan, C., et al, Cancer Stem Cells, NEJM 2006.

373. Julie Ma, M.D. Mania Resulting From Brain Tumor, UCLA School Medicine, Clinical Vignette, http://www.med.ucla.edu/modules/wfsection/article.php?articleid=120 v

374. Jung, C., et al, HOX B 13 Homeodomain Protein Suppresses the Growth of Prostate Cancer, Can Res 2004 V 64 pp 3046-3051.

375. Kaczkowski, B, Computational Cancer Biology: From Carcinogenesis to Metastasis, PhD Thesis University of Copenhagen, April 2012.

376. Kaelin, E. F., Heidegger's Being and Time, Florida State (Tallahassee) 1988.

377. Kanamori, Y., et al, Correlation Between Loss of PTEN Expression and Akt Phosphorylation in Endometrial Carcinoma, Clin Can Res, V 7, 2001, pp 892-895.

378. Kang et al, Discrimination between the human prostate normal cell and cancer cell by using a novel electrical impedance spectroscopy controlling the cross-sectional area of a microfluidic channel, Biomicrofluidics. 2013 Jul; 7(4): 044126

379. Kang et al, The Beclin 1 network regulates autophagy and apoptosis, Cell Death and Differentiation (2011) 18, 571–580

380. Kang T et al, Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response, BJU Int 2007 May;99:1024-7 Epub 2007 Jan 22.

381. Kang, T et al, Functional heterogeneity of prostatic intra-epithelial neoplasia: Length of hormonal therapy influences response, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 24, No 18S (June 20 Supplement), 2006: 4648

382. Kantoff, P. et al, Prostate Cancer, Lippincott (Philadelphia) 2002.

383. Karasarides, M., B-RAF is a therapeutic target in melanoma, Oncogene (2004) 23, 6292–6298.

384. Karp and Falchook, Targeted Cancer Therapy and Immunotherapy, 2nd Ed, Wolters Kluwer, 2019

385. Kartarjian, H., et al, Hematologic and Cryptogenic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia, NEJM, Vol 346, No 9, 2002.

386. Kasinski, A., F., Slack, miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse model of Lung Adenocarcinoma, Cancer Res Published OnlineFirst September 10, 2012.

387. Khalil, A.M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., Thomas, K., Presser, A., Bernstein, B.E., van Oudenaarden, A., et al. (2009). Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl. Acad. Sci. USA 106, 11667-11672.

388. Kibel, A., et al, CDKN1A and CDKN1B Polymorphisms and Risk of Advanced Prostate Cancer, Can Res 2003, pp 2033-2036.

389. Kılıçkesmez et al, Diffusion-weighted MRI of urinary bladder and prostate cancers, Diagn Interv Radiol 2009; 15:104–110

390. Kilkov, V., Identifying Gene Regulatory Networks from Gene Expression Data,.

391. Kim Y, et al, HOX B 13 promotes Androgen Independent Growth, Molecular Cancer, 2010 Vol 9-124.

392. Kim, H., X. Yang, Prevalence of High Grade Prostatic Intraepithelial Neoplasia and its Relationship to Serum Prostate Specific Antigen, Clin Uro, V 28, 2002, pp 413-417.

393. Kim, N., et al, A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition, J. Cell Biol. Vol. 195 No. 3 417–433, 2011.

394. Kim, S., et al Can Markov Chain Models Mimic Biological Regulation, Jrl Bio Sys 2002, pp 337-357.

395. Kim, S., et al, Inferring Gene Networks from Time Series Microarray Data Using Dynamic Bayesian Networks, Brief on Bioinfo 2003, pp 228-235.

396. King, J., Cooperativity of TMPRSS2-ERG with PI3 kinase pathway Activation in Prostate Oncogenesis, Nature Gen, V 41, 2009, pp 524-526.

397. Kinkaide, C., et al, Targeting Akt/mTOR and ERK MAPK Signalling Inhibits Hormone Refractory Prostate Cancer in Preclinical Mouse Model, Jrl Clin Inv 2008, 99 3051-3064.

398. Klemm, K., S. Bornholdt, Topology of Biological Networks and Reliability of Information Processing, PNAS 2005 pp 18414-18419.

399. Klipp, E., et al, Systems Biology, Wiley (Weinheim, Germany) 2009.

400. Knight et al, Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity, Open Biology, V 3 130130, 2013

401. Kohane, I., et al, Microarrays for an Integrative Genomics, MIT Press (Cambridge) 2003.

402. Kokkola et al, AROS has a context-dependent effect on SIRT1, FEBS Letters 588 (2014) 1523–1528

403. Kokontis, J., et al, Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long Term Androgen Deprivation, J Can Res, V 54, 1994, pp 1566-1573.

404. Konstadoulakis, MM, Messaris, E, Zografos, G, et al. Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci 2000; 44:211.

405. Koppers-Lalic et al, Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles, Oncotarget, Vol. 7, No. 16, 2016

406. Korbecki et al, CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer, Int. J. Mol. Sci. 2022, 23, 2168

407. Korn, A Multiparametric MRI for the Classification and Grading of Prostate Cancer, UCSF PhD Thesis, 2019

408. Kornienko, A., et al, Gene regulation by the act of long non-coding RNA transcription, BMC Biology 2013, 11:59.

409. Korpelainen et al, RNA0seq, CRC (Boca Raton) 2015

410. Kota, J., et al, Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model, Cell 137, 1005–1017, June 12, 2009.

411. Kovalchuk, I., O., Kovalchuk, Epigenetics, FT Press (Upper Saddle River, NJ) 2012.

412. Krane, D., M. Raymer, Bioinformatics, Benjamin Cummings (New York) 2003.

413. Krause, D., R. VanEtten, Tyrosine Kinases as Targets for Cancer Therapy, NEJM 2005 pp 172-187.

414. Krown, SE, Niedzwiecki, D, Hwu, WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006; 107:1883.

415. Kumar et al, QIN "Radiomics: The Process and the Challenges", Magn Reson Imaging. 2012 November; 30: 1234–1248

416. Kuo et al, NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming, Molecular Cell 44, 609–620, November 18, 2011

417. Kwan and Wai, Autophagy in Multidrug-Resistant Cancers, http://dx.doi.org/10.5772/64274, Intech, Autophagy in Current Trends in Cellular Physiology and Pathology, 2016

418. Labbe, D., et al, Role of Diet in Prostate Cancer, the Epigenetic Link, Oncogene, 2014.

419. Lacovara J., et al, Fibronectin Enhancement of Directed Migration of B16 Melanoma Cells, Cancer Research, 1984.

420. Laird, P., R. Jaenisch, DNA Methylation and Cancer, Human Molecular Genetics, Vol 3, 1487-95, 1999.

421. Laird, P., R. Jaenisch, DNA Methylation and Cancer, Human Molecular Genetics, Vol 3, 1487-95, 1999

422. Lam, E., et al, FOXO Transcription Factors, Biochem Soc Trans 2006, pp 722-726.\

423. Lambert et al, Emerging Biological Principle of Metastasis, Cell 168, Feb 9, 2017

424. Larrea et al, New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies, Int. J. Mol. Sci. 2016, 17, 627

425. Lawrie, MicroRNAs in Medicine, Wiley, 2014

426. Lawson, D., et al, Isolation and Functional Characterization of Murine Prostate Stem Cells, PNAS, 2007, V 104 pp 181-186.

427. Lawson, D., O. Witte, Stem Cells in Prostate Cancer Initiation and Progression, Jrl Clin Inv, 2007 pp 2044-2050.

428. Lawton CA; Won M; Pilepich MV; Asbell SO; Shipley WU; Hanks GE; Cox JD; Perez CA; Sause WT; Doggett SR; et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991 Sep;21:935-9.

429. Leder, K., etal, The Theraputic Implications of Plasticity of the Cancer Stem Cell Type, PLOS One V 5 Dec 2010.

430. Lee, A., GRP78 Induction in Cancer, Can Res 2007 pp 3946-3499.

431. Lee, J., Epigenetic Regulation by Long Noncoding RNAs, SCIENCE VOL 338 14 DECEMBER 2012.

432. Lee, J., et al, Plasma or Serum TIMP-1 is a Predictor of Survival Outcomes in Colorectal Cancer, Jrl Gastro Intest Liver Dis, 2011, pp 287-291.

433. Lefkowitz, G., et al, Follow Up Interval Prostate Biopsy of High Grade Prostatic Intraepithelial Neoplasia is Associated with High Likelihood of Prostate Cancer Independent of Change in Prostate Specific Antigen Levels, Journal of Urology, Vol 168, Oct 2002.

434. Leite, K., et al, Repeat Prostate Biopsies Following Diagnoses of Prostate Intraepithelial Neoplasia and Atypical Small Gland Proliferation, Inter Brazil Jrl Uro, V 31, 2005, pp 131-136.

435. Lepor, H., R. Lawson, Prostate Diseases, Saunders (Philadelphia) 1993.

436. Levine, A., A. Puzio-Kuter, The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes, Science, 2010, pp 1340-1344.

437. Li, G., et al, Selective Anticancer Strategies via Intervention of the Death Pathways Relevant to Cell Transformation, Cell Death and Diff 2008 pp 1197-1210.

438. Li, J., et al, Non-Invasive Biomarkers for Early Detection of Breast Cancer, Cancers 2020, 12, 2767

439. Li, J., et al, PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer, Science, V 275, 1997, pp 1943-1947.

440. Li, Q., Selective anticancer strategies via intervention of the death pathways relevant to cell transformation, Cell Death and Differentiation (2008) 15, 1197–1210.

441. Li, X., et al, NKX3.1 is Regulated by Protein Kinase CK2 in Prostate Tumor Cells, Mol Cell Bio, V 26, 2006, pp 3008-3017.

442. Liang and Lauterbur, Principles of Magnetic Resonance Imaging, IEEE Press, 2000.

443. Lin, H., et al, Regulation of Androgen Receptor Signalling by PTEN, Mol Endo, V 18, 2004, pp 2409-2425.

444. Lipsyc-Sharf et al, Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor– Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer, Journal of Clinical Oncology, June 4, 2022

445. Lisanby SH, Kohler C, Swanson CL, Gur RE., Psychosis Secondary to Brain Tumor. Semin Clin Neuropsychiatry. 1998 Jan; 3:12-22.

446. Liu and Tang, MicroRNA Regulation of Cancer Stem Cells, Cancer Res; 71 September 15, 2011

447. Liu et al, Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond, Int. J. Mol. Sci. 2018, 19, 2822

448. Liu et al, Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma, World Journal of Surgical Oncology (2021) 19:42

449. Liu et al, The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nature Medicine, 17, pp 211–215, (2011)

450. Liu, A., et al, Correlated Alterations in Prostate Basal Cell Lauer and Basement Membrane, Int Jrl Bio Sci, V 5, 2009, pp 276-285.

451. Liu, F., et al., MiTF links Erk1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells, Molecular Cancer 2010, 9:214.

452. Liu, J., et al, Oncogenic BRAF regulates b-Trcp expression and NF-jB activity in human melanoma cells, Oncogene (2006), 1–5.

453. Liu, W., et al, The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis, Cancer Res 2008;68:8104-8112. Published online September 30, 2008.

454. Lobo, N., et al, The Biology of Cancer Stem Cells, Ann Rev Cell Dev 2007 pp 675-699.

455. Lobo, N., Yohei Shimono, Dalong Qian, and Michael F. Clarke, The Biology of Cancer Stem Cells, Annu. Rev. Cell Dev. Biol. 2007. 23:675–99.

456. Lodish, H., et al, Molecular Cell Biology, 4th Ed Freeman (San Francisco) 2000.

457. Lohman, I., W. McGinnis, HOX Genes, Current Biology, 2002, V 12 pp 514-516.

458. Long and Wong, The Chemistry of Molecular Imaging, Wiley, 2015

459. LoPiccolo, J., et al, Targeting the PI3K/Akt/mTOR Pathway, Drug Res Up, 2008, pp 32-50.

460. Lotam and Roehrborn, Sensitivity And Specificity Of Commonly Available Bladder Tumor Markers Versus Cytology: Results Of A Comprehensive Literature Review And Meta-Analyses, UROLOGY 61 , 2003

461. Lou et al, MicroRNAs in cancer metastasis and angiogenesis, Oncotarget, 2017, Vol. 8, (No. 70), pp: 115787-115802

462. Lu and Thompson, Metabolic regulation of epigenetics, Cell Metab July 3, 2012

463. Lu, Y., et al, A Bayesian Approach to Simultaneously Adjusting for Verification, Statst Med 2010 V 29, pp 2532-2543.

464. Lubomir et al, Deep Learning Approach for Assessment of Bladder Cancer Treatment Response, Tomography.Org, Volume 5 Number 1, March 2019

465. Luca, M., et al, Expression of Interleukin-8 by Human Melanoma Cells Up-Regulates MMP-2 Activity and Increases Tumor Growth and Metastasis, American Journal of Pathology, Vol. 151, No. 4, October 1997.

466. Lufkin, The MRI Manual, Year Book Med Pub, 1990

467. Lukas et al, More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance, Nature Cell Biology Volume 13 , Number 10 , October 2011

468. Luo, C., microRNAs Involved in the Aggressiveness of Malignant Melanoma, PhD Thesis Heidelberg, Dec 2011.

469. Luo, S., et al, Introduction of Grp78/BiP by Translational Block, Jrl Bio Chem, 2003 pp 37375-37385.

470. Luttman et al, Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade, Cell Commun Signal (2021) 19:59

471. Luu et al, miRNAs associated with prostate cancer risk and progression, BMC Urology (2017) 17:18

472. Lu-Yao, G., et al, Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer, JAMA, V 300 2008 pp 173-181.

473. Lyden et al, Cancer Metastasis, Cambridge (New York) 2011

474. Maas, et al, Extracellular vesicles: unique intercellular delivery vehicles, Trends Cell Biol. 2017 March ; 27: 172–188

475. Maas, et al, Extracellular vesicles: unique intercellular delivery vehicles, Trends Cell Biol. 2017 March ; 27(3): 172–188

476. Maddodi, N., et al, Induction of Autophagy and Inhibition of Melanoma Growth In Vitro and In Vivo by Hyperactivation of Oncogenic BRAF, 2010 The Society for Investigative Dermatology, Journal of Investigative Dermatology (2010), Volume 130.

477. Maira, S., et al, PI3K Inhibitors for Cancer Treatment, Biochem Soc Trans, V 37, 2009, pp 265-272.

478. Maize, J., A. B. Ackerman, Pigmented Lesions of the Skin, Lea & Fabiger (Philadelphia) 1987.

479. Majumder, P., et al, A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer 2008 146-155.

480. Marcucci, G., et al, High Expression Levels of the ETS Related Gene ERG Predict Adverse Outcome, Jrl Clin Onc, V 25, 2007, pp 3337-3343.

481. Marini et al, MicroRNA Role in Thyroid Cancer Development, Journal of Thyroid Research · May 2011

482. Marinkovic et al, Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy, Oxidative Medicine and Cellular Longevity, Volume 2018, Article ID 8023821, 18 pages

483. Marks et al, Cellular Signal Processing, 2nd Ed, Garland (New York) 2017

484. Marks, F., et al, Cellular Signal Processing, Garland (New York) 2009.

485. Marrugo-Ramirez et al, Blood Based Cancer Biomarkers in Liquid Biopsy: A Promisaing Non-Invasive Alternative toTissue Biopsy, Int Jrl Mol Sci 2015

486. Martínez-Fernández et al, EZH2 in Bladder Cancer, a Promising Therapeutic Target, Int. J. Mol. Sci. 2015, 16, 27107–27132

487. Martinez-Vincente, M., et al, Protein degradation and aging, Experimental Gerontology 40 (2005) 622–633.

488. Martins et al, Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring, Genes 2021, 12, 349

489. Marx, Autophagy: Is It Cancer’s Friend or Foe?, Science Vol 312 26 May 2016 pp1160-1161.

490. Massi, G., P. Leboit, Histological Diagnosis of Nevi and Melanoma, Springer (Darmstadt) 2004.

491. Mathew et al, Extracellular Vesicles as Biomarkers in Cancer Immunotherapy, Cancers 2020, 12, 2825

492. Mathieu et al, Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication, Nature Cell Biology, Vol 21, January 2019,pp 9–17

493. Maury and Hashizume, Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies, Epigenetics, 2017, Vol. 0, NO. 0, 1–17

494. Mazar, J., et al, Epigenetic Regulation of MicroRNA Genes and the Role of miR-34b in Cell Invasion and Motility in Human Melanoma, PLOS One, September 2011, Volume 6, Issue 9

495. McCabe, M., et al, Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications, Clinical Cancer Res 3927 2009;15 June 15, 2009.

496. McCombie et al, Next-Generation Sequencing in Medicine, CSHL Press (Cold Spring Harbor) 2019

497. McIntosh, M, N., Urban, A Parametric Empirical Bayes Method for Cancer Screening, Biostat 2003 V 4, pp 27-40.

498. McKee, P., E. Calonje, Melanocytic Pathology, Mosby (New York) 2009.

499. McMenamin, M., et al, Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer, Can Res, V 59, 1999, pp 4291-4296.

500. McMurry, J., Begley, T., The Organic Chemistry of Biological Pathways, Roberts & Company Publishers, 2005.

501. McRobbie et al, MRI, From Picture to Proton, Cambridge, 2003.

502. McWilliams, RR, Brown, PD, Buckner, JC, et al. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003; 78:1529.

503. Meeks et al, Genomic characterization of high-risk non-muscle invasive bladder cancer, Oncotarget, Vol. 7, No. 46, 2016

504. Mehlen and Puisieux, Metastasis: a question of life or death, Nature Reviews, Vol 6 June 2006 p. 449

505. Mehraj et al, Role of MRI in Staging Urinary Bladder Tumors, 2017 Annals of Medical and Health Sciences Research, Vol 7, Special Issue 2

506. Meiling-Wesse, The Identification and Characterization of six novel ATG genes, Thesis, Institut für Biochemie der Universität Stuttgart, 2009

507. Mello, C., Return of the RNAi World: Rethinking Gene Expression and Evolution, Nobel Laureate Lecture 2006.

508. Melo et al, Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis, Cancer Cell, Volume 26, Issue 5, p707–721, 10 November 2014.

509. Mendelsohn, M., Cell Cycle Kinetics and Mitotically Linked Chemotherapy, Can Res V 29 pp 2390-2393, 1969.

510. Messina, J., et al, 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?, Scientific Reports (Nature), 24 October, 2012.

511. Metzker, M., Sequencing Technologies, Nature Rev V 11, 2010, pp 31-46.

512. Miller, A., M. Mihm, Melanoma, New England Journal Med pp. 355; 1 July 6, 2006.

513. Milo and Phillips, Cell Biology by the numbers, Garland (New York) 2016.

514. Milo, R., et al, Network Motifs: Simple Building Blocks of Complex Networks, Science, 2002, pp 824-827.

515. Miranda, T., P. Jones. DNA Methylation: The Nuts and Bolts of Repression, Cell Phys 2007 pp 384-390.

516. Misra, U., Ligation of Prostate Cancer Cell Surface GRP78 Activates a Proproliferative and Antiapoptotic Feedback Loop: A Role for Secreted Prostate-Specific Antigen, Jrl Bio Chem 2011, pp 1248-1259.

517. Miyamoto, S., et al, PHLPP-1 Negatively Regulates Akt Activity and Survival in the Heart, Cir Res, 2010.

518. Moody et al, Methods and novel technology for microRNA quantification in colorectal cancer screening, Clinical Epigenetics (2017) 9:119

519. Mooi, W., D. Peeper, Oncogene Induced Cell Senescence, NEJM, 2006 pp 1037-1045.

520. Mora, L., et al, Prostate Adenocarcinoma: Cellular and Molecular Abnormalities, Can Contrl, V 8, 2001, pp 551-561.

521. Morgan, D., The Cell Cycle, Sinauer (London) 2007.

522. Mori, Y, Kondziolka, D, Flickinger, JC, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998; 42:581.

523. Morton, D. et al, Sentinel-Node Biopsy or Nodal Observation in Melanoma, England Journal Med pp. 355;13 September 28, 2006.

524. Moscatelli, D., F. Wilson, PINing Down the Origin of Prostate Cancer, Science Translational Medicine, 4 August 2010 Vol 2 Issue 43 pp 43-48.

525. Mosquera, J., et al, Characterization of TMPRSS2-ERG Fusion in High Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications, Clin Can Res, V 14, 2008, pp 3380-3385.

526. Mosquera, J., et al, Morphological Features of TMPRSS2-ERG Gene Fusion Prostate Cancer, Jrl Path 2007 pp 91-101.

527. Mosquera, J., et al, Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States, Clin Can Res, V 15, 2009, 4706-4711.

528. Mostoslavsky and Bardeesy, Reprogramming Enhancers to Drive Metastasis, Cell 170, August 24, 2017

529. Mounce, H. O., Wittgenstein, U Chicago Press (Chicago) 1981.

530. Mulcahy et al, Targeting autophagy in cancer, Nature Reviews Cancer Y7, 528-542 (2017)

531. Munksgaard et al, Low ANXA10 expression is associated with disease aggressiveness in bladder cancer, British Journal of Cancer (2011) 105, 1379 – 1387

532. Munson and Shukla, Exosomes: Potential in Cancer Diagnosis and Therapy, Medicines 2015, 2, 310-327

533. Murphy, G., A. Herzberg, Atlas of Dermatopathology, Saunders (Philadelphia) 1996.

534. Murphy, K., S. Mian, Modelling Gene Expression Data Using Dynamic Bayesian Networks,.

535. Murphy, M., Diagnostic and Prognostic Biomarkers and Theraputic Targets in Melanoma, Humana (New York) 2012.

536. Murray, J., Mathematical Biology, Springer (New York) 1989.

537. Murtaza M et al, Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (2013) Nature.

538. Mustafa et al, Evaluation of Staging Accuracy of Dynamic MRI in Urinary Bladder Cancer, The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 , Page 3806-3811

539. Nadel, L. et al, Neural Connections and Mental Computation, MIT Press (Cambridge, MA), 1989.

540. Namkoong et al, Autophagy Dysregulation and Obesity-Associated Pathologies, Mol. Cells 2018; 41(1): 3-10

541. Nantermet, P., et al, Identification of Genetic Pathways Activated in Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland, Jrl Bio Chem, V 279, 2004. pp 1310-1322.

542. Narayanan, B., et al, Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti Inflammatory Drugs, Clin Can Res 2004 pp 7727-7737.

543. Nelson, E., et al, Inhibition of Akt Pathways in the Treatment of Prostate Cancer, 2007, Pros Can and Pros Dis, pp 331-339.

544. Nelson, W. G., et al, Prostate Cancer, NEJM, V 349 N 4 July 2003, pp 366-381.

545. Nelson, W., et al, The Role of Inflammation in the Pathogenesis of Prostate Cancer, Jrl Uro 2004 pp 1-7.

546. Neumann, A., R. Reddel, Telomere Maintenance and Cancer – Look, no Telomerase, Nature Review Cancer, V 2, Nov 2002.

547. Neuwirt, H., at al, Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer, Am Jrl Path, 2009, pp 1921-1930.

548. Neuzillet et al, IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer, BMC Cancer (2017) 17:636

549. Newton et al, Cell Survival and Cell Death, CSHL Press, 2020

550. Ng et al, Urinary biomarkers in bladder cancer: A review of the current landscape and future directions, Urologic Oncology: Seminars and Original Investigations, (2020)

551. Nguyen et al, Improving Bladder Cancer Imaging Using 3T Functional Dynamic Contrast-Enhanced MRI, Invest Radiol. 2014 June ; 49: 390–395

552. Nickerson, R.S., Using Computers, MIT Press (Cambridge, MA), 1986.

553. Nimmerjahn, P., J., Ravetch, Translating basic mechanisms of IgG effector activity into next generation cancer therapies, Can Immune, 2012, V 12 N 13.

554. Niu, Y., et al, Androgen Receptor is a Tumor Suppressor and Proliferator in Prostate Cancer, PNAS 2008 pp 12182-12187.

555. Nusse, R., Relays at the Membrane, Nature, 2005, V 438, pp 747-748.

556. O’Connor, Fluorescence In Situ Hybridization (FISH), Scitable, 2008

557. O’Hara, T., et al, Targeting the BCR-ABL Signaling Pathway in Therapy Resistant Philadelphia Chromosome Resistant Leukemia, Clin Can Res, Nov 2010.

558. O’Shaughnessy, J, et al, Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development, Clinical Cancer Research, Vol. 8, 314–346, February 2002.

559. O’Shaughnessy, J, et al, Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development, Clinical Cancer Research, Vol. 8, 314–346, February 2002.

560. Odom, D., et al, Core Transcriptional Regulatory Circuits in Human Hepatocytes, Mol Sys Bio, 2006, pp 1744-1754.

561. O'Driscoll, Expanding on Exosomes and Ectosomes in Cancer, NEJM, June 11, 2015

562. Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993 Jan 6;269:57-60.

563. Ohsumi, Y, Autophagy, Nobel Lecture 2016.

564. Organ, S., M. Tsao, An overview of the c-MET signaling pathway, Therapeutic Advances in Medical Oncology 3 , 2011, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225017/pdf/10.1177_1758834011422556.pdf

565. Orom, U.A., Derrien, T., Beringer, M., Gumireddy, K., Gardini, A., Bussotti, G., Lai, F., Zytnicki, M., Notredame, C., Huang, Q., et al. (2010). Long noncoding RNAs with enhancer-like function in human cells. Cell 143, 46-58.

566. Ott, R., et al, JunB is a gatekeeper for B-lymphoid leukemia, Oncogene (2007) 26, 4863–4871

567. Ovalle, W., P. Nahirney, Netter’s Essential Histology, Saunders (New York), 2008.

568. Oz et al, The Role of Computerized Tomography in the Assessment of Perivesical Invasion in Bladder Cancer, Pol J Radiol, 2016; 81: 281-287

569. Ozkumur, E., Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells, Sci Transl Med 3 April 2013: Vol. 5, Issue 179, p. 179.

570. Padhani, Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions, J Magn Reson Imaging. 2002 Oct;16:407-22

571. Palapattu, G., et al, The Case for the Role of Chronic Inflammation in the Development of Prostate Cancer, US Onc Rev, 2006, pp 112-113.

572. Pali, S., K. Robertson, Epigenetic Control of Tumor Suppression, Clin Rev in Euk Gene Exp 2007, pp 295-316.

573. Pali, S., K. Robertson, Epigenetic Control of Tumor Suppression, Critical Reviews™ in Eukaryotic Gene Expression, 17(4):295–316 (2007).

574. Pandya et al, Modes of Invasion during tumor dissemination, Mol Onc, 11, 2016

575. Panebianco et al, Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS, Eur Urol Sep 2018

576. Papatsoris, A., et al, The Power and Promise of "Rewiring" the Mitogen Activated Protein Kinase Network in Prostate Cancer Theraputics, Mol Can Ther, V 6, 2007, pp 811-819.

577. Paquette, et al, mTOR Pathways in Cancer and Autophagy, Cancers 2018, 10, 18

578. Pardini and Calin, MicroRNAs and Long Non-Coding RNAs and Their Hormone-Like Activities in Cancer, Cancers 2019, 11, 378

579. Park et al, MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer, Cancers 2021, 13, 632

580. Parker, Image Reconstruction in Radiology, CRC, 1990

581. Partin, A., et al, Combination of Prostate Specific Antigen, Clinical Stage and Gleason Score, JAMA, 1997 V 277 pp 1445-1451.

582. Pastell, R., M. Nevalainen, Prostate Cancer, Humana (Totowa) 2008.

583. Payne, S., C. Kemp, Tumor Suppressor Genetics, Carcinogenesis, V 26, 2005, pp 2031-2045.

584. Payne, S., C. Kemp, Tumor Suppressor Genetics, Carcinogenesis, V 26, 2005, pp 2031-2045.

585. Pecorino, L., Molecular Biology of Cancer, Oxford (New York) 2008.

586. Pei et al, MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites, 124 , Nature , VOL 470 , 3 February 2011

587. Pekarik, V., et al, Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs, Current Medicinal Chemistry, 2013, Vol. 20, No. 4

588. Pekarik, V., et al, Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs, Current Medicinal Chemistry, 2013, 20, 534-544

589. Peng and Croce, The role of MicroRNAs in human cancer, Signal Transduction and Targeted Therapy (2016) 1, 15004

590. Peng, C., et al, An Introduction to Logistic Regression Analysis and Reporting, Jrl Ed Res, V 96 2002 pp 3-9.

591. Pepe, M., The Statistical Evaluation of Medical Tests for Classification and Prediction, Oxford (New York) 2003.

592. Percus, J., Mathematics of Genome Analysis, Cambridge (New York) 2004.

593. Perego, M., et al, Heterogeneous Phenotype of Human Melanoma Cells with in Vitro and in Vivo Features of Tumor Initiating Cells.

594. Perkins, T., et al, Inferring Models of Gene Expression Dynamics, Journal of Theoretical Biology, Vol 230, 2004, pp. 289-299.

595. Peruzzi, B., D. Battero, Targeting the c-Met Signaling Pathway in Cancer, Clin Cancer Res 2006;12:3657-3660.

596. Pestell, R., M. Nevalainen, Prostate Cancer, Humana (Totowa, NJ) 2008.

597. Peter W. Laird, P., R. Jaenisch, DNA Methylation and Cancer, Human Molecular Genetics, Vol 3, 1487-95, 1994. http://hmg.oxfordjournals.org/content/3/suppl_1/1487.abstract?sid=0ef56eee-6b89-4808-9ded-2004a353783f

598. Peterson, Petri Nets, Computing Surveys, Vol. 9,No. 3,September 1977

599. Petralia and Thoeny, DW-MRI of the urogenital tract: applications in oncology, Cancer Imaging (2010) 10, S112S123

600. Petrella et al, Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?, Metabolites 2021, 11, 756

601. Petrocca, F., et al, Emerging Role of miR-106b-25/miR-17-92 Clusters in the Control of Transforming Growth Factor β Signalling, Can Res 2008, pp 8191-8194.

602. Pfeffer et al, Detection of Exosomal miRNAs in the Plasma of Melanoma Patients, J. Clinical Medicine 2015, 4, 2012–2027;

603. Phe, V., et al, Methylated Genes as Potential Biomarkers in Prostate Cancer, BJUI, 2010 pp 1364-1370.

604. Piao et al, Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker, Int. J. Mol. Sci. 2021, 22, 1713

605. Pinzani et al, Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors, Clin Chem Lab Med 2021; 59: 1181–1200

606. Planet, P. et al, Systematic Analysis of DNA Microarray Data: Ordering and Interpreting Patterns of Gene Expression, Cold Spring Harbor, Genome Research, 2001 pp 1149-1155.

607. Poliseno, L., et al, Identification of the miR-106b-25 MicroRNA Cluster as a Proto-oncogenic PTEN-targeting Intron That Cooperates with Host Gene MCM7 in Transformation, Science Signalling, 2010

608. Pollack A, Zagars GK, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 1;18:3904-11.

609. Pootrakul, L., et al, Expression of Stress Response Protein Grp78 is Associated with the Development of Castration Resistant Prostate Cancer. Hum Can Bio 2006 pp 5987-5993.

610. Porkka, K., Differentially Expressed Genes in Prostate Cancer, Doctoral Dissertation, Univ Tampere, Finland, 2003.

611. Poulikakos, P., D. Solit, Resistance to MEK Inhibitors, Science Signalling, 2011 pp 1-2.

612. Powell et al, Disruption of a Sirt1-Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation, Cancer Res; 71(3) February 1, 2011

613. Powell, E., et al, Contribution of p53 to Metastasis, Cancer Discovery, April 2014.

614. Powell, M., et al, Disruption of a Sirt1 -Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation, Cancer Res Published OnlineFirst December 28, 2010.

615. Prat et al, Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer, Lancet, Vol 75 Month January, 2022

616. Prescott, J., et al, Epidemologic Evidence for the Role of Telomere Dysfunction in Cancer Etiology, Mutation Res, 2011.

617. Pritchard et al, MicroRNA profiling: approaches and considerations, Nature Reviews Genetics, May 2012

618. Pritchard, C., et al, MicroRNA profiling: approaches and considerations, Nature Reviews, 358 , MAY 2012, VOLUME 13.

619. Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, DíAmico AV. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. IJROBP (1999 Oct 1) 45:563-6.

620. Provenzano and Allayeh, Liquid Biopsy to Detect DNA/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction, Frontiers in Oncology, 1 July 2020, Volume 10, Article 778

621. Pulla, V., et al, IRT1 Pathway in T2DM, https://www.researchgate.net/publication/259223485_SIRT1_Pathway_in_T2DM

622. Punglia, R., et al, Effect of Verification Bias on Screening for Prostate Cancer, NEJM, 2003 V 349, pp 335-342.

623. Putzi, M., A. De Marzo, Morphologic Transitions Between Proliferative Inflammatory Atrophy and High Grade Prostatic Intraepithelial Neoplasia, Adult Uro 2000 pp 828-832.

624. Puzio-Kuter et al, Inactivation of p53 and Pten promotes invasive bladder cancer, Genes & Development 23:675–680 ! 2009

625. Qin, J., et al, The PSA−/lo Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that Resist Castration, Cell Stem Cell, Volume 10, Issue 5, 556-569, 4 May 2012.

626. Quintana, E., et al, Efficient Tumor Formation by Single Human Melanoma Cells, Nature V 456, Dec 2008, pp 593.

627. Qureshi and Sacan, A novel method for the normalization of microRNA RT-PCR data, BMC Medical Genomics 2013

628. Rabie et al, Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer, J Clin Diag Res 2016

629. Rabinowitz and White, Autophagy and Metabolism, Science, Vol 330 3 Dec 2010

630. Radbill, AE, Fiveash, JF, Falkenberg, ET, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004; 101:825.

631. Radu, A., et al, PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1, Mol and Cell Bio, V 23, 203, pp 6139-6149.

632. Rahman and Islam, Mammalian Sirt1: insights on its biological functions, Cell Communication and Signaling 2011, 9:11

633. Rak, Organ Seeking Vesicles, Nature, Nov 2015

634. Rakhlin, O. et al, MicroRNA-34 Mediates AR-dependent p53-indiced Apoptosis in Prostate Cancer, Can Bio & Therapy 2008 pp 1288-1296.

635. Ramos, D., et al, Analysis of Integrin Receptors for Laminin and Type IV Collagen on Metastatic B16 Melanoma Cells, Cancer Research, 1990.

636. Ramoutar, R., J. Brumaghim, Antioxidant and Anticancer Properties and Mechanisms of Inorganic Selenium, Oxo Sulfur, and Oxo Selenium Compounds, Cell Biochem 2010, pp 1-23.

637. Rando, Combinatorial complexity in chromatin structure and function: revisiting the histone code, Curr Opin Genet Dev. 2012 April ; 22(2): 148–155.

638. Rao, Autophagy: a programmed cell death, Arch Gen Int Med, 2017, V1 No 1

639. Rappa et al, Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy, Int Jrl Mol Sci, 2019

640. Rattue, P., Repeat Prostate Biopsies, Medical News Today, February 2012.

641. Reddy, MicroRNA (miRNA) in cancer, Cancer Cell International (2015) 15:38

642. Ren et al, Detection of miRNA as Non-Invasive Biomarkers of Colorectal Cancer, Int. J. Mol. Sci. 2015, 16, 2810-2823

643. Reuland, S., et al, MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD), Journal of Investigative Dermatology , (29 November 2012) , doi:10.1038/jid.2012.400.

644. Reuland, S., et al, MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD), Journal of Investigative Dermatology , (29 November 2012) , doi:10.1038/jid.2012.400.

645. Reya, T., et al, Stem Cells, Cancer, and Cancer Stem Cells, Nature, 2001 pp 105-111.

646. Reya, T., H. Clevers, Wnt Signalling in Stem Cells and Cancer, Nature V 434 p 843, 2005.

647. Richard et al, MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors, Cancers 2021, 13, 5332

648. Rinn, J., H. Chang, Genome Regulation by Long Noncoding RNAs, Annu. Rev. Biochem. 2012. 81:145–66.

649. Risbridger, G., R. Taylor, Regulation of Prostatic Stem Cells by Stromal Niche in Health and Disease, Endocrinology 2008 149:4303-4306.

650. Rizzo et al, Radiomics: the facts and the challenges of image analysis, European Radiology Experimental (2018) 2:36

651. Roach M, DeSilvio M, et. al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol (2003 May 15) 21: 1904-11.

652. Robert, C., et al, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, NEJM, 2011, pp 1-20.

653. Robert, J., Interpreting the Homeobox; Metaphors of Gene Action and Activation in Development and Evolution, Evo & Dev, 2001 V 3:4 pp 287-295.

654. Robertson, K., A. Wolffe, DNA Methylation in Health and Disease, Nat Rev Gen 2000 pp 11-19

655. Robertson, K., DNA methylation, methyltransferases, and cancer, Oncogene (2001) 20, 3139-3155

656. Roesch, A. et al, A Temporarily Distinct Subpopulation of Slow Cycling Melanoma Cells Is Required for Continuous Tumor Growth, Cell V 141 , May 2010, pp 583-594.

657. Rosen, E., et al, Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency Implicating Wnt Signalling, Cell Neuron, 2911, pp 1030-1042.

658. Rosen, J., C. Jordan, The Increasing Complexity of the Cancer Stem Cell Paradigm, Science, 2009, pp 1670-1672.

659. Rosenberg, S., Gene Therapy for Cancer, JAMA 1992 pp 2416-2419.

660. Rosenberg, S., The Transformed Cell: Unlocking the Mysteries of Cancer, Harper (New York) 1993.

661. Ross, L. et al, Psychiatric, Hospitalizations among Survivors of Cancer in Childhood or Adolescence, NEJM August 14, 2003.

662. Rossi et al, Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant, (SNV) Single Cell Analysis, Cancers 2022, 14, 3925

663. Roy, S., et al, Inhibition of PI3K/AKT and MAPK/ERK pathways causes Activation of FOXO Transcription Factor, Jrl Mol Sig 2010, pp 1-13.

664. Rubin, M., A. Chinnaiyan, Bioinformatics Approach Leads to the Discovery of the TMPRSS2:ETS gene Fusion in Prostate Cancer, Lab Inv 2006, pp. 1099-1102.

665. Rubin, M., et al, Overexpression Amplification and Androgen Regulation of TPD52 in Prostate Cancer, Can Res 2004 pp 3814-3822.

666. Sachs, K., et al, Causal Protein Signalling Networks Derived from Multiparameter Single Cell Data, Science, 2005, pp 523-529.

667. Saha, Basics of PET Imaging, Springer, 2010

668. Saha, S, Meyer, M, Krementz, ET, et al. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1994; 1:38.

669. Saitou, N., M. Nei, The Neighbor Joining Method: A New Method for Reconstructing Phylogenetic Trees, Molecular Biological Evolution, Vol 4 1987 pp 406-425.

670. Salmanoglu et al, A glance at imaging bladder cancer, Clin Transl Imaging. 2018 August ; 6: 257–269

671. Salvati, M, Cervoni, L, Caruso, R, Gagliardi, FM. Solitary cerebral metastasis from melanoma. Clin Neurol Neurosurg 1996; 98:12.

672. Samaratunga, H., J. Epstein, What is the Molecular Pathology of Low Risk Prostate Cancer, World J Uro, V 26, 2008, pp 431-436.

673. Sampson, JH, Carter, JH Jr, Friedman, AH, Seigler, HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11.

674. Sanda, M., I. Kaplan, A 64 Year Old Man with Low Risk Prostate Cancer, JAMA, V 301, 2009, pp 2141-2151.

675. Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V. Adjuvant Androgen Deprivation Impacts Late Rectal Toxicity After Conformal Radiotherapy Of Prostate Carcinoma. Br J Cancer 2002 Jun 17;86:1843-7

676. Sankaran, S. M. & Gozani, O. Characterization of H3.3K36M as a tool to study H3K36 methylation in cancer cells. Epigenetics 12, 917–922 (2017).

677. Sankaran, S. M., Wilkinson, A. W., Elias, J. E. & Gozani, O. A PWWP domain of histone-lysine N-methyltransferase NSD2 binds to dimethylated Lys-36 of histone H3 and regulates NSD2 function at chromatin. J. Biol. Chem. 291, 8465–8474 (2016).

678. Sanli et al, Bladder cancer, Nature Reviews, Disease Primers, Volume 3, Article Number 17022, 2017

679. Santoni et al, Urinary Markers in Bladder Cancer: An Update, Frontiers in Oncology , 1 September 2018 , Volume 8 , Article 362

680. Sanyal et al, Polymorphisms in DNA repair and metabolic genes in bladder cancer, Carcinogenesis vol.25 no.5 pp.729--734, 2004

681. Sarkar, D., et al, mda-9/Syntenin: More than Just a Simple Adapter Protein When It Comes to Cancer Metastasis, Cancer Res 2008; 68:. May 1, 2008.

682. Sauter, Reliable Biomarkers to Identify New and Recurrent Cancer, Eur J Breast Health 2017; 13: 162-7

683. Savli, H., et al, Gene Network and Canonical Pathway Analysis in Prostate Cancer, Exp Mol Med, V 40, 2008, pp 176-185.

684. Sawaya, R, Bindal, RK. Metastatic brain tumors. In: Brain Tumors, Kaye, AH, Laws, ER Jr (Eds), 1995, Churchill Livingstone, New York 1995. p.923.

685. Scherl, A., et al, Prostatic Intraepithelial Neoplasia and Intestinal Metaplasia in Prostates of Probasin-RAS Transgenic Mice, The Prostate 2004 pp 448-459

686. Schmidt, U., et al, Quantitative Multi Gene Expression Profiling of Primary Prostate Cancer, The Prostate V 66 pp 1521-1534, 2006.

687. Schmitt, A, H., Chang, Long RNAs wire up cancer growth, Nature, 14 August, 2013.

688. Schnell. S, T. Turner, Reaction Kinetics in Intracellular Environments with Macromolecular Crowding, Biophys and Molec Bio vol 85 2004 pp. 235-260.

689. Schnitt, Biopsy Interpretation Of The Breast 3rd Ed, 2018 Wolters Kluwer.

690. Schoder and Larson, Positron Emission Tomography for Prostate, Bladder, and Renal Cancer, Sem in Nucl Med, 2004

691. Schroder, F., et al, Screening and Prostate Cancer Mortality in a Randomized European Study, NEJM, 2009 V 360 pp 1320-1328.

692. Schroder, F., Progress in Understanding Androgen Independent Prostate Cancer, Euro Uro, V 53, 2008, pp 1129-1137.

693. Schroder, F., R., Kranse, Verification Bias and the Prostate Specific Antigen Test, NEJM, 2003, V 349, pp 393-395.

694. Schultheiss TE; Lee WR; Hunt MA; Hanlon AL; Peter RS; Hanks GE. Late GI and GU Complications in the Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys 1997 Jan 1;37:3-11)

695. Schulz, W., Molecular Biology of Human Cancers, Springer (New York) 2007.

696. Schuster, C., et al, MicroRNA expression profiling of specific cells in complex archival tissue stained by immunohistochemistry, Laboratory Investigation (2011) 91, 157–165.

697. Schwartz, J., Homeobox Genes, Fossils, and the Origin of the Species, Anat Rec 1999 V 257 pp 15-31.

698. Schwartzentruber, D., et al, gp100 Peptide Vaccine and Interleukin 2 in Patients with Advanced Melanoma, NEJM, 2011, pp 2119-2122.

699. Schwarzenbach and Gahan, MicroRNA Shuttle from Cell-To-Cell by Exosomes and Its Impact in Cancer, Non-coding RNA 2019, 5, 28;

700. Scott and Munkley, Glycans as Biomarkers in Prostate Cancer, Int. J. Mol. Sci. 2019, 20, 1389

701. Scott, M., A Rational Nomenclature for Vertebrate Homeobox, Nu Acid Res 1993 V 21 No 8 pp 1687-1688.

702. Segura, M., et al, Melanoma MicroRNA Signature Predicts Post-Recurrence Survival, Clin Cancer Res Published OnlineFirst February 23, 2010.

703. Segura, M., et al, MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy, Carcinogenesis (2012) doi: 10.1093/carcin/bgs205 First published online: June 12, 2012 http://carcin.oxfordjournals.org/content/early/2012/08/30/carcin.bgs205.abstract.

704. Selek, U, Chang, EL, Hassenbusch SJ, 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004; 59:1097.

705. Sengupta et al, Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress, Molecular Cell 40, October 22, 2010

706. Seoane, J., et al, Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation, Cell 2004, pp. 211-223.

707. Serrano and Munoz-Espi, Cellular Senescence in Disease, Academic, 2022

708. Setlur, S., et al, Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer, Cancer Res, V 67, 2007, pp 10296-10303.

709. Sevigani, C., et al, Mammalian microRNAs: A Small World for Fine-tuning Gene Expression, Mam Gene V 17 2006, pp 189-201.

710. Sevli, S., et al, The function of microRNAs, small but potent molecules, in human prostate cancer, Prostate Cancer and Prostatic Diseases (2010) 13, 208–217

711. Shackelford, D., R. Shaw, The LKB1–AMPK pathway: metabolism and growth control in tumour suppression, Nature Reviews, Cancer Volume 9, August 2009, 563

712. Shackleton, M., E. Quintana, Progress in understanding melanoma propagation, Mol Oncol. 2010 October ; 4: 451–457.

713. Shah et al, Circulating Extracellular Vesicles in Human Disease, NEJM, Sept 6, 2018

714. Sharifi, N., et al, Androgen Deprivation Therapy for Prostate Cancer, JAMA, V 294, 2005, pp 238-244.

715. Sharma, A., et al, Targeting Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Kinase in the Mutant (V600E)B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases, Cancer Res 2006; 66:. August 15, 2006.

716. Shaw, R., et al, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress, Proc Natl Acad Sci U S A. 2004 Mar 9;101:3329-35. Epub 2004 Feb 25.

717. Shay, J. et al, Cancer and Telomeres - An Alternative to Telomerase, Science, 15 June 2012, Vol 336, pp 1388-1390.

718. Shay, J., W. Wright, Telomerase therapeutics for cancer: challenges and new directions, Nature Reviews Drug Discovery AOP, published online 9 June 2006.

719. Shen and Rubin, Prostate Cancer, CSHP, 2019

720. Shen et al, Identification of Potential Biomarkers for Thyroid Cancer Using Bioinformatics Strategy: A Study Based on GEO Datasets, BioMed Research International, Volume 2020

721. Shen, M., C. Abate-Shen, Roles of the Nkx3.1 Homeobox Gene in Prostate Organogenesis and Carcinogenesis, Dev Dynam, V 228, 2003, pp 767-778.

722. Sherbet, Growth Factors, Elsevier, 2011

723. Shi X, Sun M, Liu H, Yao Y, Song Y. (2013) Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Letters, August 2013.

724. Shigeyasu et al, Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers, AACR, Clinical Cancer Research, 2017

725. Shmulevich, I, et al, Gene Perturbation and Intervention in Probabilistic Boolean Networks, Bioinfo 2002 pp 1319-1331.

726. Shmulevich, I. et al, Control of Stationary Behavior in Probabilistic Boolean Networks, J Bio Sci 2002, pp 431-445.

727. Shmulevich, I., E., Dougherty, Genomic Signal Processing, Princeton (Princeton) 2007.

728. Shmulevich, I., et al, From Boolean to Probabilistic Networks as Models of Genetic Regulatory Networks, Proc IEEE 2002 pp 1778-1792.

729. Shyam, E. et al, The ERG Gene: A Human Gene Related to the ETS Oncogene, PNAS 1987, pp 6131-6135.

730. Sica, G., Bias in Research Studies, Radiology, 2006 V 238 pp 780-789.

731. Siderovski, D., F. Willard, The GAPs, GEFs, and GDIs of Heterotrimeric G protein alpha subunits, Int Jrl Bio Sci, 2005, pp 51-66.

732. Sigova, A.A., Mullen, A.C., Molinie, B., Gupta, S., Orlando, D.A., Guenther, M.G., Almada, A.E., Lin, C., Sharp, P.A., Giallourakis, C.C., and Young, R.A. (2013). Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. Proc. Natl. Acad. Sci. USA 110, 2876-2881.

733. Silverman, Kaja, The Subject of Semiotics, Oxford University Press (New York), 1983.

734. Simmons et al, Diverse Roles of SIRT1 in Cancer Biology and Lipid Metabolism, Int. J. Mol. Sci. 2015, 16, 950-965

735. Simon, W., Mathematical Techniques for Biology and Medicine, Dover (New York) 1986.

736. Sinnamon and Czaplinski, RNA detection in situ with FISH-STICs, RNA 20:260–266; Published by Cold Spring Harbor Laboratory Press for the RNA Society, Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.041905.113 , 2014

737. Sirvent, A., et al, Cytoplasmic signalling by the c-Abl tyrosine kinase in normal cancer cells, Bio Cell V 100 2008 pp 617-631.

738. Skibber, JM, Soong, Sj, Austin, L, et al. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3:118.

739. Slaby, O., et al, MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009 Nov 14;8:102. doi: 10.1186/1476-4598-8-102.

740. Slingerland, J., M. Pagano, Regulation of Cdk Inhibitor p27 and Its Deregulation in Cancer, Jrl Cell Phys 2000 pp 10-17.

741. Smalley, K., K. Flaherty, Integrating BRAF/MEK Inhibitors into Combination Therapy for Melanoma, Brit Jrl Cancer, 2009 pp 431-435.

742. Smith and Guzzo, Urinary markers for bladder cancer, F1000Prime Reports 2013, 5:21

743. Smith MR, Finkelstein JS, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb;87:599-603

744. Soheilifar et al, Angioregulatory microRNAs in Colorectal Cancer, Cancers 2020, 12, 71

745. Sole and Lawrie, MicroRNAs and Metastasis, Cancers, 2020, V 12, No 96

746. Sole, R., Cancer Stem Cells as the Engine of Tumor Progression, Journal of Theoretical Biology 253 (2008) 629– 637.

747. Solit and Rosen, Resistance to BRAF Inhibition in Melanomas, New Engl J Med 364;8 772 February 24, 2011.

748. Soung et al, Exosomes in Cancer Diagnostics, Cancers 2017, 9, 8

749. Spirtes, P., et al, Constructing Bayesian Network Models of Gene Expression Networks from Microarray Data,.

750. Stahl, J., et al, Deregulated Akt3 Activity Promotes Development of Malignant Melanoma, CANCER RESEARCH 64, 7002–7010, October 1, 2004.

751. Steffan, J., et al, HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers, Journal of Cell Science 123, 1151-1159, 2010.

752. Stein, G., et al, The Molecular Basis of Cell Cycle and Growth Control, Wiley (New York) 1999.

753. Stephen, A., et al, Dragging Ras Back in the Ring, Cancer Cell 25, March 17, 2014.

754. Stone, A, Cooper, J, Koenig, KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest 2004; 22:492.

755. Strahl and Allis, The language of covalent histone modifcations, Nature ,Vol 403 , 6 January 2000

756. Strathdee, G., R., Brown, Aberrant DNA Methylation in Cancer; Potential Clinical Interventions, Exp Rev Mol Med, 2002, pp 1-17

757. Stressman C., et al, Azacytidine causes complex DNA methylation responses in myeloid leukemia, Mol Cancer Ther. 2008 Sep;7:2998-3005.

758. Stribu and Tavel, What are Biomarkers, Curr Opin HIV AIDS. 2010 November ; 5: 463–466

759. Strong, J., Concepts of Classical Optics, Freeman (San Francisco) 1958.

760. Studier, J., K. Kappler, A Note on the Neighbor Joining Algorithm, Molecular Biological Evolution, Vol 5 1988 pp 729-731.

761. Styerberg, E., et al, Prediction of Indolent Prostate Cancer, Jrl Uro, 2007, V 177, pp 107-112.

762. Su et al, Function and Regulation of Let-7 Family microRNAs , MicroRNA, 2012, 1, 34-39

763. Su, F., et al, RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, N Engl J Med 366;3 nejm.org January 19, 2012.

764. Su, L., Early Diagnosis and Treatment of Cancer: Prostate Cancer, Saunders(New York) 2010.

765. Sugeeta et al, Biomarkers in Bladder Cancer Surveillance, Frontiers in Surgery , 1 September 2021 , Volume 8 , Article 735868

766. Suh, B., B. Hille, PIP2 is a necessary cofactor for ion channel function: How and why? Annu Rev Biophys. 2008; 37: 175–195.

767. Sullivan et al, The Emerging Roles of Extracellular Vesicles as Communications Vehicles within the Tumor Microenvironment and Beyond, Front in Endocrin, August 2017

768. Sumimoto, H. et al, The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, The Rockefeller University Press, Vol. 203, No. 7, July 10, 2006 1651–1656.

769. Sun et al, The Emerging Functions of Circular RNAs in Bladder Cancer, Cancers 2021, 13, 4618.

770. Sun M, Kraus WL. (2013) Minireview: Long Non-Coding RNAs: New “Links” Between Gene Expression and Cellular Outcomes in Endocrinology. Mol Endocrinol, August 2013.

771. Suzuki, H. et al, Roles and causes of abnormal DNA methylation in gastrointestinal cancers, Asian Pac J Cancer Prev. 2006 Apr-Jun;7:177-85.

772. Swanson, K, et al, Prostate Specific Antigen, Am Jrl Clin Path, 2006, V 125 pp 331-333.

773. Swiatoniowski, G et al, E-cadherin and Fibronectin Expressions Have No Prognostic Role in Stage II Ductal Breast Cancer, ANTICANCER RESEARCH 25: 2879-2884 (2005).

774. Szallasi, Z. System Modeling in Cellular Biology: From Concepts to Nuts and Bolts. MIT Press (Cambridge) 2006.

775. Taby, R., J-P Issa, Cancer Epigenetics, CA 2010 pp376-392.

776. Tadin et al, Diagnostic Accuracy of Ultrasound T-staging of the Urinary Bladder Cancer in Comparison with Histology in Elderly Patients, Coll Anthropol 38, 2014

777. Tai et al, Exosomes in cancer development and clinical applications, Cancer Science. 2018;109:2364–2374

778. Taichman, R., et al, The Evolving Biology and Treatment of Prostate Cancer, Jrl Clin Invest 2007, pp 2351-2360.

779. Tam et al, Optimization of miRNA-seq data preprocessing, Briefings in Bioinformatics, 16, 2015, 950–963

780. Tamura et al, Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer, Extracell Vesicles Circ Nucleic Acids 2021;2:148-74

781. Tang, D., et al, Prostate Cancer Stem/Progenitor Cells, Mol Car 2007 pp. 1-14.

782. Taveira da Cruz , A., M. Galvonas Jasiulionis, miRNAs and Melanoma: How Are They Connected? Dermatology Research and Practice, Volume 2012, Article ID 528345, 12 pages doi:10.1155/2012/528345.

783. Taylor, B., Integrative Genomic Profiling of Human Prostate Cancer, Cancer Cell, V 18, 2010, pp 1-12.

784. Taylor, W., et al, p27 Deficiency Promotes Prostate Carcinogenesis But Does Not Affect the Efficacy of Retinoids in Suppressing the Neoplastic Process, BMC Cancer, 2010 10:541.

785. Tefferi, A., J. Vardiman, Myelodysplastic Syndromes, N Engl J Med 2009; V 361: pp 1872-85

786. Tekes et al, Dynamic MRI of Bladder Cancer: Evaluation of Staging Accuracy, AJR:184, January 2005

787. Teng, G., F Papavasiliou, Long Noncoding RNAs: Implications for Antigen Receptor Diversification, Advances in Immunology, Volume 104, 2009.

788. Teschendorff, A., et al, Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules, BioMed, BMC Cancer, 2010.

789. Thery et al, Circulating Tumor Cells in Early Breast Cancer, JNCI Cancer Spectrum (2019) 3

790. Thestrup et al, Biparametric versus multiparametric MRI in the diagnosis of prostate cancer, Acta Radiologica Open, 5 1–8, 2016

791. Thind and Wilson, Exosomal miRNAs as cancer biomarkers and therapeutic targets, Journal of Extracellular Vesicles 2016, 5:

792. Thomas et al, Excision Margins in High-Risk Malignant Melanoma, New England Journal Med, pp 350; 8 February 19, 2004.

793. Thompson, I. et al, Operating Characteristics of Prostate Specific Antigen, JAMA 2005 V 294 pp 66-70.

794. Thompson, I., et al, Assessing Prostate Cancer Risk, Jrl Nat Cancer Inst V 98 2006 pp 529-534.

795. Thompson, J., et al, Textbook of Melanoma, Martin Dunitz (New York) 2004.

796. Thomsen, M., et al, Loss of JUNB/AP-1 promotes invasive prostate cancer, Cell Death & Differentiation , (19 December 2014) doi:10.1038/cdd.2014.213.

797. Tiainen, M. et al, Growth arrest by the LKB1 tumor suppressor: induction of p21 WAF1/CIP1 , Human Molecular Genetics, 2002, Vol. 11, No. 13 1497–1504.

798. Tiberio et al, Challenges in Using Circulating miRNAs as Cancer Biomarkers, Hindawi Publishing Corporation, BioMed Research International, Volume 2015, Article ID 731479

799. Tollefsbol, Epigenetics in Human Disease, Academic (New York) 2012.

800. Tomlins, A., ETS Rearrangements and Prostate Cancer Initiation, Nature, V 448, 2007, pp 595-599.

801. Tomlins, S., et al, ETS Gene Fusion in Prostate Cancer, Eur Jrl Uro 2009 pp 1-12.

802. Tomlins, S., et al, Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer, Science, V 310, 2005, pp 644-648.

803. Trang, P., et al, MicroRNAs as potential cancer therapeutics, Oncogene, V 27 2009.

804. Trojan, J., et al, 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer, Jrl Med Gen 2000;47:272–276.

805. Tsao et al, Case 6-2004: A 48-Year-Old Woman with Multiple Pigmented Lesions and a Personal and Family History of Melanoma, New England Journal Med pp. 350;9

806. Tschopp, J., et al, Apoptosis: Silencing the death receptors, Current Biology Volume 9, Issue 10, 20 May 1999, Pages R381–R384.

807. Turing, A., The Chemical Basis of Morphogenesis, Phil Trans Royal Soc London B337 pp 37-72, 19459.

808. Türkbey et al, Diffusion-weighted MRI for detecting and monitoring cancer: a review of current applications in body imaging, Diagn Interv Radiol 2012; 18:46–59

809. Turkel et al , Late Onset Psychosis in Survivors of Pediatric Central Nervous System Malignancies, J Neuropsychiatry Clin Neurosci 19:293-297, August 2007

810. Turner et al, Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial, Vol 21, Lancet Oncology, 2020.

811. Turner, D., The Role of ETS Transcriptional Regulation in Hormone Sensitive and Refractory Prostate Cancer, Open Can Jrl, 2010, V 3, pp 40-48.

812. Tuxhorn, J., et al, Reactive Stroma in Human Prostate Cancer, Clin Cancer Res V 8 2002 pp 2912-2923.

813. Vader. et al, Extracellular vesicles: emerging targets for cancer therapy, Trends in Molecular Medicine, July 2014, Vol. 20, No. 7

814. Vaidyanathan et al, SNP-SNP interactions as risk factors for aggressive prostate cancer, F1000Research 2017, 6:621 Last updated: 01 JUN 2017

815. van der Heide, L., et al, The Ins and Outs of FOXO Shuttling, Biochem Jrl 2004, pp 297-309.

816. Vanacore et al, Micrornas in prostate cancer: an overview, Oncotarget, 2017, Vol. 8, (No. 30), pp: 50240-50251

817. Vandekerkhove et al, Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer, AACR Sept 2017

818. Vander Heiden, M., et al, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, SCIENCE VOL 324 22 MAY 2009.

819. Vasiljevic, N , et al, Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer, Prostate Cancer and Prostatic Disease (2013) 16, 35–40.

820. Vasiljevic, N , et al, Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer, Prostate Cancer and Prostatic Disease (2013) 16, 35–40

821. Vazquez, F., et al, The PTEN Tumor Suppressor Protein, Biochimica et Biophysica, 2000 pp 21-25.

822. Venet et al, Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome, PLOS, http://www.ploscompbiol.org/article/info%3Adoi%2F10.1371%2Fjournal.pcbi.1002240

823. Vester B, Wengel J (2004). LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43, 13233–13241.

824. Viatour, P., et al, Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation, Trends in Biochemical Sciences Volume 30, Issue 1, January 2005, Pages 43–52.

825. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? Int J Radiat Oncol Biol Phys. 2001 Dec 1;51:1200-8.

826. Vidwans, S. et al, A Melanoma Molecular Disease Model, PLOS ONE March 2011 V 6 No 3. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018257.

827. Vis, A., F. Schroder, Key Targets of hormonal treatment of prostate cancer; Part 2 the androgen receptor and 5α reductase, BJUI 2009 pp 1191-1197.

828. Visser et al, Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer, Nature, Prostate Cancer and Prostatic Diseases, July 9, 2022

829. Vliestra, R., et al, Frequent Inactivation of PTEN in Prostate Cancer Cell Lines and Xenografts, Can Res, V 58, 1998, pp 2720-2723.

830. Vogelstein, B., K., Kinzler, Cancer Genes and the Pathways They Control, Nature Med, V 10, 2004, pp 789-799.

831. Vohradsky, J., Neural Network Model of Gene Expression, FASEB Journal, Vol 15, March 2001, pp. 846-854.

832. Vokoyama, S. et al, A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma, Nature 480, 99–103 (01 December 2011)

833. Volinia et al, A microRNA expression signature of human solid tumors defines cancer gene targets, PNAS February 14, 2006 vol. 103 no. 7 2257–2261

834. Vollmer, R., Predictive Probability of Serum Prostate Specific Antigen for Prostate Cancer, Am Jrl Clin Path 2006 V 125, pp 336-342.

835. von Knobloch, R., et al, Genetic Pathways and New Progression Markers for Prostate Cancer Suggested by Microsatellite Allelotyping, Clin Can Res, V 10, 2004, pp 1064-1073.

836. Wajapeyee, N., et al, Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7, Cell 132, 363–374, February 8, 2008.

837. Walsh, P., et al, Localized Prostate Cancer, NEJM, V 357, 2007, pp 2696-2705.

838. Walterfang M, Wood SJ, Velakoulis D, Copolov D, Pantelis C.Diseases of white matter and schizophrenia-like psychosis.: Aust N Z J Psychiatry. 2005 Sep;39:746-56

839. Wang et al, Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research, BioMed Research International, Volume 2014, Article ID 789561

840. Wang et al, Serum miR-22 may be a biomarker for papillary thyroid cancer, Oncology Letters 17: 3355-3361, 2019

841. Wang et al, Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation, Nature Communications , (2019) 10:95

842. Wang et al, The Blood Biomarkers of Thyroid Cancer, Cancer Management and Research 2020:12

843. Wang et al, UPK1B promotes the invasion and metastasis of bladder cancer via regulating the Wnt/β-catenin pathwayBax et al, Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways, Cancers 2019, 11, 1244

844. Wang J., et al, Germline mutations of the LKB1 (STK11) gene in Peutz-Jeghers patients, J Med Genet 1999;36:365–368.

845. Wang, C., et al, Serum TIMP-1 in Gastric Cancer Patients, Ann Clin Lab Sci, 2006, pp 23-30.

846. Wang, E., Cancer Systems Biology, CRC (New York) 2010.

847. Wang, R. et al, Rational Approach to Implementation of Prostate Cancer Antigen 3 into Clinical Care, Cancer, Nov 2009.

848. Wang, The Capable ABL: What Is Its Biological Function?, Molecular and Cellular Biology p. 1188–1197 April 2014 Volume 34 Number 7

849. Wang, X, et al, Notch-1 Expressing Cells are Indispensible for Prostatic Branching Morphogenesis, Jrl Bio Chem, V 279, 2004, pp 24733-24744.

850. Wang, X., et al, A Luminal Epithelial Stem Cell That is a Cell of Origen for Prostate Cancer, Nature 2009 V 461 pp 495-500.

851. Wang, X., et al, Signal transducers and activators of transcription 3 mediates up-regulation of angiotensin II-inducted tissue inhibitor of metalloproteinase-1 expressed in cultured human senescent fibroblasts, Clin Med Jrl, 2006, pp 1094-1102.

852. Wang, Y., et al, Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma, BMC Medicine 2010, 8:14.

853. Wang, Z., M. Shen, Revisiting the concept of cancer stem cells in prostate cancer, Oncogene (2011) 30, 1261–1271.

854. Warburg, O., On the Origin of Cancer Cells, Science 24 February 1956, Volume 123, Number 3191.

855. Ward and Bryan, Liquid biopsies for bladder cancer, Transl Androl Urol 2017;6:331-335

856. Washeti, S., et al, Computational analysis of noncoding RNAs, WIREs RNA 2012. doi: 10.1002/wrna.1134.

857. Watson, D. et al, ETS Transcription Factor Expression and Conversion During Prostate and Breast Cancer Progression, Open Access Cancer Journal, 2010, pp 24-39.

858. Watson, J, F. Crick, Molecular Structure of Nucleic Acids, Nature, pp 737-738, April 25, 1953.

859. Watson, J., et al, Molecular Biology of the Gene, 6th Edition, Pearson (New York) 2008.

860. Weber DC; Bieri S; Kurtz JM; Miralbell R. Prospective Pilot Study of Sildenafil For Treatment of Postradiotherapy Erectile Dysfunction In Patients With Prostate Cancer. J Clin Oncol 1999 Nov;17:3444-9.

861. Weedon, D., Skin Pathology, Churchill (New York) 1997.

862. Weinberg, R., The Biology of Cancer, Garland (New York) 2007.

863. Wellbrock, C., R. Marais, Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation, The Journal of Cell Biology, Vol. 170, No. 5, August 29, 2005 703–708.

864. Wen et al, The potential of using blood circular RNA as liquid biopsy biomarker for human diseases, Protein Cell 2021, 12:911–946

865. Werbowetski-Ogilvie, T., et al, Evidence for the Transition of Neoplastic Properties From Transformed to Normal Human Stem Cells, Oncogene, V 30, pp 4632-4644, 2011.

866. Werhli, A., D. Husmeier, Reconstructing Gene Regulatory Networks with Bayesian Networks, 2007 Bioinfo and Stat pp 1-45.

867. Westbrook and Talbot, MRI in Practice, 5th Ed, Wiley, 2019

868. Westbrook, MRI Technique, 4th Ed, Wiley, 2014

869. Wiluscz, J., et al, Long noncoding RNAs: functional surprises from the RNA world, Genes Dev. 2009 23: 1494-1504.

870. Winston, Artificial Intelligence, 2nd Ed, Addison Wesley 1984

871. Wojcik et al, The Paris System for Reporting Urinary Cytology, Academic, 2022

872. Wojno, K., et al, Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study, Am Health Drug Benefits. 2014;7:129-134

873. Wolf, D., et al, Transcriptional Down Regulation of c-myc in Human Prostate Carcinoma Cells by the Synthetic Mibolerone, Br Jrl Cancer, V 65, 1992, pp 376-382.

874. Wolfram Kleeberger, G. Steven Bova, Matthew E. Nielsen, et al., Roles for the Stem Cell–Associated Intermediate Filament Nestin in Prostate Cancer Migration and Metastasis, Cancer Res 2007;67:9199-9206. Published online October 1, 2007.

875. Wong, S., O. Witte, The BCR ABL Story; Bench to Bedside and Back, Ann Rev Imm, 2004, pp 247-306.

876. Wright, J., P. Lange, Newer Potential Biomarkers in Prostate Cancer, Rev Uro, V 9 N 4, 2008.

877. Wronski, M, Arbit, E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93:9.

878. Wu et al, Deep Learning Approach for Assessment of Bladder Cancer Treatment Response, www.Tomography.Org , Volume 5 Number 1, March 2019

879. Wu, L. et al, Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer, Am J Transl Res 2012; 4:127-150.

880. Wu., F.X. et al, Modeling Gene Expression From Microarray Expression Data with State Space Equations.

881. Xia, H., Great Potential of MicroRNA in Cancer Stem Cell, Jrl Can Mol 2008 pp 79-89.

882. Xie et al, Potential Regulatory Roles of MicroRNAs and Long Noncoding RNAs in Anticancer Therapies, Molecular Therapy: Nucleic Acids Vol. 13 December 2018

883. Xu et al, Identification of RNA Expression Profiles in Thyroid Cancer to Construct a Competing Endogenous RNA (ceRNA) Network of mRNAs, Long Noncoding RNAs (lncRNAs), and microRNAs (miRNAs), Med Sci Monit, 2019; 25: 1140-1154

884. Xu et al, miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR, Mol Cancer Ther; 12 February 2013

885. Xu et al, The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer, Technology in Cancer Research & Treatment Volume 19: 1-9, 2020

886. Yaghooti, H., et al, Angoitensin II Differentially Induces Matrix Matalloproteinase 9 and Tissue Inhibitor of Metalloproteinase-1 Production and Disturbs MMP/TIMP Balance, Avicenna Jrl Med Bio, 2010, pp 79-85.

887. Yamakuchi, MicroRNA regulation and SIRT1, Frontiers in Physiology, Vascular Physiology, March 2012 Vol 3 Art 68,

888. Yamamura, S., et al, MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells, PLOS One, January 2012, Volume 7, Issue 1, e29722

889. Yang and Lai, Alternative miRNA Biogenesis Pathways and the Interpretation of Core miRNA Pathway Mutants, Molecular Cell, V 43 Is 6, Sept 2011

890. Yang, G., et al, Elevated Skp2 Protein Expression in Human Prostate Cancer, Clin Can Res, 2002 pp 3419-3426.

891. Yang, J., et al, Activation of FOXO3 is Sufficient to Reverse Mitogen Activated Protein/Extracellular Signal, Can Res, 2010 pp 4709-4718.

892. Yang, L., et al, lncRNA-dependent mechanisms of androgen receptor-regulated gene activation programs, Nature, 14 August, 2013.

893. Yemelyanov, A., et al, Tumor Suppressor Activity of Glucocortoid Receptor in the Prostate, Oncogene, 2006, pp 1-12.

894. Yen, K., et al, Myc Driven Murine Prostate Cancer Shares Molecular Features with Human Cancer, Cancer Cell, 2003, pp 223-238.

895. Yi, M., E. Ruoslahti, A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis, pp 620–624, PNAS, January 16, 2001, vol. 98, no. 2.

896. Yoruker et al, MicroRNA Expression Profiles in Papillary Thyroid Carcinoma, Benign Thyroid Nodules and Healthy Controls, Jrl of Cancer, 2016 7

897. Young et al, A technical review and guide to RNA fluorescence in situ hybridization, (2020), PeerJ

898. Yu et al, Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer, Cancer Medicine 2018; 7(2):471–484

899. Yu, C, Chen, JC, Apuzzo, ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002; 52:1277.

900. Yu, H., et al, The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes, The American Journal of Pathology, Vol. 174, No. 6, June 2009.

901. Yu, J., et al, An Integrated Network of Androgen Receptor and TMPRSS2-ERG Fusiona in Prostate Cancer Progression, Cancer Cell 2010 pp. 443-454.

902. Yuan et al, High-resolution imaging diagnosis and staging of bladder cancer: comparison between optical coherence tomography and high-frequency ultrasound, Journal of Biomedical Optics 13, 2008

903. Zaborowski, et al, Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study, August 2015, Vol. 65 No. 8, BioScience

904. Zacest, AC, Besser, M, Stevens, G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg 2002; 96:552.

905. Zak, D., Continuous Time Identification of Gene Expression Models, Journal of Integrative Biology, Vol 7 No 4 2003 pp 373-386.

906. Zehavi, et al, Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor, Molecular Cancer 2012, 11:44 Page 8 of 15, http://www.molecular-cancer.com/content/11/1/44.

907. Zelefsky MJ, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41:491-500.

908. Zent, R., A., Pozzi, Cell-Extracellular Matrix Interactions in Cancer, Springer (New York) 2010.

909. Zhang et al, ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation, Cancer Letters 519 (2021) 237–249

910. Zhang et al, Exosomes in cancer: small particle, big player, Jrl Heme & Onc 2015, 8, 83

911. Zhang et al, miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway, International Journal Of Molecular Medicine 35: 1301-1308, 2015

912. Zhang et al, Targeting autophagy in obesity: from pathophysiology to management, Nature Reviews Endocrinology Volume 14, pages 356–376 (2018)

913. Zhang et al, The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases, Int. J. Biol. Sci. 2021, Vol. 17

914. Zhang et al, Upregulation of HOXA13 as a potential tumorigenesis and progression promoter of LUSC based on qRT-PCR and bioinformatics, Int J Clin Exp Pathol 2017

915. Zhang, L. et al, NF-kB Regulates Androgen Receptor Expression and Prostate Cancer Growth, Am Soc Invest Path, V 175, 2009, pp 489-499.

916. Zheng, B., et al, Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation, Molecular Cell 33, 237–247, January 30, 2009.

917. Zhou, X., et al, Statistical Methods in Diagnostic Medicine, Wiley (New York) 2002.

918. Zhu et al, A review on the accuracy of bladder cancer detection methods, Journal of Cancer 2019, Vol. 10

919. Zhu, Y., MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein, Nucleic Acids Research, 2011, 1–11.

920. Zhu, Y., MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein, Nucleic Acids Research, 2011, 1–11.

921. Zietman AL, Prince EA, Nafoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vitro tumor system. Int J Radiat Oncol Biol Phys (1997 Jul 15) 38: 5: 1067-70.

922. Zigler, M., et al, PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis, Cancer Res. 2011 Nov 1; 71:6561-6. Epub 2011 Oct 18.

923. Zijlstra and Stoorvogel, Prostasomes as a source of diagnostic biomarkers for prostate cancer, The Journal of Clinical Investigation, Volume 126 Number 4 April 2016

924. Zilberman, D., The Evolving Functions of DNA Methylation, Curr Opin in Plt Bio, 2008, pp 554-559.

925. Zilberman, D., The Evolving Functions of DNA Methylation, Curr Opin in Plt Bio, 2008, pp 554-559.

926. Zong, Y., et al, ETS Family Transcription Factors Collaborate with Alternative Signalling Pathways to Induce Carcinomas from Adult Murine Prostate Cells, PNAS, V 106, 209, pp 12465-12470.

927. Zsippai, A., et al, mRNA and microRNA expression patterns in adrenocortical cancer, A, J Can Res 2011, pp 618-628.

12 INDEX